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Why an eBook?   
● The textbooks in Pharmacology for use with Biomedical/Science or Allied Health 
Students are very good but contain more information than can reasonably be taught in 
one semester to these students, which is the usual time allotted 
 
● Most textbooks, including Pharmacology textbooks, pack information in a condensed 
form (for economic reasons) and academics need to unpack this material so that 
students can grasp and comprehend it more easily 
 
● Suitable textbooks are too expensive to expect all the students to be able to afford to 
purchase 
 
● Textbooks take a long time to get to publication, and are out of date as soon as they 
are published.  eBooks, without an ISBN, can be continually updated, and kept 
current 
 
● An eBook can be used as an intermediary between topics of a unit/course and 
published literature 
 
● An eBook can be a tailored resource for the unit/course, instead of an expensive 
textbook that is not 
 
● An eBook can have tailored content related to unit/course learning outcomes 
 
● eBooks/eChapters are very popular with International Students, Advanced Standing 
Students, and Working Students 
 
 
What do you mean by flexible? 
 The eBook will be flexible by continuing to be developed and updated – a new 
version will appear every semester.  Also, new authors and reviewers are welcome. 
 
 The eBook adds flexibility for the learning of students i.e. attend or not attend 
lectures, internal or external study 
 
 The teacher decides the content they want to use and can create their own eBook 
 
 The teacher is able to change any of the content to suit their teaching or class 
 
 For some subjects, there is flexibility in choice of eChapters.  For instance, in a shared 
Unit/Course, the eChapters on Drugs and Local Hormones, and Drugs and Neurotransmission may be 
more useful/suitable than the detailed eChapters on Drugs and Local Mediators and Autonomic 
Nervous System or Central Nervous System, respectively 
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Summary This eChapter has an introduction to pharmacology and drug nomenclature 
followed by a detailed discussion of routes of administration starting with oral administration 
(with absorption from the gastrointestinal tract, and first pass liver metabolism). This is 
followed by a discussion of rectal, sublingual and injection routes of administration 
(intravenous, intra-arterial, subcutaneous, intramuscular, intrathecal and epidural).  Then the 
topical, pulmonary and intraosseus routes of administration are considered. 
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1.1 Introduction to Pharmacology 
Pharmacology is the study of all aspects relating to drugs or medicines.  Some of us, use the 
term ‘drugs’ to cover medicines (prescription and non-prescription) and drugs of abuse (legal 
and illicit), and this is how I am going to use ‘drugs’ in this Unit.  The popular press often 
uses the term ‘drugs’ to mean drugs of abuse, and this can be confusing.  Some medicines can 
also be drugs of abuse, which further complicates the issue.  For example, morphine is both a 
potent pain reliever and a drug of abuse. 
There are a huge number of drugs available in Australia.  Currently there are 27,000 drugs on 
the Australian Register of Therapeutic Goods (ARTG) and, of these, 3,500 are registered as 
prescription only. 
Pharmacology can be divided into two parts; pharmacokinetics and pharmacodynamics.   
Pharmacokinetics is ‘What the body does to the drug’.  After administration, the drugs 
usually has to be absorbed into the body, may be distributed around the body, and/or 
metabolised, and will eventually be excreted/eliminated.  Absorption (A), distribution (D), 
metabolism (M) and excretion/elimination (E), sometimes referred to as ADME, are all 
pharmacokinetic processes and they may be altered in disease states.  This is important, as we 
most commonly use drugs in disease states. 
Pharmacodynamics is ‘What the drug does to the body’.  When we administer a drug to a 
person, we hope that the drug will have a beneficial effect.  In order to do so, the drug will 
have to cause an alteration in a physiological, biochemical or pathological process.  This 
alteration is called the mechanism of action or pharmacodynamics of the drug.  It is the 
molecular mechanism of action of the drug, and the actions of the drug in the human body 
that follow from this mechanism of action. 
Pharmacokinetics and pharmacodynamics are related, as shown in Figure 1.1.   
.  
Figure 1.1 Relationship between pharmacokinetics and pharmacodynamics (Copyright QUT, 
Sheila Doggrell) 
Pharmacokinetics includes ADME; Absorption, Distribution, Metabolism and Elimination.  
After administration, drugs undergo absorption into the systemic circulation, this is the 
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circulation that takes blood to most parts of the body, and will take the absorbed drugs with 
it.  Drugs can be further distributed into tissues or fat, and may also be released back into the 
circulation from the tissues and fat.  Drugs are often targeted to have actions at specific sites, 
and when the drug reaches this site, the process of pharmacodynamics starts.  
Pharmacodynamics is a change in the body system – hopefully for a beneficial effect.  After 
having an effect, the drug often returns to the circulation, where it will be taken in the 
circulation to its site of metabolism, which is commonly the liver.  After metabolism drugs 
are removed from the body by excretion, commonly from the kidney.  Some drugs are not 
metabolised but are directly eliminated via the kidneys. 
In addition to pharmacokinetics and pharmacodynamics, there are some other 
pharmac…..terms used in pharmacology.  The first is pharmaceutics, which has some 
overlap with pharmacokinetics.  Pharmaceutics is designing formulations of drugs suitable 
for administration to people.  Pharmacogenetics is the genetic basis for variation in drug 
response.  This variation can have a basis in pharmacokinetics or pharmacodynamics, and we 
will discuss examples of these later.  Pharmacovigilance is the detection, assessment, 
understanding, and prevention of adverse drug effects and adverse drug interactions.  Some 
of these adverse effects and adverse drug interactions are at the level of pharmacokinetics and 
some at the level of pharmacodynamics.  Examples of pharmacovigilance will be discussed 
later.   
1.2 Drug Nomenclature 
An important issue to learn about at the start of a Unit in pharmacology is drug 
nomenclature.   When I tell people that I am a pharmacologist, people often respond by 
saying “I’m taking Tenormin for my hypertension – do you know anything about this drug?”  
Tenormin is a tradename, and pharmacologists do not use trade names.  So, I usually reply 
that “Tenormin is a tradename, and I can’t tell you anything about it unless you give me the 
real name of the drug”.  Tenormin is actually atenolol, a β-blocker commonly used in the 
treatment of hypertension, and I know a lot about atenolol. 
Each drug actually has 3 names.  The first is the chemical name, and is the name used by 
chemists to describe the chemical structure.  The second name is the generic, and this is the 
one used by pharmacologists.  The generic name is also known as the non-proprietary name 
to distinguish it from the proprietary or trademark name.  The trade name is used by the 
pharmaceutical companies.  To give an example: the chemical name for diazepam is 7-
chloro-1,3-dihydro-1-methyl-5-phenyl-2H-,1,4-benzodiazepin-2-on, and from this name, a 
chemist could draw the structure.  The generic name is diazepam, which is a commonly used 
sedative.  The third name is the proprietary or tradename.  Each company can have a different 
tradename (brand name) for the same drug, the best known proprietary or tradename for 
diazepam is Valium (from the pharmaceutical company Roche), but other proprietary names 
for diazepam include Valpam (Arrow), Antenex (Alphapharm) and Ducene (Sauter).  Thus, 
there are at least 4 different trade names for the same drug.  Pharmaceutical companies 
probably like the use of their tradename, as this gives them some free advertising.  However, 
it is more correct (and less confusing) to use generic names.  Generic names are used 
throughout this Unit and eBook. 
 
1.3 Introduction to drug administration and absorption of drugs 
The first step in pharmacokinetics is the administration and absorption of drugs.  The 
chemical structure and nature of a drug may determine which route of administration can be 
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used for? a drug.  Drug absorption depends on the route of administration.  When a drug is 
administered into the mouth (orally), absorption will be from the gastrointestinal tract.  
However, if a drug is administered into a vein (intravenously), absorption will be from the 
circulation. 
1.4 Routes of drug administration 
The routes of drug administration are described as enteral, which means into the 
gastrointestinal tract, or parenteral (not into the gastrointestinal tract); Figure1.2.   
 
Figure 1.2 Enteral and parenteral routes of administration (Copyright QUT, Sheila Doggrell) 
Routes that are enteral (into the gastrointestinal tract) are oral and rectal.  Routes that are 
parenteral include sublingual (under the tongue) and injection, which can be to a variety of 
sites e.g. into the vein (intravenous), into the muscle (intramuscular), under the skin 
(subcutaneous).  Other parenteral routes include topical, which is to a body surface, such as 
the skin, nose, eyes etc. and pulmonary, which is delivery to the lungs.  These routes of drug 
administration are considered in sequence.  The route of administration used for a drug may 
also depend on whether a systemic (around the body) effect is required.  Local administration 
is a way of trying to limit the effects of a drug to a local area.  
1.5 Oral administration, absorption from gastrointestinal tract, and first pass 
liver metabolism 
The oral route of administration is the most convenient: subjects prefer to take an oral 
preparation rather than have an injection, or rectal administration.  Oral administration is also 
the safest.  For instance, we have more time to reverse the effects of a drug administered 
orally than when it is administered directly into a vein.  Oral is the most commonly used 
route of administration.  Oral administration usually gives systemic effects (around the body) 
rather than local effects of drugs.  Thus, after oral administration, a drug ends up in the 
systemic circulation being widely distributed to tissues and organs, with the possibility of 
having a widespread effect.  
A disadvantage of oral administration can be the slow onset of action, as the drug has to be 
absorbed and taken to its required site of action before it can start to have an effect.  In an 
emergency, drugs that are active after oral administration, may be given intravenously to 
speed up their onset of action.  If the patient is vomiting, the drug may never reach the 
intestine to be absorbed.  Thus, when the patient is vomiting, oral is not an appropriate route 
of drug administration.  
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Oral preparations can take several forms.  Tablets are compressed powder, often with starch 
added to swell when in contact with fluids, to aid dissolution (breakdown of the tablet).  
Capsules contain a shell of gelatine, which is a tasteless natural substance.  Hard gelatine 
capsules contain the drug as solid, whereas soft gelatine capsules contain drug as an oily 
liquid.  Capsules are often preferred to tablets as they disguise the taste.  For instance, the 
antibiotic amoxycillin is given in capsule form to prevent its bad taste upsetting the subject.  
Children often have problems swallowing tablets or capsules.  If swallowing is a problem, 
oral liquid preparations can be used. 
The gastrointestinal tract is designed to handle food and fluids not drugs.  Drugs piggyback 
on the physiological processes to handle food.  Also, the physiological processes that 
normally impact on food and fluids, can affect drug delivery.  For instance, the digestive 
enzymes that breakdown proteins in the diet, can also breakdown some peptide drugs e.g. 
insulin.  Thus, when insulin is being used to treat diabetes, it is not administered orally.  The 
absorption of some drugs is inhibited by forming complexes with components of the diet e.g. 
the tetracycline antibiotics form non-absorbable complexes with calcium (dairy products).  
Some drugs irritate the lining of the gastrointestinal tract to cause emesis (vomiting), and 
such drugs cannot be used orally e.g. some of the cytotoxic (cell killing) anti-cancer drugs. 
The processes that need to happen to get drug delivery from the gut into the circulation are 
given in Figure 1.3.  Firstly, the drug has to be released from the dosage form (tablet or 
capsule).  Secondly, the drug has to separate and/or dissolve; this is called drug dissolution.  
After dissolution most drugs are absorbed by simple diffusion, although a few drugs are 
transported by physiological processes.    
   
Figure 1.3 Processes to get drug delivery from gut (Copyright QUT, Sheila Doggrell) 
The body has many membrane transporters.  These are like being transported by a bus; 
they pick up drugs and take them to their destination across membranes.  For instance, after 
the proteins have been broken down to amino acids, the amino acids are absorbed by active 
transport across the gut membrane.  Drugs with similar structures to the natural substrates 
(substances) for these transporters can use these transporters.  For instance, thyroxine, which 
is commonly used in the treatment of hypothyroidism, uses the physiological transporter for 
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amino acid absorption.  Another example is the drug L-dopa, which is used in the treatment 
of Parkinson’s disease.  L-dopa is a naturally occurring compound, and has its own 
transporter. 
The most common method for drug absorption is diffusion.  As cell membranes are lipid, to 
diffuse through the lipid cell membranes, drugs must be lipid soluble (lipophilic).  ‘Philic’ 
means likes, whereas ‘phobic’ means does not like.     Drugs that are not water soluble 
(hydrophobic) are often lipophilic, and absorbed by diffusion.  In contrast, water soluble 
drugs (hydrophilic), which are not lipid soluble (lipophobic drugs; e.g. curare), are not well 
absorbed after oral administration.   
The case of curare tells us a lot about routes of drug administration.  Curare was used on the 
tips of the arrows of South Americans to kill animals.  Once the curare was injected into the 
animal, it became paralysed.  However, when the South Americans ate the curare-injected 
animals, they were not paralysed.  This is because curare is a strong base and not absorbed 
from the gastrointestinal tract, so has no effect after oral administration.  However, it is 
absorbed after intramuscular injection to give its muscle relaxant effect.  Curare is still used 
today to cause muscle relaxation during operations.  In addition to strong bases, strong acids 
are poorly absorbed after oral administration, and have to be given by another route. 
Strong acids and strong bases (e.g. curare) are not absorbed.  Thus, drugs are usually 
designed to be weak acids (e.g. aspirin) or weak bases (e.g. morphine), as these are more 
lipid soluble and readily diffuse through the gastrointestinal cells membranes.  Weak acids 
are lipophilic at low pH (which occurs in the stomach) and are capable of being absorbed 
from the stomach.  In contrast, weak bases are lipophilic at high pH (in the intestine), and are 
absorbed from the intestine. 
The stomach is acidic, with a pH of 1-3, compared with the small intestine, which has a pH in 
the range 5-8.  Acidity is increased at night, and this may increase the absorption of some 
drugs.  In contrast, antacids decrease the acid in the stomach, and can inhibit the absorption 
of some drugs.  As the acidity in the stomach leads to the association of weak acids, some of 
these are absorbed from the stomach.  However, the stomach is not designed for absorption, 
and most absorption occurs in the small intestine, which is designed for absorption with villi 
(projections) and microvilli giving a large surface area. 
Drugs will reach the small intestine more rapidly, if administered with water to a patient, 
whose stomach is empty of food. If a drug is absorbed lower down the gut, the volume of 
gastric contents will determine the delay before absorption starts.  Gastric contents are not the 
only determinant of rate of gastric emptying and, hence, drug absorption in the intestine.  
Gastric emptying rate is slowed by diet, especially a diet containing fatty foods or a high bulk 
diet.  Diseases of gastrointestinal tract, such as gastric ulcers or pyloric stenosis, can slow 
gastric emptying.  Gastric emptying is also slowed during pregnancy.  Certain drugs (e.g. 
anti-muscarinics) and alcohol also slow gastric emptying.  Indeed, one of the uses of 
antimuscarinics is to slow gastric emptying in dysentery.  With slow gastric emptying, there 
is more time for the breakdown of drugs by the enzymes and/or acid in the stomach, and this 
means the subsequent levels in the blood may be lower. 
Gastric emptying rate is promoted by hunger, anxiety and certain drugs (e.g. 
metoclopramide).  Increased gastric emptying may promote the absorption of any drug, and 
lead to increased blood levels.  Metoclopramide is not used to promote gastric emptying but 
as an anti-emetic (prevention of nausea and vomiting).  During this use of metoclopramide, 
there may be higher blood levels of other drugs being used at the same time. 
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The small intestine is the primary site of drug absorption.  The longer the drug remains in the 
small intestine (residence time), the greater the absorption of the drug from the intestine.  
However, some drugs are metabolised and inactivated by the intestinal mucosa e.g. 
progesterone, which means they are not very effective after oral administration.  Thus, orally 
active progesterone-like drugs, designed to be active after oral administration, are part of the 
oral contraceptive, rather than progesterone itself.  Norethisterone is a progesterone-like 
drug (progestogen), which is used as an oral contraceptive 
Drugs may have a short action if their dissolution and absorption in the gastrointestinal tract 
is too quick, or metabolism is too quick.  This may mean that a drug has to be taken often, 
say every 2 or 3 hours.  People are not very good at remembering to take drugs every 2 or 3 
hours, especially during the night, and with such regimens, people miss doses; their 
adherence to the dosage regimen is low.  For this reason, it is best to formulate drugs so that 
they only need to be taken once or twice a day. To achieve this controlled/slow (sustained) 
release preparations have been developed.  These have a slowed rate of dissolution in the 
gastrointestinal tract allowing them to be used less frequently and/or allowing the 
maintenance of a therapeutic effect overnight.  For instance, the use of nifedipine in the 
treatment of hypertension was initially not very effective as nifedipine is rapidly metabolised, 
and therefore has to be taken frequently, which patients find difficult to adhere to. With 
nifedipine SR, there is a slower dissolution of the tablet, and prolonged delivery, which 
allows nifedipine SR to be used twice a day, so nifedipine SR allows a more effective control 
of blood pressure.   
Some drugs are ineffective when administered by the oral route as they are destroyed by the 
acid in the stomach e.g. erythromycin.  Enteric-coated preparations are designed to 
prevent destruction by acid in the stomach, and this allows some of the drug, which would 
otherwise be destroyed by acid, to be effective after oral administration.  The antibiotic 
erythromycin can be used in an enteric-coated preparation. 
An important term that is often used in association with the use of medicines is 
bioavailability.  Bioavailability is the fraction of an ingested dose of a drug that gains access 
to the systemic circulation.  To reach the circulation (see Figure 1.3), drugs must penetrate 
the intestinal mucosa and avoid metabolism by the intestinal and liver enzymes.  Drugs that 
reach the blood vessels of the gastrointestinal tract are carried in the blood supply directly to 
the liver by the portal vein.  The liver is a major source of enzymes, and these enzymes are 
involved in the biochemical processes in the body.  While, none of these enzymes have drugs 
as their natural substrates, they do metabolise drugs.  Indeed, many drugs are inactivated by 
metabolism.  After oral administration, drugs cannot avoid being taken to the liver.    
Metabolism after absorption from the gut is known as First Pass Metabolism. If drugs 
undergo extensive first pass metabolism after oral administration, they are often 
administered by another route to avoid this inactivation e.g. sublingual, rectal. 
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Figure 1.4 First pass metabolism (Copyright QUT University, Sheila Doggrell) 
Whether drugs are administered orally or by other routes, they often end up in blood vessels, 
and, to reach their target site, have to then be absorbed from blood vessels.   This occurs 
predominantly by diffusion.  Cardiovascular disease can lead to low perfusion of tissues (e.g. 
in heart failure, there is low perfusion of tissues) and this can slow the absorption of drugs.  
Conversely, exercise increases blood flow, and will increase the absorption of drugs from the 
blood vessels in skeletal muscle. 
In addition to oral administration, routes of drug administration include sublingual, rectal, 
injection, topical, and pulmonary.  Each of these routes has both advantages and 
disadvantages when compared to oral administration. 
1.6 Sublingual 
Extensive first pass liver metabolism makes it difficult to administer some drugs by the oral 
route.  Sublingual (under the tough) administration can be used to avoid first pass liver 
metabolism.  Drugs that are absorbed via the oral mucosa drain into the superior venae cavae 
to the heart and systemic circulation; they are not transported directly to the liver, and thus do 
not undergo first pass liver metabolism.  Once in the systemic circulation, only part of the 
drug will pass through the liver with each circulation - the rest will go through other organs 
or tissues, which may not metabolise the drug to destroy it: Figure 1.4. 
 
Figure 1.4 Sublingual drug administration (Copyright QUT University, Sheila Doggrell) 
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The sublingual route of administration increases the bioavailability of drugs that are 
extensively metabolised by the liver.  The best known example of a drug that is used 
sublingually to avoid first pass liver metabolism is glyceryl trinitrate (nitroglycerin).  Oral 
nitroglycerin is ineffective as it is extensively metabolised by the liver, and little enters the 
circulation if taken orally.  In an attack of angina, nitroglycerin administered sublingually 
does get into the circulation, and rapidly provides relief from the attack of angina.   
1.7 Rectal 
The rectum is at the end of the large intestine, and is about 15-20 cm long.  Drugs are 
specially formulated for rectal administration, and the Solid Drug Formulations for Rectal 
Use are known as suppositories. 
Rectal administration avoids first pass liver metabolism.  This is because, after insertion into 
the lower part of the rectum, absorption is into rectal veins and then into the general 
circulation.  As the absorption is not into the portal vein, this avoids first pass metabolism.  
Another advantage of rectal administration is that the rectum has little enzymatic activity, and 
this route avoids upper gastro-intestinal acids and enzymes, which destroy many drugs.  
Rectal administration may be useful in the presence of upper gastrointestinal disease, which 
affects the absorption of the drug given via oral administration.  
Rectal administration can be useful when oral administration is not possible.  For instance, in 
nausea and vomiting, or in subjects who have difficulty in swallowing, oral administration is 
not possible.  Post-operative vomiting prevents oral administration, but drugs can be 
administered rectally to reach the circulation to be effective.  The antiemetic 
Prochlorperazine can be used rectally when nausea and vomiting are preventing oral 
administration. 
In children in status epilepticus, it is not possible to get the child to swallow, but rectal 
diazepam can be used to control the epilepsy.  Rectally administration can be by carer or 
paramedic.   
In addition to being used to achieve systemic effects, the rectal route can also be used to give 
a local effect.  For example, suppositories can be used in the treatment of haemorrhoids. 
Suppositories and enemas are different.  Enemas contain hypertonic solutions that draw 
water to them to produce a laxative effect, and are used in subjects with constipation. 
The major disadvantage of rectal administration is that it is not popular with people. 
1.8 Injection 
There are mainly sites that drugs can be injected into, and the absorption will be different 
from each of these sites.  The sites include intravenous (into the vein), intra-arterial (into 
the artery), intradermal (into the dermis layer of skin), subcutaneous (under the dermis, in 
the subcutaneous tissue), intramuscular (into the muscle) (Figure 1.5), intrathecal (into the 
cerebral spinal fluid), and epidural (into the epidural). 
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Figure 1.5 Intradermal, Subcutaneous, Intravenous and Intramuscular routes (Copyright 
QUT, Sheila Doggrell) 
1.8.1 Intravenous 
Injection into a vein (intravenous) relies on the skill of finding a vein, getting a needle into 
the vein, and keeping the vein open during the injection.  This is a skill that relies on practice 
at the patient’s expense!  One of the major advantages of the intravenous (i.v.) route is that it 
gives more immediacy and accuracy than other routes.  Immediacy may be required in an 
emergency situation. In an emergency situation it may be necessary to sedate the subject 
quickly.  After oral administration of a drug, it takes between 15-30 minutes to start to get 
any sedation.  When the sedative midazolam is used intravenously, sedation occurs in 2-4 
minutes.   
In a situation where a subject has intense pain, quick pain relief is required.  Morphine is a 
potent analgesic (pain reliever).  For quick pain relief, morphine is administered 
intravenously, and pain relief occurs in 10-15 minutes, whereas if morphine is administered 
orally, to takes 30 minutes to cause pain relief. 
After oral administration, in addition to the time lag for absorption, there may be a reduction 
in drug activity by liver metabolism, which gives a range of bioavailability, which is specific 
for each drug.  In contrast, intravenous administration avoids first pass liver metabolism, 
allows for a rapid effect, and the bioavailability is 100%.  Because of the greater 
bioavailability after intravenous administration, a lower dose may be required after 
intravenous administration than oral administration. For instance, when the pain killer 
pethidine is administered orally, the dose is 100 mg, and there is extensive first pass liver 
metabolism.  When pethidine is administered intravenously, there is no first pass metabolism, 
and the dose is 25 mg. 
The intravenous route of administration can be used for drugs that are not active after oral 
administration e.g. ionised drugs, peptides.  The intravenous route of administration can often 
be used for drugs that irritate the intestinal mucosa, as blood vessel walls are quite 
insensitive.  Many of the cytotoxic (cell killing) anti-cancer drugs irritate the intestinal 
mucosa but not the blood vessels walls, and are given intravenously 
One disadvantage of the intravenous route is that it is not suitable for all drugs.  Drugs in oily 
vehicles or drugs that precipitate blood constituents or haemolyse red blood cells cannot be 
used intravenously.  Another disadvantage of the intravenous route is that, with oral 
administration of the wrong drug or the wrong dose of a drug, there is an opportunity to 
remove the drug during absorption, and before it reaches the circulation, but this is not 
possible after intravenously administration.  Thus, it is a disadvantage that the actions of an 
intravenously administered drug are often not easily reversed. 
1.8.2 Intra-arterial 
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The main disadvantage of intra-arterial injection (injection into an artery) is that it requires 
great care, and should only be done by experts.  If you get it wrong, there will be blood 
everywhere!  Intra-arterial (i.a.) injections are used to localise effects of a drug to a particular 
tissue or organ e.g. in the treatment of renal tumours or head/neck cancers, drugs can be 
injected into the renal artery or carotid artery, respectively.  After intra-arterial 
administration, the highest concentrations are localised and have their maximum effect 
locally.  As the drug moves away from its site of injection, it is diluted in the circulation, and 
this reduces the toxicity of the drug.  Another advantage of intra-arterial injection to the site 
of action is that it avoids first pass liver and lung metabolism. 
1.8.3 Subcutaneous 
Subcutaneous is injection of a drug under the skin.  An advantage of subcutaneous (s.c.) 
administration is that it avoids first pass liver metabolism, as the drug is released into the 
circulation, rather than specifically into the portal vein.  From the subcutaneous area, 
absorption is often by diffusion.  The drug is administered in a depot under the skin with 
absorption into plasma, and then to the circulation often sufficiently constant and slow to 
provide a sustained effect.  Thus, subcutaneous administration can provide a slow release 
preparation for ongoing effects.  Also, the rate of absorption after subcutaneous 
administration can be varied.  For instance, in diabetics, soluble insulin with rapid absorption 
can be injected subcutaneously to mimic the rapid rise in blood insulin observed with a meal.  
Whereas an insoluble suspension of insulin can be used for the slow absorption required to 
give the low constant fasting level of insulin. 
The area affected by the subcutaneous administration of a drug can be limited by the injection 
of a vasoconstrictor (e.g. adrenaline) with the drug.  The localised vasoconstriction response 
to adrenaline limits the transport of the drug away from the site of injection in the circulation. 
This method is used with local anaesthetics to keep the effect of the anaesthetic confined to a 
local area.  Without a vasoconstrictor, the local anaesthetic and the anaesthetic effects spread 
from the site of injection, and are no longer local. 
1.8.4 Intramuscular 
Intramuscular is injection into the muscle.  An advantage of intramuscular (i.m.) 
administration is that it avoids first pass liver metabolism, and it may be suitable for drugs 
that undergo extensive first pass liver metabolism.  The intramuscular route is often suitable 
for drugs that are mucosal irritants or drugs that are irritants after subcutaneous injection. 
Drugs in aqueous solution are absorbed quite rapidly from muscle, but the rate of absorption 
will depend on the rate of blood flow at the injection site.  If the blood flow is high, the rate 
of absorption will also be high.  The rate of absorption of an aqueous solution is greater from 
the deltoid (shoulder muscle) or vastus lateralis (above the knee muscle) than from the 
gluteus maximus (butt muscle).  Absorption from gluteus maximus is particularly slow in 
females who have more subcutaneous fat in this area than males, because fat slows the 
absorption.  Gardasil, the vaccine designed to prevent most cases of cervical cancer, is 
injected into the deltroid for quick absorption.   
Blood flow to the legs is increased during jogging.  If insulin is injected into the leg, rather 
that into the arm or abdominal wall, as recommended, it is absorbed quickly during jogging.  
With higher levels of insulin than expected, there is an increased take up of glucose into the 
tissues, which can cause an unwanted major drop in blood glucose leading to an episode of 
hypoglycaemia. 
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1.8.5 Intrathecal 
Intrathecal is injection into the cerebral spinal fluid; Figure 1.6.  
Figure 1.6 Difference between intrathecal and epidural injection (Copyright QUT, Sheila 
Doggrell) 
 
Intrathecal is a method for direct delivery of a drug to the central nervous system.  Intrathecal 
is used with local anaesthetics to give spinal/regional anaesthesia, often prior to perform 
operations on low limbs.   
The opioid µ-receptors that mediate pain are in the spinal cord.  Drugs that are administered 
to the cerebral spinal fluid are being delivered to this site of pain mediation.  Thus, the 
intrathecal route of administration can be used with the opioid antagonist morphine to give 
good pain relief. 
1.8.6 Epidural 
An epidural is an injection into the epidural, which is the area above the dura mater, the layer 
before the cerebral spinal fluid (Figure 1.6).  The best known example of epidural injections 
is when used with local anaesthetics during childbirth to prevent the pain associated with 
childbirth. 
1.9 Topical 
Topical administration is to the surface, and is used to give local effects.  Topical 
administration avoids first pass metabolism.  However, drugs that are absorbed into the 
circulation after local administration may then have systemic effects.   
The topical surface can be skin or mucous membranes, and these have different properties.  
Mucous membranes used for drug administration include those of the conjunctiva (eye), 
nasopharynx (nose), oropharynx (throat), vagina, urethra, and urinary bladder.  Absorption 
from these mucous membranes occurs readily.  Topical administration to the skin and 
selected mucous membranes are discussed below. 
1.9.1 Skin 
Topical administration of drugs to the skin usually uses patches or ointments, which are 
applied to the skin.  The outer layer of the skin (the epidermis) is a lipid barrier, and aqueous 
solutions will only be absorbed slowly.  If necessary, absorption can be enhanced by 
suspending the drug in an oily substance and rubbing the resulting preparation into the skin.  
The epidermis is the main determinant of the rate of absorption from the skin, as the inner 
layer of the skin (the dermis) is freely permeable.  Avoidance of first pass liver metabolism is 
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a major advantage with administration.  Thus, drugs that undergo extensive first pass liver 
metabolism can be used topically.  For instance, the nitrates can be given in patches that 
provide long term release and long term prevention of angina.  The nitrates have their effect 
on blood vessels, and thus require absorption into the systemic circulation to be effective.  
Scopalamine patches are another example of tradsdermal patches.  Transdermal scopolamine 
patches are used to prevent motion sickness. 
Topical administration can be also be used to produce local effects and avoid systemic 
effects/side effect, when this is required.  The anti-inflammatory glucocorticoids can have 
severe adverse effects if they get into the blood stream.  However, they can be used safely in 
skin diseases with local application.  Topical administration to the skin provides the highest 
concentrations of glucocorticoids, and the majority of their effects at the required site (the 
skin).  Only low concentrations of the glucocorticoids will enter the systemic circulation with 
the potential to cause adverse effects. 
Controlled-release preparations for topical administration to the skin are increasing being 
used to give a long term steady state level of drug.  For instance, nicotine patches are 
controlled-release preparations that help to reduce cravings in smoking cessation.  Another 
example is the scopolamine patche, which is a slow release preparations to prevent motion 
sickness. 
1.9.2 Nasal mucosa 
The nasal mucosa is highly porous and permeable to drugs.  The nasal mucosa is highly 
vascularised.  The nasal mucosa also has a relatively large surface area as a result of 
microvilli on the epithelial cells, and this aids absorption from the nasal mucosa.  One 
disadvantage to the nasal route is that the drug may be rapidly removed by a runny nose.  
Thus, it is an unreliable route of administration in subjects with a cold or hayfever. 
Recently there has been an increased use of the intranasal route for the emergency/quick 
effect of drugs.  For example, intranasal midazolam is used in the hospital setting to quickly 
stop an attack of status epilepticus 
Most of the drugs that are commonly administered intranasally are those with effects on the 
nose.  For example, decongestants (such as pseudoephedrine) are administered into the 
nose, when it is congested in a cold. 
1.9.3 Eye  
When a drug is a liquid/drop form, it is placed on the conjunctiva, and the released drug 
dissolves in the tears, and following blinking, is distributed to the site of absorption, the 
cornea.  Local effects usually require absorption of the drug through the cornea.  Although 
eye drops are used for their local effects, absorption can lead to systemic effects as the drug is 
drained from the eye through the nasolacrimal canal.  As this drainage is not subject to first 
pass liver metabolism, it can lead to systemic side effects.  Absorption may be increased by 
corneal infection or trauma, and dosage and care is needed in these conditions.  An example 
of a drug that is used as eye drop is the β-blocker timolol, which is used in the treatment of 
glaucoma, high intraocular pressure.  The highest concentration of timolol is in the eye, and 
that is where the predominant effects are.  Major systemic effects are not observed after 
timolol is applied topically to the eye. 
Drugs can also be administered to the eye in the form of an ointment.  A small amount of 
ointment is put along the inside of the lower eyelid.  Then, blinking will spread the ointment 
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over the cornea, and the drug will be absorbed.  This provides a more prolonged contact time 
with the cornea, and more prolonged absorption.  With ointments, the application to the eye is 
less often than with drops. 
1.9.4 Vaginal 
Suppository-shaped medications are available for vaginal administration. These are known as 
pessaries, and are designed to obtain a local effect.  An example of a drug used in a pessary 
is clotrimazole, an anti-fungal drug for the treatment of vaginal candidiasis (thrush). 
1.10 Pulmonary – Inhalation 
Drugs used for effects on the pulmonary system are often administered by inhalation to give 
the highest concentrations of the drug in the lung.  The human respiratory tract has a 
considerable surface area, which should aid absorption, but most of this is deep in the 
alveolar region of the lung and it is difficult to deliver drugs deep into the lung.  Inhalation is 
not actually a very good way of delivering drugs to the lung, as only about 10% of a drug that 
is inhaled actually goes to the lungs, the rest is swallowed, and may be absorbed from the 
gastrointestinal tract. 
With inhalation, predominant local effects are achieved in pulmonary diseases (e.g. bronchial 
asthma) by having the highest concentration of the drug in the lung.  In asthma, metered-
dose inhalers are used.  These have an inert propellant gas, and require good hand-breath co-
ordination to achieve inhalation, rather than swallowing.  An example of a drug that is used in 
a metered-dose inhaler is salbutamol for the treatment of bronchial asthma.  Another way to 
deliver drugs to the airways is to use a nebulisers.  Nebulisers produce fine droplets in the air 
(aerosol), and are used to deliver large doses of drugs in an emergency.  Thus, in the 
emergency treatment of asthma, large doses of salbutamol can be delivered by a nebuliser. 
Local pulmonary effects can be achieved by using drugs that are poorly absorbed.  For 
example, the glucocorticoid beclomethasone is poorly absorbed from the pulmonary 
epithelium in bronchial asthma.  Thus, it remains in the lung to have an anti-inflammatory 
effect in asthma.  Localised pulmonary effects without major systemic adverse effects can 
also be achieved by inhaling drugs that undergo extensive liver metabolism.  For example, 
after inhalation, the glucocorticoid budesonide has anti-inflammatory effects on the lung.  As 
budesonide is rapidly metabolised by liver this prevents it from having serious systemic 
adverse effects. 
After inhalation, when a drug is deep into the lung, access to the circulation is rapid because 
the lung has a large surface area.  Thus, inhalation can also be used for widespread effects, 
including central effects.  For instance inhalation is used for gaseous and volatile 
anaesthetics, which are rapidly absorbed through the pulmonary epithelium and mucous 
membranes of the respiratory tract, and have their anaesthetic effect within the central 
nervous system.   
Methoxyflurane was introduced as an inhalation anaesthetic, but was withdrawn because of 
toxicity.  Lower less toxic doses of methoxyflurane are analgesic and are used for the 
treatment of acute pain in the emergency situation. The analgesic effect of methoxyflurane is 
mediated by the central nervous system. 
1.11 Intraosseous 
Intraosseous is into the bone marrow.  The bone marrow is highly vascular, which means that 
drugs injected into the bone marrow are rapidly circulated.  The needle injection is through 
the outer bone layer to the soft marrow interior.  The injection is usually done just below 
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knee.  Intraosseous is not the first choice for drug administration.  It is usually only done after 
two attempts at inserting a line to do an intravenous infusion have failed.  Examples of when 
intraosseous can be used include, a child 5 years or younger who is unconscious, 
unresponsive and in immediate danger of dying.  Intraosseus is also used when 
cardiopulmonary resuscitation support is required, and this is for patients of all ages, and in 
circulatory shock treatments where there is collapse of the circulation making cannulation 
difficult.  
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2.1 Introduction 
After a drug has been administered and absorbed into the systemic circulation, it has to be 
distributed in the blood, to its site of action, where the pharmacodynamic process 
(mechanism of action, actions in the body) will take place.  The drug is then usually 
metabolised and excreted.   Distribution, metabolism and excretion are discussed in the 
following chapters.  Absorption, distribution, metabolism and excretion are all important 
determinants of the plasma levels of drugs.   The plasma levels of drugs are also discussed.  
 
2.2. Drug Distribution 
 2.2.1 Introduction 
Blood is aqueous, and only hydrophilic (water soluble) drugs will dissolve in it.  For 
absorption, most drugs have to be lipid soluble.  Lipophilic drugs are transported in the blood 
attached to proteins. 
 
 2.2.2 Protein binding 
Plasma proteins, such as albumin and globulin, were not designed to carry drugs, but are 
quite effective at doing so.  Acidic drugs bind to albumin, whereas basic drugs bind to 
globulin.  In the plasma there is equilibrium between the protein-bound and free drug (Figure 
2.1).   
 
Figure 2.1 Protein binding and distribution (Copyright QUT, Sheila Doggrell) 
 
The bound drug cannot leave the blood stream whereas the free drug can leave the 
circulation, often to have its pharmacodynamic effect.  When free drug leaves the blood 
vessel, more drug is released from the binding, to maintain the equilibrium.  Thus, drug is 
gradually being released from plasma proteins. 
 
Bilirubin is a yellow breakdown product from red blood cells.  Bilirubin binds to albumin.  In 
liver disease, the levels of bilirubin may be high, giving the condition known as jaundice.  
High levels of bilirubin will also displace drugs from binding to plasma proteins.  Thus, the 
blood levels of free drug may increase in jaundice, with the effect of the drug going from 
therapeutic to toxic.  Thus, in jaundice, the doses of some drugs have to be decreased. 
 
In addition to bilirubin, drugs can compete for the same site on the plasma protein (Figure 
2.2).  
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Figure 2.2 Drugs competing for binding site (Copyright QUT University, Sheila Doggrell) 
 
Figure 2.2 shows drugs A and B competing for the same binding site on a plasma protein.  
Aspirin and warfarin are examples of drugs that have the same binding site on a plasma 
protein.  Aspirin and warfarin are often used together in cardiovascular disease.  Warfarin is 
used as an anti-coagulant, and the anti-coagulant effect is dependent on the free concentration 
of warfarin.  When aspirin displaces warfarin from their binding site, the free concentration 
of warfarin will be increased, and there may be  too much anti-coagulation, which may lead 
to haemorrhage.  Thus, when aspirin and warfarin are given to a person, it may be necessary 
to reduce the dose of warfarin. 
 
2.2.3 Factors that modify protein binding and drug distribution? 
A decrease in blood proteins leads to an increase in free drug concentration and effects, and 
the effects may go from therapeutic to toxic.  Blood proteins are decreased by dietary protein 
insufficiency (malnutrition), liver disease causing decreased synthesis of proteins, and by 
burns.  When there are decreased plasma proteins, it may be necessary to decrease the dose 
of drug, to decrease the free concentration of a drug, to go from a toxic effect to a therapeutic 
effect. 
 
Conversely, when there is an increase in blood proteins, there may be a decrease in the free 
drug concentration and the effect of the drug may be lost, as the free plasma concentration 
goes below that needed for a therapeutic effect.  For instance, in multiple myeloma, there is 
excessive production of immunoglobulin proteins, which bind and inactivate certain drugs.  
Thus, in multiple myeloma, it may be necessary to increase the dose of a drug to increase 
the free concentration, and get a therapeutic effect. 
 
The lipid solubility of a drug is an important factor determining distribution.  Lipophilic 
drugs are accumulated in fat tissue, and are only slowly released from fat tissue.  For 
instance, the anti-arrhythmic drug amiodarone is very lipophilic, and is accumulated to a 
great extent in lipids.  When the administration of amiodarone is stopped, amiodarone 
continues to be released out of the fat tissues for weeks.  Amiodarone can be a toxic drug.  
Unfortunately, the toxic effects of amiodarone are slow to reverse, as reversal requires the 
removal of amiodarone, and that may take weeks.   
 
Another example of a highly lipophilic drug is marijuana.  After a single use of marijuana, 
marijuana accumulates in the fat and is slowly released.  As a result of this, marijuana can be 
detected in blood 6 weeks after a single use. 
 
 2.2.4 Blood brain barrier 
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In the systemic circulation, there are gaps between endothelial cells lining blood vessels 
(Figure 2.3) and, as the basement membrane is freely permeable, this allows most free water 
and lipid soluble drugs to move out of the systemic circulation (Figure 2.3). 
 
Figure 2.3 Distribution across blood vessels (Copyright QUT University, Sheila Doggrell) 
 
In the cerebral circulation, there are no gaps between the endothelial cells, and this forms a 
barrier (referred to as the blood brain barrier) mainly to water soluble drugs.  Because of this 
barrier, water soluble drugs cannot get into the brain from the cerebral circulation.  Only 
lipophilic drugs, and drugs that are actively transported, can cross the blood brain barrier.  
Most drugs used for central nervous system effects are lipophilic.  The sedative diazepam is 
a lipophilic drug that moves across lipid membranes into the brain.  L-dopa is an example of 
a drug that it is actively transported into brain.  The barrier is deficient in chemoreceptor 
trigger zone, and some drugs act in this zone to exert emetic (vomiting) effects. 
 
For central nervous system effects, we need drugs that cross the blood brain barrier.  
Alternatively, drugs can be administered into the cerebral spinal fluid to bypass the blood 
brain barrier.  For instance, penicillin does not cross the blood brain barrier, which is fine 
when we have a peripheral infection, but not if the infection is within the central nervous 
system.  For central infections, penicillin has to be administered into the cerebral spinal fluid 
(CSF) by the intrathecal route of drug administration. 
 
For peripheral effects, drugs that do not cross the blood brain barrier are preferred.  This is 
because, any central effects of a drug administered for a peripheral effect, may be adverse 
effects.  For instance, the anti-histamine diphenhydramine was developed to treat allergy, a 
peripheral condition, but diphenhydramine crossed the blood brain to have central effects, 
notably a central sedative effect.  Thus, subjects given diphenhydramine for allergy were at 
risk of falling asleep.  The second generation anti-histamines (e.g. fexofenadine) were 
developed to have a reduced ability to cross the blood brain barrier and, consequently, do not 
exert a sedative effect.  Presently, only the second generation anti-histamines are used to treat 
allergy, and diphenhydramine has been developed as a mild sedative.  
 
2.2.4 Volume of distribution 
The volume of distribution of a drug or the (apparent) volume of distribution, as it is 
sometimes called, is not a real distribution, but a parameter that is useful in determining 
whether haemodialysis can be used to rid the body of a particular drug or whether a loading 
dose of a drug is necessary (loading doses are discussed in chapter 6.4).  The (apparent) 
volume of distribution Vd is defined as the volume of fluid required to contain the total 
amount of drug in the body, at the same concentration as in the plasma.  The volume of 
distribution will be calculated for us when the drug is first developed.  Thus, we don’t need to 
know how to calculate it, but we do need to know how to interpret it.  For instance, compare 
Drugs A and B, each administered at 100 mg. They may have different distributions and 
therefore different volumes of distribution.  If after administration Drug A has a plasma level 
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of 20 mg/ml, and Drug B has a plasma level of 2 mg/ml – it is obvious that Drug B is more 
widely distributed than Drug A. That is, more of Drug B is distributed outside of the plasma.  
For Drug A, Vd is 100 mg/20 mg = 5 L, and for Drug B, Vd is 100 mg/2 mg = 50 L. 
 
The plasma volume in a 70 kg adult = 3L (i.e. ~0.04 L/kg).  Any drug that is confined to 
plasma will have similar volume of distribution to the plasma (0.04 L/kg).  Drugs that are 
evenly distributed throughout body (go everywhere at same concentration as plasma) have a 
Vd of 0.57 L/kg.  Drugs that are accumulated in tissues have a greater volume of distribution. 
 
A low volume of distribution indicates that a drug is  largely confined to plasma, and can be 
removed by haemodialysis.  Conversely, drugs with a large Vd will be accumulated in fat or 
elsewhere, and cannot be removed by haemodialysis, which only removes drugs from blood.  
For instance, heparin is mainly confined to blood, has a Vd of 0.06 L/kg, and can be 
removed by haemodialysis.  Conversely, the antidepressant nortriptyline has a Vd of 14 
L/kg, due to tissue binding outside of the blood stream, and cannot be removed by 
haemodialysis.  Unfortunately, most lipid soluble drugs e.g. amiodarone have high volumes 
of distribution, due to accumulation in fat tissues, and cannot be removed by haemodialysis. 
 
2.3. Drug Metabolism 
 2.3.1 Introduction 
As we discussed previously (Section 2.2), absorption from the gastrointestinal tract is best for 
lipid soluble drugs.  Lipid soluble drugs are also readily reabsorbed from the kidney tubule.  
Thus, lipid soluble drugs are difficult to get rid of, as even when they get into the kidney 
tubule, they are reabsorbed rather than excreted.  Water soluble compounds are readily 
excreted from the kidney.  Thus, for excretion of a drug, it is necessary to turn a lipid soluble 
drug into a water soluble (hydrophilic) drug, which can then be excreted in the urine.  This 
change from a lipid soluble to a water soluble compound involves metabolism, which usually 
has two phases, Phase I and II metabolism.  In addition to increasing water solubility, 
metabolism usually produces metabolites that are inactive, and thus reduces the activity of the 
drug. 
 
Our enzyme systems are not designed to metabolise drugs.  However, the normal 
physiological enzyme pathways for metabolism of endogenous compounds (substances found 
in the body) are used in drug metabolism.  The body also has systems for metabolising 
xenobiotics (substances foreign to the body), as part of the body’s defence system.  These 
xenobiotic metabolising enzymes are also used in drug metabolism. 
 
The liver is the main site of metabolism.  Because of this, drug metabolism is changed in 
hepatic insufficiency.  However, the liver is not the only site of drug metabolism.  In addition 
to the liver, metabolising enzymes are present in high concentrations in the intestine, nasal 
mucosa and lung, and these tissues are all capable of metabolising certain drugs.  Most of the 
discussion of metabolism in this chapter is of liver metabolism. 
 
 2.3.2 Phase I 
The first phase of metabolism is Phase I.  Phase I reactions involve common chemical 
reactions such as oxidation (interaction with an oxygen), reduction (interaction with a 
hydrogen), and hydrolysis (interacting with water).   
 
The liver has a huge number of metabolising enzymes.  The best characterised metabolic 
pathways are those catalysed by cytochromes, which are haem proteins.  The Cytochrome 
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P450 system (CYP) is a superfamily of distinct enzymes, known as CYP1, 2 and 3, with 
more than 50 haem-containing enzymes identified to date. The CYPs are found in the 
endoplasmic reticulum of the liver cell.   
  
One of the most important of the CYPs for drug metabolism is CYP3A4.  In this 
nomenclature for CYP3A4, 3 is for the family of enzyme, A for the subfamily, and 4 is the 
enzyme isoform (Figure 2.4).  
 
 
 
Figure 2.4 Cytochrome P450 families, sub-families and isoforms: CYP3A4 (Copyright QUT 
University, Sheila Doggrell) 
 
The classification of CYP enzymes into families, subfamilies and isoforms is based on the 
similarities of the genes encoding for them. CYP3A4 is the most abundantly expressed, and is 
involved in the metabolism of about 50% of clinically used drugs.  CYP2D6 and CYP2C8/9 
are also commonly involved in drug metabolism.  Drug interactions often occur at the level of 
these metabolising enzymes, and will be discussed in more detail in the section on drug 
interactions.  The levels of these enzymes are subject to induction and inhibition, and the 
activity of the enzymes may vary with a subject’s genetic makeup (see Chapter 11). 
 
  2.3.2.1 Induction 
When there is induction of an enzyme, there is an increased rate of metabolism of drugs by 
that enzyme, and this leads to a decreased plasma concentration of drug, so that it may 
become ineffective.  Lowering the concentration of a therapeutic drug may lead to it 
becoming ineffective.  For instance, hyperforin (a component of St John’s Wort), an over-
the-counter medicine for depression, induces CYP3A4.  Use of St John’s Wort can lead to the 
failure of oral contraceptives, which are metabolised by CYP3A4.  To avoid adverse effects, 
low doses of oral contraceptives are used to prevent conception.  When the metabolism of 
oral contraceptives is increased by St John’s Wort, the levels of the oral contraceptives may 
fall below those needed for contraception, resulting in pregnancy. 
 
Cigarette smoke and charboiled meats induce CYP1A, which is involved in the metabolism 
of paracetamol.  Thus, smokers will have lower plasma levels of paracetamol for the same 
dose as non-smokers.  Lowering the levels of paracetamol will lower the pain relief. 
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An example of autoinduction is alcohol, where chronic alcohol consumption induces the 
enzyme CYP2E1, which is involved in its metabolism.  This partly explains the tolerance to 
alcohol that develops with repeated administration, whereby the same dose of alcohol makes 
a alcohol-naïve person drunk, with little apparent effect on an alcoholic person, who has 
induced CYP2E1, and greater metabolism of alcohol.   
 
  2.3.2.2 Inhibition 
Conversely, the plasma levels of drugs may be increased when there is inhibition of 
enzymes.  Thus, inhibition of enzymes will lead to a decreased rate of metabolism, and 
increased plasma concentration of drugs.  Under these circumstances, a therapeutic drug may 
become a toxic drug.  It was recently discovered that components of grapefruit juice are 
potent inhibitors of CYP3A4, and this can lead to dangerously high levels of the many drugs 
that are normally metabolised by this enzyme.  Consequently, it is advisable not to take drugs 
at breakfast with a grapefruit or grapefruit juice, as this may lead to drug toxicity. 
 
Ketoconazole, a commonly used anti-fungal agent is a potent inhibitor of CYP3A4.  Thus, 
ketoconazole will increase the plasma concentrations of the drugs metabolised by this CYP, 
which includes the anti-HIV viral protease inhibitors.  The anti-HIV viral protease 
inhibitors have the potential to be quite toxic, especially if their levels are raised.   
 
 2.3.3 Phase II: Conjugation 
The second phase of drug metabolism is conjugation, which is a Phase I metabolite joining 
to another compound.  Conjugation is very important, as this is the phase that increases the 
water solubility of the drug, which is needed to allow excretion of the drug.  The conjugation 
substates are naturally occurring substances with the most common Phase II conjugation 
products being glucuronides and sulphates.  Glucuronic acid is a product of glucose 
metabolism, and conjugation with glucuronic acid forms glucuronide metabolites.  In 
addition to increasing water solubility, conjugation with glucuronic acid has another 
important function, it inactivates the drug.  This is because the glucuronide metabolites are 
inactivate. 
 
Some glucuronide metabolites are excreted by the kidney in the urine.  However, many 
glucuronide metabolites are transported in the bile to the gastrointestinal tract and undergo 
enterohepatic recycling (Figure 2.5).  In addition, some glucuronide metabolites are partly 
excreted from the kidney, and partly transported in the bile acid. 
 
Figure 2.5 Entero-hepatic recycling (Copyright QUT, Sheila Doggrell) 
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In enterohepatic recycling, Drug C arrives at the liver in the circulation.  The metabolism of 
Drug C involves conjugation with glucuronic acid to form Drug C glucuronide that is 
transported in the bile to the gastrointestinal tract.  Once in the gastrointestinal tract, some of 
the glucuronide is excreted in the faeces, and some of it may be deconjugated by the bacterial 
enzyme β-glucuronidase to yield back the active Drug C, that can be reabsorbed, and taken 
to the liver, with some of the active drug re-entering the circulation. 
 
Many glucuronides undergo this recycling, and this alters their kinetics (the relationship 
between plasma concentration and time).  The plasma levels may be higher than expected 
because the drug is being recycled.  To counter this, the dose of a drug may need lowering.   
An example of a drug that undergoes this recycling is glicazide, which is used in the 
treatment of type 2 diabetes.  As type 2 diabetes is very common among indigenous 
Australians, it was of interest to determine whether there were any genetic differences in the 
recycling of glicazide by Caucasians and indigenous Australians.  It was found that there is a 
slight difference, 30% of the dose in Caucasians is recycled compared to 20% in the 
indigenous group.  Theoretically, this means that for the same dose, the plasma levels could 
be lower in the indigenous group meaning the the glycaemic control might be slightly lower. 
 
When antibiotics are administered they kill the good as well as the bad (disease causing) 
bacteria.  By killing the good bacteria in gut, antibiotics inhibit bacterial enzyme β-
glucuronidase, which inhibits the enterohepatic recycling.  Without this recycling of a 
glucuronide, plasma drug levels may be lowered, and the drug may become ineffective.  For 
instance, oral contraceptives undergo enterohepatic recycling, and with antibiotic use, the 
plasma levels are reduced which may lead to the preparations providing less contraceptive 
benefit.  This could result in unplanned/unwanted pregnancy.. 
 
2.3.4 First pass metabolism and bioavailability 
The relationship between first pass metabolism and bioavailability has been discussed 
previously (Chapter 1), and is only discussed briefly here.  Drugs with extensive first pass 
liver metabolism have poor bioavailability after oral administration.  An example of a drug 
that undergoes extensive first pass liver metabolism is glyceryl trinitrate (nitroglycerin), 
which is used in the treatment of angina.  Due to this metabolism, glyceryl trinitrate has to be 
administered by other routes of administration.  Glyceryl trinitrate is used sublingually. 
 
When drugs have considerable first pass liver metabolism, but a proportion still gets to the 
systemic circulation, it may be possible to increase the dose of drug, to increase the amount 
of drug that reaches the systemic circulation.  This is the case with the painkillers morphine 
and pethidine.  Large doses of the anti-Parkinson’s drug L-dopa are also required to produce 
effective plasma levels of L-dopa. 
 
In liver disease, the metabolism of certain drugs may be inhibited, increasing bioavailability.  
With increased bioavailability, there will be increased effects of a drug.  Indeed the plasma 
levels maybe increased enough to cause toxic effects.  Thus, in liver disease, it may be 
necessary to decrease the doses of drugs metabolised by the liver.  
 
 2.3.5 Prodrugs 
Prodrugs are pharmacologically inactive drugs that have active metabolites.  They are 
designed so that the maximum amount of active drug reaches the relevant site of action to 
have the required pharmacodynamic effect.  An example of a prodrug is enalaprilat.  
Enalaprilat is a potent inhibitor of angiotensin converting enzyme (ACE), and ACE inhibitors 
27 
 
are commonly used in cardiovascular disease.  However, it would be pointless to administer 
enalaprilat orally, as it is not absorbed after oral administration.  To circumvent this, the 
pharmacological inactive prodrug enalapril is used.  Enalapril is absorbed and has an oral 
bioavailability of ~60%.  Enalapril is converted by esterases in the liver to enalaprilat, which 
is the beneficial ACE inhibitor.  
 
 2.3.6 Pharmacologically active metabolites 
Some drugs produce pharmacologically active metabolites.  Morphine is a 
pharmacologically active metabolite of heroin.  Morphine acts as an agonist at a particular 
binding site, the opioid μ-receptors, to cause pain relief.  Stimulation of the opioid μ-
receptors also underlies the euphoric effects of morphine, and gives its potential for abuse.  
When morphine is given orally, it undergoes extensive first pass liver metabolism, which 
lowers the concentration.  Morphine only enters the brain slowly.  Thus, only low 
concentrations reach the brain to have an effect. 
 
Heroin is diacetylmorphine, and is more lipid soluble than morphine.  Thus, heroin enters the 
brain more readily than morphine.  Once, in the brain, heroin is metabolised to morphine, 
which gives the pain relief and euphoria.  For the same dose, much higher levels of morphine 
in the brain can be obtained with heroin than morphine.  This is a key factor for opioid 
addicts, who prefer heroin to morphine as their drug of abuse. 
 
 2.3.7 Pharmacological toxic metabolites 
In addition to the metabolites of drug being therapeutic, metabolites may be toxic.  
Paracetamol is considered by many to be a relatively safe drug.  It is considered safe enough 
to be sold without a prescription.  Normally most of the paracetamol is conjugated and 
excreted in urine (Figure 2.6). 
 
Figure 2.6 Metabolism of paracetamol (Copyright QUT, Sheila Doggrell) 
 
However, a small amount of paracetamol is metabolised by the CYP enzyme system to 
NAPQI.  NAPQI is potentially very toxic to the liver.  Fortunately small amounts of NAPQI, 
in the presence of glutathione, are readily excreted in the urine.  Thus, normally, we do not 
observe toxicity with paracetamol.  However, when high doses of paracetamol are 
administered, the glutathione gets used up, NAPQI levels build up, and become toxic.  The 
main feature of paracetamol poisoning is liver failure.  Paracetamol poisoning will be 
discussed further under treatment of poisoning. 
 
2.4. Drug Elimination 
 2.4.1 Introduction 
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The most common way from administration of drug to elimination is by liver metabolism and 
kidney excretion (Figure 2.7).  After oral administration, drugs are taken from the 
gastrointestinal tract in the circulation for metabolism in the liver. 
 
Figure 2.7 Drug Elimination (Copyright QUT, Sheila Doggrell) 
 
Drugs administered by other routes (e.g. sublingual, via injection) also end up in the 
circulation being carried to the liver for metabolism.  After metabolism in the liver, the 
metabolites are carried in the circulation to the kidney for excretion in the urine.  A few drugs 
are excreted without metabolism.  Some drug metabolites are transported in the bile to the 
gastrointestinal tract, where they may be recycled or eliminated in the faeces. 
 
2.4.2 Kidney 
  2.4.2.1 Introduction 
The kidney is the most important site for excreting drugs.  Drugs are eliminated from the 
body either after conversion to metabolites that are excreted, or they are excreted unchanged. 
 
Kidney function and drug excretion varies with the life cycle.  When renal function is low or 
impaired, the excretion of drugs may be reduced, leading to a build up of drug and toxicity.  
For instance, renal function is low in the neonate but matures rapidly in the first few months.  
This means that neonates may need very small doses, even measured as per kilogram, 
compared to older people.  After maturation, kidney function declines about 1% per year in 
adulthood.  Thus, older-adults (≥ 65 years) may have functional kidney impairment, and 
require small doses of drugs that undergo excretion from the kidney than the doses used in 
younger adults.  
 
The first step in excretion from the kidney is glomerular filtration.  Drugs are delivered to the 
kidney in the blood stream, and free drug (water soluble or free fraction of lipid soluble 
drugs), with the exception of macromolecular substances (heparin), freely diffuse into 
glomerular filtrate.  Drugs bound to albumin (e.g. warfarin) are held back.  Free warfarin 
and most other drugs/drug metabolites are freely filterable.  Some drugs are actively secreted 
into the kidney tubules. 
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2.4.2.2 Secretion and Reabsorption 
In the adult there are about a million kidney tubules.  In these tubules, movement out of the 
tubule into the interstitial fluid, and, hence, to the blood is known as reabsorption.  Movement 
of substances into the tubules is known as secretion (Figure 2.8). 
 
Figure 2.8 Reabsorption and secretion from kidney tubule (Copyright QUT, Sheila Doggrell) 
 
Lipid soluble drugs are readily reabsorbed, so they will continue to be recycled back into 
circulation.  It is only when drugs are water soluble that they remain in the kidney tubule to 
be excreted. 
 
Endogenous compounds that are positively charged (choline, dopamine) are actively secreted 
into the proximal tubule using transporters.   Many positively charged drugs can be secreted 
on these transporters (e.g. ranitidine), and are excreted following active transport into the 
urine.  Similarly, endogenous compounds that are negatively charged are also secreted into 
the proximal tubule via transporters, and drugs can use this transporter.  Drugs secreted using 
this transporter include the ACE inhibitor captopril. 
 
The drug probenecid has two distinct actions on the kidney.  The first action is related to uric 
acid.  Uric acid (one of the body’s waste products) is actively reabsorbed from the kidney 
tubule, and an excessive accumulation of urate in the plasma leads to gout.  The pain of gout 
is due to crystals of urate in the joints.  Some drugs used to treat gout are known as uricosuric 
agents.  The uricosuric agents (e.g. probenecid) inhibit the reabsorption to promote the 
excretion of urate, and prevent the accumulation of urate in joints.  The second action of 
probenecid relates to penicillin levels.  Penicillin is rapidly eliminated from the body, as 90% 
of penicillin is secreted into the proximal tubule, and excreted.  Thus, after administration, the 
levels and effectiveness of penicillin declines rapidly.  However, this can be inhibited by 
probenecid.   Thus, probenecid can be used to increase and prolong the plasma levels of 
penicillin, to increase the effectiveness of penicillin. 
 
  2.4.2.3 Renal insufficiency 
In renal insufficiency, (e.g in neonates, and with age-related renal impairment), the duration 
of action of drugs excreted unchanged from the kidney is prolonged.  Examples of drugs 
30 
 
excreted unchanged by the kidney include the aminoglycoside antibiotics and digoxin.  The 
levels of these drugs may increase in renal insufficiency and produce toxicity.  Both of these 
drugs have a small therapeutic window, which means that the concentrations that cause 
toxicity effects are only slightly above the concentrations that cause a therapeutic effect. The 
toxicity with aminoglycosides includes ototoxicity (ringing in ears to deafness).  Digoxin is 
used to increase the force of the heart beat in heart failure, and has a small therapeutic 
window, with toxicity including cardiac arrhythmias.  When renal excretion is impaired, it 
may be necessary to decrease the dose of these drugs and/or increase the dose interval. 
 
Clearance is term given to the combination of metabolism and excretion of a drug.  When a 
drug is metabolised by the liver and the metabolite is excreted via thekidney, renal 
insufficiency can lead to increased plasma concentrations and adverse effects.  Thus, we need 
to lower doses when there is kidney insufficiency.  But how do we know when there is renal 
insufficiency? We assess kidney function.  
 
Kidney function is assessed from the creatinine clearance.  Creatinine clearance is the 
removal of creatinine from the body.  Creatinine is natural metabolite of creatine (found in 
muscle).  The properties that make creatinine ideal for assessing kidney function are that 
creatinine has a steady level in the blood and is freely filtered by the kidney.  Thus, with 
normal function, the plasma and urine levels of creatinine will be similar.  In kidney 
insufficiency plasma creatinine levels are increased, and urine levels are decreased. 
 
When creatinine clearance is inhibited, this indicates renal insufficiency, and that it may be 
necessary to decrease the dose of drug to avoid toxicity.  This can occur with morphine in 
renal insufficiency.  An important metabolite of morphine is morphine-6-glucuronide, 
which has similar pharmacological actions to morphine.  Morphine-6-glucuronide is excreted 
from kidney.  In renal insufficiency, morphine-6-glucuronide builds up and increases efficacy 
(pain relief).  Unfortunately, increased levels of morphine-6-glucuronide also lead to an 
increased likelihood of adverse effects, such as respiratory depression.  In elderly patients, 
lower doses of morphine are used partly to compensate for loss of kidney function  
 
 2.4.3 Other routes of excretion 
Anaesthetic gases are administered by inhalation, and are also excreted from the lung. 
 
Some drugs are excreted in breast milk, and the excreted drugs are a source of unwanted 
effects in the nursing infant.  For instance, morphine and other lipid soluble drugs are 
excreted in breast milk.  While it is best to avoid all drugs during breast feeding, there are 
some breast feeding women who need to take medications.  Epileptic mothers may have to 
continue their medication.  Some of the older anti-epileptic drugs e.g. diazepam, are known 
to get into breast milk and should be avoided during breast feeding.  There is little 
information about whether the newer agents get into breast milk, but it is considered that the 
levels are likely to be too low to have effects in the new-born. 
 
2.5. Blood levels 
 2.5.1 Introduction 
When using drugs as therapeutics, the aim is to produce a specific effect. In most cases, to 
achieve this it is necessary to get the drug into the plasma at concentrations high enough to 
produce the effect.  However, it is also important not to administer too much drug, as this 
could lead to a range of non-specific toxic effects.  As can be seen in Figure 2.9, the ideal 
plasma concentration range is between the minimum concentration required to be effective 
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(minimum effective concentration or MEC) and the concentration, above which toxic effects 
are seen (minimum toxic concentration).   
 
 
 
Figure 2.9 Minimum effective and toxic concentrations (Copyright Monash University, Liz 
Davies) 
 
Graphs are used to describe the relationship between blood levels of drugs over time.  From 
these graphs, we can learn things about drugs that help us to determine how to use them in 
people. 
 
2.5.2 Elimination half-life 
The elimination half-life is the time from the maximum concentration to half maximum 
concentration.  The elimination half-life is dependent on the rates of metabolism and 
elimination of the drug.  Thus, slowly metabolised and slowly eliminated drugs will have 
long half-lives.  Whereas, rapidly metabolised and rapidly eliminated drugs will have short 
half-lives.  The half-life is an important determinant of the frequency a drug needs to be 
administered.  Drugs with short half-lives need to be given more often than those with long 
half-lives. 
 
Provided there is a method for measuring the levels of the drug in the plasma, we can 
graphically plot the drug concentration against time (Figure 2.10). 
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Figure 2.10 Elimination half-life (Copyright QUT, Sheila Doggrell) 
 
In Figure 2.10, Drug A was administered intravenously, giving a maximum concentration 
straight away, and then the concentration diminishes over time, as the drug is metabolised 
and excreted.  The elimination half-life is the time from the maximum concentration to half 
maximum concentration.  Thus, we need to determine the 50% maximal response, and then 
determine the time from maximal to half-maximal response, which with Drug A is about 4.4 
hours.  Drug A will have to be administered at least 2 times a day, and maybe more, as it is 
rapidly metabolised and/or eliminated.   
 
Elimination half-lives can also be determined when drugs are administered orally.  When 
Drug B is administered orally, it has to be absorbed into the blood stream, so blood levels rise 
slowly over time to a maximum.  Once again, the elimination half-life is the time from the 
maximum concentration to half maximum concentration.  So we need to estimate the time of 
the maximal response, which is about 6.2 hours for Drug B.  The levels of Drug B have fallen 
to half-maximal after 13.4 hours.  Thus, the elimination half-life is 13.4 – 6.2 hours, which is 
7.2 hours.  Drug B may be suitable for administration 2 times a day or less, as it is less 
quickly metabolised and/or eliminated than Drug A 
 
 2.5.3 First and zero order kinetics 
Graphs of plasma levels against time, can also tell us about the kinetics of the metabolism of 
the drug (Figure 2.11). 
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Figure 2.12 Metabolism and Kinetics (Copyright QUT, Sheila Doggrell) 
 
With most drugs, there is a rapid fall in drug levels, as most drugs are readily metabolised, 
and there is an excess of enzyme available for the metabolism.  Thus, the enzyme never 
becomes saturated with drug.  This is known as first order kinetics (top, Figure 2.12).  In 
first order kinetics, increasing the concentration of the drug increases the metabolism of the 
drug.  First order kinetics is also observed with drugs that are eliminated unchanged. 
 
With some drugs there is a limited amount of enzyme available to metabolise the drug, and 
when that limit is reached, metabolism occurs at a constant rate.  Thus, the enzyme becomes 
saturated with drug.  This is known as zero order kinetics, and is seen as a straight line on 
the graph (bottom, Figure 2.10).  In zero order kinetics, increasing the concentration of drug 
above a certain point does not increase the rate of metabolism.  The best known example of 
zero order kinetics is alcohol.  There are no notable examples of therapeutic drugs that have 
saturable metabolism and zero order kinetics.  However, some therapeutic drugs taken in 
excess can have saturable kinetics.  Examples include aspirin and the anti-epileptic drug 
phenytoin. 
 
 2.5.4 Minimum effective and steady-state concentrations  
The Minimum Effective Concentration (MEC) is the minimum plasma concentration 
required for the drug to be effective.  When we use drugs, we want to use the appropriate 
dose and dosing interval to achieve plasma concentrations about the MEC to give an ongoing 
beneficial effect. 
 
The steady-state concentration is a reasonably even concentration achieved with repeat 
dosing or continued infusion, which gives a continued beneficial effect. 
 
 2.5.5 Maintenance doses and loading doses 
 
A maintenance dose is a small, fixed dose.  When you use maintenance doses, it may take 
long time to reach the minimum effective concentration, as the plasma concentration only 
slowly builds up to reach and then exceed the minimum effective concentration (top, Figure 
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2.12).  This is an inappropriate way to administer drugs in serious conditions or emergency 
situations, where you need the drug to be effective immediately. 
 
With some drugs, especially those with a large volume of distribution, it may be necessary to 
give a loading dose (a big dose) initially to get above the minimum effective concentration 
and get the beneficial effect quickly.  In such situations, a loading dose is used to reach the 
minimum effective concentration, and then maintenance doses are given to maintain the 
minimum effective concentration (bottom, Figure 2.11).  With a loading dose, the minimum 
effective concentration is reached much quicker than using the maintenance dose. 
 
Figure 2.12 Maintenance doses and loading dose (Copyright QUT, Sheila Doggrell) 
 
An example of a drug that is used with a loading dose and maintenance doses is the anti-
platelet drug clopidogrel.  Intravenous clopidogrel is given as a loading dose in percutaneous 
coronary intervention to prevent clotting straightaway, and this is followed by oral 
maintenance doses to prevent coagulation, as the subject recovers from the surgery. 
 
Steady-state concentrations are eventually reached with both maintenance and 
loading/maintenance dosing (Figure 2.12). 
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Drugs are used to have an effect on the body and, hopefully, this effect is beneficial.  The 
process of drugs altering things in the body is known as pharmacodynamics.  
Pharmacodynamics includes the mechanism of action of the drug, and the resulting actions in 
the body.  By knowing the mechanism of action of a drug, we can often predict the actions in 
the body, and the resulting clinical uses of a drug.  Also, by knowing the mechanism of a 
drug, we can often predict the adverse effects it will have. 
 
3.1. Pharmacodynamics – enzymes, ion channels, transporters and pumps 
3.1.1 Introduction to pharmacodynamics 
The two main branches of pharmacology are pharmacokinetics (“What the body does to the 
drug”) and pharmacodynamics (“What the drug does to the body”).  Drugs are administered 
to have a beneficial effect.  In order to have a beneficial effect, drugs need to cause changes 
in some of the body’s processes.  These can be a physiological, biochemical or pathological 
processes (Figure 3.1).   
 
 
Figure 3.1 Pharmacodynamics (Copyright QUT, Sheila Doggrell) 
 
The initial step in pharmacodynamics is the binding to distinct sites.  Although the body does 
not have any binding sites that were specifically designed for drug binding, it has lots of 
binding sites for endogenous compounds, and drugs can use these binding sites. 
 
3.1.2 Drug binding sites 
Enzymes have binding sites that are usually intended for substrates of that enzyme.  The 
substrate binds to the enzyme, the enzymatic reaction takes place, and a product is produced 
(Figure 3.2).  Drugs can also bind to these sites to have an effect (Figure 3.2).  Mostly drugs 
bind to enzymes to inhibit their actions.  Thus, the substrate cannot be turned into the 
product.  This may give a change in a biochemical process for a beneficial effect. 
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Figure 3.2 Drug and binding site on enzyme (Copyright QUT, Sheila Doggrell) 
 
Ion channels are pores in membrane that open and close to control the movement of ions, 
such as Na+, Ca2+, and K+, in and out of cells.  The movement of ions in and out of cells 
controls many physiological processes, and is regulated by binding sites.  Drugs can bind to 
these sites to enhance or inhibit the ionic movements (Figure 3.3). 
 
 
Figure 3.3 Drug and binding site on ion channel (Copyright QUT, Sheila Doggrell) 
 
Carriers can be divided into transporters and pumps.  Both of these carry endogenous 
substances across membranes.  Carriers have binding sites for their particular endogenous 
substance, and drugs may bind to this site, typically to inhibit the carrier (Figure 3.4).  For 
instance, if the activity of a carrier is enhanced in a pathological state, a drug can be used to 
inhibit the carrier to restore normal function. 
 
 
 
Figure 3.4 Drug and transporter (Copyright QUT, Sheila Doggrell) 
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Naturally occurring substances, such as neurotransmitters and hormone bind to specific 
receptive substances, which limits their effects to specific sites.  Over the years, specific 
receptive substance has been shortened to receptor.  Drugs can bind to receptors to have an 
action.  The binding can be considered to analogous to a key and lock (Figure 3.5).   
 
 
 
Figure 3.5 Neurotransmitter, hormone, keys and receptors (Copyright QUT, Sheila Doggrell) 
 
If the drug mimics the effect of the naturally occurring substance at the receptor, the drug is 
known as an agonist.  The key fits the lock, and opens the door.  If the drug prevents the 
action of the endogenous substance, the drug is known as an antagonist.  In this case, the key 
had fitted into the lock but has not opened the door, but has prevented any other keys getting 
into the lock. 
 
After a receptor is stimulated by an endogenous substance, some intracellular processes occur 
that lead to the final action.  These intracellular processes are known as cell signaling.  Drugs 
can combine with components of the cell signaling to either enhance or inhibit the cell 
signaling, and hence the final action.  Examples of drugs that use all these different binding 
sites are discussed in turn. 
 
The final actions of a drug depend on the distribution of the binding sites.  Although we 
give drugs to have a beneficial effect, they may also have detrimental effects.  Both 
pharmacological and toxicological actions of drugs are dependent on the use of binding sites.  
Some endogenous compounds (some enzymes and some neurotransmitters) are widely 
distributed and have widespread binding sites.  Consequently, a drug that uses such binding 
sites will have widespread effects, and these could include beneficial and detrimental effects.  
In contrast, some enzymes and hormones are localised, and have localised binding sites.  
Drugs that bind to localised sites will have a local effect that is, hopefully, beneficial without 
any widespread detrimental effects. 
 
Another thing that helps localise the effects of drugs, is that there are subtypes of receptors.  
For instance, the receptor for noradrenaline and adrenaline in the body was originally known 
as adrenoreceptors, and has been shortened to adrenoceptors over the years.  However, 
noradrenaline and adrenaline do not have identical effects in the body, some are the same, 
some are different, and the only way this can be explained is by subtypes of receptors, 
initially α- and β-adrenoceptors (Figure 3.6). 
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Figure 3.6 Subtypes of receptors (Copyright QUT, Sheila Doggrell) 
 
Further studies have shown that there are many adrenoceptor subtypes. Drugs that stimulate 
all the adrenoceptors will have widespread effects.  Drugs that select one adrenoceptor will 
have less widespread effects.  Noradrenaline and adrenaline stimulate all adrenoceptors to a 
certain degree, and have the potential to have widespread actions.  In contrast, drugs that 
select the subtypes, as selective agonists or selective antagonists may have localised actions.  
Selective means it has a greater effect at one receptor than others, it does not mean the drugs 
specifically stimulates one receptor. 
 
Although adrenoceptors are widespread, the lung has high amounts of one particular type of 
adrenoceptor, the 2-adrenoceptors.  Salbutamol is a selective 2-adrenoceptor agonist, and 
will have effects predominantly mediated by these receptor, including the 2-adrenoceptors of 
the lung.  Stimulation of the β2-adrenoceptors in the lung causes bronchodilation.  Thus, 
salbutamol is used as bronchodilator, which does not have all the other widespread effects 
observed with noradrenaline and adrenaline.   
 
Another example of this is the heart, which has high amounts of 1-adrenoceptors, and 
stimulation of the 1-adrenoceptors leads to an increase in heart rate and force.  Atenolol is 
a selective antagonist at 1-adrenoceptor, and acts to decrease heart rate and force, leading to 
a reduction in blood pressure.  Atenolol is used in the treatment of hypertension.  The effects 
of atenolol are predominantly limited to heart, and no widespread, potentially detrimental 
effects, are observed with atenolol.   
 
Receptors are not the only things that have subtypes.  There are subtypes of enzymes, ion 
channels, and carriers.  Drugs that selective one of the subtypes have more localised effects 
than drugs that do not differentiate between the subtypes. 
  
3.1.3 Enzymes 
Enzymes have binding sites, and these are targets for drugs; typical drugs that inhibit enzyme 
activity, and two examples of such drugs are discussed. 
 
3.1.3.1 Inhibition of acetylcholinesterase 
The first example is the drug neostigmine, which inhibits the enzyme acetylcholinesterase 
and is used in the treatment of myaesthenia gravis, an autoimmune disease.   
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To understand how the drug works, it is necessary to understand the physiology and 
pathophysiology at the neuromuscular junction.  Every time I contract the muscles in my arm, 
I am activating my somatic (or voluntary) nervous system to release the neurotransmitter 
acetylcholine, Ach (Figure 3.7). 
 
Figure 3.7 Neuromuscular junction – physiological (Copyright QUT, Sheila Doggrell) 
 
The released acetylcholine activates receptors for acetylcholine on the muscle.  Like 
noradrenaline, acetylcholine has receptor sub-types, and the ones on the muscle are called 
nicotinic, as they can be stimulated by nicotine.  Stimulation of the nicotinic receptors leads 
to muscle activity, the contraction of the muscles.  However, it is difficult to keep the 
muscles contracted, as the action of acetylcholine is very short lived.  This is because, there is 
an enzyme, acetylcholinesterase, lurking, which breaks the acetylcholine down to acetate 
and choline.  Thus, it is difficult to maintain a flexed arm. 
 
In myasthenia gravis, there is a loss of nicotinic receptors (Figure 3.8). 
 
Figure 3.8 Neuromuscular junction – myasthenia gravis (Copyright QUT, Sheila Doggrell) 
 
In myasthenia gravis, the nerves is working fine; it is still releasing acetylcholine, and the 
acetylcholine is still being broken down.  However, as there are reduced nicotinic receptors, 
there is reduced muscle activity.  The drug used to treat myasthenia gravis is neostigmine, 
which inhibits acetylcholinesterase to prevent the breakdown of acetylcholine (Figure 3.9). 
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Figure 3.9 Neostigmine in myasthenia gravis (Copyright QUT, Sheila 
Doggrell) 
 
Inhibiting the breakdown of acetylcholine, leads to a build up in the concentration of 
acetylcholine in the synapse, and this causes more stimulation of the existing nicotinic 
receptors.  The build up of acetylcholine, in the absence of acetylcholinesterase, means that 
the acetylcholine can diffuse further without breakdown to reach other nicotinic receptors.  
This restores muscular activity in myasthenia gravis.  Myasthenia gravis is a rare disease, but 
drugs that act as enzyme inhibitors are also used in common disorders. 
 
3.1.3.2 Inhibition of cyclooxygenase 
For instance, cyclooxygenase is an enzyme involved in pain and fever, and the 
cyclooxygenase inhibitor paracetamol is used in the treatment of pain and fever.  Normally, 
we have low levels of free arachidonic acid as it is mostly stored as a component of the cell 
membrane (Figure 3.10). 
 
Figure 3.10 Activation of cyclooxygenase (Copyright QUT, Sheila Doggrell) 
 
Many stimuli, including bacterial infection can reverse this to cause the release of arachidonic 
acid (Figure 3.10).  Once released, arachidonic acid is readily metabolised to prostaglandins, 
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in the presence of the widespread enzyme cyclooxygenase.  The prostaglandins are mediators 
of pain and fever. 
 
Paracetamol is a cyclooxygenase inhibitor (Figure 3.11). 
 
Figure 3.11 Mechanism of action of paracetamol 
 
Inhibition of the enzyme cyclooxygenase with paracetamol leads to reduced levels of 
prostaglandins, and consequently of the pain and fever mediated by prostaglandins. 
 
3.1.4 Ion channels 
 3.1.4.1 Introduction 
The second target for drug binding is ion channels.  Ion channels are protein pores (hole) in 
the lipid membrane that can be opened or closed, similar to a gate that can be opened or 
closed.  When an ion channel is closed, there is no ion transfer across the membrane.  In 
contrast, when the ion channel is open, the opening is small and only allows ions to flow.  
When the channel is open, ions flow down their concentration gradient.  The movement of 
ions underlies many physiological processes.  Ion channels are specific for a species of ions 
(Na+ channels, K+ channels, Ca2+ channels), and there are also subtypes of ion channels.  Ion 
channels have binding sites on them that drugs can use to inhibit or enhance the movement of 
ions, to alter the physiological function of the ion channel. 
 
3.1.4.2 Inhibition of sodium channels 
A good example of how inhibiting a channel can change function is the blockage of sodium 
channels with local anaesthetics e.g. lignocaine.  When you have tissue damage, the afferent 
nerves are activated and a message is sent along the afferent (sensory) nerves to the brain, 
which originates the feeling of pain (Figure 3.12). 
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Figure 3.12 Na+ channels and lignocaine (Copyright QUT, Sheila Doggrell) 
 
The pain message is carried along the nerve as part of the wave form known as the action 
potential.  The upstroke or depolarization phase of the action potential is due to sodium 
entering the nerve cell.  Na+ channel blockers, like lignocaine, block the Na+ channels, so 
there are no longer action potentials, and without this messenger there is no pain. 
 
3.1.5 Transporters 
  3.1.5.1 Introduction 
Another target at which drugs can bind as the first step in pharmacodynamics is carriers, such 
as transporters and pumps.  A transporter is like a bus, the endogenous compound hops on at 
one site (A) and is transported across a membrane to another site (B), where it hops off 
(Figure 3.13).  Transporters are involved in both pharmacokinetics and pharmacodynamics.  
Thus, in drug absorption, transporters are used to transport certain drugs across the 
membrane.  Thus, if Drug C has a similar structure to the endogenous compound, it may be 
transported across the membrane.  With pharmacodynamics, we often use drugs to inhibit the 
transport of endogenous compound.  Thus, Drug D binds to the transporter, but is not 
transported.  However, by binding to the transporter, Drug D prevents the endogenous 
compound from being transported. 
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Figure 3.13 Drugs and transporters (Copyright QUT University, Sheila 
Doggrell) 
 
3.1.5.2 Inhibition of the serotonin transporter 
An important group of drugs that inhibit transporters are the antidepressants.  The 
biochemical cause of depression may be abnormal function of the neurotransmitters in the 
brain.  One of the main neurotransmitters implicated in depression is 5-hydroxytryptamine 
(5-HT), which is also known as serotonin.  One thing we do know about depression is that 
there is long-term effectiveness in depression of drugs that increase the levels of 5-HT in the 
brain. Inhibitors of the 5-HT transporter increase the levels of 5-HT in the synapses of the 
brain.   
 
To understand how this works, we first need to review the physiological process.  On 
activation of the nerve terminal, 5-HT is released, and then stimulates 5-HT receptors to have 
an effect (Figure 3.14).   
 
Figure 3.14 SERT transporter 
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The action of 5-HT is short lived, as it is rapidly inactivated.  The 5-hydroxytryptamine (5-
HT) is inactivated by transport back into the neurone, on a transporter that is selective for 5-
HT, the SERT (the SERotonin Transporter).  When it is stored in nerve endings, with no 
access to its receptors, the 5-HT is inactive.  SERT is inhibited by Prozac (Fluoxetine).  This 
inhibits inactivation of 5-HT, and increases the levels of 5-HT in the synapse, with increased 
stimulation of receptor, and an increased effect. It takes a bit of time, but eventually raising 
the levels of 5-HT in the brain synapses has an antidepressant effect. 
 
 3.1.6 Pumps 
In addition to transporters, another form of carrier is a pump, which often actively pumps 
endogenous compounds from one site to another.  
 
  3.1.6.1 Inhibition of the proton pumps 
Probably, the best characterised pump is the proton pump.  Acid secretion, via the proton 
pump, in the stomach is required for normal digestion.  Dyspepsia (excessive acid secretion) 
is caused by bad cooking, overindulgence and anxiety, and can lead to acid-peptic disease.  In 
acid-peptic disease there is an imbalance between the aggressive factors of the disease, which 
are the acid, pepsin, and the bacteria Helicobacter pylori, and the protective factors, such as 
bicarbonate, mucus, and prostaglandins.  One way to restore the balance is to decrease the 
aggressive acid.   
 
The proton pump is present on the parietal cells of the stomach, and is driven by the activity 
of an enzyme H+/K+ ATP-ase (Figure 3.15). 
 
Figure 3.15 The proton pump (Copyright QUT, Sheila Doggrell) 
 
The proton pump is stimulated by histamine, gastrin and acetylcholine.  Regardless of what is 
stimulating the pump, the pump is inhibited by proton pump inhibitors (PPIs).  This makes 
PPIs the most effective inhibitors of acid secretion.  Omeprazole is the prototype PPI. There 
are other drugs that have names ending with prazole, and these are all PPIs.   
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The pharmacokinetic properties of the PPIs are interesting.  They are prodrugs, requiring 
activation in an acidic environment.  The only very acidic environment in the body is the 
stomach, and this is where the prazoles are activated, and this limits their action to the site, 
where they are required to act.  Thus, there are no widespread unwanted effects with the PPIs. 
 
 
 
3.2. Pharmacodynamics – receptors and cell signaling  
3.2.1 Receptors 
One of the most important targets for drug binding is receptors.  These were originally known 
as specific receptive substance, which is a good description of what they do, they are 
specific receptive substance for individual endogenous compounds.  Over the years, this has 
been shortened to receptors.  There are receptors for many endogenous compounds, 
including hormones (endocrine and local), neurotransmitters, and growth factors.  Each 
receptor is specific for one endogenous compound, which is also known as the endogenous 
regulatory ligand, with endogenous meaning contained within body/physiological, and ligand 
meaning a naturally occurring substance that binds to receptor. 
 
Drugs that bind to receptors are either agonists or antagonists.  Agonists usually mimic the 
effect of the endogenous ligand.  In contrast, antagonists usually prevent the effect of the 
endogenous ligand. There are two main types of receptors.  The first involves G-protein-
coupled receptor (GPCR) signaling, and these are cell surface receptors that cross the cell 
membrane.  Endogenous substance binds to the receptor on the outside of the cell to cause a 
change inside the cell, which is the first step in the cell signaling leading to an effect.  GPCR 
signaling happens quickly (second/minutes), and is over quickly. For an ongoing effect, 
repeated stimulation of the receptor is needed.   
 
The second type of receptors is receptors regulating nuclear transcription.  To reach 
nuclear receptors, the endogenous compound must be able to cross the cell membrane. With 
nuclear receptors, the endogenous regulatory ligand binds to intracellular receptors, and the 
combination moves to the nucleus, and activates the first step in cell signaling leading to 
production of proteins.  Protein synthesis requires some time, so this type of receptor 
activation is slower, and has a longer time course.  Examples of these receptor types are 
discussed next. 
 
  3.2.1.1 G-protein coupled receptors 
Adrenaline is a hormone released from adrenal medulla that has widespread effects including 
stimulating bronchial GPC 2-adrenoceptors to induce bronchodilation via cell-signaling 
involving adenylate cyclise (Figure 3.16). 
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Figure 3.16 GPCR – β2-adrenoceptor 
 
The β2-adrenoceptor spans the membrane.  This allows the adrenaline, which does not enter 
the cell, to talk to the inside of the cell.  The G proteins are so named as they require GTP 
(guanosine triphosphate) for action.  There are lots of different G proteins.  The one linked to 
the β2-adrenoceptor is stimulatory G-protein (Gs), and amplifies the message, leading to 
stimulation of a membrane bound enzyme, adenylate cyclase, which catalyses the conversion 
of ATP (adenosine triphosphate) to cAMP, which eventually leads to relaxation of the 
bronchial muscle, bronchodilation.   
 
Salbutamol is a selective agonist at β2-adrenoceptor.  Salbutamol does not mimic all the 
effects of adrenaline, just those mediated by β2-adrenoceptor.  This leads to the relaxation of 
bronchial smooth muscle, and salbutamol is used as a bronchodilator in asthma. 
 
3.2.1.2 Intracellular receptors 
An example of an intracellular receptor is the receptors for the glucocorticoids, which are the 
steroids produced by the adrenal cortex.  The physiological glucocorticoids, such as 
hydrocortisone (H) diffuse into cells.  The cells that are regulated by glucocorticoids have 
intracellular receptors (R) for glucocorticoids.  Stimulation of intracellular receptors leads 
to transcription of target genes (Tr), which modulate the proteins made be the cell (Figure 
3.17). 
 
Figure 3.17 Intracellular receptors (Copyright QUT, Sheila Doggrell) 
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The physiological action of the glucocorticoids that pharmacologists are particular interested 
in is their anti-inflammatory actions.  These are not very pronounced with the physiological 
glucocorticoids, but changes to the glucocorticoid structure have produced more potent anti-
inflammatory agents.  Beclomethasone is a potent synthetic glucocorticoid that mimics the 
effects of hydrocortisone.  Beclomethasone is used as an anti-inflammatory agent in the 
treatment of asthma, where it is used to decrease the inflammation and reduce the likelihood 
of having an asthma attack. 
 
 3.2.2 Agonism 
3.2.2.1 Introduction to agonism and antagonism 
Salbutamol and beclomethasone are agonists at different receptor types.  Drugs that act at 
receptors can be either agonists or antagonists.  Two properties are used to characterize 
agonists and antagonists.  These are affinity and efficacy.  Affinity is the attraction of the 
drug for the receptor.  If a drug has high affinity, low concentrations of the drug bind to the 
receptor.  If a drug has low affinity, high concentrations of the drug are required to get any 
binding to the receptor.  If the drug has no affinity, no concentrations of the drug bind to the 
receptor.  The best drugs are the ones that have high affinity for their target receptor to 
initiate a beneficial effect, and little or no affinity for other receptors, so that they have as few 
unwanted effects as possible.  Both agonists and antagonists have affinity. 
 
Efficacy is also known as intrinsic activity or effect.   If a drug binds to receptor and has no 
effect, it has an efficacy of zero.  If a drug binds to receptor and, at the higher concentrations, 
can have the same maximum effect as the endogenous compound, it has an efficacy of 1.  
Agonists have efficacy, antagonists do not. 
 
To reiterate, agonists have affinity and efficacy (i.e. binds to receptor and have an effect) 
whereas antagonist has affinity but no efficacy (i.e. binds to receptor but does not have an 
effect alone).  Although receptor antagonists have no effects, they are important drugs as their 
binding prevents the binding of the endogenous compound and its effects. 
 
  3.2.2.2 Full and partial agonism 
There are several types of agonism including full, and partial agonism, which are best 
understood from graphs.  In a graph of effect against long agonist concentration, a full 
agonist gives the same maximum response as the endogenous ligand, and has a nominally 
efficacy of 1 (Figure 3.18). 
 
Figure 3.18 Full and partial agonist (Copyright QUT, Sheila Doggrell) 
 
A partial agonist has a smaller maximum effect than the endogenous ligand or full agonist, 
and has an efficacy less than 1. 
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An example of a partial agonist is buprenorphine.   Morphine stimulates opioid -receptors 
to induce analgesia, but another effect mediated by opioid -receptors is respiratory 
depression, which can occur with the higher concentrations of morphine.  Indeed, respiratory 
depression is a common side effect associated with full agonists at opioid -receptors.  
Buprenorphine is a partial agonist at opioid -receptors.  Buprenorphine causes analgesia but, 
as it has a lesser maximum effect; it is unlikely to cause any excessive respiratory depression.  
This means that buprenorphine can be a safer drug than morphine to use. 
 
3.2.2.3 Potency and selectivity of agonist 
Potency and selectivity are two other properties of agonists that are important in determining 
whether they will useful clinically.  Potency is measured as the half-maximal response to the 
drug being tested.  The parameter is known as the EC50, the concentration of agonist that 
causes have maximal response.  From the graph, the maximal response is determined, and for 
50% of that, the EC50 value is read off (Figure 3.19). 
 
Figure 3.19 Measuring agonist potency (Copyright QUT, Sheila Doggrell) 
 
Regardless of whether the agonist is a full agonist or a partial agonist, EC50 values are 
measured at half the maximal response to the agonist.  The lower the EC50 value, the more 
potent the agonist is.  In the Figure 8.5, the full agonist is more potent than the partial agonist, 
but it is possible to have partial agonists that are more potent than full agonists.  Clinically, 
potent agonists are usually preferable, especially if they are also selective. 
 
A drug that has a greater potency at receptor A than receptor B, is selective for receptor A, 
but is still capable of having effect at receptor B.  A drug that is potent at receptor A and has 
no effect at other receptors would be specific for receptor A, and would not be capable of 
having effects at other receptors.  Drugs are usually selective not specific. 
 
Potency and selectivity go hand in hand, and can be illustrated by comparing noradrenaline 
and isoprenaline.  Noradrenaline, the neurotransmitter released from the sympathetic 
nervous system, acts on cardiac 1-adrenoceptors to increase heart rate.  Isoprenaline is a 
synthetic drug that has a similar structure to noradrenaline. On the cardiac 1-adrenoceptors, 
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isoprenaline is more potent (has a lower EC50) value than noradrenaline (Figure 3.20). 
 
Figure 3.20 Potency and selectivity at β1-adrenoceptors (Copyright QUT, Sheila Doggrell). 
 
Noradrenaline released from the sympathetic nervous system, also acts on vascular 1-
adrenoceptors to cause vasoconstriction.  At the vascular 1-adrenoceptors, isoprenaline is 
much less potent (has a higher EC50) value than noradrenaline (Figure 3.21). 
 
Figure 3.21 Potency and selectivity at α1-adrenoceptos 
 
Taken together, these graphs show that noradrenaline does not select, but isoprenaline is 
selective for 1- over 1-adrenoceptors.  Thus, if we want to selectively mimic the effects 
of noradrenaline at 1-adrenoceptors, it is better to use isoprenaline than noradrenaline, as 
noradrenaline will have effects elsewhere, which could be detrimental effects. 
 
3.2.3 Cell signaling 
Another potential target for drug binding is cell signaling.  When endogenous compounds 
bind to receptors, they initiate cell signaling that leads to the final action of the endogenous 
compound.  Drugs can bind to elements of the cell signaling to enhance or inhibit this 
process.  An example is with cell signaling on bronchial smooth muscle.  Adrenaline is the 
ligand for the β2-adrenoceptor, and when adrenaline is bound to the receptor, signaling 
involves activation of adenylyl cyclase (AC) to increase the levels of intracellular cAMP.  
There is more cell signaling, which eventually leads to relaxation of smooth muscle 
(bronchodilation) (Figure 3.22). 
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Figure 3.22 Cell signaling (Copyright QUT, Sheila Doggrell) 
 
The effect of adrenaline stimulation is short-lived, as the action is terminated by the 
breakdown of cAMP in the presence of the intracellular enzyme phosphodiesterase.  
Theophylline is a drug that modifies this cell signaling.  The mechanism of action of 
theophylline is to inhibit the phosphodiesterase.  The resulting effects is an increased 
concentration of cAMP and, as cAMP levels dictate the degree of relaxation, increased 
relaxation of smooth muscle.  The clinical use of theophylline is as a bronchodilator in 
bronchial asthma. 
 
 3.2.4 Antagonism 
  3.2.4.1 Competitive reversible 
In addition to acting at receptors to mimic the effects of endogenous compounds and initiate 
cell signaling, drugs can act at receptors as antagonist.  Receptor antagonists have affinity, 
but not efficacy; they have no effect on their own.  The most common type of receptor 
antagonism is competitive reversible.  Endogenous compounds and agonists (Ag) have 
readily reversible (electrostatic) binding to receptor (Figure 3.23). 
 
Figure 3.23 Competitive reversible antagonism I (Copyright QUT, Sheila Doggrell) 
 
Competitive reversible antagonists have readily reversible binding to same site on receptor as 
the agonist.  Increasing the concentration of the antagonist, decreases the concentration of the 
agonist bound to the receptor, and the resulting effect.  Importantly, the effects of a 
competitive reversible antagonist can be overcome by increasing the concentration of the 
agonist, and this is useful in poisoning. 
 
Atenolol is an example of a competitive reversible antagonist.  Atenolol is a competitive 
reversible antagonist at 1-adrenoceptors, which means it has no effect alone (Figure 3.24).  
However, atenolol decreases the amount of noradrenaline (NA) bound to receptors, and this 
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decreases the effect of noradrenaline.  On the heart, noradrenaline increases heart rate and 
force, and for any concentration of noradrenaline, atenolol will decrease the ability of 
noradrenaline to increase heart rate and force (Figure 3.24).   
 
Figure 3.24 Competitive reversible antagonism II (Copyright QUT, Sheila Doggrell) 
 
The graph shows that the higher the concentration of atenolol, the greater the inhibition of the 
response to noradrenaline.  Atenolol causes a parallel rightward shift of the noradrenaline 
concentration response, but if you add enough noradrenaline, a maximum response is 
obtained.  Atenolol is used clinically as an anti-hypertensive drug. 
 
  3.2.4.2 Functional 
Another type of antagonism is functional antagonism.  As always, the endogenous 
compounds and agonists (Ag) have readily reversible (electrostatic) binding to receptor 
(Figure 3.25).  The functional antagonist binds at site other than the receptor for the 
endogenous compound to inhibit the response.  This site could be the ion channel opened by 
stimulation of the receptor. 
 
Figure 3.25 Functional antagonism I (Copyright QUT, Sheila Doggrell) 
 
An example of a functional antagonist is verapamil.  Verapamil is a Ca2+ channel blocker, 
and as such, a functional antagonist of responses mediated by cardiac 1-adrenoceptors.  
Activation of cardiac 1-adrenoceptors with noradrenaline leads to the opening of calcium 
channels, and an increase in intracellular calcium increases heart rate.  Verapamil reduces 
noradrenaline-induced increases in heart rate (Figure 3.26).  Graphically, with a functional 
antagonist, there is a non-parallel rightward shift of the concentration-response curves, often 
with a depression of the maximal response to the agonist. 
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Figure 3.26 Functional antagonism II (Copyright QUT, Sheila Doggrell) 
 
Verapamil is used clinically to treat an overactive pacemaker. 
 
3.2.5 Anti-cancer drugs 
 
Anti-cancers drugs used to all be cytotoxic drugs, which mean they kill cells.  Unfortunately, 
this means that cytotoxic drugs kill normal cells as well as cancer cells, and the killing of 
normal cells will lead to adverse effects.   
 
  3.2.5.1 Cytotoxic anti-cancer drugs 
One of the characteristics, of cancers cells, is that they are very rapidly dividing, compared to 
most normal cells.  In the G1 phase of the cell cycle cells grow, and then in the S phase there 
is replication of the DNA.  After replication of the DNA, cells go through the G2 phase were 
they are preparing to divide.  The division is called mitosis (M), and you end up with 2 cells.  
Any drug that interferes with this cell cycle will reduce the generation of new cells, including 
cancer cells. 
 
Probably one of the best known cytotoxic drugs is cyclophosphamide.  Cyclophosphamide 
inhibits the cell cycle by preventing the production of RNA for the new cell.  
Cyclophosphamide is used in a variety of cancers, including leukemia and lymphoma.  As a 
cytotoxic drug, cyclophosphamide causes lots of adverse effects.  Severe bone marrow 
suppression can occur 1-2 weeks after treatment.  Cyclophosphamide can also cause anaemia 
and thrombocytopenia, and haemorrhagic cystitis.  Indeed the adverse effects with 
cyclophosphamide and other cytotoxic drugs are endless.  Cyclophosphamide can also cause 
nephrotoxicity, nausea and vomiting, gastrointestinal dysfunction, hair loss, impaired wound 
healing, darkening of skin, gonadal suppression (missed menstrual periods), cardiotoxicity 
etc. 
 
Thus, it is obvious that cytotoxic drugs are not the ideal anti-cancer drugs, and that it would 
be better to have drugs that killed the cancer cells but not the normal drugs.  This led to the 
idea of targeted anti-cancer drugs. 
 
3.2.5.2 Targeted anticancer drugs 
Targeted cancer medicines block the growth and spread of cancer by interfering with 
SPECIFIC molecules/cells involved in tumor growth and progression.  Why is this 
important?  Firstly, the drug maybe more effective, as it is will be preferentially killing the 
cancer cells.  Secondly, the drug may have less severe side effects if it is not killing all the 
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normal cells.  Most importantly, it is possible that we can get a cure with some of the specific 
drugs 
 
One targeted approach is similar to a mechanism we have already discussed – enzyme 
inhibition. An activated enzyme, tyrosine kinase Bcr-Abl, underlies chronic myeloid 
leukemia.  Thus, the obvious treatment for chronic myeloid leukemia is to inhibit the tyrosine 
kinase Bcr-Abl.  This can be done with imatinib (Gleevec).  With imatinib, the response rate 
is about 70%, which means they get better, and if these subjects continue to take imatinib for 
several years, many are cured. 
Unfortunately, despite being developed to target an enzyme associated with the cancer, it 
does not mean that it is specific for that enzyme.  Thus, adverse effects do occur with 
imatinib, and these include gastrointestinal (pain, diarrhoea, nausea), fatigue, headache, and 
cardiotoxicity. 
 
Another approach to targeted anti-cancer drugs is monoclonal antibodies.  Monoclonal 
antibodies are similar to the endogenous antibodies produced by the body’s immune system 
to fight off bacteria and viruses.  They are made to specifically target and block a substance 
in the body or a specific cell type e.g. something specific to the cancer. 
 
Tumours need to have blood vessels in them to survive i.e. all cells need oxygen and nutrients 
delivered by blood vessels to function.  Vascular Endothelial Growth Factor A (VEGF-A) is 
required for blood vessel growth in tumours. Bevacizumab is a monoclonal antibody to 
VEGF-A which is used to prevent blood vessels developing in cancerous tumours.  
Bevacizumab is used in the treatment of colorectal, breast, renal and non-small cell lung 
cancers, especially in metastases.  Many of the common adverse effects are cardiovascular 
and may be related to inhibiting blood vessel growth as it will inhibit the growth of all blood 
vessels, not just those in tumours.  
 
Trastuzumab is a monoclonal antibody to the HER2/neu receptor that is overexpressed in 
some breast cancer.  HER2 receptor overexpression leads to the rapid growth of breast cancer 
cells.  Trastuzumab improves survival in late-stage/metastatic HER2-positive breast cancers, 
but it does also have side effects.  Thus, trastuzumab is contraindicated in subjects with heart 
failure, and cardiac dysfunction is a major problem with the use of trastuzumab.   
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4. Drug development 
From some of the sensational reporting about medicines, you might expect medicine 
development to be haphazard with little regard for the safety of animals or humans.  This is 
not in fact the case.  Drug development is precisely regulated and has regard for animals and 
humans.  A general understanding of the processes of drug development should dispel many 
myths about drug development.  
 
Why are drugs developed?  Drugs are developed so that we can turn fatal or non-fatal 
diseases into a routine therapeutic exercise.  For instances, before the development of anti-
hypertensive drugs, hypertension was a fatal disease with people dying in a year or two of 
developing high blood pressure.  Now, millions of people with hypertension are successfully 
managed long term with anti-hypertensive drugs. 
 
Drug development is divided into preclinical and clinical drug development. 
 
 4.1 Preclinical drug discovery 
Preclinical drug discovery is the process before clinical testing of drugs.  The first step in 
preclinical drug development is the discovery or synthesis of a new drug.  At least, 10,000 
new molecules are discovered/synthesized for each successful new drug introduced.  
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Extensive preclinical safety and efficacy testing of new drugs are required in animals, and 
this takes an average of 1.5-3 years.    
 
There are three main ways in which new drugs are derived; chemical modification, rationale 
drug design, and random screening (Figure 4.1).  Serendipity (accidental discovery of 
something fortunate) may also have a role in drug development. 
 
 
Figure 4.1 Three methods of drug discovery 
 
An important group of drugs that were made by chemical modification were the diuretics.   
However, the initial step was serendipity; an observant physician noticed that sulfanilamide 
(antibiotic) caused a sodium bicarbonate diuresis the loss of sodium, bicarbonate and water 
from the kidney.  Thus, it was reasoned that a sulphanilamide-like drug could be made that 
promoted water loss from the body.  After a string of chemical modification, chlorothiazide 
was synthesised.  Chlorothiazide increases sodium chloride and water excretion.  Further 
modification of the structure of chlorothiazide led to the discovery of frusemide, which is a 
very potent diuretic.  The thiazide diuretics, such as chlorothiazide, and frusemide are 
commonly used in the treatment of hypertension and heart failure to promote water loss. 
 
The second method for drug discovery is rationale drug design, and we will consider a new 
example of this (zanamivir – Relenza).   
 
Rationale drug design usually includes computer design, which is known as in silico.  A 
computer model is made of the site that you want the drug to bind to, and then of the drug 
with best fit for binding.  Then the chemical is synthesised, and then tested pharmacologically 
to determine, whether the chemicals do as predicted.  A drug that was developed in this way 
is zamanivir (Relenza).  Zamanivir can prevent or shorten the flu, which is a virus.  
Neuramidinase is an enzyme involved in viral replication, and the structure of this enzyme 
has been determined.  The structure shows a pocket, where we may be able to get a drug in to 
inhibit the enzyme.  Zamanivir binds in the pocket to inhibit the activity of neuramidinase, 
and consequently the replication of the flu virus. 
 
A third approach to drug discovery is random screening.  This uses high-throughput 
screening managed by robotics.  There is random screening for biological activity.  For 
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instance, if you wanted to develop a H2-receptor antagonist the chemicals would be screened 
for activity at H2-receptors.  The screening may be of banks of previously discovered 
chemicals, or of natural products, or of libraries of peptides and nucleic acids. 
 
 4.2 Pharmacological profiling 
Once a lead compound has been discovered (e.g. a drug with activity at a certain biding site), 
the compound undergoes pharmacological profiling.  A large number of experiments are 
undertaken, mainly using animals, to determine the pharmacodynamics and pharmacokinetics 
of the drug.  Questions asked include; Does the drug do what we expect?  Does it do anything 
else?  Is it active after oral administration?  The initial profiling usually depends on the 
pharmacological goal e.g. anti-infectives will be tested against infectious organisms.  Anti-
diabetic drugs will be tested for their ability to lower blood glucose in animal models of 
diabetes. 
 
 4.3 Safety and toxicity 
New drugs undergo extensive safety and toxicity testing in animals.  This testing was 
increased after the thalidomide disaster.  Thalidomide was developed as a hypnotic 
(calming) and anti-emetic drug in the 1950s.  It was used as a hypnotic and extensively to 
prevent morning sickness.  For severe morning sickness, it was more beneficial than any 
other drugs available at the time.  Limited toxicity testing in rats had suggested it was safe in 
pregnancy.  To women who took thalidomide during pregnancy, 10,000 children were born 
with phocomelia, which is the absence of arms or legs with hands or feet attached to body 
trunk.  Obviously, when it was shown that thalidomide was the causative agent, it was 
withdrawn and litigation followed, costing the pharmaceutical company responsible to pay 
millions in compensation. 
 
What was learnt from the thalidomide disaster?  The animal rights movement claimed that the 
thalidomide disaster showed that the testing of drugs in animals was not predictive of toxicity 
in humans, and should be abandoned.  Toxicity testing should be in humans. 
 
There is another interpretation.  Birth defects are rare in rats.  Rats are more likely to reabsorb 
defective foeti.  Closer analysis of toxicity testing of thalidomide showed lower litter 
numbers, which probably indicated the potential to cause birth defects in humans.  More 
extensive toxicity in animals probably would have prevented the thalidomide tragedy.  More 
extensive toxicity in animals is now undertaken. 
 
This preclinical safety and toxicity testing takes two to five years, and involves the collection 
and analysis of lots of data.  This testing is closely supervised by an independent Animal 
Ethics Committee that works to minimise the number of animals used, and the harm done to 
animals.  Acute toxicity of single doses and chronic toxicity of repeated doses of drugs is 
often tested on mice.  The effects of drugs on reproductive function and teratogenicity (ability 
to cause birth defects) are tested in a variety of animal species.  For drugs that are going to be 
used long term in chronic illness, the carcinogenic potential has to be tested in animals 
longterm.  Mutagenic potential is undertaken in bacteria. 
 
 4.4 Clinical trials – introduction 
At some stage in the drug development procedure, a drug patent has to be applied for, to 
protect your discovery from other companies.  Patents are valid for 15-17 years.  During the 
patent, all monies made by that drug are returned to the pharmaceutical company that 
invested in the development.  However as preclinical testing takes on average 1.5 to 5 years, 
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and clinical trialling take 5 to 7 years on average, there may not be much time for the 
developing company to recoup their investment.  After a patent expires, the generic drug can 
be made by other companies, commonly known as generic companies.  The generic 
companies make drugs but they do not pay towards the development of the drug.  After the 
patent expires, the pharmaceutical company that discovered the drug, no longer receives all 
the money from that drug.  
 
After successful preclinical testing, a few new drugs enter the next stage, which is clinical 
trialling.  Clinical trials are experiments in humans to evaluate drugs, medical devices, 
biologics etc.  Thus, clinical trials are to evaluate interventions in general.  The results of 
clinical trials are presented to the authorities for assessment.  This assessment is carried out 
be the Federal Drug Administration (FDA) in US, or the Therapeutic Goods Administration 
(TGA) in Australia.  If the FDA or TGA accept that the drug does more good than harm, it is 
registered for clinical use.  The clinical development of drugs does not stop at registration, as 
there is ongoing preclinical and clinical assessment.  It is presently considered that it costs 
A$1.2 billion for a single, successful new drug. 
 
Only about 10% of compounds that enter clinical trial are approved/registered for sale.  
Clinical trials are under stringent law enforced guidelines.  These guidelines include ethics, 
which is assessed by human ethics committee, and patient consent.  For patient consent, they 
must be fully informed in lay language of exactly what is happening in the trial.  Clinical 
trials of drugs are often funded by pharmaceutical company with independent investigators.  
Without this funding, there would be little development of new drugs.  There is some 
government funding available for clinical trials of complementary and alternative medicines 
in the US, which allows these medicines to be properly evaluated.  Clinical trials are not 
quick, as they take 7-9 years. 
 
4.5 Ethics in clinical trials 
The atrocities of the Nazis on concentration camp inmates, such as cutting people and seeing 
how long they bled for, were investigated after World War II in Nuremberg Tribunal.  The 
tribunal developed the Nuremberg Code, which is started the modern era of ethics.  There are 
4 main aspects of modern ethics.  Firstly, there is non-maleficence, which means to do no 
harm.  The second aspect, is the reverse of this, it is beneficence, which is to do good.  
Combining non-maleficence and beneficence means that clinical trials have to maximize 
benefits and minimize harm to the patient.  The third aspect of ethics in clinical trials is 
justice, which means that the benefits of research should be distributed fairly, not just to the 
rich and powerful.  The fourth aspect is respect for person.  This has three parts, Firstly, 
individuals be regarded as autonomous agents, and their opinions and choices respected, 
regardless of how daft or illogical they are.  The second part is veracity, the truth must be 
told to participants.  Participants have to be able to understand the clinical trial, and the 
benefits and risks, and these are provide in a Plain Language Statement, prior to consent 
being asked for.  Finally, confidentiality, the participants name, details etc are to be kept 
confidential. 
 
Ethics are policed by IRBs, Institutional Research Boards, which are also known as Ethics 
committee.  This process involves peer review of proposed research.  Peer review is 
independent review of the proposed clinical trial to determine whether the trial is appropriate.  
Universities often have ethics committees both for peer reviewing animal experiments and 
human experiments.  For instance, QUT has a Human Research Ethics committee, an 
Animal Ethics committee and a Biosafety committee. 
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 4.6 Clinical trial design 
There are a number of factors that make a good clinical trial design.  There should be 
similarity of the control group, who do not receive the drug, with the group receiving the 
intervention (drug).  Otherwise any difference between the control and intervention group, 
may be due to other differences between the groups, other than due to the drug intervention.  
One way of achieving similarity between groups is the random assignment of patients to 
control and intervention group.  In initial clinical trials, the control group was untreated 
whereas the treated group were given the drug.  This is almost guaranteed to show a 
beneficial effect with the drug, as people like to believe the drug is going to do them good.  
To avoid this, the control group are given an inert replica of the drug, which is known as the 
placebo.  Placebos are very good for you!  The placebo response (which means “I shall 
please”) is 40% of relief of pain in labour, and up to 60% in relieving depression.  This is the 
key reason for not accepting anecdotal evidence, and requiring placebo-controlled clinical 
trials. 
 
Another danger in clinical trials is observer bias.  The observer of the patients will want the 
patient to get better and will be looking for signs of benefit with the drug, which may or may 
not be present.  To avoid this problem, blinding is used.  There are two types of blinding.  In 
single blinded clinical trials, only the study participants are blinded, not the investigator, and 
this happens when it is considered important that the investigator knows which participant 
has the active drug.  In double-blinded clinical trials, neither the participants nor the 
investigator know who is taking the active drug.  The best design for a clinical trial is the 
randomized, double-blind, placebo-controlled trial.  Such a trial has the highest likelihood 
of revealing the truth about the effects of a drug.  The randomized, double-blind, placebo 
controlled trial has a very simple design (Figure 4.2). 
 
Figure 4.2 Randomized, double-blind, placebo-controlled trial (Copyright QUT, Sheila 
Doggrell) 
 
In a randomized, double-blind, placebo-controlled trial, the selected patient population is 
randomised to either the placebo (dummy tablet) or the drug, and the health of the 
participants is monitored. 
 
 4.7 Phases of clinical trials 
In drug development, it mandated that new drugs have to go through 4 Phases with each 
phase having different requirements.  Clinical trialling starts with small numbers of 
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participants and is mainly to test safety, and only when some safety has been established, 
does testing in larger numbers of participants occur. 
 
Phase I clinical trials are often performed in University Hospitals using experts in clinical 
pharmacology.  They are open with both subject and observer knowing what is happening.  
Phase I clinical trials use small numbers (20-80) of healthy volunteers.  The exception to this 
is when testing toxic drugs for cancer and HIV.  As these would be toxic to healthy 
volunteers, the Phase I testing of cancer and HIV drugs is in patients.  The dose tested in 
Phase I will be a small fraction of that shown to cause toxicity in animals.  The main reason 
for the trial is to establish safety, and the trial will measure toxicity and, possibly, efficacy.  
In Phase I, provided an assay is available to measure the drug, blood samples may be taken to 
measure the pharmacokinetics of the drug.  If a drug shows unacceptable toxicity, the clinical 
trialling will stop after Phase I. 
 
Phase II clinical trials are also often performed in University Hospitals using experts.  They 
are single-blinded i.e. they use placebo/dummy tablets to prevent the subject knowing which 
is active drug, but the physician does know which is the active drug.  Phase II trials may have 
a comparison with standard treatment.  If there is a standard drug available for a certain 
conditions, it has to be established that the new drug is better than the standard drug before it 
can be registered.  Phase II trials are in 10-200 patients with the disease the drug is indicated 
for.  The Phase II trial is to establish the efficacy and toxicity of the drugs.  This information 
is needed for more extensive Phase III trialling.  If a drug does not show efficacy in Phase II 
trialling, it will not go forward to Phase III. 
 
Phase III clinical trials are usually performed in the setting the drug will eventually be used 
in.  Thus, if a drug is to be used in hospital, it will be tested in hospital, whereas if a drug is 
used in general practice, it will be tested in general practice.  The investigators are usually 
specialists in the disease being treated.  Phase III trials are double-blinded; neither the 
observer nor the subject knows which is active drug.  A third person holds the code 
identifying the drug, which is not broken until the trial is completed.  Phase III trials enrol 
large numbers of patients, and are expensive.  Phase III clinical trials establish efficacy and 
toxicity. 
 
Positive results in Phase III lead to applications for registration to market the drug to the 
Therapeutics Goods Administration (TGA).   
 
Phase IV clinical trialling is also known as post-marketing surveillance.  Even though 
Phase III trials enrol large numbers of patients, this may not be large enough to detect any 
rare or long-term adverse effects, and this is done in Phase IV.  Phase IV is under the actual 
conditions the drug will be used.  It is monitoring safety in large numbers of patients and over 
longer periods of time than previous Phase.  Phase IV clinical trials, especially the monitoring 
of adverse effects, involves, all health professionals, not just investigators. 
 
4.8 Therapeutics Goods Administration 
The Therapeutic Goods Regulations (TGA) is responsible for the quality, safety, efficacy, 
and timely availability of drugs and medical devices in Australia.  The TGA regulates 
prescription, over-the-counter and complementary medicines.  It usually accepts the 
recommendations coming from the Australian Drug Evaluation Committee (ADEC).  
ADEC is a committee of specialists that are able to evaluate pharmaceutical and chemical 
data, animal pharmacology and toxicology data, and clinical data.  Applications are usually 
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100,000 pages in length, and the review by physicians/scientists takes up to 3 years.   For 
serious conditions, may get approval earlier in the trialling process and in a shorter time.  
After registration, drugs can be administered to patients outside of clinical trials at full cost. 
 
 4.9 Pharmaceutical Benefits Scheme 
After registration, drugs are available at full cost.  Only drugs that accepted into the 
Pharmaceutical Benefits Scheme (PBS) are subsidised as part of Medicare.  Before 
acceptance onto the PBS, a pharmacoeconomic analysis is done.  This analysis weighs up 
the benefits of the drug against the cost to the government (Medicare).  Broadly speaking, 
they are asking “are you worth it”.  One of the drugs discussed extensively in the press 
recently is Herceptin (trastuzumab).   Trastuzumab is very useful in certain types of breast 
cancer.  However, the full cost is $60,000/year.  Initially, women with this type of breast 
cancer could only have the treatment, if they paid for it.  Under the PBS, trastuzumab is 
$33/prescription. 
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5.1 Pharmacovigilance 
Pharmacovigilance is the part of pharmacology that relates to the detection, assessment, 
understanding, and prevention of adverse drug effects and adverse drug interactions.  Initially 
we will consider adverse drug effects and their monitoring, then discuss pharmacodynamic 
and pharmacokinetic examples of adverse drug interactions, and finally discuss therapeutic 
drug monitoring.  It is not possible to discuss all the adverse drug effects or adverse drug 
interactions.  This chapter is just an introduction to pharmacovigilance.  A good source of 
information about adverse drug effects and adverse drug interactions is the Australian 
Medicines Handbook, and an alternative is MIMS.  When adverse drug effects or adverse 
drug interactions have been identified, the ideal solution (if possible), is to avoid the drug or 
drug combination. 
 
 5.1.1 Adverse drug effects 
Adverse drug effects are also known as adverse drug reactions, or side effects of drugs.  The 
World Health Organization (WHO) definition for this is “a response to a drug that is noxious 
and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or 
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therapy of disease, or for modification of physiological function”.  This means that for the 
same plasma concentrations, both beneficial and adverse effects may be observed. 
 
  5.1.1.1 Types 
Adverse drug effects have been classified as 3 types; A, B, and C.  A is for Augmentation.  
These side effects are extensions of the drug actions.  This can be because the same binding 
site underlies beneficial and adverse effects of the drug.  For instance, digoxin is used to 
increase the force of the heart beat in people with heart failure.  Digoxin is a Na+K+-ATPase 
inhibitor.  Inhibition of the cardiac Na+K+-ATPase produces both the beneficial effect 
(increased heart force) and adverse effects (cardiac arrhythmias) of digoxin on the heart.  In 
addition, Na+K+-ATPase is present in all cells.  Inhibition by digoxin of Na+K+-ATPase in 
non-cardiac cells for can cause other adverse effects, such as blurred vision and visual 
disturbances. 
 
Another example of Type A adverse effects is when drugs that show limited selectivity for a 
binding site cause a beneficial action at their target binding site but an adverse effect at 
another binding site.  For example, atenolol is a selective β1-adrenoceptor antagonist that has 
a beneficial effect (antihypertensive) by blocking the cardiac β1-adrenoceptor to decrease 
heart rate and force.  However, as atenolol is only selective, not specific, for β1-
adrenoceptors, this means that atenolol will also have some effect at β2-adrenoceptors.  β2-
adrenoceptors mediate bronchodilation and some metabolism relating to glucose.  The β2-
adrenoceptor blocking action of atenolol is such that it is contraindicated (not to be used) in 
asthmatics. 
 
In type B adverse effects, the B is for Bizarre or idiosyncratic, adverse effects.  For these 
adverse effects, we do not know what the exact mechanism is.  Type B adverse effects 
include allergy.  As drugs are foreign to the body, it is not surprising that allergic reactions to 
drugs are common.  Drug allergy occurs when the body forms antibodies to a particular 
drug, causing an immune response when the person is re-exposed to a drug.  Thus, the 
allergic response is small on first exposure, but can be large on subsequent exposure.  The 
reason for asking new patients “Are you allergic to any drugs?” is to avoid major allergic 
responses.  People who are allergic to the penicillins develop a rash on first exposure. In 
addition, on repeated exposure, people allergic to penicillin develop angioedema (marked 
swelling of the lips, tongue, and face) and anaphylaxis (respiratory distress, hypotension, 
unconsciousness). 
 
In type C adverse effects, the C is for Continuous.   These adverse effects are a consequence 
of continuous (long term) use of drug.  An example is with the continuous use of some of the 
older drugs for schizophrenia, such as haloperidol.  Schizophrenia is an ongoing condition 
requiring continuous medication.  However, the long term use of haloperidol can lead to 
tardive dyskinesia.  Tardive dyskinesia is uncontrollable lip smacking, tongue darting, 
constant chewing movements, and tics.  Some people also have jerky, uncontrolled 
movements of arms and legs. 
 
  5.1.1.2 Monitoring of adverse effects 
The adverse effects of drugs are monitored throughout clinical development, in Phase I, II, 
and III clinical trials.  Phase IV of clinical trialling is post-marketing surveillance.  The 
Therapeutic Goods Administration (TGA) regulates Australia’s medicines, medical devices, 
blood, tissues, and chemicals.  In addition, the TGA has an Adverse Drug Reactions 
Advisory Committee (ADRAC), which is responsible for monitoring the adverse effects of 
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drugs when they are widely available (Phase IV post-marketing surveillance).  ADRAC relies 
on anecdotal reporting; Mrs Smith took drug A and developed a rash, i.e where there is no 
direct evidence of a link, and the finding could be coincidental.   However, if lots of reports 
come in that drug A causes a rash, the evidence begins to mount.  ADRAC relies on receiving 
voluntary reports from health professionals, which they monitor.  If they think that the 
evidence linking a drug to an adverse effect is substantial, ADRAC may ask for intensive 
adverse event monitoring for that particular drug.  ADRAC reports its findings in the 
Australian Adverse Drug Reactions Bulletin. 
 
As a health professional, how do you tell whether a reaction is an adverse reaction of a drug?  
There are two general questions to ask the patient.  First, does the reaction get worse with 
increasing doses of the drug?  Most adverse effects of drugs are dose related – the more you 
take, the worse it gets.  If this is the case, it indicates an adverse effect.  Secondly, does the 
reaction go away when the drug is stopped?  Many adverse effects are reversible on removing 
the drug.  If this is the case, it also indicates an adverse effect of the drug. 
 
 5.1.2 Adverse drug interactions 
The second part of Pharmacovigilance is adverse drug interactions.  These can be between a 
prescription drug and a prescription drug or between a prescription drug and a 
complementary or alternative drug.  There are numerous drug interactions, and many of these 
are listed in the Australian Medicines Handbook.  These interactions can be 
pharmacodynamic or pharmacokinetic, and examples of each of these follow. 
 
  5.1.2.1 Pharmacodynamic interactions 
An example of a pharmacodynamic interaction is considered.  Atherosclerosis is usually the 
underlying cause of angina (coronary artery disease) and erectile dysfunction.  Men who 
develop atherosclerosis often have angina and erectile dysfunction.  Nitroglycerin is used to 
relieve or prevent attacks of angina.  Sildenafil (Viagra) is used to treat erectile dysfunction.  
Nitroglycerin acts by mimicking endogenous nitric oxide to stimulate the enzyme guanylate 
cyclase to convert GTP to cGMP, which after a few more steps leads to vasodilation to 
relieve the angina (Figure 5.1).  There is only a small decrease in blood pressure with 
nitroglycerin.   
 
Figure 5.1 Pharmacodynamic drug interaction (Copyright QUT, Sheila Doggrell) 
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Normally, erectile function is mediated by endogenous nitric oxide that stimulates the 
guanylate cyclase to increase the levels of cGMP in the corpus carvenosum, which produces 
relaxation, and blood rushes in to cause penile erection.  The effects of cGMP are short-lived 
as it is rapidly inactivated by the enzyme phosphodiesterase V.  When men take nitroglycerin 
for angina and sildenafil for erectile dysfunction, the sildenafil will inhibit phosphodiesterase 
V in the corpus carvenosum and blood vessels to increase the effect of nitroglycerin (Figure 
5.1).  Thus, the effects of nitroglycerin are increased, and there is a large decrease in blood 
pressure with postural hypotension (dizziness and fainting when standing up).  As a result of 
this interaction, sildenafil is contraindicated in men taking nitroglycerin. 
 
5.1.2.2 Pharmacokinetic interactions 
The enzyme CYP3A4 metabolises 50% of all drugs, and this is source of many drug 
interactions.  The anti-fungal drug ketoconazole inhibits CYP3A4, and this increases plasma 
levels of drugs metabolised by CYP3A4, of which there are many.  For instance, sildenafil 
(Viagra) is metabolised by CYP3A4.  The combination of ketoconazole and sildenafil leads 
to increased levels of sildenafil.  Lower doses of sildenafil are used in men taking 
ketoconazole  
 
 
5.1.3 Therapeutic drug monitoring 
It is obvious that it will be expensive to monitor the levels of drugs by taking blood samples, 
and detecting the levels of drugs in them.  Therapeutic drug monitoring is usually not needed 
if the toxic levels are above the therapeutic concentrations. However therapeutic drug 
monitoring may be needed if toxic levels are similar or overlap therapeutic concentrations.   
 
In practice, therapeutic drug monitoring is required for a number of drugs including the anti-
epileptic, phenytoin.  Therapeutic drug monitoring is used early in treatment with phenytoin 
to find dose that gives therapeutic effect.  Phenytoin is being given to prevent seizures.  If a 
seizure occurs, it may indicate the concentration of phenytoin in the plasma is below the 
therapeutic dose.  Thus, therapeutic drug monitoring of phenytoin commonly occurs after a 
seizure.  Finally, the levels of phenytoin are measured after a change of dose.  
 
Another use of therapeutic drug monitoring is in poisoning to determine the treatment 
required, and this occurs with paracetamol overdose.  If levels are above a certain standard, 
treatment of the overdosage is needed to prevent liver toxicity.  This treatment is discussed in 
eChapter 6.  
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5.2 Introduction to pharmacogenetics 
Pharmacogenetics, or pharmacogenomics as it is also known, is the study of the genetic basis 
for variation in drug response.  These genetic variations are often due to polymorphism, 
which is a variation in the DNA sequence that is present at a frequency of 1% or greater in a 
population.  Polymorphisms differ within human populations e.g. Caucasians, Chinese. These 
polymorphisms can be in enzymes, receptors, ion channels etc, and some examples are 
discussed below. For most polymorphisms, functional information is not available, as the 
study of pharmacogenetics is its infancy.  The ultimate goal of pharmacogenetics is to 
individualise drug treatments on the basis of individual genetics.   
 
 5.2.1 Enzymes 
The example of a polymorphism in an enzyme is with CYP2D6.  About 15-25% of all drugs 
are substrates for this enzyme.   For instance, haloperidol is metabolised by CYP2D6.  With 
polymorphisms of CYP2D6 gene, 5-10% of people have slow metabolism of these drugs.  
The people who are slow metabolisers are likely to have higher plasma levels of drugs 
metabolised by CYP2D6, and more likely to have toxic effects.  Thus, toxicity to haloperidol 
(e.g. tardive dyskinesia) is likely to be more common in slow metabolisers. 
 
With some forms of the polymorphism, the people do not metabolise the drugs normally 
metabolised by this enzyme.  For instance, the conversion of codeine to morphine, which is 
responsible for the analgesic effect of codeine, requires CYP2D6.  Polymorphism in CYP2D6 
leads to 10% of Caucasians not being able to convert codeine to morphine.  In these 10%, 
there is a lack of efficacy of codeine, i.e. it does not have a sufficient analgesic effect. 
 
 5.2.2 Receptors 
Polymorphisms are not always associated with loss of activity.  This is shown in the example 
of the receptor polymorphism; epidermal growth factor receptors.  Epidermal growth 
factor receptors (EGFR) are from the receptor tyrosine kinase (TK) family.  EGFR are 
overexpressed in many cancers, and promote the growth of the cancer.  Gefitinib inhibits 
EGFR-tyrosine kinase, and is used in the treatment of some cancers.  There is a subset of 
patients who respond very well (and much better than most patients) to gefitinib.  This subset 
of patients has a polymorphism in their EGFR-tyrosine kinase.  Gefitinib is a more potent 
inhibitor of the polymorphism than the wild-type (normal) EGFR-tyrosine kinase.  Thus, 
there is a better response to gefitinib in patients with this polymorphism. 
 
 5.2.3 Ion channels 
An example of an ion channel polymorphism is the HERG channel, a potassium channel on 
the heart.  On the electrocardiogram (ECG), QT is a measure of ventricular repolarisation 
(relaxation of heart prior to new beat).  The “Long QT syndrome” is associated prolonged 
relaxation of the heart, such that the heart may not be fully relaxed and ready to beat again.  
This leads to syncope (temporary loss of consciousness and posture) and cardiac 
arrhythmia/sudden death.  This polymorphism is in a particular cardiac potassium channel: 
the HERG channel and can lead to sudden death in young people.  In addition, several drugs 
have been shown to prolong the QT interval by blocking the HERG, and this leads to an 
increased risk of cardiac arrhythmias and sudden death.  Several commonly used drugs have 
been withdrawn, as they have been shown to prolong the QT interval, e.g. some commonly 
used antihistamines were withdrawn after they had been on the market for several years.  To 
make sure this does not happen again, in drug development, it is now mandatory to test 
whether a new drug is an inhibitor of HERG channels. 
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6. Poisoning with drugs 
All drugs are poisons.  Unfortunately, when medicines are given at higher doses than 
recommended, their effects are no longer limited to beneficial with the possibility of some 
adverse effects, but become poisonous.  Drugs of abuse are also poisonous.  Poisoning with 
drugs is a relatively common reason for attendance at the emergency department of the 
hospital.  For example, In Western Australia, there are about 500 hospital admissions for 
paracetamol poisoning each year. 
 
 6.1 Acute poisoning 
Drugs that can cause poisoning include prescription medicines, OTC (Over-The-Counter) 
medicines (complementary and alternative medicines), alcohol, herbal remedies, and illegal 
drugs. The drugs most commonly associated with fatalities are analgesics (paracetamol and 
aspirin), sedative-hypnotics/antipsychotics, antidepressants, stimulants and street drugs 
(including opioids and cocaine), and cardiovascular drugs (digoxin and Ca2+ entry blockers). 
 
In acute poisoning, the general symptoms are nausea, vomiting, dizziness, fitting, drowsiness, 
confusion, coma, and breathing difficulties.  Overdosage is the main reason for poisoning, 
and this overdosage can be accidental or intentional (drug abuse or self-harm). 
 
 6.2 Treatment of poisoning – general 
For most cases of poisoning, there are no specific treatments.  The medical care is to treat 
patients not the poison.  Thus, the medical care is of the symptoms, and to support the vital 
functions (breathing, circulation) of the subjects.  For a few poisons, there are specific 
treatments or specific antidotes.  After promptly, maintaining vital functions, especially if 
their impairment is imminent, other treatments can be considered.  The goals of this treatment 
is to keep concentration of drug/poison in crucial tissues as low as possible by preventing 
absorption and enhancing elimination, as this will obviously limit the effects of the poison.  
The second goal is to combat the pharmacological and toxicological effects at the effector 
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site.   This is especially important when it is not possible to get rid of the poison quickly.  
Examples of ways to prevent absorption, enhance elimination, and to combat the 
pharmacological and toxicological effects are now discussed. 
 
 6.3 Preventing absorption 
The standard treatment of poisoning used to be to make the patient sick (emesis).  However, 
emesis with syrup of ipecac is now rarely used.  When used soon after the intake of certain 
drugs, emesis can be useful, but it is often difficult to ascertain when the poison was taken 
and hence how much poison is still in the stomach. 
 
In several situations, emesis can do more harm than good.  For instance, if the patient 
becomes comatose, emesis can cause aspiration of the gastric contents.  Similarly, if the 
patient is delirious, aspiration can occur.  Aspiration is when the contents of the stomach are 
delivered to the lung, and can be fatal.  Also, if the patient has ingested a central stimulant, 
and is delirious or has hallucinations, the further stimulation associated with vomiting may 
precipitate convulsions. 
 
Syrup of ipecac is derived from a plant source, and is available on prescription or OTC 
(Over-The-Counter).  It has both a local irritant effect on enteric tract and stimulates the 
chemoreceptor trigger zone (CTZ) or emetic centre in the area postrema of the medulla to 
induce emesis.  Syrup of ipecac is indicated when it can be administered to conscious, alert 
patients within 60 minutes of poisoning, and produces vomiting in 15-30 minutes 
 
In addition to emesis, there are two other ways to limit drug absorption.  The first is gastric 
lavage, which is restricted to patients who have taken a life-threatening amount of drug 
within the last 60 min.  For gastric lavage, a tube and large syringe are required.  The 
contents of the stomach are aspirated (sucked up), and then the stomach is lavaged (washed) 
with saline. 
 
The second alternative to emesis is activated charcoal. Activated charcoal adsorbs many 
drugs preventing their absorption and toxicity.  Activated charcoal, does not need to be 
removed artificially, nature can takes its course.  The use of activated charcoal has increased 
recently.  It is indicated for life-threatening amounts of the anti-epileptic drug 
carbamazepine.  
 
 6.4 Enhancing elimination 
The first example of a drug that it is possible to enhance elimination is paracetamol.  A 
minor metabolite of paracetamol NAPQI is extremely toxic to the liver.  Normally most of 
the paracetamol is conjugated and excreted (Figure 6.1).  However, with high poisonous 
levels of paracetamol, the glutathione (GSH) becomes depleted, and NAPQI levels increase.  
N-Acetylcysteine provides a source of GSH to promote the elimination of NAPQI.  GSH 
may also combine with NAPQI to reduce the toxicity to this compound, and hence to 
paracetamol (Figure 6.1). 
69 
 
 
Figure 6.1 Promoting elimination of NAPQI (Copyright QUT, Sheila Doggrell) 
 
Another way to promote the elimination of drugs is to increase their ionisation, as ionised 
drugs are readily excreted.  For instance, aspirin is a weak acid and is readily reabsorbed 
from kidney tubule.  Thus, aspirin is recycled and remains poisonous.  Urine alkalinization 
with sodium bicarbonate increases the ionization of aspirin, and ionized aspirin is readily 
eliminated.   The enhanced elimination of aspirin reduces its toxicity.   
 
 6.5 Combating pharmacological and toxicological effects 
There are a number of ways of combating pharmacological and toxicological effects of drugs.  
For instance, as discussed in Section 3.5, hemodialysis (cleaning of the blood) can be used to 
remove drugs with low volume of distribution e.g. heparin.  This is because drugs with a low 
volume of distribution are largely confined to the plasma and can be removed by 
heamodialysis.  Drugs with high volume of distribution e.g. the antidepressant nortriptyline, 
and the lipid soluble drugs, cannot be removed with haemodialysis.  
 
Another approach is competitive reversible antagonism.  For example, naloxone is a 
competitive reversible antagonist at opioid μ receptors, which are the receptors that morphine 
stimulates.  Morphine stimulates opioid μ receptors to be analgesic.  With high doses of 
morphine, the stimulation of opioid μ receptors can cause excessive respiratory depression.  
The opioid μ receptor competitive reversible antagonist naloxone can be used to overcome 
excessive respiratory depression with morphine. 
 
For some poisons, specific antidotes have been developed.  For instance, in life-threatening 
digoxin intoxication, anti-digoxin immunotherapy can be used to combine with the digoxin 
and inactivate it.  Digoxin is used in the treatment of heart failure.  Digoxin has a low 
therapeutic index (overlap of therapeutic and toxic levels).  Toxicity with digoxin includes 
life threatening cardiac arrhythmias.  In life-threatening digoxin intoxication, anti-digoxin 
immunotherapy is used.  The anti-digoxin immunotherapy combines with digoxin to 
inactivate it  
 
Finally, chemical antagonism can be used to combat toxicological effects.  The best known 
example of chemical antagonist is to heparin.  Thus, heparin induced life-threatening 
hemorrhage can be overcome with chemical antagonism.  Heparin is strongly acidic.  
Protamine sulphate is strongly basic.  Heparin and protamine combine and the combined 
product is inactive.  
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PERIPHERAL NERVOUS SYSTEMS 
 
The nervous systems can initially be divided up into the central and peripheral nervous 
systems.  The central nervous system is the brain and spinal cord and drugs that modify the 
central nervous system are considered as a subject in systematic pharmacology (therapeutics) 
section.  Everything neural, other that the central nervous system, can be considered 
peripheral nervous systems.  The peripheral nervous systems can be divided into the 
autonomic (involuntary) nervous system, which is the system that performs without your 
conscious help, and the somatic or voluntary nervous system, which you can consciously 
control (Figure 7.1).  In addition the autonomic nervous system is divided into the 
sympathetic and parasympathetic nervous systems. 
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Figure 7.1 Nervous systems (Copyright QUT, Sheila Doggrell) 
 
This eChapter sequentially considers drugs and the sympathetic nervous system, the 
parasympathetic nervous system.  The somatic nervous system is discussed in eChapter 8. 
 
7.1. Drugs and the sympathetic nervous system 
 
 7.1.1 The sympathetic nervous system 
They activity of the sympathetic nervous system is controlled by the central nervous system, 
where the nerves arise, and travel down the spinal cord.  The sympathetic nerves come out of 
the spinal cord at the thoracic-lumbar region, and there are short pre-ganglionic nerves 
(Figure 7.2).  There are two parts of the sympathetic nervous system, one part has ganglia.  In 
the first part, the preganglionic fibres release acetylcholine on to nicotinic receptor on the 
neurones at the ganglia, and these receptors are known as nicotinic neurone receptors.  
Activation of the these receptors, leads to the release of noradrenaline from the long post-
ganglionic fibres on to an adrenoceptor on an end organ, which is often cardiac or smooth 
muscle or glands. 
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Figure 7.2 Sympathetic Nervous System (Copyright QUT, Sheila Doggrell) 
 
In the other part of the sympathetic nervous system, the acetylcholine from the preganglionic 
fibres is also released on to nicotinic neurone receptors, but these are on specialised ganglia, 
known as the adrenal medulla.  Stimulation of the NN receptors on the adrenal medulla 
initiates the secretion of adrenaline into the circulation.   
 
As discussed in eChapter 3, there are subdivisions of adrenoceptors. The receptors for 
noradrenaline and adrenaline were originally called adrenoreceptors but this has been 
shortened to adrenoceptors over the years.  As noradrenaline and adrenaline do not have 
identical responses in the body, it was decided that there must be more than one kind of 
adrenoceptors, and the receptors were divided into α- and β-adrenoceptors.  Molecular 
biology techniques have now been able to distinguish 10 subtypes of adrenoceptors.  Drugs 
that stimulate all or most of the adrenoceptor subtypes, which noradrenaline and adrenaline 
do to a certain extent, will have widespread effects, and these effects can either be beneficial 
or detrimental.  Drugs that select one adrenoceptor will have less widespread effects and, 
hopefully, less detrimental effects.  The effects mediated (functional responses) are well 
defined for 1-, 2 -, 1-, 2- and 3- adrenoceptors, and we have drugs that can mimic or 
inhibit these responses.  Functional responses are poorly defined for most subdivisions of 1- 
and 2 -, and 4-adrenoceptors, and we have few drugs that select for these subdivision.  The 
effects mediated by the adrenoceptor subtypes are discussed in the next section. 
 
7.1.2 Effects of the sympathetic nervous system 
The effects of the sympathetic nervous system are exerted on most end organs/systems.  The 
discussion of effects given here is limited to those we modify commonly with drugs, and we 
need to know these to understand how the drugs work.  On the cardiovascular system, 
activation of the sympathetic nervous system leads to the release of noradrenaline that goes 
on to stimulate the β1-adrenoceptors of the heart and the α1-adrenoceptors on the blood 
vessels (Figure 7.3). 
73 
 
 
Figure 7.3 Noradrenaline on cardiovascular system 
 
Noradrenaline stimulates the β1-adrenoceptors of the sino-atrial node (pacemaker region of 
the atria) to increase the heart rate.  Noradrenaline also stimulates the β1-adrenoceptors of the 
ventricles to increase the force at which the heart beats.  This combination of increased heart 
rate and increased heart force leads to an increase in the cardiac output.  On release from the 
sympathetic nervous system, noradrenaline also stimulates the α1-adrenoceptors on the blood 
vessels.  On the veins, noradrenaline causes venoconstriction, and noradrenaline also 
constricts the arterioles in the skin and mucous membranes.  The noradrenaline β1-
adrenoceptor-induced increase in cardiac output and α1-adrenoceptor-mediated 
vasoconstriction combine to give an increase in blood pressure. 
 
Adrenaline released from the adrenal medulla part of the sympathetic nervous system also 
has effects on the cardiovascular system.  The effects of adrenaline on the cardiovascular 
system are different to those of noradrenaline, and also depend on the concentration of 
adrenaline.  Low concentrations of adrenaline stimulate -adrenoceptors on arterioles in 
the skin and mucous membranes to cause vasoconstriction, which is similar to noradrenaline.  
But in contrast to noradrenaline, adrenaline also stimulates 2-adrenoceptors on blood vessels 
in skeletal muscle and coronary arteries to cause vasodilation.  This mix of vasodilation and 
vasoconstriction with adrenaline means there may be no effect overall on blood pressure.  
Instead, with adrenaline, there is a redistribution of blood from cutaneous vessels to heart and 
skeletal muscle.  Low concentrations of adrenaline have little effect on the heart. 
 
With higher concentrations of adrenaline, the fight or flight response is observed.  These 
responses are similar to those observed when adrenaline is being used as drug, as the higher 
concentrations of adrenaline are used as a medicine.  With the higher concentration of 
adrenaline, all of the effects observed with low concentrations of adrenaline persist and may 
intensify, plus a more pronounced effect on heart is observed.  High concentrations of 
adrenaline stimulate the cardiac 1- adrenoceptors to induce a racey heart, a high heart rate. 
 
Sympathetic nerves innervate the kidney, and when these nerves are activated, noradrenaline 
is released and acts on β1-adrenoceptors to induce the secretion of renin into the blood stream 
(Figure 7.4). Once renin has been secreted the hormones angiotensin II and aldosterone are 
formed and carried in the blood stream. 
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Figure 7.4 Sympathetic NS and kidney (Copyright QUT, Sheila Doggrell) 
 
Angiotensin II acts on blood vessels to cause vasoconstriction.  Aldosterone acts on the 
kidney to promote salt and water retention.  Both of these hormonal effects lead to an 
increase in blood pressure. 
 
On the urinary bladder, noradrenaline acts at 1- adrenoceptors in the neck and sphincters 
to promote contraction, and contraction in these areas promotes urinary retention.   
 
On the prostate, noradrenaline acts at 1- adrenoceptors, which are the 1A-adrenoceptor 
subtype, to contract the smooth muscle in the prostrate capsule. 
 
The effects of adrenaline released from adrenal medulla include those on the lung, where the 
tracheal and bronchial smooth muscle contains 2-adrenoceptors, and adrenaline stimulates 
these to cause bronchodilation.  The bronchial glands also have 2-adrenoceptors, and 
stimulation of these receptors leads to a decrease in secretions.   
 
On the eye, adrenaline may act at 2-adrenoceptors on ciliary epithelium to increase aqueous 
humour formation. 
  
Adrenaline has some major effects on metabolism.  On the liver, adrenaline stimulates β2-
adrenoceptors to activate the enzyme glycogen phosphorylase which catalyses 
glycogenolysis, which is the breakdown of glycogen to glucose.  Also on the liver, adrenaline 
stimulates β2-adrenoceptors to promote the process of gluconeogenesis, which is the 
conversion of amino acids to glucose. 
 
These effects of noradrenaline and adrenaline can be mimicked by drugs known as 
sympathomimetics, or inhibited by antagonists at the adrenoceptors, the adrenoceptor 
antagonists. 
 
7.1.3 Sympathomimetics 
The sympathomimetic drugs can be divided into those that do not show much selectivity for 
adrenoceptors, and these include adrenaline itself, ephedrine, and dopamine.  The other 
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sympathomimetics are those that show selectivity for one of the receptors, and hence only 
mimic some of the effects of the sympathetic nervous system.  Selective sympathomimetics 
include dobutamine, salbutamol and salmeterol. 
 
The most obvious way to mimic the effects of adrenaline is to use adrenaline as a medicine. 
When used as a medicine, adrenaline stimulates all types of adrenoceptors.  Adrenaline is 
used clinically for its ability to cause an -adrenoceptor mediated vasoconstriction.  
Adrenaline is used clinically as an additive to local anaesthetic preparations, where the local 
intense vasoconstriction decreases the absorption of the local anaesthetic to help limit the 
effect of the local anaesthetic to a local area.  Without the adrenaline, the local anaesthetic 
will spread, and the action will no longer be local but spreading/widespread.  Secondly, 
adrenaline can be applied topically to bleeding surfaces, where vasoconstriction reduces the 
surface for blood loss, and hence the blood loss.  For instance, adrenaline can be applied to 
bleeding peptic ulcers during endoscopy. 
 
Adrenaline is also used clinically for its ability to cause a 1-adrenoceptor-mediated 
increase in heart rate and force.  Thus, adrenaline is used intravenously in heart block and 
cardiac arrest.   
 
Historically, adrenaline was used to cause a 2-adrenoceptor-mediated bronchodilation.  
However, when adrenaline was used to alleviate bronchial asthma, it caused tachycardia due 
to stimulation the 1-adrenoceptor of the heart, an unwanted effect in the treatment of asthma.  
What is needed in asthma is a selective 2-adrenoceptor agonist that causes bronchodilation 
without tachycardia.  Salbutamol is a selective 2-adrenoceptor agonist, and is preferred to 
adrenaline in the treatment of asthma. 
 
Adrenaline is used in the treatment of hypersensitivity reactions including anaphylaxis, 
where there is excessive vasodilation, which can lead to circulatory collapse, and excessive 
bronchoconstriction.  This excessive vasodilation is overcome by adrenaline causing an α-
adrenoceptor-mediated vasoconstriction and the excessive bronchoconstriction by a β2-
adrenoceptor-mediated bronchodilation.   
 
In addition to having widespread effects and not being after oral administration, another 
limitation to the clinical use of adrenaline is that it is a very potent medicine, and it is difficult 
to moderate its effect.  This has been overcome by developing less potent drugs such as 
ephedrine, which also have the benefit of being active after oral administration.  Ephedrine, 
also known as pseudoephedrine, is a mixed acting amine, which means it has direct and 
indirect effects at receptors.  The direct effect is that ephedrine is a weak agonist at - and -
adrenoceptors, and the indirect effect is that ephedrine causes the release of noradrenaline.   
Most of the effect of ephedrine is probably mediated by the release of small amounts of 
noradrenaline.  The noradrenaline causes an -adrenoceptor-mediated vasoconstriction, 
which makes it useful as a nasal decongestant.  In nasal congestion (bunged up nose) there is 
intense vasodilation, which collects lots of material.  With vasoconstriction, the blood starts 
to move again and take away the collected material to clear the nose.  Ephedrine also causes a 
small amount of 2-adrenoceptor-mediated bronchodilation, which helps clear the chest.  
Thus, ephedrine is used to treat the nasal and lung congestion of the common cold. 
 
Phenylephrine is a selective α-adrenoceptor agonist, which has no effect on β-adrenoceptors.  
Like pseudoephedrine, phenylephrine causes an α-adrenoceptor-mediated vasoconstriction to 
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produce a decongestant effect.  However, phenylephrine does not cause a β2-adrenoceptor-
mediated bronchodilation.  Most people prefer ephedrine over phenylephrine for the 
treatment of a cold, probably because of the β2-adrenoceptor-mediated bronchodilation.   
 
Higher concentrations of dopamine act as a mixed acting amine (ephedrine-like).  The direct 
action is being a weak agonist at - and - adrenoceptors, and the indirect action is releasing 
noradrenaline, with both of these actions leading to vasoconstriction.  Dopamine is used 
intravenously in the treatment of circulatory shock (collapse) to produce vasoconstriction to 
maintain circulation. 
 
Dobutamine is a selective 1-adrenoceptor agonist, which means it has a greater effect at 
1-adrenoceptor than at other receptors.  It is used to selectively mimic the effect of the 
sympathetic nervous system on the 1-adrenoceptors of the heart.  Thus, dobutamine is used 
to increase in heart force.  Dobutamine is not active after oral administration, and is used I.v. 
in the treatment of circulatory shock to produce an increase in heart force (inotropic) 
response. 
 
The last group of sympathomimetics are the selective 2-adrenoceptor agonists such as 
salbutamol and salmeterol.  Salbutamol and salmeterol have no effect at -adrenoceptors, 
and are selective for 2- over 1-adrenoceptors.  Salbutamol is the standard selective 2-
adrenoceptor agonist, whereas salmeterol is a long acting selective 2- adrenoceptor agonist.  
Both medicines cause a 2-adrenoceptor-mediated bronchodilation.  Inhaled salmeterol is 
used to prevent bronchial asthma, whereas inhaled salbutamol is used in an asthma attack 
to overcome an attack, and can also be used intravenously in severe asthma attacks. 
 
Adrenoceptor antagonists are used to prevent the effects of the sympathetic nervous system.  
Clinically used agents include the selective 1-adrenoceptor antagonists, doxazosin and 
tamsulosin, the non-selective -adrenoceptor antagonists propranolol, timolol and esmolol, 
and the selective 1-adrenoceptor antagonists metoprolol and atenolol. 
 
 7.1.4 Selective α1-adrenoceptor antagonists 
Prazosin is a selective 1-adrenoceptor blocker.  The 1-adrenoceptor blockade with 
prazosin causes a decrease in the noradrenaline 1-adrenoceptor mediated vasoconstriction, 
which effectively gives a vasodilation, and as a result there is a decrease in blood pressure.  
Prazosin is occasionally used as 3rd/4th line treatment of hypertension.  Thus, if people have 
very high blood pressure, which is still not controlled with 2 or 3 of the standard drugs for the 
treatment hypertension, Prazosin may be added to the regimen to increase the likelihood of 
controlling blood pressure. 
 
Tamsulosin is the first example of an uroselective blocker, that is a selective 1-adrenoceptor 
blocker, which additionally shows selectivity for 1A-adrenoceptors (which are found on the 
prostate) over 1B-adrenoceptors, which are found of blood vessels.  Thus, tamsulosin has a 
greater ability to reverse noradrenaline 1A-adrenoceptor-mediated contraction of the smooth 
muscle of the prostate than to reverse noradrenaline 1B-adrenoceptor-mediated contraction 
of the blood vessels.  Tamsulosin is used in the treatment of benign prostatic hyperplasia 
where the growth of the prostrate obstructs the bladder neck, making urination difficult in 
older men.  Tamsulosin relaxes the prostate muscle to reduce the obstruction.  Tamsulosin 
also reduces the 1-adrenoceptor contraction in the neck and sphincters of the urinary 
bladder, which makes urinating easier. 
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 7.1.5 β-adrenoceptor antagonists 
Propranolol and timolol are non-selective -adrenoceptor antagonists. On the heart, 
noradrenaline stimulates 1-adrenoceptors to increase heart rate and force.  Propranolol 
prevents this from happening, and effectively gives a decrease in heart rate and force (Figure 
7.5). 
 
Figure 7.5 Propranolol and heart and kidney (Copyright QUT, Sheila Doggrell) 
 
On the kidney, noradrenaline stimulates 1-adrenoceptors to cause the activation of the renin-
angiotensin-aldosterone system, with angiotensin II causing vasoconstriction, and aldosterone 
causing salt and water retention (Figure 7.5).  Propranolol prevents this from happening 
effectively reducing the activity of the renin-angiotensin-aldosterone system.  As angiotensin 
II is a potent vasoconstrictor, and aldosterone promotes salt and water retention, both of 
which increase blood pressure, there removal with propranolol leads to a decrease in blood 
pressure.   
 
Overall, propranolol has two mechanisms to decrease blood pressure.  Firstly, propranolol 
acts on the heart to decrease cardiac out and, hence, to decrease blood pressure.  Secondly, 
propranolol acts on the kidney to decrease the activity of the renin-angiotensin-aldosterone 
system, and hence, to decrease blood pressure.  This suggests that -blockers should be 
useful in the treatment of hypertension, and they are but there are a few problems with the 
-blockers.  
 
The first problem with using non-selective -blockers in hypertension is that they have 
adverse effects on the cardiovascular system.  Subjects with hypertension do not feel unwell, 
and are very intolerant of taking drugs that give adverse effects.  Propranolol adversely 
affects exercise.  When you exercise, there is an activation of the sympathetic nervous 
system, release of noradrenaline, and increased heart rate and force, which allows an 
increased exercise tolerance (Figure 7.6).  Propranolol inhibits this to give a decreased 
exercise capacity, which is disconcerting for exercise junkies who have become hypertensive, 
and prescribed -blockers. 
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Figure 7.6 Propranolol and exercise (Copyright QUT, Sheila Doggrell) 
 
Adrenaline 2-adrenoceptor mediated vasodilation is also inhibited by -blockers.  With 
decreased vasodilation, there is decreased heat delivered to the extremities (toes and fingers), 
and these may become cold. 
 
In addition to problems because of adverse effects, non-selective -blockers are 
contraindicated in asthma and diabetes.  On the lung, adrenaline secreted from the adrenal 
medulla, acts at the 2-adrenoceptors to relax the bronchial smooth muscle to give a 
bronchodilation.  Propranolol prevents this happening, reducing the bronchodilation to 
effectively give a bronchoconstriction.  People with normal lung function can tolerate this, 
and there is no serious effect.  In contrast, in subjects with asthma, the bronchoconstriction 
observed with propranolol can precipitate an attack of asthma.  Consequently, non-selective 
-blockers are contraindicated in asthmatics.  Most 1-blockers are selective not specific for 
1-adrenoceptors - they have some effects at 2-adrenoceptors.  Consequently, selective 1-
adrenoceptor antagonists are also contraindicated in asthmatics 
  
When a person becomes hypoglycaemic, this is signal for the release of adrenaline, which 
stimulates the 2-adrenoceptors of the liver to promote both the conversion of glycogen and 
of proteins to glucose to overcome the hypoglycaemia. Propranolol inhibits this process, but 
this is not usually a problem in non-diabetics, as there are other ways to control glucose 
levels.  However, when metabolism is compromised or being treated in diabetes, the ability 
of -blockers to inhibit these metabolism pathways can be a problem, and the diabetic taking 
-blockers can remain or become hypoglycaemic. 
 
The 1-selective adrenoceptor antagonists, metoprolol and atenolol, are selective, not 
specific, for 1-adrenoceptors, and have some effects at 2-adrenoceptors.  The selective 1-
blockers are preferred to propranolol in the treatment of hypertension, but not really for any 
benefits relating to the selectivity, more because they have less centrally-β-adrenoceptor 
mediated side effects e.g. nightmares, due to a lesser ability to get into the central nervous 
system than propranolol.  Metoprolol and atenolol are, like the non-selective -blockers, 
contraindicated in asthmatics, but (unlike propranolol) can be used with caution in subjects 
with diabetes. 
 
Esmolol was developed as a short acting non-selective -adrenoceptor blocker for 
intravenous use in critically ill patients with hypertensive emergency.  In some critically ill 
patients, blood pressure fluctuates widely. Esmolol is rapidly metabolised.  In critically ill 
patients who are hypertensive, esmolol is administered by continuous intravenously to reduce 
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blood pressure.  If the blood pressure suddenly dips, the esmolol infusion is stopped, and the 
-adrenoceptor blockade is quickly removed. 
 
On the eye, adrenaline stimulates 2-adrenoceptors to promote aqueous humour formation, 
and the more aqueous humour is in the eye, the higher the pressure is in the eye.  Timolol is a 
competitive reversible antagonist at these receptors, and is used locally to prevent the 
production of aqueous humour, and decrease the pressure in the eye, making it useful in 
glaucoma, where there is an increased intraocular pressure.  Glaucoma is the leading cause of 
irreversible blindness.  It is usually associated with elevated pressure in the eye (elevated 
intraocular pressure).  This pressure leads to damage to the optic nerve (optic neuropathy), 
which in turn leads to loss of vision, starting with peripheral vision.  Timolol is a non-
selective -blockers, which potentially has the potential to block all the -adrenoceptors in 
the body, but by applying timolol directly to the eye, we limit its effects to a local area.  
 
The effects of the sympathetic nervous system are often opposed by the other part of the 
autonomic nervous system, the parasympathetic nervous system. 
 
 
7.2. Drugs and the parasympathetic nervous system 
 
 7.2.1 The parasympathetic nervous system 
The parasympathetic nerves emerge from the cranio-sacral region of the spinal cord, and have 
long pre-ganglionic fibres that release acetylcholine on to NN receptors at the ganglia (Figure 
14.1).  The short post-ganglionic fibre also releases acetylcholine, but this time on to 
muscarinic receptors. 
 
Figure 7.7 Parasympathetic nervous system (Copyright QUT, Sheila Doggrell) 
 
There are at least 3 types of functional muscarinic receptors in the periphery: M1- (which are 
found in the stomach), and muscarinic M2- and M3-receptors (which are found on other end 
organs and glands). 
 
7.2.2 Effects of the parasympathetic nervous system 
Many of the effects of the parasympathetic nervous system oppose those of the sympathetic 
nervous system.  For instances, on the heart, acetylcholine is released from the 
parasympathetic nervous system to act at M2 receptors on the sinoatrial node (the pacemaker 
in the atria) to slow the heart rate.  Acetylcholine also acts on the M2 receptors on the 
ventricles, but this only causes a small decrease in heart force.  The predominant effect of the 
parasympathetic nervous system on the heart is to slow the heart beat. 
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On the lung, acetylcholine stimulates M2 and M3 receptors on trachea and bronchial smooth 
muscle to induce bronchoconstriction.  On the lung, acetylcholine also stimulates M2 and 
M3 receptors on glands, to promote the release of secretions. 
 
On the gut, acetylcholine stimulates M2 and M3 receptors to increase motility and tone.  On 
the gut, acetylcholine also stimulates M2 and M3 receptors on sphincters to cause 
relaxation.  Thirdly, on the gut, acetylcholine stimulates M2 and M3 receptors on glands to 
promote release of secretions. 
 
On the urinary bladder, acetylcholine predominantly stimulates M3-receptors on the 
detrusor muscle of the bladder (bulb part) to cause contraction.  Acetylcholine predominantly 
stimulates M3 on the trigone and sphincter muscle to cause relaxation, and release the urine.  
Thus, the overall effect of acetylcholine on the bladder leads to micturition (urination). 
 
On the eye, acetylcholine Ach stimulates M2 and M3 receptors on the sphincter muscle of the 
iris to cause miosis (constriction of pupil).  Acetylcholine also stimulates M2 and M3 
receptors on the ciliary muscle to cause contraction for near vision.  Finally, acetylcholine 
stimulates M2 and M receptors on the lacrimal glands to increase the secretion of tears. 
 
The effects of the parasympathetic nervous system can be mimicked with muscarinic agonists 
and prevented with the anti-muscarinic agents. 
 
 7.2.3 Muscarinic agonists 
The most logical way to mimic the parasympathetic nervous system is to give acetylcholine. 
Acetylcholine is not active after oral administration, and intravenous acetylcholine has 
widespread peripheral effects, some of which are beneficial and some of which are 
detrimental.  As a quaternary ammonium compound, acetylcholine does not penetrate the 
central nervous system after intravenous administration, and consequently has no central 
effects.  Acetylcholine is rapidly degraded by the enzyme pseudocholinesterase, and is found 
in the plasma, which means that acetylcholine has a very short half-life.  For all these 
reasons, acetylcholine is not suitable for clinical use. 
 
Pilocarpine is a muscarinic agonist that can by used clinically.  Pilocarpine is a naturally 
occurring cholinomimetic alkaloid, which does not have much similarity to acetylcholine in 
structure, but does selectively stimulate muscarinic receptors.  Pilocarpine is used topically.  
Pilocarpine is resistant to cholinesterases, which means they have a longer action than 
acetylcholine.  Pilocarpine is selective for muscarinic receptors, and is used to mimic 
particular effects of the parasympathetic nervous system. 
 
On the eye, acetylcholine stimulates aqueous humour outflow, and when the aqueous humour 
leaves the eye, the intraocular pressure decreases.  Pilocarpine eye drops are used in 
glaucoma to increase aqueous humour outflow, which decreases intraocular pressure and the 
damage caused by an increased intraocular pressure.  The miotic action of stimulating 
muscarinic receptors with pilocarpine also reverses the sight distortions associated with 
glaucoma. 
 
 7.2.4 Antimuscarinic agents 
The antimuscarinics agents can be used to reverse the effects of the parasympathetic nervous 
system.  There are three groups of antimuscarinics agents.  Firstly, the naturally occurring 
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alkaloids such as atropine and hyoscine (which is also known as scopolamine) were the first 
antimuscarinics agents characterised.  Secondly, there are the semi-synthetic derivatives such 
as Homatropine and ipratropium.  Thirdly, there are synthetic congeners such as 
oxybutynin. 
 
Homatropine has a shorter duration of action than atropine, and is used when a short acting 
effect is required e.g. some eye applications.  Ipratropium is quaternized and does not cross 
the blood brain barrier or readily cross membranes, and is used when systemic absorption is 
not required e.g. nasal spray for rhinorrhea, inhalation for bronchial effects. 
 
Atropine is active after oral administration, does not select between M receptors, and has 
widespread effects, both beneficial and detrimental.  Atropine is not commonly used 
clinically, as it will have many adverse effects.  The exception is the use of atropine for its 
ability to reverses the effect of acetylcholine to slow heart rate.  Thus, atropine is used to treat 
bradyarrhythmias (slow irregular heart rhythms), in the emergency situation, where it is 
administered intravenously. 
 
Inhalation of ipratropium provides the reversal of bronchoconstriction (bronchodilation).  
Ipratropium is used in the treatment of allergic rhinitis (as a nasal spray), and in asthma, and 
Chronic Obstructive Pullmonary Disease (COPD) by inhalation.  COPD is the combination 
of chronic bronchitis and emphysema, which is common in long term smokers.  
Antimuscarinics in combination with β2-adrenoceptor agonists are also available for use in 
COPD e.g ipratropium with salbutamol.  Improvement with ipratropium in COPD is 
relatively small, but it is used as there are no drugs that give major benefits in the treatment 
of COPD. 
 
Acetylcholine increases gut motility.  Antimuscarinic agents decrease gut motility.  Hyoscine 
is occasionally used in the treatment of the diarrhea associated with irritable bowel 
syndrome, and as an aid to endoscopy. 
 
Functional muscarinic M receptors on the urinary bladder are M3, and this has prompted the 
search for M3 selective antagonists to use in overactive bladder, as by selecting for M3 
receptor, many detrimental effects due to blocking the other M receptors would be avoided.  
Oxybutynin shows some selectivity for M3 receptors.  As a consequence, oxybutynin lower 
intravesicular (bladder) pressure, increase capacity, and reduces the frequency of contraction 
of the urinary bladder.  Oxybutynin is used in the treatment of overactive urinary bladder 
disease, and enuresis (bed wetting) in children.  However, the selectivity for M3 receptors 
with oxybutynin is only partial, and the oral administration of these agents is still associated 
with dry mouth and dry eyes, which are side effects due to blocking M2 receptors. 
 
Atropine blocks the effects of acetylcholine on the eye to cause mydriasis (dilation of the 
pupil) and cycloplegia (paralysis of ciliary muscle, and loss of accommodation, and this is the 
basis for the ophthalmologic uses of antimuscarinics agents.  The antimuscarinics are given 
as eye drops to promote mydriasis and cycloplegia.  The mydriasis is required for the 
examination of retina and optic nerve.  Cycloplegia is required to allow measurement of 
refractive errors.  In ophthalmology, the shorter acting antimuscarinics such as homatropine 
are preferred, as they allow the subject to recover/see more quickly.  
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 8.1 The somatic nervous system 
The somatic/voluntary nervous system is distinguishable from the branches of the autonomic 
nervous system by having no ganglia.  The nerves arising from the spinal cord release 
acetylcholine onto NM, the nicotinic receptors associated with skeletal muscle (Figure 8.1). 
 
Figure 8.1 Neuromuscular junction (Copyright QUT, Sheila Doggrell) 
 
Acetylcholine receptors were initially divided on their basis of responses to nicotine and 
muscarine, into those that responded to nicotine, nicotinic receptors, and those that responded 
to muscarine, muscarinic receptors.    The NN receptors are found at the autonomic ganglia, 
adrenal medulla and within the central nervous system.  The NM receptors are found on 
skeletal muscle innervated by the somatic nervous system.  The NM receptor can be 
stimulated by increasing the concentration of acetylcholine in the synapse and inhibited by 
neuromuscular blockers. 
 
8.2 Anticholinesterases 
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In order to stimulate NM receptors, anticholinesterases are used to prevent the breakdown of 
acetylcholine, and build up the concentrations of acetylcholine at the NM receptors.  This was 
discussed in eChapter 3. 
 
 8.3 Neuromuscular blockers 
There are two types of neuromuscular blockers, non-depolarizing (which are competitive 
antagonists) and depolarizing antagonists.  The non-depolarizing (competitive) antagonists 
have no effect alone, but prevent Ach binding to NM-receptors.  The first non-depolarizing 
antagonist was tubocurarine.  Tubocurarine was known as curare and was used on in arrow 
heads to immobilize animals.  Newer examples of non-depolarizing neuromuscular blockers 
include mivacurium, vecuronium, and rocuronium.  Tubocararine is long acting, and 
difficult to fully reverse.  The long acting non-depolarizing agents have been replaced by 
intermediate (vecuronium) and short-acting neuromuscular blockers (mivacurium).  
Vecuronium and mivacurium have a clinical duration of 60-90 minutes and 12-18 minutes, 
respectively, whereas rocuronium has a rapid onset (1-2 minutes) and intermediate duration 
(30-60 minutes). 
 
The depolarizing neuromuscular blocker is succinylcholine (also known as 
suxamethonium), which initial causes depolarization/agonism with small contractions of the 
skeletal muscle.  This is followed by causing persistent depolarization, which prevents the 
activation by acetylcholine and the skeletal muscle remains flaccid (relaxed).  The effects of 
succinylcholine usually last for 5 minutes as it is rapidly metabolised by 
pseudocholinesterase.  One in 3000 people are deficient in pseudocholinesterase, and in these 
people the effects of succinylcholine lasts for 20 h, as it is slowly metabolised. 
 
The neuromuscular blockers are used to cause paralysis of skeletal muscle.  The last muscles 
to be affected are the intercostal and diaphragm muscles.  This means that there can be 
paralysis of other skeletal muscles without paralysis of respiration, which is good as paralysis 
of respiration can be deadly.  The neuromuscular blockers are quaternary N+ compounds.  As 
discussed in eChapter 1, quaternary N+ compounds are poorly absorbed after oral 
administration, and are used intravenously. 
 
The main clinical use of neuromuscular blockers is an adjuvant in surgical anaesthesia to 
cause relaxation of skeletal muscle.  The neuromuscular blockers are also used to cause 
relaxation of skeletal muscle in intensive care.  The use of neuromuscular blockers is limited 
to anesthesiologists or other clinicians with extensive training in their use, and the choice of 
agent depends on duration of paralysis required. 
 
The neuromuscular blockers have to be given to cause relaxation of muscles in arms and legs, 
without paralysing respiration muscle.  When too much neuromuscular blocker has been 
given, it is essential to understand the interaction with anti-cholinesterases.  Non-
depolarizing/competitive reversible antagonism can be overcome by increasing the 
concentrations of acetylcholine in the synapse with an anti-cholinesterase (e.g. neostigmine).  
Ach will compete with non-depolarising agent for receptor and displace it, and thus decrease 
the effect of the antagonist.  Depolarizing antagonism cannot be overcome by increasing the 
concentrations of acetylcholine in the synapse with an anti-cholinesterase. Ach will cause 
further depolarisation and make the block worse  
 
 8.4 Botox 
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Anaerobic bacterium Clostridium botulinum produces several toxins including botulinum 
toxin A (commonly known as Botox).  Botox blocks the release of acetylcholine from all 
cholinergic nerve endings.  This means that Botox inhibits the release of acetylcholine from 
the preganglionic nerves of the autonomic nervous system (both parasympathetic nervous 
system and sympathetic nervous system), from the postganglionic nerves of parasympathetic 
NS, and from the somatic nervous system.  Thus, Botox inhibits the actions of the autonomic 
and somatic nervous system.  The blockade with Botox lasts 3 to 4 months, and restoration of 
function requires nerve growth.  Clinically, Botox is used to treat muscle spasms in a variety 
of conditions.  Botox is best known for its use in cosmetic surgery.  Because Botox is 
extremely toxic, miniscule amounts are used and with intramuscular administration, there is 
only a local effect. 
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9. Drugs and neurotransmitters 
9.1 Introduction 
Every step, in the physiological system for a neurotransmitter, is a possible step at which 
drugs can modify the effects of the neurotransmitter.  Thus, most neurotransmitters are 
synthesised, stored, released, and have receptor mediated effects involving cell signaling, 
before the neurotransmitter is inactivated by being broken down (metabolism) or be transport 
back into the nerve.  Thus, synthesis, release, receptors, cell signaling, and inactivation are all 
sites at which drugs can modify the actions of neurotransmitters.  In theory, drugs can 
increase or decrease any of the steps.  In this chapter, one or two important examples of drugs 
acting at each of these steps is considered. 
 
9.2 Synthesis 
The example of a drug that can increase the synthesis of a neurotransmitter is L-DOPA.  L-
DOPA is used to increase the levels of dopamine, a neurotransmitter in the brain, in 
Parkinson’s disease.  Normal ageing is associated with a loss of dopaminergic neurones 
(nerves that contain dopamine) in the central nervous system.  However, there is a greater 
loss of dopaminergic neurones in Parkinson’s disease, which was first described by 
Parkinson.  Thus, a 70-80% loss of dopaminergic neurones is associated with Parkinson’s 
disease.  
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The clinical syndrome that distinguishes Parkinson’s disease consists of 4 parts.  Firstly, there 
is bradykinesia (which is a slowness/poverty of movement).  Secondly, there is muscular 
rigidity, which makes starting a movement difficult.  There may also be resting tremors but 
these usually stop during voluntary movement.  Lastly, there is impairment of balance, with 
disturbances of gait (movement of limbs) and the subjects with Parkinson’s disease lean 
forward.  Impairment of balance leads to an increased risk of falling. 
The main treatment of Parkinson’s disease is to enhance the dopaminergic system.  Probably, 
the most obvious way to enhance the dopaminergic system is to give dopamine.  However, 
dopamine is not active after oral administration as it is metabolised by 2 enzymes (monamine 
oxidase and catechol-O-methyl transferase), which are found in the gut.  To avoid intestinal 
metabolism, dopamine can be administered intravenously.  But, after intravenous 
administration, dopamine does not cross the blood brain barrier to have central effects.  Thus, 
we cannot use dopamine in Parkinson’s disease. 
A very important way to enhance the dopaminergic system is to increase the synthesis of 
dopamine.  L-DOPA is the precursor of dopamine.  It is absorbed from the gut on the 
transporter system for the aromatic amino acids.  L-DOPA also gains entry into central 
nervous system, with transport across the blood brain barrier also being mediated by the 
transporter for the aromatic amino acids.  Once in dopaminergic neurones, L-DOPA is 
converted to dopamine.  When the dopaminergic neurones are activated, the dopamine is 
released and overcomes the symptoms of Parkinson’s disease. 
9.3 Release 
The next level at which the actions of a neurotransmitter can be modified is at the level of 
release.  Theoretically, drugs can be used to inhibit or increase the release of 
neurotransmitters.  A drug that inhibits the release of neurotransmitters is lignocaine.  
Lignocaine is a Na+ channel blocker.  The conduction of impulses along nerves requires the 
opening and closing of sodium channels.  Lignocaine is commonly used as a local 
anaesthetic, as application to afferent/sensory nerves stops the conduction of impulses that 
translate into the sensation of pain in the brain.  Thus, prior to minor surgery, lignocaine can 
be used locally to dull pain. 
 
A drug that increases the release of a neurotransmitter is amantadine.  Thus, a second 
approach to enhancing dopaminergic neurotransmission in Parkinson’s disease, is to promote 
the release of endogenous dopamine.  Amantadine increases the release of dopamine from the 
dopaminergic nerves in the brain.  Amantadine is not very effective alone.  It is only used 
alone in the early stages of Parkinson’s disease where there are still sufficient stores of 
endogenous dopamine to allow amantadine to release dopamine. 
9.4 Receptors 
Drugs can act at receptor to mimic the effect of the endogenous substance, and this is known 
as agonism.  Conversely, drugs can act at receptors to block the effects of endogenous 
substances, and this is antagonism.  The sites of actions of drugs can be limited, if the drug 
shows selectivity for a receptor.  Examples from the sympathetic nervous system are to be 
used to explain this.  Noradrenaline (released from the sympathetic nervous system) and 
adrenaline (released from the adrenal medulla) stimulate all the peripheral adrenoceptors to 
have widespread effects.  They can act on the β2-adrenoceptors in the lung to cause 
bronchodilation, and they can act on the β1-adrenoceptors of the heart to increase heart rate 
and force.  The selective β2-adrenoceptor agonist salbutamol has no effect at α-
adrenoceptors, and is selective for β2- over β1-adrenoceptors.  Salbutamol is the standard 
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selective β2-adrenoceptor agonist used to cause bronchodilation in an asthma attack. The β1-
selective adrenoceptor antagonist atenolol is selective, not specific, for β1-adrenoceptors, and 
have some effects at β2-adrenoceptors.  The selective β1-blockers are used in the treatment of 
hypertension. 
 
9.5 Cell signaling 
There are not a lot of drugs used for their ability to interfere with the cell signaling of 
neurotransmitters, probably because it is usually easier to target the receptor for the 
neurotransmitter. Benzodiazepines (e.g. diazepam) are the main drugs used to treat anxiety 
and insomnia, and to cause sedation.  The benzodiazepines potentiate the effects on an 
inhibitory neurotransmitter in the central nervous system by modifying its cell signaling.  
This inhibitory neurotransmitter is gamma (γ)-aminobutyric acid (GABA).  There are cell 
surface receptors for GABA and there are two main types GABAA and GABAB.  The 
GABAA receptor is the one the benzodiazepines interact with.  The GABAA receptor has 5 
subunits that form a Cl- channel (Figure 9.1).  Benzodiazepines bind to a distinct binding site, 
the benzodiazepine binding site on the GABAA receptor to potentiate the effect of GABA, 
which is to open the chloride channel, and the more chloride that goes through the channel, 
the bigger the inhibitory effect.  Benzodiazepines have no effect alone, and are only effective 
when GABA is present. 
  
Figure 9.1 Benzodiazepine binding site, GABAA receptor and chloride channel (Copyright 
QUT, Sheila Doggrell) 
9.6 Inactivation 
Neurotransmitter can be inactivated by metabolism or by being transported back into the 
nerve to be used.  Drugs that modify the actions of the neurotransmitter at the level of 
metabolism usually inhibit it to increase the level of the neurotransmitter.  Similarly drugs 
that modify at the level of the transporter usually inhibit, and the level of the 
neurotransmitter.  
 
9.6.1 Inactivation by metabolism 
A drug used to inhibit the metabolism of a neurotransmitter is entacapone, which is used to 
increase the levels of dopamine in Parkinson’s disease.  Parkinson’s disease is a progressive 
disease, which means there is a progressive loss of dopaminergic neurones.  The 
dopaminergic neurons are needed to convert the L-DOPA to dopamine.  Thus, with a 
decreasing number of dopaminergic neurones present, there is decreasing ability of 
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dopaminergic neurones to convert L-DOPA to dopamine.  Catechol-O-methyl-transferase 
(COMT) is one of the enzymes involved in the metabolism of dopamine. In the periphery, 
catechol-O-methyl-transferase also metabolises L-DOPA, and this metabolism leads to 
inactivation of the L-DOPA.  Entacapone is an inhibitor of catechol-O-methyl-transferase.  In 
the periphery, the ability of entacapone to inhibit the inactivation of L-DOPA leads to more 
L-DOPA being available to be transported into the central nervous system.  In the central 
nervous system, entacapone lead to increased levels of dopamine by preventing its 
metabolism by entacapone.  
  
9.6.2 Inactivation by transport back into the nerve 
An example of a drug that inhibits the inactivation of a neurotransmitter back into a nerve is 
fluoxetine (Prozac).  Fluoxetine inhibits the inactivation of the neurotransmitter 5-
hydroxytryptamine (5-HT), which is useful in the treatment of major depression.  Major 
depression is depression out of proportion with the cause of the depression.  Major depression 
is classically characterized by feelings of intense sadness and despair, mental slowing and 
loss of concentration, pessimistic worry, lack of pleasure, self-deprecation, and agitation or 
hostility.  Major depression is characterised by physical changes, such as insomnia or 
hypersomnia (sleeping too much), altered eating patterns, decreased energy and libido, and 
disruptions of normal circadian rhythms (e.g. hormonal secretion times are altered). 
On activation of the tryptaminergic nerve terminal, 5-HT is released and stimulates 5-HT 
receptors on the postjunctional membrane to have an effect.  5-Hydroxytryptamine (is 
inactivated by transport back into the neurone on the serotonin transporter (SERT), and this 
leads to the termination of action of 5-HT.  The short term effect of fluoxetine (Prozac) is to 
selectively inhibit the SERT transporter, which inhibits the inactivation of 5-HT.  
Consequently, there are increased levels of 5-HT in the synapse, which leads to an increased 
stimulation of receptor, and an increased effect.  Fluoxetine is selective for the SERT 
transporter, and has little effect on the transport of noradrenaline.  Fluoxetine is one example 
of a group of drugs known as the selective serotonin reuptake inhibitors (SSRIs). 
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LOCAL CHEMICAL MEDIATORS 
Cell-to-cell communication is the key to most processes in the body, and this cell-to-cell 
communication uses chemical mediators.  Chemical mediators are classified into four groups: 
nervous, endocrine, paracrine, and autocrine (Table 10.1). 
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Table 10.1 Chemical mediators (modified from Table 29.1 in Bullock S et al) 
 
Nerves secrete neurotransmitters that act over a short range, and have a relatively rapid 
action.  The neurotransmitters in the peripheral nervous systems have already been discussed  
and drugs and the central nerve system will be discussed in future chapters.  Endocrine glands 
secrete hormones into the blood, where they circulate until they find their target receptor.  
The actions of hormones are relatively prolonged.  Various hormones are discussed further in 
Systematic pharmacology.  The other groups of chemical mediators, paracrine and autocrine 
secretion, are involved in local actions.  Paracrine secretions are of local hormones released 
into the circulation to have an effect on a neighbouring cell.  These actions are relatively 
rapid.  The local hormones to be discussed are the prostaglandins, nitric oxide and endothelin.  
Actually, some of the actions of the prostaglandins are autocrine, whereby the action is on the 
secreting cell.  Histamine, 5-hydroxytryptamine (5-HT) and cytokines also have some 
autocrine activity.  As there is overlap between the paracrine and autocrine actions of some 
chemical mediators, I prefer just to call the combination of local hormones and autocoids, 
local chemical mediators.  In the following sections, some important local chemical 
mediators are discussed, and how drugs can modify the effects of these chemical mediators 
are considered. 
 
10.1 Histamine and Cytokines 
 
The highest concentrations of histamine in the body are stored in mast cells, a cell found in 
connective tissue that contains granules of chemicals including histamine.  In the periphery, 
histamine is an autocoid.  The two best characterised effects of histamine are its major roles 
in allergy and in gastric secretion. Histamine is stored in secretory granules in mast cells, and 
basophils (circulating equivalent of mast cells).  The highest levels of histamine are found in 
lungs, followed by the mucous membranes, skin, stomach, and central nervous system.  
Histamine is released from mast cells and basophils in tissue damage or in hypersensitivity 
reactions.  Histamine H1- receptors mediate hypersensitivity, while histamine H2- receptors 
mediate gastric acid secretion.   
 
 10.1.2 Actions of histamine 
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Histamine has a major role in Type 1 allergic reaction, which is the most common type of 
allergic reaction.  Type 1 allergy can lead to anaphylactic reactions.  Type I allergy is also 
known as immediate hypersensitivity reaction, and is often just called allergy.  Allergy can be 
caused by a number of things including grass pollen, house dust mites, certain foods, animal 
fur….  Medicines that can cause allergy include aspirin, angiotensin converting enzyme 
inhibitors, and penicillin.  With allergy, there is the release of contents of the mast cells and 
basophils.  The contents of mast cells include histamine, eicosanoids, and cytokines.  There 
local chemical mediators cause vasodilation, oedema, and inflammation.  Sometimes allergy 
is limited to certain sites e.g. food allergies affect gastrointestinal tract.  Whereas contact 
allergies may be limited to skin, where allergy is manifest as urticaria (hives) and atopic 
dermatitis (itching + raised red rash).  Allergy to inhalants e.g. grass pollen, may be limited to 
the respiratory system and manifest as rhinitis and asthma.  Mild allergic conditions may be 
treated with antihistamines.  Antihistamines are not effective in severe allergic reactions e.g. 
anaphylaxis, as mediators other than histamine are also involved. 
 
On the lung the hypersensitivity reaction of histamine is a H1-receptor-mediated 
bronchoconstriction.  On the nasal mucous membranes/skin, the hypersensitivity reaction is a 
H1-receptor-mediated dilation of terminal arterioles, which leads to the accumulation of red 
blood cells and produces the redness associated with allergy.  In the severe hypersensitivity 
reaction anaphylaxis, histamine H1-receptor mediated dilation causes a major decrease in 
blood pressure (hypotension).  The H1-receptor-mediated contraction of the endothelial cells 
of capillaries increases the space between the cells, allowing the contents of the capillaries 
(fluids, proteins) to flow into extracellular space to cause oedema (hives) (Figure 10.1). 
 
Figure 10.1 Oedema with histamine (Copyright QUT, Sheila Doggrell) 
 
The other major effect of histamine in the periphery is a H2-receptor mediated increase in 
gastric secretion.  Histamine is released, possibly from the enterochromaffin cells in the gut, 
and acts at H2-receptors on the parietal cells.  Stimulation of the H2-receptors leads to 
activation of adenylate cyclase, which in turn activated the H+/K+ ATP-ase, the proton pump.  
The proton pump, pumps H+ into the stomach to cause the acid environment. 
 
10.1.3 Drugs that modify the actions of histamine 
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Theoretically, the effects of histamine (and any other chemical mediator) can be modified at 
every level of the system; i.e. at the level of synthesis, release, receptors, cell signaling and 
breakdown.  With histamine we have important drugs that modify at the level of release and 
receptors.  The release of histamine from mast cells is inhibited by cromoglycate, which is 
occasionally used to prevent allergic rhinitis.  Cromoglycate is only effective if the histamine 
is still in the mast cells.  After the histamine has been released, it is too late for cromoglycate 
to have an effect.  
 
Another level at which the effects of histamine is at the receptors.  Antagonists at H1-
receptors are commonly used in the treatment of allergic rhinitis, conjunctivitis (allergy of 
the eye), and chronic urticaria (skin allergy).  The first generation (older) H1-receptor 
antagonists crossed the blood brain barrier and caused sedation. Examples of first generation 
H1-receptor antagonists include dexchlorpheniramine and diphenyhydramine. 
Dexchlorpheniramine is still used in the treatment of allergic rhinitis, conjunctivitis, and 
chronic urticaria, whereas diphenyhydramine is no longer used for hypersensitivity reactions, 
but is used as a mild sedative in insomnia.  The second generation H1-receptor antagonists are 
less able to cross the blood brain barrier and cause less sedation.  An examples of a second 
generation H1-receptor antagonists is fexofenadine.  
 
Antagonists at H2-receptors revolutionized the treatment of peptic acidity conditions such 
as peptic ulcer disease, gastro-oesphogus reflux disease (GORD), and dyspepsia, as there had 
been no good treatments previously.  An example of an H2-receptor antagonist is ranitidine 
(Ranitic).  Ranitidine is a relatively safe drug and is available over-the-counter (OTC) 
without a prescription in low doses.   
 
As histamine acting at the H2-receptor is only one of the stimulants of acid secretion, H2-
receptor antagonists are only effective against the histamine component.  There are other 
stimulants of gastric secretion such as gastrin and acetylcholine, and H2-receptor antagonists 
do not inhibit this stimulation of acid secretion whereas proton pump inhibitors do.  Thus 
proton pump inhibitors are often preferred to the H2-receptor antagonists in peptic acidity 
conditions, as they are more effective. 
 
 10.1.4 Cytokines 
In addition to allergy, cytokines have a role in inflammatory conditions, especially in 
autoimmune-inflammatory conditions such as rheumatoid arthritis.  Cytokines are small 
secreted proteins that mediate and regulate inflammation, immunity, and haematopoiesis.  
Cytokines generally act over short distances, short time spans, and at very low 
concentrations.  They act to alter gene expression.   
 
Interleukins (IL) are cytokines made by one leukocyte and acting on other leukocytes.  
There are many interleukins, but IL-1 is the main one associated with inflammation.  IL-1 
stimulates T-lymphocytes to produce IL-2, which promotes inflammation, and causes fever.  
IL-2 stimulates growth and activation of other T cells and NK (natural killer) cells.   
 
Tumour necrosis factor (TNF) is the other cytokine that has a prominent role in 
inflammation.  TNF kills tumour cells, and hence the name.  TNF stimulates the activities of 
T cells and eosinophils, which are cells involved in the inflammatory process. 
 
The interleukin, IL-1, is the main one associated with inflammation.  Anakinra is an IL-1 
antagonist used in the severe inflammation associated with rheumatoid arthritis.  It is 
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administered subcutaneously.  Anakinra commonly causes allergy, and treatment has the 
possibility of allowing serious infection, as the interleukins also have a major role in 
immunity.   
 
Tumour necrosis factor (TNF) is the other cytokine that has a prominent role in 
inflammation.  Infliximab is an antibody to TNF.   Infliximab is administered intravenously, 
every 8 weeks in the hospital setting. During treatment with infliximab, bacterial infection is 
infrequent.  Infliximab is used in the treatment of rheumatoid arthritis and ankylosing 
spondylitis (degenerative inflammatory arthritis affecting the spine and sacroiliac joints). 
 
10.2 Eicosanoids  
Eicosanoids are also known as the arachidonic acid derivatives.  There are 3 types of 
eicosanoids; prostaglandins (PGs), thromboxanes (TXs), and Leukotrienes (LTs).  The 
eicosanoids are local hormones, which means they have effects close to where they are 
produced. 
 
 10.2.1 Cyclooxygenase (COX) and lipooxygenase system 
Arachidonic acid is acquired either as part of meat or from dietary linoleic acid (Figure 17.1).  
Normally, there is little free arachidonic acid, as it is readily incorporated into the 
phospholipids of the cell membrane. 
 
Figure 10.2 Cyclooxygenase and lipooxygenase pathways (Copyright QUT, Sheila Doggrell) 
 
The release of arachidonic acid from the phospholipids of the cell membranes requires the 
activation of the enzyme phopholipase A2.  Phospholipase A2 is activated by a whole range 
of physical, chemical, hormonal, neuronal and immunological stimuli.  Once released, 
arachidonic acid is readily metabolised.  In the areas where the enzyme cyclooxygenase is 
present, arachidonic acid is metabolised to prostaglandins and thromboxanes.  In the areas 
where the enzyme lipooxygenase is present, arachidonic acid is metabolised to leukotrienes 
(Figure 10.2).   
 
The eicosanoids produced from the cyclooxygenase pathways are prostaglandins (PGs), 
including PGI2 (which is also known as prostacyclin), and thromboxane A2 (TXA2).  The 
eicosanoids produced from the lipooxygenase pathways are known as leukotrienes (LTs).  
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The effects of all the eicosanoids are local and receptor mediated.  The actions of the 
eicosanoids are short, as they are rapid metabolised (inactivated) and there are no prolonged 
effects due to recirculation.  PGD2 acts at DP receptors, PGE2 acts at EP receptors (which 
have been further divided into EP1 and EP2), PGF2α acts at FP receptors, PGI2 acts at IP 
receptors, and TXA2 acts at TP receptors.  The products of the lipooxygenase pathway, the 
LTs, act at LT receptors. 
 
10.2.2 Actions of eicosanoids 
The eicosanoids have many, many actions.  The actions discussed here are those that we 
modify with medicines.   
 
Eicosanoids from both the cyclooxygenase and lipooxygenase pathways have a major role in 
inflammation.  With a variety of physical, chemical, bacterial, and immunological stimuli, 
phospholipase A2 is activated, and the cyclooxygenase pathway is activated to produced 
prostaglandins, and the lipooxygenase pathway to produced leukotrienes, and this 
combination leads to inflammation (Figure 10.3). 
 
Figure 10.3 Eicosanoids and inflammation (Copyright QUT, Sheila Doggrell) 
 
There are 3 components to inflammation; pain, erythema (redness) and oedema (swelling).  
The pain is partly due to prostaglandins E2 and I2 which sensitive afferent nerve endings (the 
sensory nervous system), and this causes an amplification of pain.  The erythema is due to 
both leukotrienes and prostaglandins, with the redness being due to vasodilation and 
congestion of blood vessels, with localised high concentrations of red blood cells.  The 
oedema is due to the leukotrienes increasing vascular permeability, and causing proteins to 
leave blood vessels in much the same way as histamine causes oedema (Figure 16.1).  To 
overcome eicosanoids-induced inflammation, drugs must inhibit both the cyclooxygenase and 
lipooxygenase pathways. 
 
The other actions of eicosanoids discussed here are those of the cyclooxygenase pathway 
only.  Firstly, PGE2 has a major role in fever.  Fever is associated with disease states, 
infections, tissue damage, and malignancy.  Fever involves increased PGE2 synthesis in 
hypothalamus, and PGE2 increases set point of body temperature to give the fever.  In some 
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situations this can be useful, e.g. increased body temperature probably helps fight bacterial 
infections by killing the bacteria.  However, excessive increases in temperature are harmful to 
a body designed to act at 370C.  To reduce fever, drugs need only inhibit the cyclooxygenase 
pathway. 
 
Secondly, the products of the cyclooxygenase pathway have important roles on the 
cardiovascular system.  PGs cause vasodilation of most vascular beds. An important role for 
PGE2 and PGI2 is to keep a specialised blood vessel, the ductus arteriosus (lung bypass), open 
prior to birth.  Often the effects of PGI2 and TXA2 oppose each other, thus whereas PGI2 
causes vasodilation, TXA2 causes vasoconstriction of most vascular beds.   
 
Platelets are a form of blood cells produced in the bone marrow.  Platelet aggregation is the 
first step in coagulation, and PGI2 prevents platelet aggregation, whereas TXA2 increases 
platelet aggregation.  The PGI2 is produced by the activity of the COX in the endothelial cells 
that line the inside of the blood vessels.  PGI2 activates the IP receptors on the platelet cells to 
increase the activity of adenylate cyclase and levels of cAMP, which prevents platelet 
aggregation (Figure 10.4). 
 
Figure 10.4 Prostacyclin and platelet aggregation (Copyright QUT, Sheila Doggrell) 
 
Thromboxanes do the opposite to prostacyclin i.e. TXA2 causes platelet aggregation.  When 
there is damage to a blood vessel, the area is no longer protected by endothelium released 
PGI2, and the platelets stick to collagen.  Once activated platelets produce TXA2, which 
initiates more platelet aggregation, by having the opposite effect on the platelet to 
prostacyclin.  Thus, TXA2 inhibits adenylate cyclase, to decrease levels of cAMP, and 
increase platelet aggregation.   
 
Platelet aggregation has an important role in blood vessel repair.  When the blood vessel is 
damaged, platelet aggregation is the first step in blood vessel repair, which takes place under 
the protection of the clot.  Unfortunately, excessive platelet aggregation is quite common, and 
can be part of several cardiovascular conditions.  Excessive platelet-platelet aggregation can 
partially block the blood vessel.  Blood flow can then dislodge the clump of platelets and they 
can move downstream to block a smaller vessel, the blockage is known as a thrombus, and 
the condition is thrombosis.  Coronary thrombosis underlies myocardial infarction (heart 
attacks).  Thus, it is important to avoid excessive platelet aggregation, which can be done by 
decreasing the levels of TXA2. 
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Thirdly, prostaglandins are cytoprotective in the stomach.   
 
Figure 10.5 Prostaglandins and acid production (Copyright QUT, Sheila Doggrell) 
 
PGE2 and PGI2 give protection from the damaging effects of acid in the stomach.  Thus, acid 
secretion induced by histamine, gastrin and food is countered by PGE2 and PGI2, which 
inhibit the acid secretion (Figure 10.5).  In addition to inhibiting acid secretion, PGE2 and 
PGI2 stimulate the production of mucus, which protects cells from acid. 
 
Finally, PGE2 and PGF2α, with the hormone oxytocin, contract the uterus to initiate labour 
and childbirth.  If these PGs are produced too early, labour occurs prematurely leading to 
preterm birth. 
 
The leukotrienes, produced by the lipooxygenase pathway, have a major role in immediate 
type hypersensitivity.  Thus, after an antigen-antibody reaction, mast cells release histamine 
and leukotrienes.  Histamine causes a histamine H1-receptor mediated bronchoconstriction, 
but this is minor compared to the effects of leukotrienes.  As the histamine H1-receptor 
antagonists are only effective against histamine, not leukotrienes, this explains why histamine 
H1-receptor antagonists are not effective in severe hypersensitivity, where leukotrienes are 
the major players.  The leukotrienes LTC4, LTD4 and LTE4 are potent bronchoconstrictors, 
which can lead to bronchospasm, and LTB4 is a chemotractant for neutrophils and 
eosinophils, which are cells prominent in inflammation.  The leukotrienes also stimulate 
mucous production. 
 
 10.2.3 Drugs that modify the actions of eicosanoids 
There are a number of ways that medicines are used to modify the actions of eicosanoids.  
Firstly, at the level of synthesis, the production of all the eicosanoids can be inhibited by 
inhibiting phospholipase A2 with the glucocorticoids.  Also, at the level of synthesis, the 
production of prostaglandins and thromboxanes, but not leukotrienes, can be inhibited by 
inhibiting COX.  There are two forms of COX, and both forms are inhibited by non-selective 
COX inhibitors such as aspirin, paracetamol, ibuprofen, and piroxicam.  COX-2 is selectively 
inhibited by celecoxib and diclofenac.  Secondly, the actions of the eicosanoids can be 
modified at the levels of the receptors.  Selective agonists are available for the EP receptors 
(misoprostol and dinoprostone), IP receptor (iloprost) and FP receptor (latanoprost).  These 
medicines are now discussed systematically. 
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  10.2.3.1 Inhibit phospholipase A2 
The glucocorticoids inhibit phospholipase A2 to reduce the activity of both cyclooxygenase 
and lipooxygenase, and decrease the levels of prostaglandins, thromboxanes, and 
leukotrienes.  Prostaglandins and leukotrienes are important, but not the only mediators of 
inflammation.  The glucocorticoids are potent anti-inflammatory agents and this is partly due 
to decreasing the levels of prostaglandins and leukotrienes, but this is not the only 
inflammatory mechanism of glucocorticoids. 
 
  10.2.3.2 Non-selective cyclooxygenase inhibitors 
Aspirin is a non-selective inhibitor of cyclooxygenase (COX), which leads to reduced 
production of prostaglandins, and thromboxanes, but not leukotrienes. There are a group of 
non-selective inhibitors of COX, which are known as the NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS (NSAIDs), to distinguish them from the steroid anti-
inflammatory drugs (the glucocorticoids).  NSAIDs include aspirin, paracetamol, 
ibuprofen, and piroxicam.  The NSAIDs are probably the most commonly used drugs. 
 
Aspirin is an irreversible non-selective inhibitor of COX, whereas all the other NSAIDs are 
reversible inhibitors of COX.  Aspirin reverses the effects of the prostaglandins, to be a mild 
analgesic, anti-pyretic, and partially anti-inflammatory.  Aspirin is only partially anti-
inflammatory as it only prevents the inflammatory effects to prostaglandins, not those to 
leukotrienes or other inflammatory mediators.  A novel action of aspirin is that low dose it 
inhibits platelet aggregation to be an anti-coagulant, by preferentially blocking synthesis of 
TXA2.  This preferential action may be related to the irreversible nature of aspirin.  Low dose 
inhibits platelet aggregation by preferentially blocking synthesis of TXA2, and this will be 
discussed more fully in the section on Cardiovascular Therapeutics.  Aspirin is used to 
prevent myocardial infarction/thrombosis. 
 
The two main problems with aspirin are ulcers and hypersensitivity.  Thus, chronic users of 
aspirin for its antithrombotic effect or of the other NSAIDs for analgesia, have a 2-4% of 
developing an ulcer.  The ulcers are due to removal of the cytoprotective effects of 
prostaglandins in the stomach.   
 
The hypersensitivity to aspirin is due to the inhibition of cyclooxygenase leading to a build 
up of arachidonic acid, which is then metabolised by the lipooxygenase pathway to 
leukotrienes (Figure 10.6) 
 
Figure 10.6 NSAIDs and hypersensitivity (Copyright QUT, Sheila Doggrell) 
 
Leukotrienes are potent mediators of hypersensitivity reactions such as rhinitis and asthma.  
Thus, the use of NSAIDs can be associated with hypersensitivity reactions, especially if 
people are susceptible.  For instance, 5-10% of asthmatics are sensitive to aspirin. 
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Paracetamol is an inhibitor of COX, and consequently reduces the levels of prostaglandins.  
Thus, paracetamol is effective as a mild analgesic, and as an antipyretic, and is usually 
preferred to aspirin for these indications, as it is milder on the stomach.  Paracetamol is NOT 
anti-inflammatory, possibly because some products of inflammation stop paracetamol from 
inhibiting COX.  Thus, paracetamol is not indicated for inflammation, and you need to use 
aspirin or other NSAIDs in the treatment of inflammation.  Paracetamol also has no effect on 
platelet aggregation or clotting, possibly because the effect of low dose aspirin to inhibit 
platelet aggregation and clotting may depend on aspirin being an irreversible inhibitor.  In 
contrast, paracetamol is a reversible inhibitor of COX and does not inhibit platelet 
aggregation.  The outcome of this is that you cannot substitute paracetamol for aspirin for 
cardioprotection, as it is not anti-thrombotic. 
 
Ibuprofen (Nurofen) is a non-selective COX inhibitor.  Ibuprofen can be used as an 
analgesic, an anti-pyretics and an anti-inflammatory agent in similar way as aspirin.  
Ibuprofen is effective in pain of low-to-moderate intensity, such as nonspecific relief of 
minor aches and pain (headache, arthritis, dysmenorrhea, neuralgia, myalgia).  Ibuprofen is 
also used in chronic conditions such as rheumatoid arthritis and osteoarthritis, where they are 
only partially effective as anti-inflammatory agents due to the mediators, other than 
prostaglandins, of inflammation.  Ibuprofen has a similar efficacy in these conditions as 
aspirin.  However, ibuprofen is generally preferred to aspirin as an analgesic, an anti-pyretics 
and an anti-inflammatory agent as it has greater tolerability than aspirin on chronic use i.e. 
less likely to cause ulcers.  However, ibuprofen has a lesser ability to inhibit platelet 
aggregation than aspirin, and is not suitable as agents to inhibit platelet aggregation e.g. in the 
secondary prevention of myocardial infarction or stroke. 
 
Piroxicam is a non-selective COX inhibitor, which is predominantly used as an anti-
inflammatory agent.  Independently of COX inhibition, piroxicam inhibits the activation of 
neutrophils, which is another anti-inflammatory mechanism, and contributes, to the anti-
inflammatory action of piroxicam.  Thus, piroxicam has more anti-inflammatory activity that 
the agents that just inhibit COX.  Piroxicam, like the other NSAIDs discussed above, is active 
after oral administration.  However, unlike the other NSAIDs discussed, piroxicam has a slow 
onset of action, and is slow to reach steady state (7-12 days), and has a t1/2 (half-life) of 
elimination is about 50 hours.  Because of the slow onset of action, piroxicam is not used in 
acute conditions (pain, fever), but is used in the long term treatment of chronic conditions 
such as rheumatoid arthritis and osteoarthritis. 
 
The major problem with non-selective NSAIDs is ulcers and gastrointestinal bleeding, 
especially with aspirin.  COX has too forms, COX-1 is constitutively expressed (always 
active e.g. stomach) whereas COX-2 is induced in response to stimuli.  NSAIDs inhibit 
COX-2 to reduce pain and inflammation, which are its beneficial effects, but NSAIDs also 
inhibit COX-1 to reduce levels of the cytoprotective prostaglandins, which is detrimental 
(Figure 10.7). 
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Figure 10.7 NSAIDs and COX-1 and COX-2 (Copyright QUT, Sheila Doggrell) 
 
Thus, drugs that are selective COX-2 inhibitors should give still be able to reduce pain and 
inflammation, but cause less COX-1 inhibition and less bleeding.  This was the rationale for 
developing selective COX-2 inhibitors. 
 
  10.2.3.3 Selective COX-2 inhibitors 
Rofecoxib is the most selective COX-2 inhibitor marketed to date.  Clinical trials showed 
that rofecoxib was very effective against the pain and inflammation of chronic conditions 
such as osteoarthritis and rheumatoid arthritis. Rofecoxib was very popular with patients, 
many of whom considered rofecoxib a wonder drug, as it gave them more relieve from pain 
and inflammation than NSAIDs.  As predicted, from the COX-2 selectivity, there was less 
gastrointestinal toxicity with rofecoxib than with non-selective NSAIDs.  However, 
eventually, rofecoxib was withdrawn for causing a slight increase in cardiovascular toxicity, 
mainly myocardial infarction (heart attacks).  This was an unexpected finding, and the reason 
for it is still being worked out.   
 
Celecoxib (Celebrex) is not as COX-2 selective as rofecoxib.  Unfortunately, this meant that 
it celecoxib is still able to inhibit enough COX-1 to induce some gastrointestinal toxicity.  
Indeed, clinical trials have failed to establish less gastrointestinal toxicity with celecoxib than 
with the non-selective NSAIDs.  With regard to COX-2 inhibitory effects, cardiotoxicity is 
borderline and/or disputed with celecoxib.  Celecoxib has not been withdrawn, but comes 
with a warning not to be used in subjects with cardiovascular or cerebrovascular disease i.e. 
subjects with increased cardiovascular risk.  Celecoxib is active after oral administration, 
lipophilic and widely distributed, with a t1/2 of elimination of 11 hours.  Celecoxib is 
commonly used for the relief of inflammation in osteoarthritis and rheumatoid arthritis.  
Celecoxib is also used to give relief from post-extraction dental pain. 
 
Although it has been around for many years, only recently has diclofenac (Voltaren) been 
shown to be a selective inhibitor of COX-2.  Diclofenac has a similar selectivity for COX-2 
to celecoxib.  Thus, the gastrointestinal toxicity and cardiotoxicity of diclofenac is similar to 
that of celecoxib.  Diclofenac has rapid absorption, with a short t1/2 (1-2 hours).  It is effective 
as an analgesic, antipyretic, and anti-inflammatory agent.  Diclofenac is used long term in 
osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis (a form of arthritis that affects 
the spine).  Diclofenac is also used short term use in acute musculoskeletal pain, 
postoperative pain, and dysmenorrhoea.   
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The quest for a selective COX-2 inhibitor is presently stalled, as although rofecoxib had less 
gastrointestinal toxicity than NSAIDs, it induced cardiotoxicity.  Celecoxib and diclofenac do 
not have the cardiotoxicity, but do not have acceptable levels of gastrointestinal tolerability.  
Another approach to prevent gastrointestinal toxicity is to use celecoxib and diclofenac with 
gastrointestinal protective medicines.  Diclofenac is available in combination with 
misoprostol.  Misoprostol stimulates EP receptors to provide gastric cytoprotection, as 
discussed in the next section.  The combination of diclofenac and misoprostol has decreased 
gastrointestinal toxicity, compared to diclofenac alone.  The proton pump inhibitors (PPIs) 
can also be used to give gastrointestinal protection.  Omeprazole is the prototype PPI. There 
are other –prazoles, which are all proton pump inhibitors e.g. esomeprazole.  In addition to 
being used alone in the treatment of peptic ulcer, gastric reflux etc, the PPIs are also used for 
the prevention and/or treatment of gastrointestinal adverse effects of NSAIDs. 
 
  10.2.3.4 Agonists at prostaglandin receptors 
A number of agonists, showing selectivity for one or other of the prostaglandin receptors, are 
used clinically.  Firstly, misoprostol is a selective EP1 receptor agonist.  Misoprostol was 
developed for use to provide gastric cytoprotection, and it does suppress gastric ulceration.  
Indeed, misoprostol is as effective as the H2-receptor antagonists at preventing gastric 
ulceration.  However, misoprostol alone is not commonly used to provide gastric 
cytoprotection, as the proton pump inhibitors are preferred, probably because they have a 
greater efficacy.  Misoprostol is used as a gastric cytoprotective with diclofenac, to prevent 
gastric ulceration with the diclofenac.  When misoprostol is used for gastric cytoprotection, it 
is contraindicated in pregnant women as is a powerful uterine stimulant, and may cause 
premature labour.  This was originally considered as a detrimental effect of misoprostol when 
it was being used as a gastroprotective agent.  However, this detrimental effect, lead to the 
clinical development of misoprostol for another use. 
 
One use for a uterine stimulant is to induce abortions.  However, the pharmaceutical 
companies have mainly steered clear of the abortion controversy.  Thus, the pharmaceutical 
company that developed misoprostol, as a cytoprotective agent, did not go on to develop 
misoprostol as a uterine stimulant.  This development was done by others, mainly University 
clinical academics, and represents the off-label development of misoprostol as a uterine 
stimulant.  When pregnancy is complicated by early death, misoprostol is used to remove the 
remnants.  Misoprostol is not used alone for abortion but misoprostol is used with the 
progesterone antagonist mifepristone for early abortion.  The main adverse effect, when 
using misoprostol as a uterine stimulant, is gastrointestinal (diarrhoea).  
 
Dinoprostone is a selective EP2 receptor agonist, which increases contractions of uterus.  
Dinoprostone also relaxes the cervix.  This combination of effects makes dinoprostone useful 
in the induction or augmentation (increasing) of labour, especially when the cervix is not 
dilating. 
 
Selective agonists are also available for the prostacyclin (PGI2) IP receptors.  Prostacyclin 
inhibits platelet aggregation and is a potent vasodilator.  PGI2 is not active after oral 
administration, and is rapidly broken down.  Thus to use prostacyclin clinically, a continuous 
infusion is required, and this is not always convenient.  Iloprost is a synthetic analog of PGI2, 
which stimulates the IP receptors with a longer half-life than PGI2.  Iloprost is used in the 
treatment of pulmonary hypertension, a condition in which the hypertension is limited to the 
pulmonary circulation.  Iloprost is delivered by nebuliser, which gives a high local pulmonary 
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concentration of iloprost, which is localised to the pulmonary vessel to cause dilation of the 
pulmonary vessels only. 
 
The ciliary muscle of the eye has FP receptors.  Stimulation of these receptors increases the 
aqueous humour outflow from the eye.  Latanoprost is an ester analog of PGF2α, and 
selective agonist of FP receptors.  Latanoprost is used in the treatment of ocular 
hypertension (glaucoma).  When ocular pressure is high, the optic nerve can be damaged, 
which can lead to irreversible.  By promoting aqueous humour outflow from the eye, 
latanoprost reduces intraocular pressure.  
 
  10.2.3.5 Leukotriene receptor antagonists 
Montelukast is a leukotriene receptor antagonist that is used in the prevention of asthma.  
It antagonises the LTC4, LTD4, and LTE4 receptors to reduce bronchoconstriction and 
inflammation.  
 
 
10.3 5-Hydroxtryptamine (serotonin), nitric oxide, and endothelin 
The final 3 local chemical mediators to be discussed briefly, with respect to therapeutics, are 
5-hydroxytryptamine (5-HT, also known as serotonin), nitric oxide (NO), and endothelin.  5-
HT is a neurotransmitter and a local chemical.  5-HT1 receptor subtypes and 5-HT2 receptors 
are involved in migraine, whereas 5-HT3 and 5-HT4 receptors are involved in gastrointestinal 
motility. 
 
  10.3.1 5-HT and migraine 
Excessive cranial blood vessel dilation and inflammation underlies the pain of migraine.  
Ergotamine has gone from being a poison to therapy for migraine.  Ergot alkaloids are the 
product of a fungus that grows on corn.  In biblical times, when they ate contaminated corn, it 
caused plague.  The symptoms of the plaque were due to the ergot alkaloids causing intense 
vasoconstriction of the extremities leading to gangrene, and stimulation of the uterus causing 
abortion.  Ergotamine is one of the ergot alkaloids.  The actions of ergotamine include being 
a partial agonist at 5-HT1B/1D receptors.  Stimulation of the 5-HT1B/1D receptors on cranial 
blood vessels causes vasoconstriction. The vasoconstriction with ergotamine overcomes the 
excessive vasodilation of migraine. 
 
Sumitriptan is a 5-HT1B/1D agonists also used in the treatment of migraine attacks, and has 
two mechanisms, one of which is similar to ergotamine.  The central nervous system is 
involved in the excessive vasodilation of migraine.  Stimulation of 5-HT1B/1D receptors in the 
central nervous system may decrease the release of neurotransmitter onto the cranial blood 
vessels, and the excessive vasoconstriction (Figure 18.1).  Secondly, as with ergotamine, the 
triptans cause a direct stimulation of the 5-HT1B/1D receptors on the cranial blood vessels to 
cause vasoconstriction to overcome the excessive vasodilation. 
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Figure 10.8 Mechanisms of triptans (Copyright QUT, Sheila Doggrell) 
 
In an attack of migraine, need a drug that acts quickly to relieve the attack.  When used 
orally, the bioavailability of sumitriptan is low (15%).  Also, after oral administration of 
sumitriptan, peak plasma concentrations are not reached for 1-2 hours, and onset of action 
may take up to 30 minutes, which is too slow for somebody who is having a migraine attack.  
Thus, we need a quicker effective route of administration for sumitriptan.  After 
subcutaneous or nasal spray administration of sumitriptan, the bioavailability is increased and 
the onset of action may occur in 15 minutes.   
 
Drugs used to prevent migraine attacks include the serotonin receptor antagonist 
(predominantly 5-HT2 receptor antagonist) e.g. pizotifen.  The action of pizotifen in 
preventing migraine is unknown.  However, it has been shown that two-thirds of patients, 
who regular suffer migraine attacks, have a 50% reduction in frequency of headache with 
pizotifen.  Unfortunately, pizotifen cause drowsiness, which makes it unpopular for continued 
use in patients. 
 
  10.3.2 5-HT and the gastrointestinal tract 
5-HT stimulates 5-HT3-receptors to increase vomiting.  The -etrons: e.g. ondansetron 
(prototype) are selective 5-HT3-receptor antagonists.  Ondansetron, and others in the -etron 
family are used to inhibition emesis.  The –etrons are the most effective agents for treating 
chemotherapy-induced nausea and vomiting. 
 
  10.3.3 Nitric oxide and angina 
Nitric oxide (NO) is a neurotransmitter and a local chemical mediator.  As a local chemical 
mediator, NO relaxes blood vessels.  There are a group of drugs that mimic NO by releasing 
NO, and the group is known as nitrovasodilators.  Examples of nitrovasodilators are 
nitroglycerin and isosorbide-5-mononitrate.  Nitrovasodilators release NO, which relaxes 
blood vessels, and is useful in the treatment and prevention of angina, which is due to 
diseased coronary arteries.  As diseased coronary arteries are difficult to dilate, 
nitrovasodilators have little effect on diseased coronary arteries.  Nitrovasodilators end an 
angina attack by causing venodilation, and reducing the workload on the heart, and this will 
be discussed further under Systematic Pharmacology. 
 
As discussed previously (eChapter 1), nitroglycerin undergoes extensive first pass liver 
metabolism, and cannot be used orally.  Rather, nitroglycerin is used as a sublingual tablet or 
spray (faster) in an attack of angina, and starts to work within a minute, but is only effective 
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for a short time as has a t1/2 of about 3 minutes.  For a longer effect, and to prevent an anginal 
attack, nitroglycerin patches or ointment are used.  
 
Isosorbide-5-mononitrate is the only nitrate developed to date, that has no significant first 
pass liver metabolism, and can be used orally.  Isosorbide-5-mononitrate is used orally to 
prevent an angina attack.  
 
  10.3.4 Nitric oxide and erectile dysfunction 
On the smooth muscle of the corpus carvenosum (penile smooth muscle) endogenous nitric 
oxide both as a neurotransmitter and local chemical mediator stimulated guanylate cyclase to 
promote the conversion of GTP to cGMP.  The cGMP relaxes the corpus carvenosum to 
produce a penile erection.  The rapid breakdown of cGMP by phosphodiesterase V ends the 
relaxation and the erection.  Sildenafil inhibits phosphodiesterase V to increase and prolong 
the effects of cGMP, with increased relaxation of the corpus carvenosum and increased penile 
erection. 
10.3.5 Endothelin and pulmonary hypertension 
Endothelin is a peptide local hormone, and it is a potent vasoconstrictor. High levels of 
endothelin or an increased sensitivity in pulmonary circulation to endothelin occur in certain 
forms of pulmonary hypertension, high blood pressure limited to the pulmonary circulation.  
The effects of endothelin are receptor mediated, and bosentan is a non-selective endothelin 
receptor antagonist.  Bosentan is active after oral administration.  In pulmonary hypertension, 
bosentan reduces pulmonary pressure, and this leads to a reduction in the incidence of death, 
lung transplantation, and hospitalization for pulmonary hypertension. 
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11.1 Introduction 
Local hormones or autocoids are chemical mediators that are secreted by one group of cells 
to affect the function of other nearby cells. This eChapter covers a diverse range of these 
mediators, their physiological effects, pathological implications and clinical use of drugs and 
other agents that target these systems. 
 
11.2 Eicosanoids 
The eicosanoids are all the mediators derived from arachidonic acid. These include the 
prostanoids (PGF2α, PGD2, PGE2, prostacyclin (PGI2), thromboxane), and leukotrienes. 
They are involved in the control of many systems, mainly in inflammation and immunity, and 
as messengers in the central nervous system. 
 
11.2.1 Synthesis, receptors and actions 
When phospholipase A2 is activated, arachidonic acid is released from the cell membrane. 
 
Prostanoids, thromboxane, and leukotrienes are synthesised from arachidonic acid.  
Arachidonic acid is metabolised by cyclo-oxygenase to produce the prostaglandins, 
prostacyclin and thromboxane or by lipoxygenase to produce the leukotrienes (LTs).  The 
eicosanoids are synthesised on demand and are not stored. 
 
Cyclo-oxygenase metabolites activate specific receptors to influence a range of effects. There 
are two forms of the cyclo-oxygenase enzyme COX-1 and COX-2. COX-1 is a 
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constitutively (always) expressed protein that produces prostanoids that have “house-
keeping” roles, e.g. regulation of blood flow, and gastric protection via release of 
cytoprotective mucus and inhibition of gastric acid production. They also cause uterine 
contraction in pregnancy. COX-2 is induced at sites of inflammation, and prostanoids 
produced in this setting tend to have pro-inflammatory effects e.g. hyperalgesia, 
vasodilatation, increased vascular permeability. Prostanoid receptors are G-protein coupled 
receptors (GPCRs). There are 10 prostanoid receptors which correspond to their ligand: IP1-
2 (PGI2), DP1-2 (PGD2), EP1-4 (PGE2), FP (PGF2α), TP (TXA2). 
 
Lipoxygenase metabolites are broadly divided into 2 classes, the chemotactic agent LTB4 
and the cysteinyl leukotrienes LTC4, LTD4 and LTE4, which cause bronchoconstriction 
and increase vascular permeability. Leukotrienes also act at cell surface GPCR on neutrophils 
(LTB4).  The cysteinyl-leukotrienes act at their cell-surface receptors CysLT1 and CysLT2 
on target cells to contract bronchial and vascular smooth muscle, to increase permeability of 
small blood vessels, to enhance secretion of mucus in the airway and gut, and to recruit 
leukocytes to sites of inflammation. 
 
11.2.3 Drugs that modify the arachidonic acid pathway 
Non steroidal anti-inflammatory drugs (NSAIDs) are cyclo-oxygenase inhibitors that 
prevent the production of the prostanoids from arachidonic acid.  These drugs are effective 
analgesics, anti-inflammatory agents and anti-pyretic agents. Most NSAIDs are non-specific 
and block both COX-1 and COX-2 (e.g. aspirin, ibuprofen, diclofenac), but COX-2 
selective agents (e.g. celecoxib) were developed to target COX-2 at sites of inflammation and 
thus reduce side effects.  However, these drugs may precipitate adverse cardiovascular effects 
and have limited use. Adverse effects of NSAIDs relate to inhibition of their gastro-protectant 
properties (eg PGE2 increases cytoprotective mucus secretion and decreases gastric acid 
secretion).  PGE2 mimetics (e.g. misoprostol) are used to treat peptic ulcer disease (PUD) 
and can be given with long-term NSAID use to reduce the incidence of these side effects. 
 
Paracetamol is another Other-The-Counter (OTC) pain killer that is reported to act by 
blocking COX. However it has no anti-inflammatory effects, and this is suggested to be 
because it only acts at a form of COX in the central nervous system (CNS).  Paracetamol has 
good analgesic and anti-pyretic effects. 
 
11.2.4 Drugs that act at the receptors 
PGE2 mimetics can be used to promote uterine contraction during labour or abortion. (e.g. 
misoprostol) 
 
Montelukast is a leukotriene receptor antagonist that is used in the prevention of asthma. 
 
11.2.5 Drugs that inhibit phospholipase A2  
Steroid anti-inflammatory drugs act by inhibiting phospholipase A2 and the release of 
arachidonic acid from the cell membrane. They have the additional action of inhibiting 
expression of COX. These are the most powerful anti-inflammatory agents available and 
are used to treat a range of serious inflammatory disorders including arthritis, asthma, 
Crohn’s disease, ulcerative colitis, psoriasis, eczema and others. (e.g. hydrocortisone, 
methylprednisolone, budesonide, beclamethosone) 
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11.3 Cytokines 
Cytokines are a diverse class of small cell signalling molecules secreted by immune cells. 
They include interleukins (ILs), which broadly target leukocytes (e.g. IL-1), and interferons 
(IFN), which are anti-viral and anti-tumour agents (e.g. IFNα, IFNβ. IFNγ). Colony 
stimulating factors, which stimulate the formation of leukocytes and tumour necrosis 
factors (TNF), which affect growth and development of cells (e.g. TNFa). 
 
The cytokines can be broadly sub-classified into pro-inflammatory and anti-inflammatory 
by the way they affect the inflammatory cascade. In most cases cytokines can amplify 
responses of other cytokines or alter expression of other cytokine receptors. The signalling is 
complex, given the variety of mediators and targets involved. 
 
11.3.1 Synthesis, receptors and actions 
Cytokines are protein, peptide or glycoprotein molecules synthesised by many immune cells.  
Cytokines activate cell-surface receptors to initiate intracellular signalling cascades that alter 
cell function.  
 
11.3.2 Drugs that modify the cytokine pathways 
Anakinra is a recombinant IL-1 receptor antagonist.  It is a recombinant form of the 
endogenous IL-1 antagonist, which supresses inflammatory cascades.  It is used to treat 
severe rheumatoid arthritis. 
 
The interferons bind to receptors on cell infected by viruses and are used to treat viral 
infections like hepatitis. They also have additional anti-tumour activity and are used to treat 
leukaemia and lymphoma (IFNα).  
 
The colony stimulating factors are recombinant stem cell factors used to stimulate growth of 
blood cell precursors. They are used to treat chemotherapy induced neutropenia and in bone 
marrow transplants (e.g. filgrastim). 
 
Monoclonal antibodies to TNFα bind to TNFα and inhibit its activity. They are used in 
autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. (e.g. etanercept, 
infliximab). 
 
Drugs that modify the cytokines and/or lymphocytes (white cells) are used as 
immunosuppressants in organ transplant. These include a few different targets; 
monoclonal antibody against IL-2 (e.g. basiliximab), monoclonal antibody against the T 
lymphocyte CD3 (e.g. muromonab CD3) and anti-thymocyte globulins that remove 
leukocytes from the circulation (anti-thymocyte globulins) are all used to prevent renal 
transplant rejection. 
 
Drugs that modify the cytokines and/or lymphocytes are used in treating multiple sclerosis.  
These drugs include glatiramer which blocks T lymphocyte recognition of myelin as an 
antigen, interferon β, which reduces cytokine release, while also augmenting suppressor T-
cell function and natalizumab which is thought to inhibit leukocyte migration from blood to 
CNS, reducing the inflammation and demyelination of nerves. 
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11.4 Histamine 
Histamine is involved in both acute inflammation and immediate hypersensitivity reactions, 
is a physiological regulator of gastrointestinal tract function and also acts as a 
neurotransmitter in the central nervous system. 
 
11.4.1 Synthesis, receptors and actions 
Histamine is found in virtually all tissues in the body.  It is synthesised from the precursor 
amino acid histidine via histidine decarboxylase. Once synthesised it is stored in granules in 
mast cells, basophils and enterochromafin-like cells in the gastric fundus. It is also 
synthesised in brain as a neurotransmitter. 
 
Mast and basophil histamine is released in response to exposure to antigens and venoms, and 
toxins also elicit release of histamine, for example in the insect bites. Histamine released 
from gastric cells by cholinergic stimulation and by other stimulants (e.g. gastrin) cause 
gastric acid secretion. Morphine can also cause release of histamine from mast cells and 
histamine allergic reactions are common with the use of many drugs. Once released, 
histamine is metabolised quickly and excreted. 
 
Histamine acts on specific histamine receptors, denoted H1-H4 which are all G-protein 
coupled receptors (GPCR).  Histamine H1 receptors are present on smooth muscle 
(bronchoconstriction, uterine and GIT smooth muscle contraction), endothelium (increase 
vascular permeability), CNS (motion sickness).  Allergic rhinitis is mediated via H1 
receptors, as histamine acting on these receptors causes itching (sensory nerves), mucus 
secretion (submucosal glands), vasodilatation and oedema (vascular smooth muscle and 
endothelium). 
 
Histamine H2 receptors are present on gastric parietal cells (acid secretion) and vascular 
smooth muscle cells (vasodilatation).  Histamine H3 receptors are found in the central 
nervous system.  Histamine H4 receptors are found on many cell types and are thought to be 
involved in chemotaxis. 
 
11.4.2 Drugs that modify the actions of histamine 
H1 receptor antagonists are also widely used for allergic conditions (rhinitis, hives, insect 
bites). New generation H1 antagonists are peripherally acting and therefore less sedative than 
older antihistamines that cross the blood-brain barrier (e.g. cetirizine). Histamine release 
inhibitors (e.g. cromogylcate) can be used to prevent allergic reactions asthma. These drugs 
inhibit the release of histamine from mast cells, and therefore reduce histamine-induced 
allergy and bronchoconstriction. 
 
H1 receptor antagonists that act at the vestibular apparatus in the central nervous system are 
useful as anti-emetics and for motion sickness (e.g. promethazine), and as sedatives and for 
motion sickness (e.g. diphenhydramine). Some of the H1-receptor antagonists also have 
some anti-cholinergic activity which also contributes to this effect. 
 
H2 receptor antagonists are effective in reducing acid secretion in the stomach and are used 
to treat peptic ulcer disease (PUD) and gastro-oesphageal reflux disorder (GORD) (e.g. 
ranitidine). 
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11.5 5-Hydroxytryptamine (Serotonin) 
5-Hydroxytrypatmine (5-HT) is also known as serotonin and is a widely distributed 
monoamine neurotransmitter. 
 
11.5.1 Synthesis, receptors and actions 
5-HT is synthesised from the precursor tryptophan, an essential amino acid. Synthesised 5-
HT is stored in granules which are released via exocytosis. Main storage sites include 
enterochromaffin cells (stomach and small intestine) and neurons both in the gastrointestinal 
tract (GIT) and central nervous system (CNS) in the raphe nucleus which is involved in the 
regulation of mood, appetite and sleep.  5-HT is actively transported into platelets (which do 
not synthesise 5-HT), then released upon platelet activation to induce vasoconstriction and 
assist haemostasis.  
 
There are many subtypes of 5HT receptors, denoted 5-HT1-7, all are GPCR except for 5-HT3 
which is a ligand-gated Na+-K+ channel. Many are sub-classified further.  The effects of 5-
HT include actions within the CNS leading to behavioural effects (sleep, anxiety, feeding) 
and excitation, constriction of cerebral blood vessels, contraction of GIT smooth muscle, 
gastric motility and peristalsis, centrally and peripherally-mediated emesis. 
 
11.5.2 Drugs that modify the actions of 5-HT  
Selective serotonin re-uptake inhibitors (SSRI) are an important class of anti-depressants 
with additional anxiolytic properties. They prevent reuptake of 5-HT into the nerve terminal, 
thereby prolonging 5-HT effects (e.g. fluoxetine). 
 
5-HT2 receptor antagonism is associated with some anti-psychotic effects (e.g. atypical anti-
psychotics such as clozapine and some older generation typical anti-psychotics e.g. 
chlorpromazine).  However, blockade of 5-HT receptors alone does not give an anti-
psychotic effect. 
 
5-HT3 receptor antagonists are excellent anti-emetic agents, blocking the receptors in the 
gastrointestinal tract as well as at the chemoreceptor trigger zone.  They are particularly 
useful in treating nausea and vomiting associated with cancer chemotherapy and 
radiotherapy. (eg Setrons: ondansetron) 
 
In migraine, 3 classes of drugs used to treat migraine all act on serotonergic transmission. 
The ergot alkaloids (ergotamine) and Triptans (e.g. sumatriptan) act via 5-HT1B/1D 
receptors to elicit cerebral vasoconstriction as do 5-HT2 receptor antagonists (e.g. pizotifen). 
 
11.6 Nitric Oxide 
Nitric oxide (NO) is a biological gas that is involved in a range of cell signalling events, 
including vascular regulation, neurotransmission and regulation of inflammation.  NO 
activates soluble guanylate cyclase (sGC) to produce the second messenger cGMP, resulting 
in activation of a cascade of events leading to vasorelaxation.  
 
Nitrovasodilators are drugs that donate NO, which then elicits vasodilation. They are used to 
treat angina and heart failure associated with acute myocardial infarction (glyceryl trinitrate 
and isosorbide dinitrate) 
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Drugs used in the treatment of erectile dysfunction inhibit phosphodiesterase (PDE), which 
breaks down cGMP, effectively prolonging the vasodilator action of cGMP. PDEV is 
preferentially located in the corpus cavenosum, thus inhibitors of this enzyme enhance and 
prolong penile erection (e.g. sildenafil).  
 
11.7 Endothelin  
Endothelin is a peptide mediators released from the endothelial cells that line the lumen of 
blood vessels. Release of endothelin is stimulated by hormones and also by mechanical 
factors, such as shear stress on the blood vessel lumen.  Endothelin acts at GPCR denoted 
ETA and ETB. It is a potent vasoconstrictor and has mitogenic activities involved in the 
remodelling of the vasculature following injury or during the progression of atherosclerosis.  
The endothelin receptor antagonist bosentan is used in pulmonary hypertension. 
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Under drugs and the cardiovascular system, six topics are to be considered.  In this chapter 
drugs for hypertension, drugs for angina, and drugs for heart failure are considered, and in the 
next chapter, drugs for cardiac arrhythmias, anti-thrombotic drugs, and lipid modulating 
drugs.  
 
 
12.1 Drugs for hypertension 
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 12.1.1 Epidemiology and pathophysiology 
Hypertension is high blood pressure, and is defined as anything  140 systolic/90 diastolic 
mm Hg.  It is very common disorder; 3.7 million Australians have hypertension or are being 
treated for hypertension, which about one-third of the population.  Indeed hypertension is the 
most common cardiovascular disease.  The incidence increases with age, such that at birth 
and in the young, there is a low incidence of hypertension.  During middle age, there is an 
increasing incidence of hypertension, and by old age, there is a very high incidence.  
Hypertension is considered to be “the silent killer” as, unless the blood pressure is extremely 
high, there are no symptoms.  Nevertheless the hypertension is doing harm.  Hypertension is 
the leading risk factor for mortality (death). High blood pressure alone does not kill you, it 
is the things it does that hurt or kill you.  Hypertension is the principle cause of stroke.  
Hypertension leads to coronary artery disease with myocardial infarction and sudden cardiac 
death.  Hypertension is the major contributor to retinal haemorrhage (bleeding in eye), heart 
failure, renal insufficiency, and dissecting aneurysm of aorta (splitting of aorta). 
 
The majority of people with hypertension have essential hypertension.  In essential 
hypertension, the cardiac output is normal, but the total peripheral resistance is increased.  
The exact cause of essential hypertension is unknown.  It is the combination of genetic 
disease with many loci involved, and environmental factors.  The environmental factors 
include several aspects of a Western lifestyle; stress, smoking, salt, and obesity. 
 
Essential hypertension is associated with pathological changes in heart and blood vessels.  
These pathological changes are compensatory changes to maintain cardiac output in the face 
of increasing total peripheral resistance. The heart has a thickening of the left ventricular 
wall, and this is known as hypertrophy (cardiac hypertrophy).  The arteries also have 
hypertrophy of the smooth muscle, and injury to the endothelial cells lining the blood vessels. 
 
The non-pharmacological treatments of hypertension that are effective an decreasing blood 
pressure include a body weight reduction, restricting the amount of Na+ in the diet, and 
initiating or increasing exercise.  Blood pressure is also lowered when people avoid excessive 
alcohol or manage to decrease the stress in their lives. 
 
In essential hypertension, the underlying cause is not singular, and this means we do not have 
a single target for a drug to attack.  The treatment of essential hypertension is to lower blood 
pressure by any mechanism, preferable with as few side effects as possible.  As subjects with 
hypertension lack symptoms, they are intolerant of adverse effect with drugs for 
hypertension.  Other the years, drugs for hypertension have been developed that have few 
side effects, and subjects are often prepared to take these on a regular basis.  Often diuretics, 
drugs that increase water loss from the body, are the initial drugs used to treat essential 
hypertension. 
  
 12.1.2 Diuretics for hypertension 
Diuretics are drugs that increase the loss of water from the body.  In hypertension, a common 
diuretic treatment is the combination of a thiazide diuretic and a K+-sparing diuretic 
(amiloride).  The diuretics act at different parts of the kidney tubule.  The thiazide diuretics 
act on the distal convoluted tubule, and the K+-sparing diuretics act on the collecting duct.  
Another class of diuretics, the loop diuretics (which are used mainly in the treatment of heart 
failure) act on the loop of Henle. 
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In the distal tubule (just before the collecting duct) of the kidney, thiazide diuretics inhibit 
the Na+Cl- co-transporter (Figure 12.1.1), which inhibits Na+ reabsorption to increase the 
levels of Na+ and Cl- in urine.   
 
Figure 12.1.1 Mechanism of action of thiazide diuretics (Copyright QUT, Sheila Doggrell) 
 
As water reabsorption passively follows electrolyte reabsorption along the kidney tubule, 
when the levels of Na+ and Cl- in urine are increased, so are the levels of water in the urine.  
This decreased water reabsorption leads to increased water loss from the body, which in turn 
leads to decreased blood volume, decreased venous return and decreased blood pressure. 
 
The thiazide diuretics are active after oral administration, which makes them easy to use.  
They are secreted into the proximal tubule of the kidney, and pass along the kidney tubule to 
the distal tubule, where they inhibit the Na+Cl- cotransporter in the distal tubule.  With most 
thiazide diuretics, there is a diuretic effect within an hour, and a modest maximal effect is 
observed i.e. increase in water loss is modest.  The main difference between the thiazide 
diuretics is there duration of action with hydrochlorothiazide, a commonly used thiazide 
diuretic, having a duration of action of ten hours, which allows it to be used once or twice 
daily.  After having their effect, the thiazide diuretics are excreted in urine.  They are a 
common initial treatment for hypertension, often in combination with a K+-sparing diuretic, 
an ACE inhibitor or an AT1-receptor antagonist.  
 
The thiazide diuretics are well tolerated, and have only a few adverse effects.  They can cause 
hypokalemia (low levels of potassium), as increasing the amount of water/Na+ delivered to 
the collecting duct increases K+ loss.  This problem with the thiazide diuretics can be 
overcome by using them with a K+ sparing diuretic (e.g. amiloride).  The second adverse 
effect observed with the thiazide diuretics is hyperuricemia, due to increased uric acid 
reabsorption.  Thus, thiazides should not be given to subjects prone to gout, which is due to 
the accumulation of uric acid in joints. 
 
To prevent excess K+ loss, thiazide diuretics are often administered with a K+-sparing 
diuretic.  Amiloride is a K+ sparing diuretic.   Amiloride inhibits a sodium channel in the late 
distal tubule/collecting duct (Figure 12.1.2), and this decreases Na+/K+ pumping, and the 
amount of K+ available for loss/secretion through the K+ channel.   Overall, there is an 
inhibition of the exchange of sodium for potassium in the late distal tubule/collecting by 
amiloride.   
113 
 
 
Figure 12.1.2 Mechanism of action of amiloride (Copyright QUT, Sheila Doggrell) 
 
Thus, amiloride indirectly inhibits K+ secretion (loss) into the kidney.  Although, it is called a 
diuretic, amiloride only has a small diuretic effect, with its main use being to prevent the 
excess K+ loss with the thiazide diuretics.  Amiloride is used in combination with a thiazide, 
often as a single tablet (e.g. amiloride/hydrochlorothiazide), to prevent K+ loss.  The most 
common adverse effect with amiloride is hyperkalemia (high levels of potassium), which is 
an obvious result from preventing K+ loss. 
 
Thiazide diuretics only have a modest effect on blood pressure, typically lowering it by < 10 
mm Hg. Thus, when blood pressure remains high or, as the hypertension progresses, becomes 
high, other anti-hypertensive drugs are added to the diuretics, and these include vasodilators 
and β-adrenoceptor antagonists.   
 
 12.1.3 Vasodilators for hypertension 
Some drugs cause vasodilation, and some drugs reverse vasoconstriction to effectively cause 
vasodilation, and I refer to both of these mechanisms as vasodilation. 
 
Three groups of vasodilators are used in the treatment of hypertension, inhibitors of the renin-
angiotensin system (angiotensin converting enzyme inhibitors and AT1 receptor antagonists), 
Ca2+ channel blockers, and α1-adrenoceptor antagonists. 
 
Angiotensin II is a potent vasoconstrictor, stimulates hypertrophy, and stimulates aldosterone 
secretion.  Aldosterone causes salt and water retention, and fibrosis (the laying down of 
collagen in the heart), which all worsens the hypertension.  Angiotensin converting enzyme 
has a key role in the renin-angiotensin-aldosterone system. It is involved in the conversion of 
angiotensin I, which is an inactive decapeptide to angiotensin II, the active octapeptide.  
Angiotensin converting enzyme is also involved in the breakdown of bradykinin.  
Bradykinin is a potent vasodilator, which is broken down in the presence of angiotensin 
converting enzymes to inactive fragments.  
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When angiotensin converting enzyme is inhibited with an angiotensin converting enzyme 
(ACE) inhibitor, there are decreased levels of angiotensin II, and aldosterone (Figure 
12.1.3). 
 
Figure 12.1.3 ACE inhibition (Copyright QUT, Sheila Doggrell). 
 
As angiotensin II and aldosterone both increase blood pressure, lowering their levels, will 
decrease blood pressure.  ACE inhibitors will also decrease the breakdown of bradykinin 
increasing the levels of this vasodilator, which will also contribute to the decrease in blood 
pressure observed with ACE inhibitors. 
 
The ACE inhibitors all have names that end in PRIL, such as enalapril.  The prils are used as 
vasodilators in the treatment of hypertension.   Enalapril is available alone in a tablet or in 
combination with hydrochlorothiazide.  Enalapril is metabolised in the gut to the ACE 
inhibitor enalaprilat, which has a 60% bioavailability after oral administration.  Enalaprilat 
will decrease the levels of angiotensin II (vasoconstrictor), decrease levels of aldosterone 
(Na+ and water retention) and increase the levels of the vasodilator bradykinin.  All of these 
effects contribute to the ability of enalapril to decrease blood pressure. 
 
Enalaprilat is predominantly eliminated by kidneys, which means the dose needs to be 
reduced in renal impairment to avoid increased levels and excessive vasodilation.  The prils 
can adversely cause a dry cough, which is quite common, and angiodema (rare).  Both of 
these conditions are probably due to the accumulation of bradykinin that has many effects 
other than vasodilation.  These adverse effects do not occur with the angiotensin II receptor 
antagonists, as these have no effect on bradykinin levels.  People who cannot tolerate ACE 
inhibitors are often transferred to AT1 receptor antagonists, which do not alter the levels of 
bradykinin. 
 
The majority of the cardiovascular effects of angiotensin II are mediated by AT1-receptors.  
AT1-receptor antagonists have names ending in sartan.  The sartans, such as candesartan, 
inhibit effects mediated by AT1 receptors to decrease vasoconstriction (effectively 
vasodilation) decrease hypertrophy, and decrease aldosterone secretion and the effects of 
aldosterone (Figure 12.1.4). 
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Figure 12.1.4 AT1-receptor antagonism (Copyright QUT, Sheila Doggrell) 
 
Candesartan is available alone or in combination with hydrochlorothiazide (thiazide 
diuretic).  The adverse effects with ACE inhibitors of dry cough and angiodema (rare) do not 
occur with AT-1 antagonists.  
 
By reducing blood volume, diuretics stimulate the renin-angiotensin system.  This sensitizes 
(makes the effects bigger) the patients to ACE inhibitors and AT-1 antagonists, making the 
combination of a diuretic and an ACE inhibitor or AT-1 antagonist more effective at reducing 
blood pressure than either a diuretic alone, or an angiotensin II inhibitor alone. 
 
The ACE inhibitors and the AT-1 receptor antagonist (Angiotensin Receptor Antagonist, 
ARBs) are contraindicated in pregnancy.  Hypertension is quite common in pregnancy, and 
the ACE inhibitors and ARBS must not be used to treat any hypertension associated with 
pregnancy.  If they are used in first semester, the ACE inhibitors and ARBs cause major 
congenital malformations, which are defects/damage to developing fetus.  This is probably 
because angiotensin II has a major role in fetal development.  If the ACE inhibitors or ARBs 
are uses in second and third semester, they cause fetal renal dysfunction and oligohydramnios 
(deficiency in amniotic fluid), and can lead to fetal death.  
 
The second group of vasodilators used in the treatment of hypertension are the Ca2+ entry 
blockers.  Ca2+ entry blockers are also known as Ca2+channel blockers, and Ca2+ antagonists.  
Regardless of what is contracting the blood vessel, whether it is depolarization or 
noradrenaline acting at α-adrenoceptors or 5-HT acting at 5-HT2-receptors, contraction of 
vascular smooth muscle requires Ca2+ entry into cells through Ca2+ channels (Figure 12.1.5).  
This makes Ca2+ channel blockers are effective against all vasoconstrictors. 
 
Figure 12.1.5 Ca2+ channels and vasoconstriction (Copyright QUT, Sheila Doggrell) 
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An example of a calcium channels blocker is amlodopine.  Amlodopine has a greater effect 
on the blood vessels than the heart, and thus causes vasodilation with little effect on the heart.  
Amlodopine is available as a once a day preparation.  Amlodopine is used in the treatment of 
essential hypertension.  With calcium channel blockers, the most common side effects are 
related are extensions of the therapeutic effect to excessive vasodilation causing headache, 
flushing, and dizziness. 
 
The third class of vasodilator used in the treatment of hypertension are the α1-adrenoceptor 
antagonists, such as prazosin.  On activation of the sympathetic nervous system, 
noradrenaline is released and stimulates α1-adrenoceptors on blood vessels to cause 
vasoconstriction.  Prazosin will bind to the α1-adrenoceptor to reduce the binding of 
noradrenaline, and the resulting vasoconstriction, effectively causing vasodilation and 
reducing blood pressure.  α1-Adrenoceptor antagonists can only be used to cause small 
decreases in blood pressure, as excessive vasodilation leads to adverse effects.  Presently, 
prazosin is occasionally used in combination with other anti-hypertensive drugs.  For 
instance, if the combination of a diuretic and a β-blocker fails to control blood pressure, an 
α1-adrenoceptor antagonist may be added. 
 
 12.1.4 β-Adrenoceptor blockers for hypertension 
The third group of drugs commonly used in the treatment of hypertension are the β-
adrenoceptor antagonists (β-blockers).  On the heart, noradrenaline stimulates β1-
adrenoceptors to increase heart rate and heart force, and on the kidney, noradrenaline 
stimulates β1-adrenoceptors to increase renin production, and hence angiotensin II and 
aldosterone production.  Angiotensin II causes vasoconstriction and aldosterone causes salt 
and water retention, and both of these effects increase blood pressure.  Thus, a β1-
adrenoceptor antagonist e.g. atenolol will effectively decrease these effects to cause a 
decrease in heart rate and force, and a decrease in vasoconstriction and salt and water 
retention.   The β1-adrenoceptor antagonist atenolol is commonly used in the treatment of 
essential hypertension.  Atenolol is active after oral administration.  Atenolol is hydrophilic, 
which means there is little penetration of central nervous system and no centrally mediated 
adverse effects, such as nightmares.  Atenolol has an elimination t1/2 of 5-8 h, which allows 
once-a-day administration.  Atenolol is excreted, largely unchanged, in urine, which means 
that a downward dosage adjustment may be needed in renal failure to prevent adverse effects. 
 
The β-adrenoceptor blockers are contraindicated in subjects with asthma.  These, and other 
details relating to β-adrenoceptor blockers, were discussed in detail in Chapter 7.  
 
12.2 Drugs for angina 
 
 12.2.1 Typical angina 
Angina pectoris means “choked chest”, which is a description of the symptoms in angina 
pectoris.  Angina pectoris is a heavy, pressing, substernal discomfort with pain that often 
radiates to the left shoulder. Subjects with angina pectoris describe a feeling of suffocation 
and impending death.  Angina pectoris is due to an imbalance between oxygen supply and 
oxygen demand due to coronary artery disease.  Thus, the diseased coronary arteries are 
unable to supply enough oxygen to meet the demands of the heart.  The coronary artery 
disease limits the blood supply. In coronary artery disease lipids including cholesterol 
contribute to the thickening of the artery walls, and with platelets and other blood 
components form plaques (Figure 12.2.1).  The reduced lumen of the blood vessel reduces 
blood flow. 
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Figure 12.2.1 Coronary artery disease (Copyright QUT, Sheila Doggrell) 
 
Angina pectoris is a progressive disease.  In the initial stable phase, attacks of angina do no 
occur at rest, but occur with exercise and stress.  Stable angina is associated with thickening, 
but not usually with plaque in the coronary arteries.   
 
The mechanism underlying the attack of typical angina is that during stress or exercise, there 
is activation of the sympathetic nervous system with increased release of noradrenaline and 
increase stimulation of cardiac β1-adrenoceptors.  This stimulation leads to an increased heart 
rate, heart force, and, consequently, of the work done by the heart.  To support this work, the 
heart has an increased demand for oxygen and nutrients, which are supplied by the coronary 
circulation.  In stress or during exercise, the reduced blood flow in diseased coronary is 
inadequate to meet the oxygen and nutrient demand, and this gives an attack of angina. 
 
Unstable typical angina is worsening of stable angina, so that angina attacks occur when the 
subject is at rest.  Unstable angina is associated with thickening of the blood vessels and 
plaque formation in the coronary arteries.  This is a very precarious position to be in, as 
plaque rupture with the subsequent blockade of smaller vessels leads to myocardial 
infarction (heart attack). 
 
The drugs used to treat typical angina are divided into those used during an attack and those 
to prevent an attack of angina. 
 
 12.2.2 Drugs to treat an attack of typical angina 
The group of drugs used to treat an attack of angina are the nitrovasodilators (nitroglycerin 
and isosorbide dinitrate), which are used sublingually to get a quick effect (relief of attack). 
The nitrovasodilators mimic the effect of endogenous nitric oxide (NO).  Nitric oxide 
stimulates guanylate cyclase, leading to increased intracellular cGMP, which promotes the 
relaxation of smooth muscle including vascular smooth muscle (Figure 12.2.2).  The 
nitrovasodilators release nitric oxide, which has the same effect as the endogenous NO. 
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Figure 12.2.2 Nitrovasodilators (Copyright QUT, Sheila Doggrell) 
 
Normal coronary arteries are dilated by nitrovasodilators.  Diseased coronary arteries have 
lost their elasticity, and are difficult to dilate.  Thus, nitrovasodilators only cause a small 
dilation of diseased coronary arteries, and this alone does not explain the benefit of 
nitrovasodilators in typical angina.  Nitrovasodilators end an angina attack by causing 
venodilation (dilation of veins).  Venodilation leads to pooling of the blood in the veins, 
which reduces venous return, which (in turn) reduced the work done by the heart, and reduces 
the oxygen demand.  This does not improve the function of the coronary arteries, but rather 
reduces the oxygen demand of the heart to level that can be met by the diseased coronary 
arteries. 
 
Nitroglycerin has extensive first pass liver metabolism, which means it is not active after 
oral administration.  Nitroglycerin is used as a sublingual tablet or spray to avoid first pass 
liver metabolism.  The other advantage of sublingual over oral is that it is a faster way to 
provide the nitroglycerin to the circulation in an attack of typical angina.  With 
sublingual/spray of nitroglycerin, the onset of action is within a minute, and the half-life (t1/2) 
is about 3 minutes, and this is ideal for the treatment of typical angina.  Nitroglycerin can also 
be used in the prevention of an attack of angina, where patches or ointment are used for the 
prevention of angina attacks. 
 
Isosorbide mononitrate is a nitrate that is resistant to first pass liver metabolism.  This 
means that it active after oral administration and has a longer half-life (3-6 hours) than 
nitroglycerin.  Thus, after nitroglycerin has ended the attack of angina, isosorbide 
mononitrate can be used to prevent a further attack of angina. 
 
 12.2.3 Drugs to prevent an attack of typical angina 
Three groups of drugs are used to prevent attacks of typical angina; the nitrovasodilators, the 
β-adrenoceptor blockers (such as metoprolol and atenolol) and Ca2+ channel blockers.  
Verapamil is the Ca2+ channel blocker used in an attack of angina, as it has a more 
pronounced effect on the heart than on the blood vessels.  Like nitrovasodilators, -
adrenoceptor blockers and Ca2+ -channel blocker decrease the work done by the heart/O2 
demand to levels that can be met by the diseased coronaries. 
 
The nitrovasodilators used to prevent attacks of typical angina are nitroglycerin patches, 
which are applied topically to provide slow release of the nitrovasodilators.  As isosorbide 
mononitrate has no significant first pass liver metabolism, it can be used orally to prevent 
angina attacks.  
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Long term treatment with nitrates is associated with tolerance (reduced effect) to nitrates for 
which the mechanism is unknown.  To prevent this reduced effect, drug holidays are used to 
prevent tolerance from developing.  This can be achieved by not applying the patch or 
ointment overnight. 
 
Both β-adrenoceptor antagonists and the Ca2+-channel antagonist verapamil interrupt the 
process in an attack of typical angina.  In the stable form of typical angina, exercise or stress 
provoke an attack by increasing the activity of the sympathetic nervous system and hence the 
release of noradrenaline, which acts at the cardiac β1-adrenoceptors to increase the heart rate 
and force, and the work done by the heart, which increases the oxygen demand to above that 
supplied in the diseased coronary arteries (Table 12.2.1).   β-adrenoceptor antagonists inhibit 
the binding of the noradrenaline to the cardiac β1-adrenoceptors to decrease the heart rate and 
force, and the work done by the heart, which decreases the oxygen demand to that supplied in 
the diseased coronary arteries to end the attack of angina (Table 12.2.1). 
 
Table 12.2.1 Preventing an attack of typical angina (Copyright QUT, Sheila Doggrell) 
 
The Ca2+-channel blocker verapamil inhibits at one stage later in the process of typical angina 
than the β-adrenoceptor antagonists.  Verapamil inhibits the influx of Ca2+, and this leads to a 
decreased heart rate and force, and thus work done by the heart and oxygen demand.  The 
goal is to decrease the oxygen and nutrient demand to the level that can be met by the 
diseased coronary arteries. 
  
12.2.4 Atypical angina 
Atypical angina is due to coronary artery spasm.  The spasm closes the blood vessel, and 
gives the same symptoms as typical angina.  As contraction of vascular smooth muscle 
requires Ca2 + entry into cells through Ca2+ channels, Ca2+ channel blockers, which act 
predominantly on the blood vessels (e.g. amlodopine) are effective in atypical angina.  
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12.3 Drugs for heart failure 
 
Heart failure is anything that leads to a reduced cardiac output.  Chronic heart failure is when 
the heart failure is ongoing, and drugs for chronic heart failure are the topic of this chapter. 
 
 12.3.1 The heart failure epidemic 
Heart failure is one of the most common causes of death and disability.  Congestive Heart 
Failure (CHF) is when heart failure is accompanied by congestion in the lungs.  The 
prevalence of Congestive Heart Failure in Australia, as elsewhere increases with age.  In 
Australia, at 50-59 years of age, 1% of subjects have CHF, after 60 years of age, 13% have 
CHF, and over 85 years of age, 50% have heart failure.  CHF is deadly, with a mortality rate 
of 50% at 5 years.  At present, 300,000 Australians have CHF with 30,000 new cases 
annually.  CHF is also an expensive disease with one-third of hospitalisation in the over 70 
years being due to CHF. 
 
Until fairly recently, hypertension and angina led to premature deaths due to heart attacks. 
However, good pharmacotherapy for hypertension, angina and heart attacks has reduced the 
deaths from heart attack, and subjects live on to get heart failure.  There is also a general 
ageing of the population with life expectancy continually increasing in most Westernised 
countries.  Thus, there is an increased incidence of old people with CHF. 
 
With the reduced cardiac output that is heart failure, there is poor delivery of oxygen and 
nutrients to the tissues of the body.  In heart failure, there is also reduced removal of carbon 
dioxide and waste materials from the tissues. 
 
 12.3.2 Compensatory changes in heart failure 
There are some compensatory changes associated with heart failure that are aimed at 
increasing cardiac output, but lead to the symptoms of heart failure.  When cardiac output is 
reduced, there is activation of the sympathetic nervous system to increase heart force and 
of the renin-angiotensin-aldosterone system. Both of these systems have a role in 
increasing blood pressure, which will initially help oxygen delivery and removal of waste 
from tissues.  However, with increased blood pressure, there is increased loss of fluid from 
blood vessels, and the fluid has to go somewhere, so there is increased fluid accumulation in 
legs, which is known as peripheral oedema.  Peripheral oedema leads to the swelling of the 
legs, which is a common symptom of heart failure. 
 
The increased peripheral arteriolar resistance (blood pressure) also leads to decreased renal 
blood flow, and a decreased glomerular filtration.  With a decreased glomerular filtration, the 
kidney cannot function properly, and there is an increased retention of water and electrolytes.  
Again this fluid has to go somewhere and it often goes to the lungs to cause pulmonary 
oedema, which underlies the difficulty in breathing, which is a common symptom of heart 
failure.  Poor kidney function will also contribute to peripheral oedema.  
 
 12.3.3 Diuretics for heart failure 
In hypertension, there is no accumulation of excessive fluid, but diuretics reduce blood 
pressure.  In heart failure, there is an accumulation of excessive fluid, so that it is much more 
logical to use diuretics in heart failure to remove excessive fluid.  By increase water loss from 
the body, diuretics decrease the oedema (Figure 12.3.1).   
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Figure 12.3.1 Diuretics and heart failure (Copyright QUT, Sheila Doggrell) 
 
Diuretics decrease the oedema in the peripheral tissues, which leads to a reduced swelling of 
the legs.  Diuretics also decrease the pulmonary oedema, which has two effects.  Firstly, there 
is improved breathing, and secondly there is a decreased pulmonary resistance, which allows 
an increased cardiac output (Figure 12.3.1). 
 
The diuretic combination most commonly used in heart failure is a Loop/High Ceiling 
Diuretic (usually furosemide), often in combination with a K+-sparing diuretic (e.g. 
amiloride).  Amiloride has already been discussed.  The thiazide diuretics, which are used in 
the treatment of hypertension, are often not potent enough to give a good clearance of fluids, 
and the more potent furosemide is used.  Furosemide inhibits the Na+K+2Cl- cotransporter in 
the thick ascending limb of Henle (Figure 12.3.2). 
 
Figure 12.3.2 Mechanism of action of furosemide (Copyright QUT, Sheila Doggrell) 
 
Furosemide (which is also known as frusemide) is active after oral or intravenous 
administration.  After oral administration, frusemide is readily absorbed from the 
gastrointestinal tract to give a diuretic effect within 30 minutes.  In an emergency, 
intravenous furosemide can be used to have an effect within 2 to 10 minutes.  Frusemide is 
actively secreted into the proximal tubule of the kidney, and passes along the kidney tubule to 
the thick ascending limb of Henle, where it inhibits the Na+K+2Cl- cotransporter (Na+ 
reabsorption).   As water reabsorption follows ion reabsorption, inhibition of the Na+K+2Cl- 
cotransporter leads to retention of ions and water, to increase the amount of water loss from 
the kidney.   Frusemide has a greater maximum diuretic effect than thiazide diuretics, and this 
is commonly needed in congestive heart failure.  Frusemide has a duration of action of 4 to 8 
hours, and is excreted in urine. 
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Unfortunately, the increase diuretic potency with frusemide comes with increased adverse 
effects.  An extension of the beneficial effects of frusemide leads to too much sodium being 
lost from the body producing hyponatremia (low levels of sodium in the body) and too 
much loss of fluid leading to hypotension.   
 
Frusemide can cause excessive K+ loss from the kidney, as increasing the volume of luminal 
fluid/Na+ in distal tubule promotes secretion of K+ into the kidney tubule, and K+ loss. This 
hypokalaemic (low levels of potassium) can promote cardiac arrhythmias.  Thus, when 
frusemide is being used on an ongoing basis, it may be necessary to determine plasma K+ 
levels.  If excessive K+ is being lost from the body, frusemide can be given with potassium 
supplements or in combination with the K+ sparing diuretic amiloride.   
 
Frusemide can cause hyperuricemia (high levels of uric acid).  This is due to furosemide and 
uric acid being secreted into the proximal tubule by the same mechanism, and consequently 
furosemide can inhibit uric acid secretion and excretion.  When uric acid excretion is 
inhibited, the levels rise, and this precipitates attacks of gout, especially in people with a 
previous history of gout.  Thus, frusemide use should be avoided in this group, if possible.  
Frusemide can cause ototoxicity (hearing loss) by an unknown mechanism.  Fortunately, 
hearing loss with frusemide is reversible.  Finally, frusemide can increase the loss of 
magnesium from the body, and the resulting hypomagnesemia can promote cardiac 
arrhythmias. There hypomagnesemia-induced arrhythymias can be prevented with oral 
magnesium supplements. 
 
 12.3.4 ACE inhibitors, AT1-receptor antagonists, and aldosterone receptor 
antagonists 
The second group of drugs commonly in heart failure are the inhibitors of the renin-
angiotensin-aldosterone system, the angiotensin converting enzyme (ACE) inhibitors, AT1-
receptor antagonists, and aldosterone receptor antagonists.  Enalapril is an ACE inhibitor, 
and losartan is an AT-1 receptor antagonist used in heart failure.  These drugs have benefits 
due to venodilation and arteriolar dilation.   
 
In heart failure, drugs that cause venodilation, such as enalapril and losartan, lead to a 
pooling to the blood in veins.  With pooling of blood in the veins, less fluid needs to be 
dumped in the lungs, and the decreased fluid in the lungs makes breathing easier.  Also, 
decreasing the accumulation of fluid in the lung (caused by the compensatory changes in 
heart failure), leads to reduced pulmonary resistance making it easier for the heart to pump, 
and an improved myocardial performance is observed. 
 
Arteriolar dilation with enalapril and losartan also has beneficial effects in heart failure, and 
these effects are not observed in the normal heart.  In the normal heart, cardiac output is 
independent of peripheral arteriolar resistance.  Thus, graphically plotting cardiac output 
against arterial resistance in the normal heart there is no connection.  Regardless of arteriolar 
resistance, cardiac output is constant (Figure 12.3.3).  This is because, in the normal heart, as 
resistance is increased, so is heart rate, and cardiac output remains unchanged. 
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Figure 12.3.3 Arteriolar resistance and cardiac out (Copyright QUT, Sheila Doggrell) 
 
However, the situation is very different in the failing heart, as the mechanisms to maintain 
cardiac output are already turned on, and in the failing heart, heart rate is at a maximum and 
cannot be increased.  Thus, as resistance is increased cardiac output is decreased (Figure 
12.3.3).  When arteriolar dilators, such as enalapril and losartan are used in heart failure, there 
is a decrease in arteriolar resistance, and an increase in cardiac output (Figure 21.3), but this 
only applies in the failing heart not the normal heart. 
 
The heart failure, there is excessive accumulation of sodium and water.  Aldosterone is the 
salt and water retention hormone.  The levels of aldosterone are elevated in subjects with 
heart failure.  Consequently, antagonists of aldosterone receptors are used in the treatment of 
heart failure.  Spironolactone is an antagonist at aldosterone receptors.  In the presence of 
aldosterone, spironolactone promotes the loss of sodium and water.  In a large clinical trial, 
spironolactone has been shown to decrease the mortality (deaths) and hospitalization of 
people with heart failure.  In the low doses used in the treatment of heart failure, the most 
common adverse effects of spironolactone are extensions of its beneficial effects.  Thus, 
spironolactone can cause hyperkalemia (retention of too much potassium leading to high 
potassium levels), and hyponatremia (loss of too much sodium leading to low levels of 
sodium in the body). 
  
 12.3.5 β-adrenoceptor antagonists 
For many years, it was considered that β-adrenoceptor antagonists would be detrimental in 
heart failure. Thus, 1-adrenoceptor antagonists were used in the treatment of hypertension 
and angina, but contraindicated in the treatment of heart failure.  Recently, 1-adrenoceptor 
antagonists have been shown to be beneficial in heart failure. On the normal heart, 1-
adrenoceptor antagonists decrease cardiac output, and this would be detrimental in heart 
failure, and this was the reason for not considering 1-adrenoceptor antagonists in heart 
failure.  However, we now know that 1-blockers have different effects in the failing than 
normal heart.  In heart failure, the number of 1-adrenoceptors is altered, and 1-adrenoceptor 
antagonists have been shown to increase cardiac output.  The 1-adrenoceptors, such as 
metoprolol, have been shown to decrease mortality and morbidity in subjects with heart 
failure.  1-adrenoceptor antagonists are now very commonly used in the treatment of heart 
failure. 
 
12.3.6 Digoxin 
Digoxin is derived from a plant source (the foxglove) and has been in medical use for dropsy 
(heart failure) since medieval times.  It is much more recently that it was discovered that the 
mechanism of action of digoxin is inhibition of the Na+K+ATP-ase that drives sodium and 
potassium exchange across membranes.  This leads to an increased force of myocardial 
contraction.  In heart failure, increase the force of the heart beat to increase cardiac output, 
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which helps reverse the decreased cardiac output in heart failure.  However, “Digoxin has a 
very low therapeutic index, and at least 60% of the toxic dose is required to produce a 
therapeutic effect.  Because of this narrow safety margin, it has been argued, that if digoxin 
were to be introduced as a new drug today, it would be regarded as too dangerous for clinical 
use”.  But we still use digoxin! 
 
As the Na+K+ATP-ase is present on all cells, it is not surprising that digoxin has widespread 
effects, some of which are toxic.  On the cardiovascular system, digoxin is pro-arrhythmic 
i.e. it can cause cardiac arrhythmias.  Some of the toxic effects of digoxin help to identify it 
as the culprit.  For instance, digoxin causes visual disturbances such as disturbed colour 
vision, and halos around objects.  Digoxin also causes psychiatric problems such as delirium, 
fatigue, malaise, confusion, and abnormal dreams.  Digoxin can also cause gastro-intestinal 
toxicity such as anorexia, nausea, vomiting, and abdominal pain.  In life threatening digoxin 
toxicity, anti-digoxin immunotherapy is used intravenously. 
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Drugs for cardiac arrhythmias, antithrombotic drugs and lipid modify drugs are considered in 
this section. 
 
13.1 Drugs for cardiac arrhythmias 
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13.1.1 Introduction to cardiac arrhythmia 
Sinus rhythm is normal heart rate.  Cardiac arrhythmias are abnormal rhythms of the 
heart.  Tachycardia is faster than normal atrial or ventricular rates, giving atrial tachycardia 
or ventricular tachycardia.  Flutter is fast, irregular beats of the atria or ventricles, giving 
atrial flutter or ventricular flutter.  Often the arrhythmias are progressive, tachycardia turns 
into flutter, and flutter turns into fibrillation.  Fibrillation is fast, irregular quivers of muscle, 
without a beat.  In atrial fibrillation, survival is possible provided the ventricles are still 
beating normally.  Atrial fibrillation can precipitate ventricular fibrillation.  Ventricular 
fibrillation can be deadly, as it is not possible to survive without a heart best.  Torsades de 
pointes are drug-induced ventricular tachycardia.  Infarcted or ischemic areas of myocardium 
can precipitate arrhythmias. 
 
Cardiac arrhythmias are common.  Atrial fibrillation affects 0.4% of the general population, 
but the incidence increases with age to 2-5% of persons over 60 years of age and 10% of 
those older than 70 years.  Ten percent of the survivors of myocardial infarction (MI, heart 
attack) die during the subsequent year, mostly of cardiac arrhythmias.  Fifty percent of 
patients with heart failure undergo a sudden death, which may be due to cardiac arrhythmia. 
 
13.1.2 Cardiac action potentials 
To understand how the drugs used to treat cardiac arrhythmias work, it is necessary to know 
about cardiac action potentials and the mechanisms of arrhythmias.  Cardiac action 
potentials are different in the sino-atrial node (pacemaker) and the His-Purkinje conducting 
system to the ventricles.  At the sino-atrial node, there is a slow response made up of a 
gradual depolarization, and then more definite depolarisation, followed by repolarisation 
(Figure 13.1), and this process is continual.  The more definite depolarization is due to the 
opening of Ca2+ channels with Ca2+ entry into the cells.  With every slow response, a heart 
beat is initiated. 
 
Figure 13.1 Cardiac action potentials 
 
The His-Purkinje system is responsible for conducting the impulse around the heart causing it 
to beat.  In the His-Purkinje system, there is a more complex action potential; initially there 
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is a resting membrane potential, then a rapid depolarisation that gives a fast response, 
followed by 3 phases of repolarisation (rapid, slow, and delayed) (Figure 13.1.1).  The 
rapid depolarisation is due to sodium channels opening with Na+ moving into the cardiac 
cells.  Calcium channels open letting Ca2+ into the cell and then close during the slow phase 
of repolarisation.  During the delayed repolarisation delayed outward K+ channels open, 
and K+ moves out of the cardiac cells.  Thus, drugs that act at Na+, Ca2+, and K+ channels can 
modify cardiac action potentials and, consequently, alter the activity of the heart.  In 
particular, the ion channel modulators can alter cardiac arrhythmias. 
 
13.1.3 Mechanisms of arrhythmia 
There are several mechanisms of arrhythmias. The most important cause of cardiac 
arrhythmias is cardiac injury, which includes the acute injury associated with a heart attack, 
and the chronic injury due to the ischemic heart disease associated with angina.  Other factors 
can also contribute to arrhythmias including hypoxia, acidosis, and increases in 
extracellular K+ and/or Ca2+. Stress induced increase in the activity of sympathetic nervous 
system, with an increased release of noradrenaline and adrenaline and activation of cardiac -
adrenoceptors, can also precipitate cardiac arrhythmias. 
 
Cardiac arrhythmias are either disorders of impulse formation or disorders of impulse 
conduction.  Disorders of impulse are of 3 types.  Firstly, there is a heart block, where 
injury to sino-atrio node or atrio-ventricular node causing heart to stop.  Usually, to start with 
this is only for short period, during which the person collapses, and then regains 
consciousness when the heart starts to beat again, but heart blocks do tend to be progressive; 
occurring more often and for longer.  The treatment for advanced heart blocks is a 
pacemaker.  The second disorder of impulse is an increased firing rate originating in the 
pacemaker region.  Drugs that inhibit the SLOW response i.e. the calcium channel, at the 
sino-atrio node are useful in this condition.  Thirdly, there is the development of ectopic 
pacemaker, a pacemaker outside of sino-atrial node.  Ectopic pacemaker usually develops in 
the specialised His Purkinje conduction system of the atria or ventricles.  Drugs that inhibit 
the FAST response of the specialised conducting system are useful in treating ectopic 
pacemakers. 
 
Disorders of conduction are due to damage in the Purkinje conducting system.  In the 
normal heart, impulses arise in the sino-atrial node (pacemaker) and spread around with 
atria to the atrio-ventricular node, and then around the ventricles to they meet and die out.  
Impulses leave in their wake refractory tissue, and refractory tissue cannot be re-excited for 
200-500 msec.  When the last part of heart is excited X, the impulses are surrounded by 
refractory tissue, and the impulses die out, and there is a period of electrical quiescence.  
Each of these impulse cycles is associated with a heart beat, and the process is repeated 60 to 
80 per min to give a heart rate of 60 to 80 beats per min.   
 
The most common disorder of impulse conduction is functionally defined re-entry.  In this 
there is damage leading to a unidirectional functional block, the impulse can go through one 
way, but not the other.  Thus, the impulse dies out at the damage area.  The impulses coming 
from the other area does not meet one at the bottom of the heart, and just keeps going (Figure 
13.2).  The impulse can re-enter the ventricular circuit, and cause further activation with 
quivers of the heart muscle. 
128 
 
 
Figure 13.2 Functional defined re-entry (Copyright QUT, Sheila Doggrell) 
 
Treatment for unidirectional blocks is most commonly, to turn a unidirectional block into a 
bidirectional block.  With this approach, the impulses will die out at the damaged area rather 
than the apex of the heart.  The benefit is due to preventing the impulse from re-entering.  
The other approach is to increase excitability or conduction to overcome block, and this 
returns to near normal function, with the impulses dying out at the apex.  The problem with 
this approach is that if you increase excitability too much, and ectopic centre will develop in 
the conduction system giving an extra beat.  Thus, although not the best method, turning a 
unidirectional block into a complete block is the safest approach with drug intervention. 
 
Anti-arrhythmic drugs are divided into 4 classes. 
 
 13.1.3 Class I  
Class I agents block Na+ channels, the channels involved in the rapid depolarisation in the 
Purkinje system.  Examples of class I Na+ channel blocker is lignocaine.  Lignocaine is also 
known as lidocaine, and is also used as a local anaesthetic, where the effect is also due to 
blocking Na+ channels.  The Na+ channel blockers have no effect on sinus rhythm, as Ca2+ 
channels predominantly control sinus rhythm.  Lignocaine is used in serious ventricular 
arrhythmias, where they decrease the excitability of the conduction system.   
 
 13.1.4 Class II  
Class II agents are β-adrenoceptor antagonists.  As mentioned before, a whole range of 
things can cause activation of the sympathetic nervous system; myocardial infarction, stress, 
exercise, pheochromocytoma (adrenaline secreting tumours), and hyperthyroidism.  With 
sympathetic nervous system activation, there is the release of noradrenaline and adrenaline 
and the activation of cardiac β-adrenoceptors, which can initiate or make worse 
tachyarrhythmias.  1-adrenoceptor antagonism leads to decreased effects of the sympathetic 
nervous system (SNS) on the heart, and a reduction in tachyarrhythmias. 
 
Of the β-adrenoceptor blockers, propranolol is the one that is often preferred in cardiac 
tachyarrhthymias.  Propranolol is a non-selective β-adrenoceptor blocker that may have some 
Na+ channel blocking activity, and this Na+ channel blocking activity may contribute to the 
benefit by decreasing excitability and conduction.  Propranolol is used in the treatment of 
tachyarrhythmias, where an overactive sympathetic nervous system is implicated. 
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Esmolol is an ultra-short acting β-adrenoceptor blocker used intravenously to treat atrial 
flutter and atrial fibrillation associated with operations.  When atrial flutter or fibrillation 
occurs during an operation, esmolol can be administered intravenously, to bring the heart 
back to normal sinus rhythm, and then the infusion can be stopped and the esmolol is rapidly 
metabolised. 
 
 13.1.5 Class III 
Class III anti-arrhythmic agents block the delayed outward rectifying K+ channel.  D-
sotalol, the D-isomer of the β-adrenoceptor blocker racemic sotalol, blocks the delayed 
outward rectifying potassium channel to prolong the action potential in the Purkinje system 
(Figure 13.3).  In a normal heart, D-sotalol prolongs the repolarisation, but this has little 
effect as there is a period of quiescence between action potentials (and between heart beats).  
Arrhythmias are often due to re-excitation in what should be the quiescence phase.  By 
prolonging the repolarisation, D-sotalol decreases the likelihood of re-excitation (Figure 
13.3). 
 
Figure 13.3 Mechanism of D-sotalol (Copyright QUT, Sheila Doggrell)  
 
D-sotalol is useful in a variety of supraventricular (arising in the atria) and ventricular 
arrhythmias. 
 
13.1.6 Class IV  
Class IV anti-arrhythmic agents are Ca2+ channel blockers.  Verapamil preferentially 
blocks cardiac Ca2+ channels over vascular Ca2+ channels.  Thus, verapamil inhibits the 
inward Ca2+ current associated with pacemaking.  Verapamil also slows conduction through 
the atrio-ventricular node.  Verapamil is used in arrhythmias associated with increased 
excitation of sino-atrio or atrio-ventricular node.  Verapamil is active after oral 
administration but does undergo extensive first pass liver metabolism.  Verapamil can also be 
used intravenously in an emergency. 
 
 13.1.7 Amiodarone 
Amiodarone is a unique anti-arrhythmic that has activity in all classes.  Thus, amiodarone is 
a potent K+ channel blocker, including blocking the delayed outward rectifying potassium 
channel.  However, amiodarone is also a Na+ channel blocker, and a Ca2+ channel blocker, 
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mimicking the effect of verapamil.  Amiodarone is also a blocker of - and -
adrenoceptors.  Finally, an unwanted mechanism of amiodarone is that it is an analog of 
thyroid hormone.  Thus, amiodarone interacts with nuclear thyroid hormone receptors in an 
inhibitory way, such that many of the adverse effects of amiodarone mimic those of 
hypothyroidism. 
 
Amiodarone is used orally in recurrent ventricular tachycardia/fibrillation, particularly 
when the arrhythmia is resistant to other drugs.  Also, amiodarone is used orally to convert 
atrial fibrillation into normal sinus rhythm.  Amiodarone is used intravenously for the 
termination of ventricular or supraventricular arrhythmias in an emergency.   
 
In clinical trials, it has been shown that preventative oral use of amiodarone, after myocardial 
infarction or in heart failure, reduces sudden death, which is usually arrhythmic death.  
However, amiodarone is not standard therapy after myocardial infarction or in heart failure, 
probably because it has many adverse effects, which means people do not like taking it, and 
the benefits may not exceed the risks.   
 
Amiodarone is very lipid soluble, and large amounts accumulate in fat tissues, and are only 
slowly released.  The adverse effects associated include pulmonary toxicity in 2-17% of 
patients and hypothyroidism in 2-10% of patients, but severe arrhythmias are rare. 
 
 13.1.8 Adenosine 
Adenosine is a naturally occurring substance that slows sinus node activity and conduction 
through the atrioventricular node.  It is produced in ischemia, and slows the heart rate.   
 
Adenosine can also be used clinically to slow heart rate.  Adenosine has a short duration of 
action.  The short duration limits the used of adenosine to the emergency situation for acute 
treatment of supraventricular arrhythmias.  In an emergency, adenosine is used intravenously, 
for the acute treatment of supraventricular (atrial) arrhythmias, where its rapid onset of action 
is a major advantage.  
 
 
13.2 Anti-thrombotic drugs 
 
This section concerns the anti-thrombotic drugs, and there are 3 groups these, the anti-
platelet agents, which are used to prevent platelet-platelet aggregation at the start of 
thrombus formation.  The second group are the anti-coagulants, to prevent coagulation, 
which often occurs around excessive platelet-platelet aggregation.  The third group are the 
fibrinolytics (also known as thrombolytics), which are used after clots have formed to cause 
heart attack or stroke, to breakdown the clots and restore normal blood flow. 
 
 13.2.1 Thrombus formation 
On the arteriolar side to the circulation, white/arterial thrombus form, and the whiteness is 
due to the presence of platelets, which are white cells.  When there is damage to blood vessel 
wall, this can lead to bleeding.  In order to repair blood vessels, platelets stick to the damaged 
area, and then platelet-platelet aggregation occurs at the site.  Normal platelet aggregation 
is good, as it is involved in the repair process.  However, if the platelet aggregation is 
excessive, this may occlude the areas of slower arterial blood flow.  This leads to more local 
bleeding, and the capture of red blood cells can lead to a red thrombus around the white 
thrombus.  The problem caused is local ischaemia, with the tissues normally serviced by the 
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blood vessel no longer receiving oxygen or nutrients.  If the artery is a coronary artery 
supplying the blood to the heart, and the artery has excessive atherosclerosis associated with 
platelet-platelet aggregation, this leads to transient ischaemic attacks (typical angina).  
Typical angina progresses to be unstable, and then leads to myocardial infarction.  In the 
brain, if the carotid artery is similarly affected, this leads to stroke. 
 
On the venous side, red or venous thrombus form, with the redness due to the red blood 
cells.    The blood flow is slower in the veins, and this accounts for the differences in the 
thrombus.  Whereas arteriolar thrombi are layered, blood clot on the venous side, are a mix of 
platelet-platelet aggregation, fibrin, and red blood cells.  Venous thrombi are easily detached, 
and move in the blood stream to smaller veins, which they block.  The problems caused are 
that thrombi from the calf/deep vein can move around the circulation to cause embolization 
of the pulmonary arteries, which can be deadly. 
 
 13.2.2 Platelet aggregation and anti-platelet drugs 
When a blood vessel is damaged, this exposes underlying collagen, and platelets stick to 
collagen.  The local mediator responsible for this is thromboxane-A2 (TXA2).  Thus, there is 
activation of COX-1 in the platelets, and the intermediates from this, in the presence of 
thromboxanes synthase form TXA2.  In turn, TXA2 stimulates TP receptors on platelets to 
decrease the activity of adenylate cyclase, leading to decreased cAMP, which promotes 
platelet aggregation (Figure 13.4).    
 
Figure 13.4 Thromboxane and platelet aggregation (Copyright QUT University, Sheila 
Doggrell) 
 
Platelets do not have a nucleus, and therefore cannot synthesise COX-1.  Platelets only have 
a small supply of COX-1, and once this is used up, there is no more.  Low dose aspirin 
irreversible inhibits COX-1 in platelets, decreasing the amount of intermediates available to 
be converted to TXA2.  This leads to decreased platelet aggregation.   
 
In contrast, endothelial cells have a plentiful supply of COX-1, and can synthesise more 
COX-1.  Thus, low dose aspirin has no significant effect on the COX-1 in the endothelial 
cells or on the production of PGI2 from the endothelial cells, and PGI2-mediated inhibition of 
platelet aggregation.  Overall, low dose aspirin only leads to decreased TXA2 and decreased 
platelet-platelet aggregation.  Low dose aspirin selectively inhibits TXA2 formation to reduce 
platelet aggregation.   Low dose aspirin is used to prevent myocardial infarction and 
stroke.  High dose aspirin inhibits both PGI2 and TXA2 formation and has NO EFFECT on 
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platelet aggregation, and will not be useful in the prevention of myocardial infarction or 
stroke.  
  
Thromboxane is not the only mediator of platelet aggregation.  ADP is a potent promoter of 
platelet aggregation, and this effect of ADP is mediated by purinergic P2Y receptors.  
Clopidogrel is an antagonist at P2Y receptors and inhibits ADP-induced platelet aggregation.  
Clopidogrel reduces cardiovascular events in patients with unstable angina, which often 
leads to coronary artery stenting. Clopidogrel reduces cardiovascular events in patients with 
unstable angina.  As clopidogrel and aspirin inhibit platelet aggregation by different 
mechanisms, they have an additive effect.  Clopidogrel is commonly used in combination 
with aspirin to prevent vascular events in subjects with unstable angina, recent myocardial 
infarction, and in stenting.  
 
Activated platelets develop glycoprotein IIb/IIIa receptors, which are receptors for 
fibrinogen, and mediate aggregation.  The GPIIb/IIIa receptor is the final step in platelet 
aggregation.  Inhibiting this receptor will reduce platelet aggregation, regardless of what is 
causing the aggregation (ADP, TXA2).  Abciximab is an antibody to the GPIIb/IIIa receptor, 
and acts as an antagonist to prevent platelet aggregation.  Abciximab is used in combination 
with aspirin and the anti-coagulant heparin, when angioplasty or stenting is undertaken for 
coronary thrombosis.  Used during these procedures, abciximab decreases the incidence of 
recurrent myocardial infarction and death.  Abciximab is administered intravenously, as a 
bolus, followed by a continuous infusion of a lower dose for 12 hours. The major side effect 
of abciximab, like all anti-thrombotic drugs is an increased incidence of bleeding. 
 
13.2.3 Coagulation 
Coagulation is very complicated.  The process of coagulation indicated in Figure 23.2 is a 
much simplified version.  Coagulation is a cascade of events which involves several factors 
from the liver, some of which are vitamin K-independent, and some of which (including 
prothrombin) are vitamin K-dependent.  There also tissue and platelet factors, which 
eventually lead to the conversion of prothrombin to thrombin in the circulation.  Factor Xa is 
the enzyme necessary for breaking down prothrombin to thrombin.  In turn, Thrombin is 
responsible for changing fibrinogen, which is a soluble plasma protein into fibrin, an 
insoluble protein, which is part of the clot. 
 
Figure13.5 Coagulation (Copyright QUT, Sheila Doggrell) 
 
13.2.4 Anticoagulants 
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Heparin is a large (12,000 daltons) endogenous compound found in mast cells.  For clinical 
use, heparin is extracted from porcine intestinal mucosa or bovine lung.  Many of the clotting 
factors are proteases, and heparin inhibits all clotting factor proteases to inhibit clotting 
quickly.  Heparin is precipitated by acid in gut, and not absorbed from gastrointestinal tract, 
and this means it is ineffective when administered orally.  Heparin is used intravenously or 
subcutaneously. 
 
Low-molecular-weight heparins such as enoxaparin (1-10,000 daltons) are made from 
heparin.  Enoxaparin inhibits the final protease in the coagulation cascade, which is factor 
Xa to a greater extent than the other proteases in the cascade.  Enoxaparin is used 
subcutaneously.  With heparin, and low-molecular weight heparins, the main toxicity is 
bleeding, which is just an extension of its therapeutic effect.  Heparin and low-molecular-
weight heparins are beneficial in unstable angina, and very importantly, they are effective 
immediately, which makes them ideal to use in unstable angina, especially when it is 
progressing to myocardial infarction, and an immediate anti-coagulant effect is required.  
Heparins are also used to prevent clotting in surgical and high-risk medical subjects, and in 
coronary angioplasty. 
 
Warfarin inhibits the formation of vitamin K-dependent factors for coagulation including 
prothrombin.  Warfarin is active after oral administration, and this is a major advantage over 
heparin, which has to be given intravenously or subcutaneously.  However, warfarin is not 
effective immediately, this is a major disadvantage compared to heparin, which is effective 
immediately.   
 
Warfarin is only effective when existing vitamin K-dependent clotting factors have been 
broken down, which usually takes more than 36 hours, but is dependent on levels of vitamin 
K in the body.  If vitamin K levels are low, this alone will inhibit coagulation, and further 
inhibition of coagulation with warfarin may produce haemorrhage.  Clinically, warfarin use 
is for prolonged anti-coagulation effect (e.g in the prevention of thrombosis, unstable angina).  
Heparin and warfarin are often used in sequence, heparin to give an immediate anti-coagulant 
effect, until the anticoagulant effect of warfarin kicks in.  The main toxic effect of warfarin is 
haemorrhage.  The antidote to warfarin-induced haemorrhage is vitamin K to build up the 
vitamin K-dependent factors, and promote coagulation. 
 
Direct thrombin inhibitors, such as dabigatran, have been developed recently, and may take 
over some of the present roles of the heparins and warfarin.  By directly inhibiting thrombin, 
dabigatran inhibits the conversion of fibrogen (soluble) to fibrin (insoluble) clot.  Dabigatran 
is active after oral administration, and has an immediate effect.  Dabigatran is presently used 
after hip and knee replacement surgery to prevent thromboembolism. 
 
Another group of relatively new anticoagulants are the Factor Xa inhibitors.  Fondaparinux 
is a Factor Xa inhibitor.  Fondaparinux is used subcutaneously, and is effective quite quickly.  
Fondaparinux is used to prevent thromboembolism after hip-fracture, and hip or knee 
replacement. 
 
 13.2.5 Fibrinolysis and fibrinolytics 
Fibrinolysis or thrombolysis is the breakdown of clots.  The breakdown of clots is a normal 
process, and is uses plasmin as the active fibrinolytic agent.  Plasmin breaks down both the 
soluble fibrin and the insoluble fibrin (Figure 23.3).  When there is excessive clotting and 
thrombus formation, drugs are used to activate fibrinolysis.  Streptokinase activates the 
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plasma form of plasminogen to produce plasmin, whereas alteplase activates the fibrin form 
of plasminogen, also to form plasmin for fibrinolysis (Figure 13.6). 
 
Figure 13.6 Mechanism of fibrinolytics (Copyright QUT, Sheila Doggrell) 
 
As streptokinase activates the plasma form of plasminogen, it has widespread effects.  It will 
breakdown thrombi, but it will also breakdown clots, where blood vessel repair is taking 
place.  These widespread effects of streptokinase lead to a high incidence of bleeding.  
Streptokinase is derived from hemolytic streptococci, a streptococci that breaks down blood 
clots.  Streptokinase is quite antigenic, which can lead to allergic reaction, and even severe 
allergic reaction such as anaphylaxis.  Streptokinase is administered intravenously, and to get 
a good break down of clots, a loading dose is used and this is followed with a maintenance 
dose. 
 
Alteplase is the generic or non-proprietary name for tissue type plasminogen activator (also 
known as TPA).  It is claimed that alteplase selectively activates fibrin form of plasminogen, 
which means it will be clot selective.  It was initially claimed that would lead to less bleeding 
than with streptokinase, but bleeding is a common adverse effect with streptokinase and 
alteplase.  Alteplase is prepared by recombinant DNA.  Alteplase is administered 
intravenously, and a loading and then maintenance dose is used to get the maximum effect.   
 
Both streptokinase and alteplase are used to cause the breakdown of clots, and this included 
the clots causing multiple pulmonary emboli, deep vein thrombosis, acute myocardial 
infarction, and stroke. 
 
 
13.3 Lipid modulating drugs 
 
High levels of cholesterol (hypercholesterolemia) or dyslipidemia (altered levels of 
cholesterol, some up, some down) lead to atherosclerosis.  Dyslipidemia is commonly 
associated with diabetes.  Atherosclerosis can cause myocardial infarction, peripheral 
vascular disease, and stroke, often ultimately leading to death.  Atherosclerosis can also 
contribute to angina, heart failure or cerebrovascular disease, which can also be deadly, often 
after progressing to heart attacks and strokes.  Atherosclerosis is not the only risk factor for 
most of these conditions.  For instance, other risk factors for coronary heart disease are age, 
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family history of premature coronary heart disease including diabetes, cigarette smoking, and 
obesity.  
 
 13.3.1 Cholesterol 
Cholesterol is good for you! That is, provided it is at normal levels, where it is used in 
membrane synthesis, steroid hormone synthesis and the synthesis of bile acid.  It is only 
excessive cholesterol that leads to atherosclerosis.  Dietary fat is broken down successively 
to chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IDL), low density lipoproteins (LDL), triglycerides and high density 
lipoprotein (HDL).  VLDL and IDL are carriers of triglycerides and LDL and HDL are 
carriers of cholesterol (also known as LDL-cholesterol etc).  LDL-cholesterol is the major 
reservoir of cholesterol in human plasma (60-70% of total cholesterol). 
 
If you decrease the level of LDL cholesterol “the bad cholesterol”, there is a decreased risk 
of atherosclerosis, and its consequences.  Conversely, if you increase the HDL cholesterol 
“the good cholesterol”, there is a substantial decreased risk of atherosclerosis.   
 
High LDL cholesterol is considered to be 4.94 mmol/L or above, and low HDL cholesterol 
is 0.75 mmol/L or lower.  Drug treatment is available to decrease LDL cholesterol and 
increase HLD cholesterol. 
 
 13.3.2 Statins 
The levels of LDL cholesterol are commonly decreased by using the statins, which are 
HMG CoA reductase (hydroxyl-methylglutaryl coenzyme A-reductase) inhibitors.  When the 
liver needs cholesterol to synthesise membranes, steroids or bile salts, it increases the number 
of LDL receptors.  These LDL receptors are required to capture the plasma LDL cholesterol 
for the synthesis (Figure 24.1).  One of the enzymes involved in this pathway is HMG CoA 
reductase.  When this enzyme is inhibited, there is an increased synthesis of LDL receptors 
and LDL cholesterol removal from the plasma. 
 
Figure 13.7 HMG CoA reductase (Copyright QUT, Sheila Doggrell) 
 
Simvastatin and all the other statins were developed as inhibitors of HMG CoA reductase.  
Inhibition of HMG CoA reductase with a statin leads to decreased cholesterol synthesis, and 
increased synthesis of LDL receptors to decrease plasma LDL-cholesterol.  The statins have 
been shown to decrease mortality and morbidity in subjects with coronary heart disease or at 
high cardiovascular risk e.g. diabetes.  They are preferred to all other agents that have been 
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used to decreased LDL cholesterol, as statins have a lower incidence of side effects than other 
agents. 
 
13.3.3 Fibric acid derivatives 
The fibric acid derivates (fibrates) e.g. gemfibrozil, are used to increase HDL cholesterol 
especially in subjects who have low HDL cholesterol levels e.g. diabetics. The fibrates bind 
to Peroxisome Proliferation-Activated Receptor (PPAR), a nuclear receptor that regulates 
gene expression, and stimulate it.  PPAR stimulates fatty acid oxidation to reduce the levels 
of triglycerides, and stimulates lipoprotein lipase to clear triglycerides, and increases HDL-
cholesterol.  As a result of these actions, the fibric acid derivatives decrease levels of 
triglycerides, have variable small effects on LDL-cholesterol, but increase the levels of 
HDL-cholesterol.  The fibrates are used in subjects with high levels of triglycerides and low 
levels of HDL-cholesterol, which commonly occurs in the metabolic syndrome (obese, 
hypertensive, dyslipidemia) and diabetes. 
  
13.3.4 Ezetimibe 
Ezetimibe inhibits the transporter for cholesterol absorption from the gastrointestinal tract, 
and this reduces cholesterol absorption.  This leads to decreased levels of plasma LDL 
cholesterol, but has little effect on HDL cholesterol and triglycerides.  Ezetimibe is active 
after oral administration.  It undergoes extensive enterohepatic recycling.  Ezetimibe can be 
used alone in subjects with high LDL cholesterol levels, but the statins are usually preferred 
for monotherapy.  A few people cannot tolerate statins, as it can cause myopathy (muscle 
weakness), and then ezetimibe is used as an alternative to statins to lower LDL cholesterol.  
More commonly, ezetimibe is used in combination with simvastatin, when the simvastatin 
alone fails to lower LDL cholesterol sufficiently.  Ezetimibe and simvastatin have different 
mechanisms of action, and this allows them to have an additive effect when combined to 
lower LDL cholesterol.  
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14.1 Drugs for diabetes 
Prior to discussing the drugs for diabetes, there is a brief discussion of what diabetes is and its 
effects.  In order to understand how some of the drugs work, this eChapter starts with an 
overview of the physiology of the pancreas.  The drugs, including insulin replacement 
therapy, are then discussed in sequence. 
 
14.1.1 Diabetes mellitus 
Diabetes means large volume of urine flowing through.  Diabetes mellitus is when the urine 
is sweet. Diabetes insipidus is when the urine is tasteless.  Diabetes insipidus is a rare 
condition due to impaired renal conservation of water.  Diabetes mellitus is the subject of 
this chapter.   
 
One million Australians have diabetes mellitus, including 20% of those over 65.  Diabetes is 
an enormous burden to the economy, as 10-15% of total health expenditure is on diabetes, of 
which 6% is on diabetes medications and the rest is spent on diabetic complications.  In 
diabetes the underlying syndromes is hyperglycemia, high circulating levels of glucose.  The 
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glucose sticks to many sites to interfere with many processes in the body, and this underlies 
the complications with diabetes.  The glucose sticks to haemoglobin, and we use this to 
monitor the ongoing glucose levels in diabetes.  Thus, glycosylated haemoglobin is used as a 
measure of diabetes mellitus, and effective treatments lower the percentage of glycosylated 
haemoglobin.  By sticking to things, hyperglycemia is associated with the altered metabolism 
of lipids, carbohydrates and proteins. 
 
There are two types of diabetes mellitus.  Type I diabetes mellitus (which was previously 
known as insulin-dependent diabetes mellitus (IDDM)) only accounts for 10% of diabetes.  
Type I diabetes is a juvenile onset, autoimmune disease of the pancreatic cells that secrete 
insulin. Once the pancreatic cells are destroyed the individual no longer produces or stores 
insulin.  As insulin is essential to the management of glucose in the body, the resulting high 
levels of glucose can have major effects, if left untreated.   
 
Type 2 diabetes mellitus (previously known as non-insulin dependent diabetes mellitus 
(NIDDM) or maturity onset diabetes) is the common one, and the type of diabetes that is 
epidemic in the Westernized world.  Type 2 diabetes, which accounts for 90% of the diabetes 
mellitus, is more common in adults but can occur in children or adolescents if they are 
overweight or obese. Type 2 diabetes is characterized by low levels of insulin and/or loss 
of insulin sensitivity.  Type 2 diabetes is caused by a variety of genetic and environmental 
factors.  These are multifactorial (involve many factors), heterogenous (vary between 
people), and include obesity, ethnicity, hypertension, and hyperlipidemia. 
 
Diabetes leads to many complications with nearly 60% of diabetic deaths being 
cardiovascular, predominantly myocardial infarction and stroke.  Diabetes also causes 
damage to the kidney and diabetic kidney disease is the most common cause of end-stage 
renal failure.  Diabetes used to also cause a lot of blindness and neuropathy.  Today, if 
diabetes is managed well, these conditions are slow to develop. 
 
14.1.2 Physiology of the pancreas 
Insulin is secreted from a specialized part of the pancreas known as the Islets of Langerhans.  
The beta cells of the islets secrete insulin.  The secretion of insulin is increased by glucose, 
amino acids, and fatty acids.  For glucose, the mechanism is that the glucose is transported 
into beta cells, where it is metabolized (Figure 14.1).  This glucose metabolism leads to ATP 
formation, and ATP closes the K+-ATP-dependent channel.  Normally, the K+-ATP 
channel is open and K+ moves out of the cell through this ion channel, keeping the membrane 
potential low.  When the K+-ATP channel is blocked by ATP from the metabolism of 
glucose, the amounts of K+ in the cell increases, and this depolarization opens the voltage-
dependent Ca2+ channels.  Ca2+ entry into the beta cells promotes insulin secretion. 
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Figure 14.1 Glucose and insulin secretion (Copyright QUT, Sheila Doggrell) 
 
In type 2 diabetes, drugs are used to block the K+ATP channel to increase the secretion of 
insulin.  By blocking the K+ATP channel, drugs mimic the effect of glucose to increase the 
amounts of K+ in the cell, and this depolarization opens the voltage-dependent Ca2+ channels.  
Ca2+ entry into the beta cells promotes insulin secretion. 
 
During fasting (e.g. between meals) the levels of insulin are low.  During a meal, when 
glucose stimulates the release of insulin, there is a rapid twofold rise in the concentration of 
insulin.  Insulin stimulates the conversion of glucose to glycogen in the liver, the conversion 
of glucose to triglycerides in adipose tissue, and the conversion of amino acids to protein in 
muscle.  Insulin inhibits the breakdown of glycogen, triglycerides and protein, including the 
conversion of amino acids to glucose in the liver, by the process known as gluconeogenesis.  
Thus, insulin is stimulating the clearance of glucose from the plasma, and inhibiting the 
formation of glucose, and thus, the increased levels of glucose after a meal steady decline. 
 
The alpha cells of the pancreas produce glucagon, which is a hormone that has the opposite 
effects to insulin.  For instance it promotes the conversion of glycogen to glucose.  Under 
physiological conditions, insulin and glucagon are not secreted at the same time, as they 
would cancel each other out.  Glucagon is used as a drug to treat severe hypoglycemia 
(unwanted effect of some anti-diabetic drugs). Thus, some of the anti-diabetic drugs not only 
reduce hyperglycemia to normoglycemia, but are capable of reducing normoglycemia to 
hypoglycemia. 
 
14.1.3 Insulin replacement therapy 
The logical treatment for low insulin secretion or low sensitivity to insulin is to replace the 
insulin.  The insulin for replacement is made my recombinant DNA techniques.  Insulin 
replacement therapy is indicated for all subjects with Type 1 diabetes.  Many subjects with 
Type 2 diabetes also end up by producing very little insulin and becoming very insensitive to 
the insulin they produce, and need to use insulin replacement therapy.  However, before that 
changes in diet and oral hypoglycemics (drugs that are active after oral administration, and 
increase the levels of insulin) are initial treatment for Type 2 diabetes.  Insulin is not active 
after oral administration, as it is digested in the gut.  Insulin can be administered in a variety 
of ways: intravenously, intramuscularly, subcutaneously, and by inhalation, but not by oral 
administration, and this is the major drawback to using insulin.   
 
When insulin replacement therapy is used, the goal is to mimic what the endogenous 
insulin would do, if it was there. Endogenous insulin produced by the beta cells of the 
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pancreas is injected into the portal vein, which takes in straight to the liver.  Thus, the highest 
concentrations with endogenous insulin will be in the liver, which is very convenient as this 
is the major site of action of insulin.  However, insulin replacement therapy does not mimic 
this.  With all the routes used for insulin (i.v. i.m. s.c. and inhalation), the highest 
concentrations will be at the site of administration, which is not the liver.  Endogenous 
insulin levels are determined by glucose levels, insulin replacement therapy levels is not 
sensitive to plasma levels of glucose.  Thus, insulin replacement therapy is not a perfect 
match for endogenous insulin. 
 
With insulin replacement therapy, we try and match the kinetics of endogenous insulin, by 
using combinations of normal and long-acting preparations of insulin.  Endogenous insulin 
has quite low fasting levels, but when there is a meal, the glucose stimulates insulin secretion 
and there are increased level of insulin.  Pre-breakfast and pre-supper (dinner) injection of 
normal insulin preparations mimics the meal’s effect on the insulin by increasing the insulin 
concentrations.  Long-acting preparations of insulin mimic the fasting levels of endogenous 
insulin by maintaining low levels of insulin. 
 
The meal can be mimicked by insulin injection, which is short acting.  An alternative is to 
use isophane insulin, which is an intermediate acting preparation of insulin.  The fasting 
levels of insulin can be mimicked by insulin glargine, which is a long acting preparation of 
insulin.  Commonly two forms of insulin are combined, so that one injection can be used to 
mimic the fasting and meal levels of insulin.  For instance, insulin injection and isophane 
insulin in various proportions can be used. 
 
The main adverse effect of insulin replacement therapy is hypoglycaemia (low plasma levels 
of glucose).  Hypoglycaemia is characterised by sweating, hunger, palpitations, tremor, 
anxiety, convulsions, and coma.  To prevent hypoglycaemia, regular monitoring of glucose 
levels is used.  The treatment of mildhypoglycemia is to ingest some glucose that is being 
carried.  After a few incidents of hypoglycaemia, diabetics are able to recognise the start, and 
ingest glucose.  If the hypoglycemia is severe, and occurs regularly, it is advisable to have an 
identification card saying you are diabetic or a bracelet that provides the information.  
Thus, at the convulsions/coma state, it will be known to use intravenous glucose or glucagon 
to overcome the hypoglycemia. 
 
There are quite a lot of drug interactions with insulin replacement therapy.  Things that can 
lead to hypoglycemia in combination with insulin replacement therapy include ethanol (ie 
alcohol).  Ethanol inhibits gluconeogenesis, which is the conversion of amino acids to 
glucose, and thus ethanol decreases the levels of glucose.  If a fixed dose of insulin is being 
taken, and ethanol is also taken, there may be excessive reductions in the levels of glucose, 
which may result in hypoglycemia.  Aspirin increases the sensitivity of the pancreas to 
glucose, thereby increasing the secretion of any remaining insulin to reduce levels of glucose.  
Thus, in type 2 diabetes, where there is still some endogenous insulin, the combination of 
aspirin and insulin replacement therapy may lead to hypoglycemia. 
 
A group of drugs that may cause hypoglycemia in combination with insulin replacement 
therapy are the β-adrenoceptor antagonists.  Adrenaline is secreted from the adrenal 
medulla and stimulates β-adrenoceptors that promote gluconeogenesis, the conversion of 
amino acid to glucose, and glycogenolysis, which is the conversion of glycogen to glucose.  
The β-adrenoceptor antagonists prevent these effects of adrenaline, and therefore reduce the 
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levels of glucose.  The reduced levels of glucose in combination with insulin replacement 
therapy can lead to hypoglycemia.  
 
Conversely, when the levels of adrenaline are high, as in the fight and flight response, there 
will be increased levels of glucose, and the replacement therapy may not be sufficient to 
decrease the levels of glucose, leading to hyperglycemia (high levels of glucose).  
Glucocorticoids do a lot of things, besides being anti-inflammatory.  For instance, they have 
a permissive action to increase the ability of adrenaline to generate glucose.  Thus, the 
glucocorticoids may lead to hyperglycemia in combination with insulin replacement therapy. 
 
For type 2 diabetes, a number of drugs may be used prior to insulin replacement therapy.  
These include metformin, acarbose, sulfonylureas, glitazones, exenatide and dipeptidyl 
peptidase-4 inhibitors. 
 
14.1.4 Metformin 
Despite the fact that metformin has been used in type 2 diabetes for many years, the 
mechanism of action is still not clear.  We do know the pharmacodynamic actions that 
follow.  Metformin inhibits gluconeogenesis, which is the conversion of amino acids to 
glucose in the liver.  Metformin increases the sensitivity to insulin in type 2 diabetes, and 
where there is low sensitivity to insulin, this leads to increased glucose uptake.  Metformin is 
orally active, and commonly used in the treatment of type 2 diabetes.  Metformin is anti-
hyperglycemic, it reduces hyperglycemia to normoglycemia.  Metformin is not hypoglycemic 
i.e. it does not reduce normoglycemia to hypoglycemia.  Thus, hypoglycemic adverse effects 
are rare with metformin.  The most common unwanted effects of metformin are 
gastrointestinal disturbances, such as nausea and diarrhoea.  Lactic acidosis is a rae, but often 
fatal, side effect that may occur when contraindications to its use are overlooked (eg kidney 
impairment).  One advantage of metformin over some of the anti-diabetic drugs is that there 
is no weight gain with metformin.  In contrast, insulin replacement therapy and the 
sulphonylureas commonly cause weight gain, which tends to make the diabetes worse. 
 
14.1.5 Acarbose 
Carbohydrates are broken down to glucose in the gut by the enzyme α-glucosidase, and the 
glucose is absorbed.   Acarbose is an inhibitor of α-glucosidase, thereby inhibiting the 
formation of glucose in the gut.  Acarbose is active after oral administration, and is used in 
the treatment of Type 2 diabetes only.  By inhibiting the formation of glucose in the gut, 
acarbose leads to reduced absorption of glucose.  Hopefully, the levels of glucose will be 
reduced to a level that can be handled by the remaining insulin.  The use of acarbose 
produces extra carbohydrates in the faeces, which leads to flatulence and diarrhoea.  
Acarbose has a different mechanism of action to metformin, which means it can be used with 
metformin to have an additive effect on plasma glucose levels. 
 
14.1.6 Sulfonylureas  
The sulfonylureas are a group of oral hypoglycemic agents, which includes glibenclamide.  
The sulfonylureas inhibit the K+ATP channel in the pancreatic beta cells to increase insulin 
secretion (Figure 14.1).  The sulfonylureas are active after oral administration and are given 
orally once or twice daily, which is a major advantage over insulin.  Their disadvantage over 
insulin is that they are not effective in type 1 diabetes, as they require the presence of insulin 
to work.  The major adverse effect of the sulfonylureas is hypoglycemia, and the 
hypoglycemia is enhanced by alcohol.  Thus, as with insulin, there is a need to check plasma 
glucose regularly to make sure there is no hypoglycemia and that the glucose levels are under 
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control.  Unfortunately, the sulfonylureas cause a weight gain of a few kilograms, which 
tends to counter some of the benefit with these agents.  The oral sulfonylureas may become 
less effective with time, this is due to the progression of beta-cell failure or of the insulin 
resistance, making less endogenous insulin available or making the available insulin less 
effective.   When this happens, the type 2 diabetic, may have to proceed to insulin 
replacement therapy. 
 
14.1.7 Glitazones 
An example of a glitazone is pioglitazone.  The glitazones stimulate the nuclear receptor 
peroxisome proliferation-activate receptor-γ (PPARγ), to modulate the levels of a number of 
proteins.  This modulation leads to a reduced glucose output from liver (from glycogen), an 
increase in glucose uptake into muscle, and a reduced insulin resistance.  All of these effects 
combine to decrease plasma glucose.  The glitazones are active after oral administration, and 
are used in type 2 diabetes.  The major adverse effects of the glitazones are weight gain, 
oedema and anaemia.  Hypoglycemia is not usually a problem with the glitazones. 
 
14.1.8 Glucagon-like peptide-1, exenatide and sitagliptin 
Recently, there have been some very interesting findings relating to the treatment of diabetes, 
and they stem from the discovery of a new hormone, known as Glucagon-Like Peptide-1 
(GLP-1).  GLP-1 is produced by the gut, and has a major role in controlling glucose levels.  
GLP-1 stimulates insulin secretion, and inhibits glucagon secretion, both of which will lead 
to a decrease in glucose levels. 
 
This discovery led to a new treatment for diabetes, exenatide.  Exenatide is a peptide agonist 
at GLP-1 receptors which mimics the effects of GLP-1, and so it stimulates insulin secretion 
while inhibiting glucagon secretion.  Exenatide is used subcutaneously, prior to a meal.  
Exenatide is used when there is a lack of control of type 2 diabetes with treatment with 
metformin and a sulfonylurea (glibenclamide).  In time, exenatide may replace these agents 
in the treatment of type 2 diabetes.  Hypoglycemia is an unwanted effect with exenatide.  
 
Glucagon-Like Peptide-1 (GLP-1) is broken down, which leads to inactivation, by the 
enzyme dipeptidyl peptidase-4.  Sitagliptin is an inhibitor of dipeptidyl peptidase-4, and 
inhibition of the enzymes leads to the build up of GLP-1.  Thus, the end result with sitagliptin 
is to mimic the effects of GLP-1 to increase insulin secretion and inhibit glucagon secretion.  
Sitagliptin is active after oral administration, and is increasingly often used in combination 
with other anti-diabetic drugs such as metformin or sulfonylurea (glibenclamide) or 
pioglitazone.  Sitagliptin is capable to causing the adverse effect of hypoglycaemia but this 
occurs mainly when they are used with a sulfonylurea. 
 
14.2 Drugs for obesity 
 
14.2.1 Introduction 
Obesity is derived from the Body Mass Index (BMI), which is body weight in kilograms 
divided by square of height in metres (kg/m2).  If you have a BMI of 30 kg/m2 or more, you 
are obese.  A BMI in the range of 25-30 kg/m2 is considered to be overweight.  Obesity is a 
risk factor for many disorders.  Thus, obese people are more likely to develop diabetes or the 
metabolic syndrome.  The metabolic syndrome is often a precursor to diabetes, and is a 
combination of obesity, raised triglycerides plasma levels, raised plasma glucose levels and 
hypertension.  Obesity, the metabolic syndrome and diabetes are, in turn, risk factors for 
cardiovascular diseases such as atherosclerosis, hypertension, and venous thrombosis (all of 
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which are risk factors for angina and heart attacks).  Obesity, the metabolic syndrome and 
diabetes are also risk factors for cerebrovascular disease such as stroke.  
 
Obesity is now recognised as a disease, and not necessarily a character flaw.  There is a 
genetic contribution to obesity, which varies from person to person.  There are also 
environmental factors that contribute to obesity, and these include an increased caloric 
intake and decreased physical activity. 
 
Obesity should be managed with diet and exercise.  When diet and exercise do not work 
alone, they should be used in combination with pharmacotherapy.  There are two approaches 
to reducing body weight.  The first is to decrease energy intake, and this can be achieved by 
dieting or by using certain drugs.  The second is to increase energy expenditure, and this can 
be achieved by physical activity or by using certain drugs.   
 
Even relatively small reductions in body weight are good for you.  Thus, a 5-10% weight loss 
leads to about a 60% reduction in the rate of type 2 diabetes. 
 
14.2.2 Amphetamine 
Amphetamine abusers are thin.  Amphetamine releases noradrenaline (NA), dopamine (DA) 
and 5-hydroxytryptamine (5-HT) from their respective neurones.  This release of 
neurotransmitters leads to increased levels in the synapse, and increased stimulation of their 
respective receptors.  In the central nervous system (CNS), the release of DA is associated 
with the central stimulant effect, for which amphetamines are abused.  In the CNS, the 
release of NA and 5-HT is associated with the anorectic effect.  Thus, if the anorectic effects 
of amphetamine could be separated from the central stimulant, we would have a useful 
anorectic drug.  This has been achieved to a certain extent with phentermine. 
 
14.2.3 Phentermine  
Phentermine releases NA from nerves, with a lesser ability to release DA and 5-HT.  Thus, 
phentermine is anorexic without causing a major central stimulation.  Presently, this drug is 
available for short-term use in Australia: there use is limited to a maximum 12 weeks.  This is 
primarily to prevent people becoming dependent on the remaining central stimulation effect.  
Clinical trials show that phentermine can cause about a 8% weight loss over a year.  
 
The ability of phentermine to release NA is not limited to the CNS; this drug also release NA 
from sympathetic nervous system (SNS).  This release of NA from the SNS underlies the 
contraindications to use of these agents.  Thus, phentermine is contraindicated in 
cardiovascular disease especially hypertension, hyperthyroidism, and cerebrovascular 
disease. 
 
The adverse effects of phentermine are due to the remaining small amount of central 
stimulation.  Thus, common adverse effects with phentermine and diethylpropion include 
insomnia, restlessness and nervousness.  
 
14.2.4 Orlistat 
Orlistat inhibits pancreatic lipase to inhibit the absorption of fat.  The pancreas produces a 
lipase that breaks down triglycerides in the gut to free fatty acids.  When free fatty acids are 
formed they are absorbed and go into the circulation as cholesterol and triglycerides.  By 
inhibiting this absorption, orlistat reduces the intake of fat, and this leads to weight reduction.  
Over 12 months, there is a 5-10% loss in body weight with orlistat.  Orlistat treatment has 
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also been shown to decrease plasma triglycerides and LDL-cholesterol, while increasing 
HDL-cholesterol. 
 
The intact triglycerides that are not absorbed remain in the gut and are excreted in the faeces.  
These extra triglycerides cause the adverse effects with orlistat, which are flatus with 
discharge, oily spotting, faecal urgency and oily stools. 
 
The fat soluble vitamins (A, D and E) are absorbed in fat, and there was some concern that 
the use of orlistat may decrease the absorption of these vitamins, and lead to vitamin 
deficiency.  However, the plasma levels of the fat soluble vitamins are reduced but remain 
within normal limits during orlistat treatment, and vitamin supplementation is not required.  
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DRUGS AND THE GASTROINTESTINAL TRACT 
 
The subjects covered are the agents used for the control of acidity, prokinetics (which make 
the gut work faster) and anti-emetic (drugs that prevent nausea and vomiting).  The agents 
used to treat diarrhoea, constipation and irritable bowel syndrome are also considered.   
Irritable bowel syndrome is fluctuations between diarrhea and constipation. Finally, drugs for 
inflammatory bowel disease are discussed. 
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16.1. AGENTS TO CONTROL ACIDITY 
 
Dyspepsia (abdominal discomfort) is often triggered by particular foods (spicy, high fibre, 
fatty) or by eating too quickly or overeating.  Heartburn (pyrosis) is painful, burning 
sensation in the throat (oesophagus), which is caused by the back-up of acid from stomach 
into the oesophagus leading to heartburn.  Dyspepsia and heartburn are treated mainly with 
antacids, and if serious and ongoing, with proton pump inhibitors, and sometimes histamine 
H2-receptor antagonists.   
 
In gastroesophageal reflux disease (GERD, or gastrooesophageal to give GORD) there is 
heartburn and regurgitation.  In GERD, the lower oesophageal sphincter is either weakened 
or opens too often.  The sphincter defect can be caused by a hiatus hernia, obesity or 
pregnancy.  If untreated, GERD can lead to cancers of the oesophagus.  GERD is treated with 
antacids, proton pump inhibitors, and histamine H2-receptor antagonists.   
 
Peptic ulcers are due to an imbalance between mucosal defence factors and aggressive 
factors leading to excessive acid production, as discussed in Section 7.6.1.  Helicobacter 
pylori infection is commonly associated with these ulcers.  Treatment is with antibiotics to 
overcome the infection and with proton pump inhibitors to overcome the excessive acidity.   
 
Ulcers can also be induced by the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that are 
non-selective inhibitors of cyclooxygenase (COX) (e.g. aspirin).  The ulcers are due to the 
removal of the cytoprotective prostaglandins.  The treatment of NSAIDs-induced ulcers is 
proton pump inhibitors or misoprostol. 
 
 16.1.1 Antacids 
Anti-acids (which are alkaline solutions) can be used to neutralise the acid in the stomach.  
There are lots of these available over-the-counter.  Combinations of Mg2+ and Al3+ 
hydroxides provide a relatively fast and sustained neutralising capacity.  Carbonates and 
bicarbonates also neutralise acid.   
 
Mylanta is a mixture of aluminium hydroxide and magnesium hydroxide.   
 
Gaviscon is a mixture of calcium carbonate, sodium bicarbonate and alignate, which is a 
viscous gum.  Alignate helps protective mucus stick to the oesophagus, and this prevent acid 
damage.   
 
As Mylanta and Gaviscone are available over-the-counter, it indicates that they are relatively 
safe agents.  They are also cheap, compared to visiting a doctor and paying for a prescription.  
Antacids are cleared from stomach in about 30 minutes, which means that they may need to 
be taken frequently.   
 
Antacids will increase the pH of the stomach, and altering gastric pH can affect dissolution, 
absorption and bioavailability of several drugs.  In order to prevent this problem, it is best to 
avoid concurrent administration of antacids and other drugs.  The suggestion is that there 
should be a two hour gap between taking antacids and other drugs.   
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With normal renal function, the modest accumulation of Al3+ from aluminium hydroxide is 
not a problem.  However, in renal insufficiency, the increase levels of Al3+ can contribute to 
osteoporosis and proximal myopathy.   
 
Antacids are used in the treatment of dyspepsia, heartburn, GERD, peptic ulcers and 
NSAIDs-induced ulcers.  Antacids only relieve the symptoms; they do nothing to the 
underlying conditions. 
 
 16.1.2 Proton pump inhibitors (PPIs) and antibiotics for Helicobacter pylori 
The most effective way to overcome excess acid, being produced from the parietal cells of 
the stomach, is to use proton pump inhibitors.  This is because regardless of what is 
stimulating the acid secretion (histamine, gastrin and acetylcholine), inhibiting the proton 
pump will inhibit acid secretion.  This makes the proton pump inhibitors the most effective 
inhibitors of acid secretion.   
 
Omeprazole is the prototype proton pump inhibitor but there are other –prazoles in clinical 
use.  The proton pump inhibitors are prodrugs, requiring activation in an acidic environment.  
To avoid activation of the omeprazole by the acid in the oesophagus and stomach, 
omeprazole is supplied as enteric-coated granules that dissolve only at an alkaline pH, which 
limits absorption to the intestine.  Omeprazole is then carried in the blood stream until it is 
activated in the acid environment of the stomach.   
 
The proton pump inhibitors inhibit the activity of some cytochrome P45O enzymes, and may 
decrease the clearance of benzodiazepines, phenytoin and warfarin, which will increase the 
concentration and increase the toxicity of these medicines.  Proton pump inhibitors are used 
in the treatment of GERD and peptic ulcers, and in the prevention of NSAIDs-induced ulcers. 
 
Up to 90% of peptic ulcers may be associated with Helicobacter pylori infections of the 
stomach leading to increased stimulation of acid secretion.  H. pylori are Gram-negative rods.  
Unfortunately, single antibiotic regimens are ineffective as resistance has developed to H. 
pylori. Indeed, antibiotic resistance is preventing the elimination of H. pylori.  The preferred 
combination of antibiotics used to kill H. pylori is amoxicillin and clarithromycin.  These 
antibiotics are generally used in combination with a proton pump inhibitor.  Besides reducing 
the acid secretion, the proton pump inhibitor enhances the effectiveness of pH-dependent 
antibiotics such as amoxicillin or clarithromycin. 
 
 16.1.3 Histamine H2 receptor antagonists 
Histamine H2 receptor antagonists have previously been discussed (Chapter 16.3).  An 
example of an H2-receptor antagonist is ranitidine.  Ranitidine is a relatively safe drug and is 
available over-the-counter in low doses.  As histamine acting at the H2-receptor is only one of 
the stimulants of acid secretion, H2-receptor antagonists are only effective against this 
component.  There are other stimulants of gastric secretion e.g. gastrin and acetylcholine, and 
H2-receptor antagonists do not inhibit this secretion whereas proton pump inhibitors do.  
Thus, proton pump inhibitors are often preferred to H2-receptor antagonists in peptic acidity 
conditions.  H2-receptor antagonists can be used for dyspepsia, heartburn, and GERD. 
 
 16.1.4 Misoprostol  
Misoprostol has previously been discussed (Chapter 17.3.4).  Misoprostol is a selective 
agonist at prostaglandin EP receptors.  Misoprostol is active after oral administration, and is 
long lasting.  Misoprostol is an effective inhibitor of acid secretion.  The most frequent side 
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effect with misoprostol is diarrhoea, which occurs in about 30% of patients.  The mechanism 
of the diarrhea is prostaglandin EP receptor-mediated stimulation of gut motility.  
Misoprostol also cause EP-receptor-mediated contractions of the uterus. Thus, misoprostol is 
contraindicated during pregnancy because it can cause abortion.  Misoprostol is used to 
prevent mucosal injury caused by NSAIDs. 
 
 16.1.5 Sucralfate 
After acid has damaged the lining of the intestine, pepsin can digest the mucosal proteins, and 
this contributes to mucosal erosion and ulceration.  In an acidic environment, sucralfate 
produces a viscous, sticky gel.  This gel sticks to ulcers to inhibit digestion of mucosal 
proteins.  Antacids will prevent sucralfate from working, and should not be taken at the same 
time.  By lining the intestine, sucralfate can prevent the absorption of some drugs (e.g. 
phenytoin, digoxin).  To avoid this, sucralfate should be taken after other drugs.  Sucralfate is 
occasionally used to treat ulcers. 
 
16.2 PROKINETICS AND EMETICS 
 
 16.2.1 Introduction to prokinetics 
Prokinetics enhance gastrointestinal motility and transit of material in gastrointestinal tract.  
Heartburn is due to the backup of acid from the stomach and oesophagus.  The most common 
cause of heartburn is Gastroesophageal reflux disease (GERD or GORD).  In GERD there 
is either a weakened lower oesophageal sphincter or the sphincter relaxes too frequently.  In 
GERD, prokinetics prevent the heartburn by increase the motility in the oesophagus.   
 
Gastroparesis is severely impaired emptying of stomach not caused by obstruction.  The 
usual cause of gastroparesis is the loss of neural control as a result of diabetes.  In 
gastroparesis, prokinetics increase the motility in the stomach, and this increases stomach 
emptying.   
 
Irritable Bowel Syndrome (IBS) is intermittent cramps and constipation, with alternating 
periods of diarrhoea.  Prokinetics are used in the constipation associated with irritable bowel 
syndrome. 
 
 16.2.2 Prokinetic agents 
The contraction phase of peristalsis is due to release of acetylcholine from excitatory motor 
neurones.  Prokinetic agents modify this release of acetylcholine.  For instance, dopamine 
acts at D2-receptors to inhibit the release of acetylcholine from the enteric nervous system.  
Antagonists at D2-receptors will prevent this effect of dopamine, to increase the release of 
acetylcholine and increase gut motility.   
 
Domperidone is a selective dopamine D2-receptor antagonist that prevents the inhibitory 
effect of dopamine on acetylcholine release, which leads to an increased release of 
acetylcholine locally, which is prokinetic.  Domperidone is used in GERD and gastroparesis. 
 
5-Hydroxytryptamine (5-HT), acts at the 5-HT4 receptor, to stimulate the enteric nervous 
system.   
 
Metoclopramide is prokinetic by combining these two actions.  Thus, metoclopramide acts 
as an antagonist at dopamine D2-receptors, and an agonist at 5-HT4-receptors, to stimulate the 
gastrointestinal tract.  Metoclopramide is used in the treatment of GERD and gastroparesis. 
149 
 
 
 16.2.3 Emesis with cytotoxic drugs and drugs for 
One of the most serious causes of nausea and emesis (vomiting) is cytotoxic drugs (drugs that 
kill cells), such as the anti-cancer drugs.  Some cytotoxic drugs are irritants to the gastro-
intestinal tract, and this irritation involves 5-HT3 receptors (Figure 16.1). 
 
The other route to nausea and vomiting with cytotoxic drugs is when they are carried in the 
blood, to the chemoreceptor trigger zone in the area postrema of the central nervous system.  
There is also a neural input after gastrointestinal irritation to the chemoreceptor trigger zone.  
The chemoreceptor trigger zone or emetic centre has 5-HT3-receptors, dopamine D2 
receptors, and muscarinic M1-receptors (Figure 16.1), and consequently drugs that act at 
these receptors can modify nausea and vomiting. 
 
 
Figure 16.1 Nausea and vomiting with cytotoxic drugs (Copyright QUT, Sheila Doggrell) 
 
The 5-HT3-receptor antagonists, the –etrons, such as ondansetron (prototype) act at 
centrally- and peripherally 5-HT3 receptors to inhibit emesis.  The –etrons, such as 
ondansetron, are the most effective agents for treating chemotherapy-induced nausea and 
vomiting, but they are not effective in motion sickness, which involves a different pathway. 
 
The dopamine D2-receptor antagonists, prochlorperazine and metoclopramide, act as 
antagonists at the dopamine D2-receptors in the chemoreceptor trigger zone to inhibit 
cytotoxic-induced emesis.  These drugs used to be standard treatment for cytotoxic-induced 
emesis, but their use is declining as they are less effective than the 5-HT3-receptor 
antagonists.   
 
Prochlorperazine and metoclopramide are also used in the nausea and vomiting associated 
with pregnancy (morning sickness), where the underlying pathway remains to be clarified. 
 
Substance P is a peptide neurotransmitter in the central nervous system that acts at NK1-
receptors.  By stimulating NK-receptors, substance P has a role in emetic pathways, 
especially the emesis associated with chemotherapy.  Apepitant is an antagonist at NK1-
receptors used to control chemotherapy-induced vomiting.  Apepitant is not usually used as 
the first choice in preventing the emesis associated with chemotherapy, but can be used in 
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combination with ondansetron.  Thus, when ondansetron is not effective alone, the addition 
of apepitant can increase the ability to inhibit the emesis caused by chemotherapy.   Apepitant 
is metabolised by CYP3A4, and consequently can be involved in interactions with numerous 
drugs. 
 
The glucocorticoids, especially dexamethasone, are used as anti-emetics to prevent emesis 
with cytotoxic drugs.  The anti-emetic properties of the glucocorticoids were a seredipitous 
discovery.  Thus, when dexamethasone was being used in chemotherapy, it was notices that 
there was less nausea and vomiting.  As it was a chance discovery rather than a drug designed 
for specific target, the mechanism behind the anti-emetic effect of dexamethasone is not 
clear.  The mechanism may be related to inhibition of the synthesis of prostaglandin E2, as 
PGE2 probably has a role on emesis.  Dexamethasone is not generally used alone as an 
antiemetic, but is used with other antiemetics. 
 
 16.2.4 Motion sickness and drugs for 
Drugs that are effective in the treatment of cytotoxic-induced emesis are not effective in 
motion sickness, indicating a different pathway is involved.  Motion is monitored by the inner 
ear (the vestibular system), which has an input into the cerebellum, where histamine H1-
receptors and muscarinic M receptors are involved in controlling nausea and vomiting 
(Figure 16.2). 
 
Figure 16.2 Motion sickness (Copyright QUT, Sheila Doggrell) 
 
Thus, drugs that act at histamine H1 receptors or muscarinic receptor can modify motion 
sickness. The histamine H1-receptor antagonist promethazine crosses the blood-brain barrier 
to act at cerebellum histamine H1-receptors to inhibit motion sickness.  Promethazine also act 
as an antagonist at the cholinergic muscarinic receptors, which may contribute to 
effectiveness in preventing motion sickness. 
 
The muscarinic receptor antagonist scopolamine is non-selective.  Scopolamine crosses 
blood-brain barrier to act at the cerebellum M-receptor to inhibit motion sickness.  
Scopolamine is used as a transdermal patch to prevent motion sickness. 
 
 16.2.5 Post-operative emesis 
Some of the drugs used for cytotoxic drug-induced or motion sickness-induced emesis are 
also useful in post-operative emesis.  Thus, in post-operative emesis, the dopamine D2 
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receptor antagonists (prochlorperazine, metoclopramide, the histamine H1-receptor antagonist 
promethazine, the 5-HT3-receptor antagonists (the –etrons, such as ondansetron) , and the 
muscarinic receptor antagonist scopolamine can all be useful.  
 
16.3. AGENTS USED FOR DIARRHEA, CONSTIPATION, AND IRRITABLE 
BOWEL SYNDROME 
 
Diarrhoea usually results from enteric infection and is short-lived and self-limiting, and does 
not usually require drug treatment.  Other conditions that cause diarrhoea include 
malabsorption, which is associated with lactose intolerance and gluten malabsorption.  
Inflammatory bowel disease and immune disease are also causes of diarrhea, and these 
conditions require treatment.   
 
Constipation is defined as having less than 3 stools per week.  In constipation, the colon is 
absorbing too much water due to slow movement through colon.   
 
Irritable Bowel Syndrome (IBS) is intermittent cramps and constipation, with alternating 
periods of diarrhoea.  Thus, the drugs to treat diarrhoea and constipation are used in the 
treatment of irritable bowel syndrome. 
 
 16.3.1 Treatment for diarrhea 
In the treatment of diarrhea, the replacement of fluids and electrolytes is a common treatment.  
In severe, prolonged bacterial infections, anti-bacterial drugs may be used. 
 
When people abuse the opioid heroin, they become constipated.  When the opioid morphine 
is used to relieve pain, it also causes constipation.  Heroin and morphine stimulates opioid -
receptors to decrease intestinal motility, which leads to increased absorption of water from 
the colon, and to constipation.  This adverse effect in people with normal gut function has 
been used to develop an opioid agent suitable for use in diarrhea.   
 
This agent is loperamide, which stimulates the gastrointestinal tract -receptors to be anti-
diarrheal in subjects with diarrhea.  Loperamide does not have any potential to be abused, as 
it is a poor penetrant of the central nervous system.  Also, there are no central nervous side 
effects with loperamide.  Loperamide is used in most forms of diarrhoea and in the diarrhea 
part of irritable bowel syndrome.  
 
 16.3.2 Treatment for constipation 
The first treatment for constipation is lifestyle changes such as having a diet rich in fibre, 
decreasing the dietary fat intake, and increasing the intake of fluids but these fluids should 
not be diuretics as they promote water loss from the body.  Daily exercise also stimulates 
peristalsis to overcome constipation. 
 
In terms of agents used to overcome constipation, the old remedy of castor oil is effective but 
unpleasant, and potentially toxic, and therefore rarely used these days.  Alternatives include 
bulk-forming laxatives, faecal softening agents, irritant laxatives and osmotic laxatives.   
 
Dietary fibre is resistant to enzymatic degradation and presented to colon unchanged, and 
thus increasing bulk stimulates peristalsis.  Bulk-forming laxatives mimic this effect.  
Methylcellulose (sold as Citrucel) is poorly fermented.  Poorly fermented fibre attracts water 
to increase stool bulk, which stimulates peristalsis and eases movement along the 
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gastrointestinal tract.  Bulk-forming laxatives are commonly used to prevent constipation in 
subjects prone to constipation. 
 
Another example of a bulk-forming laxative is the commonly used psyllium husk.  Psyllium 
husk is derived from the plantago seed and is in many commercial products for constipation 
(as Metamucil).  It is fermented by the colonic bacteria to increase the bulk in the colon, and 
stimulate peristalsis.  The fermentation also produces short chain fatty acids, which stimulate 
motility in the gastrointestinal tract (are prokinetic).   
 
The faecal softening agents include docusate and liquid paraffin.  Docusate acts like a 
detergent to allow water and fatty substances to mix with faecal material to soften it, and 
make it easier to pass stools.  After the oral administration of docusate, there is an excretion 
of stools in 1-3 days.  For a faster excretion, rectal administration of docusate can be used, 
and gives excretion of stools in 15 minutes. 
 
Liquid paraffin is not dangerous after oral administration, as the absorption is minimal.  The 
liquid paraffin stays in the tract, and coats stools to prevent loss of water.  The major problem 
with using liquid paraffin as a faecal softening agent is that it can prevent the absorption of 
fat soluble vitamins (A, D, E and K), which will dissolve in the liquid paraffin and be 
excreted. 
 
Agents that stimulate or irritate the colon to cause contraction include bisacodyl and 
senna.  By stimulating colon contractions, bisacodyl and senna cause bowel evacuation in 6 
to 12 hours.  The faecal-softening agents and irritant laxatives are used in constipation. 
 
The osmotic laxatives are poorly absorbed, and draw water toward them by osmosis.  
Subsequently, the osmotically-mediated water retention stimulates peristalsis.  Examples of 
osmotic laxatives include glycerol, certain salts, and lactulose.  Glycerol is an osmotic 
laxative, which is used rectally.  After rectal administration, glycerol stimulates a bowel 
movement in an hour.  Glycerol is used in constipation and constipation associated with 
irritable bowel syndrome. 
 
The salts include milk of magnesia and Epsom salts.  Lactulose is a non-digestible 
carbohydrate.  Both salts and lactulose are taken orally, and in a low dose are laxative, but at 
high dose are cathartic (uncontrollable stools).   As laxatives, the salts work in 6 to 8 hours, 
lactulose takes longer, 24 to 48 hours.   
 
 16.3.3 Opioid-induced constipation 
The opioids e.g. morphine, are commonly used in the treatment of severe pain or pain 
associated with terminal disease.  The analgesia is due to stimulation of opioid µ-receptors in 
the central nervous system.  However stimulation of opioid µ-receptors on the gastrointestinal 
tract leads to constipation.  Thus, constipation is a common side-effect of opioid use for pain 
relief or abuse for euphoria.   
 
Methylnaltrexone is an antagonist at opioid µ-receptors.  It can be administered orally, 
subcutaneously or intravenously.  Methylnaltrexone does not cross the blood-brain barrier.  
Methynaltrexone antagonises the ability of opioids to cause constipation but, because it does 
not cross the blood-brain barrier. it does not antagonise the centrally-mediated analgesic 
effect of morphine.  Methlynatrexone is used in combination with morphine to give pain 
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relief (due to the morphine) without the constipation (morphine-induced constipation 
prevented by methylnaltrexone). 
 
 
16.4. DRUGS FOR INFLAMMATORY BOWEL DISEASE 
 
Inflammatory bowel disease is distinct from irritable bowel disease/syndrome.  
Inflammatory bowel disease is chronic inflammation of small and large intestines, usually of 
unknown aetiology (cause).   
 
Inflammatory bowel disease includes Crohn’s disease, which can affect both the small and 
large bowel.  In Crohn’s disease, the inflammation is focal (localised) but can affect all layers 
of the bowel.  The symptoms of Crohn’s disease are severe abdominal pain, diarrhea (which 
may contain blood), vomiting, and weight loss. 
 
Inflammatory bowel disease also includes ulcerative colitis (ulcers in the colon), which is 
confined to the colon and characterized by chronic, superficial inflammation.  Ulcerative 
colitis always involves distal colon and extends continuously for a variable length 
proximally.   
 
As the inflammation of inflammatory bowel disease is severe, it is not overcome by using a 
NSAID.  Thus, stronger anti-inflammatory agents are required. 
 
16.4.1 Mesalazine 
Drugs related to the salicylates (i.e. aspirin), 5-aminosalicylates, such as mesalazine, are 
used in the treatment of inflammatory bowel disease.  Mesalazine inhibits both the 
cyclooxygenase pathway and lipooxygenase pathway, whereas the NSAIDs only inhibit the 
cyclooxygenase pathway.  Thus, mesalazine inhibits the production of prostaglandins in the 
cyclooxygenase pathway, which have a relatively minor effect in inflammation.  Mesalazine 
also inhibit the lipooxygenase pathway to reduce the levels of leukotrienes, which have a 
major role in inflammation.   
 
Mesalazine is effective in mild or moderate active ulcerative colitis, but is a less successful 
treatment in severe ulcerative colitis.  Mesalazine is also less useful in Crohn’s disease.  
Mesalazine alone is absorbed before the colon, which reduces its effectiveness.  Thus, 
mesalazine is used in enteric coated tablets to reduce any absorption from the stomach. 
 
 16.4.2 Glucocorticoids 
Another major treatment for inflammatory bowel disease is the glucocorticoids.  In addition 
to inhibiting the production of prostaglandins and leukotrienes by inhibiting phospholipase 
A2 (as discussed in chapter 17.3), glucocorticoids have inhibitory effects on other 
components of inflammation, such as histamine, cytokines, and adhesion molecules.  
Adhesion molecules are required for white blood cells to adhere to the site of inflammation.  
Prednisone is an example of a glucocorticoid, which inhibits all these components of 
inflammation.  Oral prednisone is the standard treatment for acute severe exacerbations of 
inflammatory bowel disease.  Indeed, prednisone gives remission in most patients with 
ulcerative colitis and active Crohn’s disease.  
 
The main problem with glucocorticoids, such as prednisone, is systemic circulation leads to 
increasing and more severe side effects with time.  Thus only short courses of treatment 
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should be used.  With prolonged systemic treatment, prednisone causes the side effects of 
hypertension, hyperglycemia, an increased susceptibility to infection, osteoporosis, 
myopathy, behavioural disturbances, cataracts and more!  Clearly, it is best to avoid long 
treatment with prednisone.  Thus, prednisone is reserved for acute severe exacerbations of 
inflammatory bowel disease.   
 
An alternative approach, if long term treatment with glucocorticoids is necessary is to use a 
glucocorticoid with extensive first pass liver metabolism to avoid some of the systemic side 
effects e.g. budesonide.   
 
The weak glucocorticoid hydocorticosterone is used in enemas for a local effect in 
inflammation limited to the rectum (proctitis). 
 
16.4.3 Infliximab 
The cytokine tumour necrosis factor-alpha (TNFα) has major role in Crohn’s disease and 
ulcerative colitis.  Thus, inhibitors of TNFα are used in the treatment of Crohn’s disease and 
ulcerative colitis.  Infliximab is an antibody to TNFα i.e. it binds to TNFα and inactivates it.  
Infliximab is used in the treatment of moderate-to-severe Crohn’s disease and moderate-to-
severe ulcerative colitis.  Infliximab is not active after oral administration and is given 
intravenously every 8 weeks to people with Crohn’s disease or ulcerative colitis. 
  
155 
 
18. 
ANTI-INFECTIVES 
 
Sheila A Doggrell1 and Elizabeth Davis2 
1. School of Biomedical Sciences, Faculty of Health, Queensland University of 
Technology, Gardens Point, GPO Box 2434, QLD 4001, Australia 
Phone +61 7 38705741 Fax +61 7 31381534 Email sheila.doggrell@qut.edu.au 
2. Department of Pharmacology, Faculty of Medicine, Nursing and Health Sciences, 
Monash University, Clayton, Melbourne, Australia 
 
Key words: antibiotics, β-lactams, penicillins, cephalosporins, benzylpenicillin, 
amoxycillin, clavulanic acid, fluocloxacillin, cephalexin, cefotaxime, imipenem, 
glycopeptides, vancomycin, tetracyclines, doxycycline, aminoglycosides, gentamicin, 
neomycin, chloramphenicol. Macrolides, erythromycin, lincosamides, clindamycin, 
oxalazidones, linezolid, trimethoprim, anti-tubercuotic, isoniazid, ethambutol, 
rifamycin, pyrazinamide, anti-viral, aciclovir, zanamivir, oseltamivir, zidovudine, 
nevirapine, ritonavir, enfuvirtide, anti-fungal, amphotericin, casofungin, fluconazole, 
terbinafine, griseofulvin 
 
Contents 
 
18.1 Antibiotics 
 18.1.1 Introduction to bacteria 
 18.1.2 Introduction to antibiotics 
 18.1.3 Inhibitors of bacterial cell wall synthesis 
  18.1.3.1 β-Lactams 
  18.1.3.2 Glycopeptides 
 18.1.4 Inhibitors of bacterial protein synthesis 
  18.1.4.1 Tetracyclines 
  18.1.4.2 Aminoglycosides 
  18.1.4.3 Chloramphenicol 
  18.1.4.4 Macrolides 
  18.1.4.5 Lincosamides 
  18.1.4.6 Oxalazidones 
18.1.5 Inhibitors of DNA synthesis 
 
18.2. Anti-tuberculotic drugs 
 18.2.1 Introduction 
 18.2.2 Isoniazid 
 18.2.3 Ethambutol 
 18.2.4 Rifamycin 
 18.2.5 Pyrazinamide 
 
18.3. Anti-viral drugs 
 18.3.1 Introduction to viruses 
 18.3.2 Drugs used to treat herpesviruses  
 18.3.3 Drugs used to treat the flu 
 18.3.4 Drugs used to treat HIV/AIDS 
 
18.4. Antifungal drugs 
156 
 
 18.4.1 Introduction to Fungi 
 18.4.2 Antifungal drugs  
 
 
In this section, the anti-infectives considered are the antibiotics, including anti-tuberculotic 
drugs, the anti-viral drugs, and the anti-fungal drugs. 
 
18.1. Antibiotics 
 18.1.1 Introduction to bacteria 
Bacteria are unicellular (one cell) micro-organisms that do not have a nucleus.  The DNA 
information of bacteria is stored in a single chromosome.  If the bacteria are spherical, they 
are called cocci, whereas if they are rod shaped, they are called bacilli.  Each bacterium 
grows to a fixed size and then divides by binary fission to give two bacteria.  Most bacteria 
are rendered harmless by the immune system, and this is one of the main functions of the 
immune system.  The most common fatal bacterial infections are respiratory infections (e.g. 
pneumonia) and tuberculosis (TB). 
 
Bacteria are separated into two groups by a stain developed by a person called Gram.  These 
groups are Gram positive and Gram negative bacteria.  Gram-positive microbials have a 
simple cell wall which is 50% peptidoglycan and 40-45% acidic polymer with a negative 
charge.  Gram-negative microbials have a much more complex cell wall.  Gram-positive 
microbials are much easier to treat than gram-negative microbials as they allow cell 
penetration by positively charged agents.  Also, because of the petidoglycan structure of 
Gram-positive microbials, inhibitors of cell wall/peptidoglycan synthesis are more effective 
against Gram-positive than Gram-negative microbials. 
 
Clinically significant Gram-positive bacteria include Staphylococci,which are associated with 
acne, and Streptococci, which can cause sore throat, middle ear infections, and bacterial 
pneumonia.  Examples of pathogenic (disease-causing) Gram-negative bacteria include 
Neisseria meningitidis (meningitis), Neisseria gonorrhoea (gonorrhea), and Salmonella 
enteria (gastrointestinal upsets).  Haemophilus influenzae, which causes bacterial meningitis 
and ear infections in children and pneumonia in adults, and is also Gram-negative. 
 
 18.1.2 Introduction to antibiotics 
The term chemotherapy is used to describe the use of drugs to treat infections caused by 
invading cells and therefore cover the anti-infective drugs and anti-cancer drugs.  However, 
many people think of chemotherapy only in the treatment of cancer. The term selective 
toxicity is mainly used to describe the anti-microbials.  Selective toxicity relates to a drug 
having toxicity to the invading microbial without toxicity to the host (e.g. the human). 
 
Selective toxicity relies on differences in bacterial (prokaryote cells) and human/mammalian 
cells (eukaryote cells).  Selective toxicity can be achieved by drugs attacking processes or 
pathways which are present in the microbial cell, but not the mammalian cell.  For example, 
both prokaryote and eukaryote cells have cell membranes, but only the prokaryote cells have 
cell walls.  Bacterial cell walls are often made of peptidoglycan, and the bacterial cell wall is 
a site at which antibacterial agents can attack.  Eukaryote cells have their genetic material 
contained within a nucleus, whereas prokaryote cells only have a single chromosome 
containing all their genetic material.  Some of the structures and processed involved in  
bacterial DNA synthesis, RNA synthesis and protein synthesis are different from those in 
the mammalian cells and can be targets for antibacterial agents.  For example, the ribosomes 
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are the place where protein synthesis takes place, and there are structural differences between 
the ribosomes in eukaryote and prokaryote cells.  Thus, the bacterial ribosomes are a site at 
which antibacterial agents can attack.  This chapter considers antibiotics that attack at these 
different sites. 
 
Antibiotics can be classed as bactericidal or bacteriostatic.  Antibiotics that are bactericidal 
cause the death of the bacteria.  To be bactericidal, antibiotics usually interfere with cell wall 
synthesis or disrupt the cell membrane.  Antibiotics that are bacteriostatic prevent the 
growth or division of bacteria.  Once the growth of the bacteria has been arrested, it is hoped 
that the body’s own immune system will takes care of the remaining bacteria by killing them.  
To be bacteriostatic, drugs usually interfere with protein or nucleic acid synthesis in the 
bacteria. 
 
Antimicrobials can be narrow or broad spectrum.  Narrow spectrum anti-microbials are only 
effective against a small number of microbials.  Broad spectrum anti-microbials are anti-
microbials that are effective against a wider range of microbial species. 
 
One topic about antibiotics that is commonly in the news is the emergence of drug-resistant 
organisms, which is largely blamed on the overuse and misuse of antibiotics.  There are two 
main types of resistance.  The first is due to chromosomal mutations in the bacteria, so that 
they take on a form that is no longer susceptible to the antibiotics.  The best know example of 
this is Methicillin-resistant Staphylococcus Aureus (MRSA), which is resistant to the drug 
methicillin, which is one of the penicillins.  MRSA causes severe infections, and is a problem 
in many hospitals.  The second type of resistance is due to the induction of enzymes or 
transporters/carriers in the microbe.  For example, microbials that have been treated 
successfully with the β-lactam penicillins in the past, have now induced their levels of the 
enzyme β-lactamase.   The induced β-lactamases increase the breakdown of the penicillins, 
making them less effective. 
 
18.1.3 Inhibitors of bacterial cell wall synthesis 
The cell wall of bacteria is a semi-rigid structure.  The cell wall not only determines the shape 
of the organism, but also contains the cell contents necessary for survival.  Anything that 
weakens the structure of the cell wall can cause the bacterium to break apart which will kill it.  
These agents are usually bacteriocidal.  Figure 18.1 outlines the steps involved in the 
synthesis of the bacterial cell wall and where antibacterial agents can act to inhibit this 
process. 
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Figure 18.1 Steps involved in the synthesis of the bacterial cell wall (Copyright Monash 
University, Elizabeth Davis) 
 
 
  18.1.3.1 β-Lactams 
Probably, the best known examples of antibiotics are the penicillins.  The penicillins are from 
the β-lactams group of inhibitors of bacterial cell wall synthesis.  The β-lactams are a group 
of chemically related agents that also includes the cephalosporins and the carbapenams. All 
of the β-lactams inhibit the synthesis of the bacterial cell wall.  In particular, the β-lactams 
inhibit enzymes (transpeptidases) involved in cross-linking the peptidoglycans.Their action 
weakens the cell wall so that the bacteria lyses (ruptures).  The β-lactams are bactericidal, 
which means they kill susceptible bacteria.  Unfortunately, resistance to the β-lactams has 
developed.  This resistance is due to induction of β-lactamases in microbials, and these β-
lactamases can breakdown some β-lactams, which makes them ineffective. The spectrum of 
activity of the different β-lactams is determined by the transpeptidase enzymes they target 
and their susceptibility to breakdown by the β-lactamases.   
 
Penicillins are considered the drugs of choice for many infections.  The first penicillins were 
the naturally occurring penicillins such as benzylpenicillin (also known as penicillin G).  
Benzylpenicillin is bactericidal and has a narrow spectrum of activity.  Benzylpenicillin is 
more effective against Gram-positive than Gram-negative microbials.  The main 
disadvantage of benzylpenicillin is that it is destroyed by the acid in the stomach, and cannot 
be used orally.  Benzylpenicillin is used intravenously or intramuscularly in serious 
infections.  For instance, benzylpenicillin is used to treat bacterial endocarditis (which is 
inflammation of inner heart with streptococci), meningitis, pneumonia, and syphilis. 
 
Further development of the penicillins was undertaken to provide an orally active compound.  
An example of an orally active penicillin is amoxycillin.  Amoxycillin is semisynthetic and 
has a moderate spectrum of activity.  However, amoxycillin is broken down by β-lactamases.  
Thus, microbials that have induction of β-lactamases, are not susceptible to amoxicillin.   
 
One way to overcome this is to use amoxycillin in combination with the irreversible β-
lactamase inhibitor clavulanic acid.  The clavulanic acid inhibits the β-lactamase, so that the 
β-lactamase cannot destroy the amoxycillin, and amoxycillin remains available to inhibit the 
synthesis of the bacterial cell wall.  Clavulanic acid therefore increases the spectrum of 
activity of amoxycillin.  The combination of amoxycillin and clavulanic acid is known as co-
amoxiclav.   
 
Amoxycillin alone is used orally or intravenously in the treatment of a number of bacterial 
infections including chronic bronchitis, pneumonia, ear infections, sinusitis and gonococcal 
infection (“the clap”). Amoxycillin in combination with clavulanic acid is used in ear and 
sinus infections unresponsive to amoxycillin alone i.e. when the amoxycillin is broken down 
by the β-lactamases.  The combination treatment is also used orally in severe pneumonia, and 
epididymo-orchitis (infection of epididymis/testis). 
 
Another approach when microbes have developed resistance to amoxycillin is to use a 
penicillin that is resistant to β-lactamases.  Flucloxacillin is not susceptible to β-lactamases, 
and this is a major advantage over amoxycillin.  Flucloxacillin is active against the β-
lactamase producing Staphylcocci responsible for a number of skin infections (e.g. boils, 
carbuncles, mastitis, and infected scabies) and are used in the treatment of these infections.  
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However, a disadvantage of flucloxacillin is that it is narrow spectrum, and is only effective 
against a small spectrum of microbes.  Flucloxacillin is also used in the treatment, of 
infections in bones and joints. 
 
One problem with the penicillins is that 10% of people are allergic to penicillins.  As 
penicillin allergy can be very severe on a second exposure, this should be avoided.  People 
who are allergic to penicillin have to take alternative antibiotics.  
 
The second group of β-lactams are the cephalosporins.  The cephalosporins are broad 
spectrum and bacteriocidal.  Like the penicillins, the cephalosporins weaken the bacterial cell 
wall. However, the cephalosporins are rarely first choice antibiotic therapy as they commonly 
cause gastrointestinal adverse effects.  They are often used to treat infections in patients 
allergic to penicillins. 
 
Cephalexin was one of the first cephalosporins synthesised, and is known as a first 
generation cephalosporin.  Cephalexin is one of the few cephalosporins active after oral 
administration.  Cephalexin is a moderate spectrum antibacterial and is more effective against 
Gram-positive than Gram-negative bacteria, Despite this, cephalexin is used to treat 
infections of the urinary tract caused by Gram-negative bacteria.  The main use of cephalexin 
is in the treatment of Straphylococcal and Streptococcal infections in subjects allergic to 
penicillin. 
 
From the structure of the first generation of cephalosporins, such as cephalexin, the scientists 
tried to change the structure to improve effectiveness against Gram-negative bacteria.  An 
example of a second generation cephalosporin is cefuroxime.  Cefuroxime is active after oral 
or intravenous administration.  Cefuroxime is a very important antibiotic as it is more 
effective against Gram-negative than Gram-positive bacteria, which provides us with an 
antibiotic that can be used in serious Gram-negative bacterial infections including those 
caused by Haemophillus influenza (e.g. hospital and community acquired pneumonia), 
meningitis and septicaemia. 
 
Further cephalosporins were developed to exploit this ability to inhibit Gram-negative 
bacteria.  An example of a third generation cephalosporin is cefotaxime.  Cefotaxime is not 
active after oral administration, which is a disadvantage.  It is used intravenously.  Like 
cefuroxime, cefotaxime is more effective against Gram-negative than Gram-positive bacteria.  
Cefotaxime is used intravenously in the treatment of severe infections such as pneumonia, 
orbital cellulitis (eye infection), bacterial meningitis and septicaemia.  
 
Other -lactams antibacterials have been developed to be resistant to breakdown by the -
lactamases.  These are the carbapenams and monobactams.  The carbapenams are considered 
to have the broadest spectrum of all antibacterials.  Imipenem is a carbapenams and is 
effective against Gram-positive and Gram-negative organisms.  It was originally resistant to 
all β-lactamases, which made it a very effective antibiotic.  However, this resistance has not 
lasted, and new β-lactamases have been induced by the bacteria to breakdown imipenem and 
reduce its effectiveness.  Imipenem is used in the treatment of life-threatening infections, 
particularly hospital-acquired infections, when other antibacterials are not considered 
appropriate. 
  18.1.4.2 Glycopeptides   
An important approach to preventing microbes developing resistance to antibiotics, is to limit 
the use of antibiotics, so that the microbes do not have the opportunity to develop resistance.  
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Thus, when new antibiotics are developed there is initially an attempt to limit their use, so 
that they remain useful in serious infections.  This occurred with the glycopeptide, 
vancomycin.  Like the β-lactams, glycopeptides inhibit the synthesis of the bacterial cell 
wall.  The glycopeptides do this by inhibiting the enzymes involved in building the 
peptidoglycan structure (transglycosidases). International guidelines have been developed to 
restrict the use of vancomycin to try to prevent the development of vancomycin resistant 
bacteria.  Vancomycin is reserved mainly for treatment of life-threatening infections with 
Methicillin-Resistant Staphylococcus Aureus (MRSA).  As the name implies MRSA is 
resistant to the penicillins, including methicillin.  Staphylococci are the commonest cause of 
hospital bloodstream infections.  MRSA spreads quickly among elderly and seriously ill 
patients.  Unfortunately, the effectiveness of vancomycin against MRSA is declining.   
 
 18.1.5 Inhibitors of bacterial protein synthesis 
Within the cell, ribosomes are the sites of protein synthesis.  The ribosomes and protein 
synthesis in bacteria and humans are different.  In particular, the structure of the bacterial 
ribosome is different from that of the mammalian ribosome. Thus, it is possible to inhibit 
bacterial protein synthesis without altering the protein synthesis of the human, and this gives 
selective toxicity against the microbes over the humans.  In the process of bacterial protein 
synthesis, the first step involves the transfer (t) RNA with an attached amino acid binding to 
the ribosome (Figure 18.2).   
 
Figure 18.2 Steps involved in bacterial protein synthesis 
 
The second step in bacterial protein synthesis is that the tRNA with the amino acid attached 
forms base pairs with the ribosome.  The third step is transpeptidation, when the amino 
acid chain is transferred onto incoming tRNA-amino acid, with the addition of the protein to 
the amino acid, so the protein has one more amino acid on it.  The fourth step is 
translocation, when the ribosome moves along the mRNA and releases the free tRNA 
allowing next tRNA-amino acid to bind.  Finally, there is separation of the protein from the 
ribosome. 
 
Every step in this bacterial protein synthesis at the ribosome is a step we can interfere with 
using drugs.  For instance, the binding of amino acid carrying tRNA- to the ribosome is 
inhibited by the group of antibiotics known as the tetracyclines.  The second step, the 
formation of base pairs, is inhibited by the aminoglycosides.   The third step, the 
transpeptidation, is inhibited by chloramphenicol, and the fourth step, the translocation of 
161 
 
the ribosome alone the mRNA, is inhibited by the macrolides.  Each of these antibiotics is 
discussed below. 
 
18.1.4.1 Tetracyclines 
Probably the best known example of a tetracycline that is used clinically is doxycycline.  The 
tetracyclines, such as doxycycline inhibit the binding of the transfer (t)RNA, which has the 
amino acid attached, to the bacterial ribosomes, and hence inhibits the synthesis of proteins in 
the bacteria. The tetracyclines are considered bacteriostatic not bactericidal.  Thus, they halt 
the multiplication of the bacteria, rather than killing the bacteria.  The tetracyclines are broad 
spectrum i.e. stop the replication of many bacteria.  The tetracyclines are used orally in the 
treatment of respiratory tract infections. They are also used in the treatment of acne.  
However, doxycycline can cause gastrointestinal upsets (nausea, vomiting and diarrhoea).  
Furthermore, the tetracycyclines combine with calcium and can cause discolouration of teeth 
and decrease bone growth.  For this reason, they are not given to young children or pregnant 
women.  Another problem with the tetracyclines is the development of widespread resistance.   
 
The resistance to the tetracyclines is due to the induction of transporters in the bacteria 
membrane that remove the tetracyclines from the bacterium.  When the tetracyclines are 
being transported out of the bacteria, there will be reduced concentrations of the tetracyclines 
in bacterium cell.  As the effectiveness of the tetracycline depends on the concentration at the 
target site, when they are transported out of the cell, the concentration in the cell will drop, 
and there will be reduced effectiveness. 
 
  18.1.4.2 Aminoglycosides 
The aminoglycosides bind to the bacterial ribosome and interfere with the binding of the 
tRNA.  This leads to the wrong amino acid being added to the peptide.    Gentamicin and 
neomycin are examples of aminoglycoside antibiotics.   
 
The entry of gentamicin into bacterium is by oxygen-dependent active transport.  Thus, 
gentamicin is much more effective against aerobic (oxygen-requiring) than anaerobic (not 
requiring oxygen) bacteria.  Gentamicin is more effective against aerobic Gram-negative than 
Gram-positive bacteria.  This is a positive, as Gram-negative bacteria are usually more 
difficult to treat than Gram-positive bacteria.  Gentamicin is used in the treatment of serious 
Gram-negative bacterial infections (e.g. septicaemia), and in cystic fibrosis and 
bronchiectasis, where there is an increased risk of infection in damaged lungs.  Resistance to 
gentamicin is increasing, and this resistance is due to induction of metabolising enzymes in 
the bacteria, that metabolise and inactive the gentamicin. 
 
Gentamicin is highly polar (ionized) and, consequently, it is not absorbed from 
gastrointestinal tract.  Gentamicin is used intraventously (iv) or intramuscularly (im) for 
systemic infections.  Gentamicin is inhaled when it is used in respiratory infections associated 
with cystic fibrosis or bronchiectasis.  Gentamicin is predominantly eliminated from the 
kidney, and consequently it is necessary to reduce the dose in patients with renal impairment 
to prevent the plasma concentration rising to toxic levels.  Gentamicin is reserved for serious 
infections that are not easily treated with other antibiotics because it cannot be used orally, 
and because it can cause serious toxicity.  The serious toxicity with gentamicin includes 
irreversible damage to the ear (ototoxicity) leading to the loss of balance, or even deafness, 
and damage to the kidney (nephrotoxicity) which fortunately is reversible.  
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Neomycin is used as a broad spectrum aminoglycoside antibiotic.  Neomycin is used 
topically for the treatment of infections of the skin and mucous membranes e.g. impetigo 
(‘school sores’) and boils.  Neomycin is also used in some anti-acne lotions, to treat acne that 
is associated with a bacterial infection. 
 
  18.1.4.3 Chloramphenicol 
The transpeptidation process in bacterial protein synthesis involves an amino acid being 
added onto a growing peptide chain.  This step is inhibited by chloramphenicol.  
Chloramphenicol is suitable for oral or intravenous use.  It is bacteriostatic against most 
bacteria but does kill Haemophilus influenza.  It can also be applied topically, e.g. in ear 
drops, to treat ear infections.  Resistance to chloramphenicol is due to presence of 
chloramphenicol acetyltransferase produced by resistant strains of Gram-positive and Gram-
negative bacteria, and the chloramphenicol acetyltransferase inactivates the chloramphenicol, 
which obviously reduces the effectiveness of chloramphenicol.   
 
Chloramphenicol is not a very well tolerated drug.  It can cause depression of bone marrow 
leading to pancytopenia (decrease in all elements of blood), which is a serious adverse effect.  
The use of chloramphenicol is limited, as its benefit must outweigh its risk, for it to be used.  
Its use it usually in infections which have failed to respond to other antibiotics or cannot be 
used.  For instance, chloramphenicol is used in meningitis when penicillin cannot be used.  
The adverse effects of chloramphenicol are not an issue when it is used topically. 
 
  18.1.4.4 Macrolides 
Erythromycin is an example of a macrolide.  The macrolides inhibit the translocation step in 
bacterial protein synthesis (i.e. the separation of the protein, after another amino acid has 
been added).  Erythromycin is bateriostatic and broad spectrum.  It is effective against Gram-
positive and against a few Gram-negative bacteria.  Erythromycin is used as an alternative to 
penicillin and cephalosporins in people who are allergic to these antibiotics.  Erythromycin is 
also used in respiratory tract infections. 
 
Erythromycin is suitable for oral or intravenous use.  Erythromycin is metabolised by the 
liver enzyme CYP 3A4.  Consequently, drugs that inhibit CYP 3A4 (grapefruit juice, 
ketoconazole) increase the levels of erythromycin, and this can lead to toxic effects of 
erythromycin.  The toxic effects of erythromycin include a prolongation of QT interval, 
which indicates a slowing of ventricular repolarisation and can lead to cardiac arrhythmia.   
 
18.1.4.5 Lincosamides 
An example of a lincosamide is clindamycin.  Clindamycin has two mechanisms of actions; 
it inhibits both bacterial transpeptidation and translocation.  Clindamycin is active against 
Gram-positive cocci, including many penicillin-resistant staphylococci and many anaerobic 
bacteria.  One of the main uses of clindamycin is, oral or topically, for the treatment of any 
bacterial infection associated with acne. 
 
18.1.4.6  Oxalazidones 
The oxalazidones are a new chemical class of antibiotics.  Linezolid is an example of an 
oxalazidone.  Oxalazidones bind to the 50S ribosomal unit of the bacteria, to prevent it 
forming the 70S complex, and without this ribosome complex there is no bacterial protein 
synthesis.  Linezolid is reserved for the treatment of drug-resistant Gram-positive organisms 
e.g. vancomycin-resistant enterococci.  Linezolid is also used as an alternative to vancomycin 
for the treatment of MRSA (Methicillin-Resistant Staphylococci Aureus). 
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 18.1.5 Inhibitors of DNA synthesis 
An example of an antibiotic that inhibits the DNA synthesis in bacteria is trimethoprim.  
Trimethoprim is classified as a folate inhibitor.  Trimethoprim inhibits the enzyme 
dihydrofolate reductase, by competing with folic acid for the enzyme.  Dihydrofolate 
reductase is necessary to promote the incorporation of folic acid into DNA.  When this 
enzyme is inhibited with trimethoprim, there is reduced production of bacterial DNA, which 
stops the bacteria from undergoing binary fission.  Trimethoprim is bacteriostatic.  Thus, it 
halts the division of existing bacterial, but does not kill the existing bacteria.  Hopefully, the 
immune system will deal with the remaining bacteria.  Trimethoprim is used orally, mainly to 
treat urinary tract infections. 
 
18.2. Anti-tuberculotic drugs 
 
In this section, there is a very brief introduction to tuberculosis, and the first-line treatment of 
it. 
 
 18.2.1 Introduction 
Tuberculosis, commonly known as TB, is caused by Mycobacteria tuberculosis, which is a 
very slow-growing bacterium.  Tuberculosis mainly affects the lungs, and infection is spread 
by inhalation of infectious aerosols.  In the developing world, 7 million new cases of TB are 
reported annually, and 3 million people die of this disease annually.  In Australia, the TB 
notification rates are 5/100,000, which means that 5 people out of every 100,000 have TB.  
TB is a disease of low social status and overcrowding, with the overcrowding promoting the 
spread of the TB.  In Australia, the people who are most likely to have TB are the refugees 
and migrants from countries with a high-incidence of TB,  people with alcohol or drug 
dependence, the homeless, HIV-(human immunodeficiency virus)-infected people, and 
indigenous people. 
 
Unfortunately, there is no single drug that is effective in the treatment of TB, partly because it 
is so slowly growing, and partly because resistance has developed to the drugs which used to 
be used to treat TB.  One of the other problems with treating mycobacterial infections is that 
the mycobacteria have a more complex cell wall structure, which is less permeable to many 
chemicals.  The mycobacteria are, therefore, resistant to many of the commonly used 
antibacterial agents.  The first-line treatment for TB is a combination of ethambutol, 
isoniazid, rifampicin and pyrazinamide for two months.  This is followed by isoniazid 
and rifampicin for a further minimum of four months.  Isoniazid and ethambutol are 
bactericidal/bacteriostatic and effective against the actively dividing Mycobacteria.  
Rifampicin and pyrazinamide have a sterilising (killing) action against the Mycobacteria 
when they are present but not dividing (i.e. dormant cells). 
 
 18.2.2 Isoniazid 
Isoniazid has a similar structure to nicotinic acid, and because of this it causes inhibition of 
nicotinamide adenine dinucleotide (NAD) synthesis.  Without NAD, there is inhibition of 
synthesis of mycolic acids, which are constituents of mycobacterial cell wall.  As a result of 
preventing the synthesis of the mycobacterial cell wall, isoniazid is bactericidal in actively 
dividing cells but bacteriostatic in resting cells.  Unfortunately, with continued use, resistance 
develops to isoniazid, and it loses effectiveness. 
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Unfortunately, isoniazid also has effects on the host.  Isoniazid interferes with Vitamin B6 
(pyridoxime) metabolism, which makes the vitamin ineffective.  Vitamin B6 is required to 
maintain the integrity of peripheral nerves.  By interfering with the Vitamin B6 metabolism, 
isoniazid causes peripheral neuropathy.  This serious adverse effect of isoniazid can be 
avoided by supplementation with Vitamin B6 tablets to avoid peripheral neuropathy.  
Isoniazid in metabolised by acetylation to hepatotoxic metabolite.  There is a polymorphism 
of the acetylating enzyme and people can be either slow or fast acetylators.  The slow 
acetylators will have higher plasma levels of isoniazid and will be at an increased risk of 
peripheral neuropathy but at decreased risk of hepatotoxicity compared to fast acetylators.  In 
contrast, the fast acetylators have higher levels of the hepatotoxic metabolite (and the 
resulting toxicity).   The fast acetylators will have lower plasma levels of isoniazid.   
 
 18.2.3 Ethambutol 
Ethambutol is only active against Mycobacteria, not other bacteria.  Ethambutol is 
bacteriostatic, not bacteriocidal.  The mechanism of action of ethambutol that underlies this 
bacteriostatic effect is unclear. 
 
The most serious adverse effect with ethambutol is optic neuritis (inflammation of the optic 
nerve).  This neuritis may lead to blindness.  Fortunately the neuritis is usually reversed by 
stopping the treatment with ethambutol.  Ethambutol, also impairs the renal clearance of uric 
acid, and this can lead to hyperuricaemia and gout. 
 
 18.2.4 Rifampicin 
Rifampicin is one of the most important drugs in the treatment of tuberculosis.  Rifampicin 
acts to inhibit RNA synthesis in the Mycobacterium.  Importantly, this makes rifampicin 
bactericidal and effective against dormant cells.  As the most difficult thing to overcome in 
TB is the slow growth and presence of dormant cells, this makes rifampicin a very useful 
drug.  Rifampicin is the most important drug in the sterilising phase of treatment, the second 
phase of TB treatment, where the objective is to kill the dormant bacteria 
 
Rifampicin has few serious adverse effects.  One problem with rifampicin is that it induces 
liver enzymes, particularly CYP450 enzymes involved in drug metabolism.  This can lead to 
a decrease in the levels, and therefore the effectiveness of these drugs (e.g. oral 
contraceptives). 
 
The combination of isoniazid and rifampicin is very useful as it gives both bactericidal and 
sterilising effects. 
 
 18.2.5 Pyrazinamide 
The mechanism of action of pyrazinamide is probably similar to isoniazid, but not identical 
as pyrazinamide is able to kill dormant cells i.e. it has a sterilising agent.  Pyrazinamide, 
shares with isoniazid, the ability to cause hepatotoxicity.  Hepatotoxicity is common with 
high doses of pyrazinamide.  Consequently, pyrazinamide has to be used in low doses to 
avoid toxicity.  Using low doses reduces the effectiveness, and this is why pyrazinamide is 
used in combination with other drugs in TB.   
 
18.3. Anti-viral drugs 
This section is a brief introduction to viruses, and only considers the treatment of 3 specific 
viruses.  The 3 viruses considered are a DNA virus (herpesvirus), a RNA virus (influenza), 
and a retrovirus (HIV/AIDs). 
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18.3.1 Introduction to viruses 
Viruses are small (20-30 nm) infective agents that require a host cell (e.g. human cells) to 
replicate.  When a virus is outside of the host, it is known as a virion.   A virion is either a 
segment of RNA or DNA enclosed in a protein coat, which is called the capsid.   The capsid 
containing the nucleic acid (RNA or DNA) is called the nucleocapsid.  Viruses may also have 
an outer lipoprotein envelope.  Also, viruses may contain some enzymes required for 
replication in the host cell.  The actual structure varies between different types of viruses. 
 
There are 3 types of viruses; DNA viruses, RNA viruses, and retroviruses.  Examples of 
DNA viruses include herpesviruses, which can manifest itself as chickenpox, shingles, cold 
sores, or glandular fever.  Other common examples of DNA viruses are the adenoviruses 
which can cause sore throat, and conjunctivitis.  DNA viruses enter the host cell nucleus, and 
then they use the host cell RNA polymerase for transcription of their own DNA to viral RNA 
(Figure 18.3).  This is followed by translation and viral protein synthesis. 
 
Figure 18.3 Initial action of viruses (Copyright QUT, Sheila Doggrell) 
DNA v and RNAv are viral DNA and RNA respectively 
 
The RNA viruses include the viruses responsible for influenza and German measles, as well 
as the paramyxoviruses (cause measles, mumps) and picornaviruses (cause colds, meningitis, 
poliomyelitis).  The RNA of the RNA viruses is translated by the host enzyme systems to 
form the protein required for the synthesis of new virions (Figure 18.3).  
 
The best known example of a retrovirus is human immunodeficiency virus (HIV). HIV 
underlies acquired immunodeficiency syndrome (AIDS), which gives the person an increased 
susceptibility to infections and cancer.  
 
Retroviruses contain RNA as their genetic material, but in order for viral replication to occur, 
DNA must first be synthesised from the RNA template.  This step involves a viral specific 
enzyme reverse transcriptase enzyme (virus RNA-dependent DNA polymerase), which 
makes a DNA copy of the viral RNA (Figure 18.3).  Then, the DNA copy becomes part of 
host genome, known as provirus.  The provirus DNA is transcripted and mRNA translated by 
the host to make new virus particles.  
 
The chemotherapy of viral infections is dependent on the identification of viral specific 
proteins that can be selective targets for antiviral drugs.  While such targets have been 
166 
 
identified, these are usually specific for a particular virus and therefore broad spectrum 
antiviral drugs are not available.  For this reason, the drugs are often classified according to 
the virus they act against rather than their mechanism of action. Furthermore, all of the 
currently used antiviral drugs are virustatic.  They are only active against the actively 
replicating cell and interfere with the spread of the infection.  As they do not kill any dormant 
forms of the virus, the dormant form of the virus may become active long after the initial 
infection (e.g. the herpes simplex virus is responsible for shingles long after an initial 
infection of chickenpox).   
 
There are a number of ways (targets) antiviral drugs can inhibit the virus.  These include 
inhibiting the attachment to and entry into the host cell of the virus, inhibition of the release 
of viral DNA/RNA and inhibition of the replication of viral DNA/RNA.  Alternative ways 
antiviral drugs can inhibit the action of viruses is to inhibit the assembly of new viral particles 
or the release of viral particles from the infected cell 
 
18.3.2 Drugs used to treat the herpesvirus 
The main drug used to treat the DNA virus, herpesvirus is aciclovir.  Aciclovir is a prodrug.  
It is converted by viral enzymes to aciclovir triphosphate, which inhibits viral DNA 
polymerase.  Thus, aciclovir acts by inhibiting the replication of viral DNA.  As it needs the 
viral enzyme to be converted to the active form, the selective toxicity of aciclovir is due to it 
being selectively ‘activated” in infected cells.   
 
Aciclovir is very good against herpes simplex (which causes cold sores, conjunctivitis, 
mouth ulcers, genital infections, encephalitis).  Herpes simplex is more susceptible to 
aciclovir than other herpesviruses such as varicella zoster (which causes chickenpox, 
shingles). 
 
Aciclovir can be used orally, but only has about a 20% bioavailability.  Aciclovir can also be 
used intravenously or topically.  Fortunately, the unwanted effects with aciclovir are minimal, 
espscially when it is used topically (eg for cold sores). 
 
18.3.3 Drugs used to treat the flu 
Viruses responsible for human flu (orthomyxoviruses) areRNA viruses (mainly 
influenzavirus A subtypes).  They cause symptoms similar to a cold.  However there are 
additional symptoms.  With the flu, the fever is greater than with a cold.  Also myalgia and 
prostration are symptoms of the flu not observed with a cold.  Infection is spread via the 
respiratory system. 
 
Each year in Australia, flu vaccines are developed against the influenza viruses that were 
most prevalent in the previous northern hemisphere winter.  The vaccine prevents the viral 
infection. 
 
Swine flu is also caused by an influenzavirus A subtype.  The symptoms of swine flu in 
humans are similar to the common human flu.  However, as it is a new virus, there is no 
natural immunity to swine flu.  It takes a minimum of 6 months to develop a vaccine to a new 
type of flu. 
 
Following replication and assembly of viral components, each virus particle exits the host 
cell, but remains attached until a viral specific enzyme (neuraminidase) releases it.   The 
neuraminidase inhibitors prevent this release, and are used to treat the flu.  Obviously, if the 
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virus cannot leave the host cell, the further cell infection will be prevented.  Zanamivir 
(Relenza) and oseltamivir (Tamiflu) are examples of neuraminidase inhibitors.  Zanamivir 
was developed in Australia by a company (Biota) associated with Monash University.  
Zanamivir is administered as an aerosol, but for maximum benefit, must be taken within 48 
hours of the onset of the flu symptoms.  Oseltamivir is taken orally, also, as soon after the 
onset of flu symptoms, as possible. 
 
Both zanamivir and oseltamivir give some relief of the symptoms of the flu, as well as 
shortening the time the symptoms last..  Neuraminidase inhibitors (mainly oseltamivir) were 
stockpiled as a treatment for bird flu.  Fortunately the bird flu epidemic never happened.  
Neuraminidase inhibitors are probably effective in the swine flu, but this has not been fully 
evaluated. 
 
18.3.4 Drugs used to treat HIV/AIDS 
There are two main classes of drug used to treat infections with the retrovirus HIV.  These are 
the reverse transcriptase inhibitors and the protease inhibitors.  The reverse transcriptase 
inhibitors can be nucleoside analogs or non-nucleoside analogs.    
 
Because of the potential for resistance to develop to the available anti-retroviral drugs, the 
current guidelines are that combination treatment is always used.  One such combination is 
known as HAART or Highly Active Anti-Retroviral Therapy.  The HAART combination is 
two of the nucleoside reverse transcriptase inhibitors with EITHER a non-nucleoside 
transcriptase inhibitors OR one or two protease inhibitors.  Drugs that inhibit the fusion (and 
therefore entry) of the HIV with the host cells  are used when resistance develops to the other 
drugs.  All of the currently HIV drugs cause adverse effects that can make it likely that 
patients will not want to take them.  This means that often the treatment regimes are changed 
and developed for the individual patient to minimise the adverse effects and increase the 
likelihood that they will take them appropriately.     
 
The first drug developed for the treatment of HIV was AZT, which is also known as 
azidothymidine and zidovudine.  Zidovudine is a nucleoside reverse transcriptase 
inhibitor.  These drugs prevent the synthesis of the provirus DNA from the viral RNA (see 
Section 18.3.1).  Nucleosides analogs are phosphorylated by host cells to give triphosphate 
substrates which are then incorporated into the DNA chain by reverse transcriptase 
action.Zidovudine is an analog of the nucleoside thymidine, and substitutes for thymidine in 
this process.  Thus zidovudine competes with the endogenous nucleosides for the reverse 
transcriptase, and, once incorporated into the DNA chain, leads to the termination of the 
formation of the provirus DNA.  
 
Zidovudine is active after oral administration.  One of the main disadvantages with 
zidovudine is that it has short half-life, which means that it has to be administered every 4 
hours to be effective.  In addition, zidovudine is only selective, not specific, for the reverse 
transcriptase.  The host mitochondrial γ-DNA polymerase is also inhibited by zidovudine, 
and this may underlie some of the side effects observed during zidovudine treatment.  In the 
treatment of HIV/AIDS, zidovudine has been shown to prolong life.  However, resistance 
develops to zidovudine, and this means it not effective alone, and has to be used in 
combination with other drugs.   
 
There are some serious adverse effects with zidovudine, probably because it can substitute for 
thymidine in many actions in the body.  Zidovudine causes bone marrow suppression leading 
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to a decreased production of red blood cells (anaemia) and of the neutrophil white blood cells 
(neutropenia).  Blood transfusions may be required to overcome both of these.  Alternatively 
if anaemia is the main problem, this can be overcome by stimulating erythropoiesis (red 
blood cell formation) with epoetin (EPO).    Zidovudine can also cause headache, which can 
be controlled with paracetamol.  
 
Zidovudine and another nucleoside reverse transcriptase inhibitor are one part of the HAART 
treatment, and the other part is either a non-nucleoside reverse transcriptase inhibitor such as 
nevirapine or a protease inhibitor, such as ritonavir. 
 
Nevirapine binds to retroviral reverse transcriptase and denatures it.  Thus, nevirapine, like 
zidovudine, prevents the formation of the provirus DNA and the HIV replication.  Nevirapine 
differs from zidovudine in that it does not need to be converted to an active triphosphate in 
order to have its action.  Nevirapine is active after oral administration.  It induces its own 
metabolism.  Thus, with ongoing use it is necessary to increase the doses of nevirapine to 
maintain therapeutic plasma concentrations.  Nevirapine is contraindicated in subjects with 
impaired liver function, as it can worsen the liver function.  Importantly, in addition to being 
useful in HIV infection, nevirapine is also useful in preventing mother-to-baby transmission 
of the HIV.  Thus, nevirapine should be given to pregnant women to stop them from infecting 
their foetus. 
 
An example of a protease inhibitor is ritonavir.  The translation of the provirus RNA by the 
host ribosomes leads to the production of polypeptides.  These polypeptides are then acted on 
by viral proteases to give the structural proteins and active enzymes for the new virion.  By 
inhibiting the viral proteases, ritonavir inhibits this process i.e. the replication of the virus. 
New viral particles are released, but they are not infective. 
 
Ritonavir is active after oral administration.  One major adverse effect with ritonavir is 
hyperglycemia.  Thus, the subject with HIV treated with ritonavir can develop new diabetes, 
or if they are already diabetic, have a worsening of diabetes.  Another serious adverse effect 
with ritonavir is that it causes hypertriglyceridemia and hypercholesterolemia, and thus the 
subject may have to be treated with lipid lowering drugs to prevent cardiovascular disease. 
 
There are numerous drug interactions involving ritonavir as it inhibits the CYP enzymes 
(CYP3A) to increase levels of other drugs.  For example, ritonavir increases the levels of 
amiodarone, amlodipine, buprenorphine etc, and these levels may reach toxic levels.  
Ritonavir may also be used in combination with other protease inhibitors to inhibit the CYP 
enzymes and reduce the metabolism of these drugs.  In this way, it acts as a “pharmacokinetic 
booster”. 
 
When the resistance to HAART is such that the HIV continues to progress, other drugs have 
to be used.  The main one of these is enfuvirtide, which inhibits the fusion of the HIV with 
the host cell.  Normally the virus binds to the host cell, and then enters the host cell.  
Enfuvirtide inhibits the binding. 
 
Enfuvirtide is administered subcutaneously.  Enfuvirtide is used in HIV infection when other 
antiretrovirals have failed to halt the HIV.  It is common to get injection site reactions with 
enfuvirtide.  Treatment with enfuvirtide is associated with an increased risk of bacterial 
pneumonia. 
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18.4 Antifungal drugs 
  
18.4.1 Introduction to Fungi 
The word fungi means mushroom, and mushrooms were one of the first fungi characterised.  
Fungi are eukaryotic (they have a nucleus) and are harder to kill than prokaryotic bacteria 
(which do not have a nucleus).  Common examples of fungi are moulds and yeasts.  Fungi are 
symbiotic, which means they live in close association with a host, and are parasitic.  Fungal 
infections are known as mycoses.  Examples of mycoses include tinea (Athlete’s foot, 
Jockstrap itch, nails), Candida albicans (Thrush), Meningitis (which can be fungal or 
bacterial) and pulmonary aspergillosis (serious for bone marrow recipients, people with 
asthma or cystic fibrosis). 
 
 18.4.2 Antifungal drugs  
The fungal cell membrane is made up of ergosterol, which differs from the phospholipid 
plasma membrane of mammalian cells.  Thus, drugs that interfere with ergosterol will affect 
the fungal cell membrane, but not have effects in humans e.g. adverse effects.  Amphotericin 
is a mixture of anti-fungal substances derived from the bacteria, Streptomyces.  Amphotericin 
binds to ergosterol to create pores in the fungi cell membrane (Figure 18.4), and this leads to 
the death of the fungus i.e. is fungicidal. 
 
Amphotericin is poorly absorbed after oral administration, and is not used orally.  
Amphotericin is used either topically or intravenously.  One common adverse effect with 
amphotericin is renal toxicity, which occurs in 80% of people who are treated with it.  
Amphotericin also causes hypokalemia in a quarter of the people treated with it, and this 
hypokalemia may require treatment with potassium supplements.  Because of its serious 
adverse effects, amphotericin is not used in minor fungal infections.  Rather amphotericin is 
used in serious fungal infections e.g. treatment of fungal meningitis, pulmonary aspergillosis.  
Amphotericin lozenges have been developed to treat oral thrush. As there is little systemic 
absorption from these, there is little risk of adverse effects.   
 
Another anti-fungal drug that is mainly used for serious fungal infections is caspofungin.  
Caspofungin inhibits the synthesis of 1,3-β-glycan, a glucose polymer required for synthesis 
of fungal cell membrane.  It is used intravenously.  There are many common adverse effects 
with caspofungin (fever, nausea, vomiting, diarrhea), which limits its use to serious fungal 
infections such as invasive thrush and aspergillosis.  In aspergillosis, the first choice drug is 
an azole, and caspofungin is second choice. 
 
The azoles, such as fluconazole inhibit the enzyme lanosine demethylase (Figure 18.4), 
which is important in the conversion of lanosterol to ergosterol, the final step in the synthesis 
of ergosterol.  
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Figure 18.4 Site of action of some antifungal drugs (Copyright QUT, Sheila Doggrell) 
 
Fluconazole is active after oral administration or after intravenous administration.  High 
concentrations of fluconazole get into the cerebral spinal fluid, and therefore reach the brain. 
For this reason, it is the drug of choice for the treatment of fungal meningitis.  Fluconazole is 
fungistatic, which means it stops the growth of the fungi, but does not kill them (i.e. it is not 
fungicidal).   The unwanted effects of fluconazole are mild.  The main problem when using 
fluconazole is that it inhibits the enzyme CYP3A4 (which is the CYP metabolising enzyme 
for many drugs).  Inhibition of CYP3A4 with fluconazole leads to increased levels of 
lignocaine, neviparine etc.  Fluconazole is used in the treatment of thrush and tinea.   
 
Terbinafine is the anti-fungal drug that is commonly used for the treatment of fungal 
infections of the nails, which is a common fungal infection.  Terbinafine inhibits the enzyme 
squalene epoxidase, which is involved in the conversion of squalene to lanosterol, in the early 
part of synthesis of fungal cell membranes (Figure 18.4).  Terbinafine is active after oral or 
topical administration.  Terbinafine is highly lipophilic, and is rapidly absorbed and taken up 
by nails and adipose tissue.  Terbinafine is very effective for fungal infections of nails. 
  
Griseofulvin interferes with fungal microtubules.  It is fungistatic.  It is reserved for when 
oral, long-term use is needed.  For instance, griseofulvin is used in tinea of head, skin, nails, 
groin, and feet, which is unresponsive to agents that are topically administered. 
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19.1 Depression and Antidepressants  
 
19.1.1 Depression 
Depression is described in the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition (DSM-IV-TR) as a “mood disorder”, characterized by extreme or prolonged 
172 
 
disturbance of mood, including sadness, lack of interest in or inability to experience pleasure, 
feelings of worthlessness and guilt, physical symptoms such as agitation, fatigue, insomnia 
and appetite changes, and often anxiety (American Psychiatric Association, 2004). In 
Australia, diagnosis of depression is made on the basis of a clinical interview using the DSM-
IV-TR criteria. The symptoms of depression may last four months or more if left untreated. 
In many cases functioning returns to normal after this, however in some cases symptoms 
linger. Recurring depressive episodes can lead to major depressive disorder. 
 
19.1.2 Neurochemistry of Depression and the Monoamine Theory 
The major neurotransmitters thought to be involved in depression are the monoamines, most 
likely noradrenaline and serotonin. 
 
Serotonin and noradrenaline are diffusely projecting neurotransmitters in the central nervous 
system, projecting from the brainstem raphe nuclei and locus coeruleus, respectively, to key 
brain regions such as the prefrontal cortex, limbic system and hypothalamus. Consequently, 
these neurotransmitters regulate behaviours such as cognition, vigilance, emotion and stress 
responses. 
 
The ‘monoamine theory of depression’ was first postulated in 1965 to suggest that depression 
is caused by a functional deficit of monamines in specific brain regions. This claim was based 
on pharmacological evidence that reserpine (from Rauwolfia serpentina) disrupts monoamine 
storage and causes depression, and that known antidepressant drugs augment the monoamine 
systems to increase available transmitters and ameliorate symptoms of depression. 
Nevertheless, monoamine levels are augmented straight away while the symptoms of 
depression take weeks to diminish. Moreover, it is shown that the delayed therapeutic effect 
of antidepressants coincides with monoamine receptor downregulation. 
 
The monoamine theory was thus revised in the 1980’s to suggest that the 
hyponoradrenergic/hyposerotoninergic state that is postulated to occur in depression leads to 
hypperresponsiveness of the adrenergic and serotoninergic receptors in certain parts of the 
brain. Accordingly, the action of antidepressants is to increase synaptic levels of 
noradrenaline and serotonin to normal, while downregulating “hyperresponsive” receptors to 
reinstate normal neuronal activities, accounting for the delayed therapeutic action of these 
drugs. 
 
19.1.3 Antidepressant Indications and Drug Classes 
Antidepressant drugs are primarily indicated for major depression, in treatment of episodes 
and prevention of relapse. They may also be prescribed for atypical depression, post-natal 
depression, depression related to a medical illness or schizophrenia, pain, and anxiety 
disorders. Antidepressants are often given to sufferers of anxiety disorders due to the 
numerous overlapping symptoms, and because current anxiolytics such as benzodiazepines 
show dependence liability and can impair learning and memory. 
 
Drugs currently used in Australia to treat depression fall into a number of major classes. The 
first antidepressant drugs to be synthesized were the tricyclic antidepressants (TCAs; 
imipramine being the prototype). Following TCAs were the irreversible monoamine oxidase 
inhibitors (MAOIs e.g. phenelzine), selective serotonin reuptake inhibitors (SSRIs; eg: 
fluoxetine), and serotonin-noradrenaline reuptake inhibitors (SNRIs; venlafaxine) and 
reversible inhibitor of monoamine oxidase A (RIMA; moclobemide).  
 
173 
 
19.1.4 General Considerations with the use of Antidepressants 
Initial antidepressant drug therapy follows “start low, go slow”, the lowest dose is usually 
administered first and gradually increased as needed. Abrupt cessation of these drugs 
generally leads to withdrawal effects, which can be quite alarming with some classes such as 
the SSRIs, thus gradual weaning over weeks to months is recommended. A combination of 
antidepressant drugs is not recommended, it does not improve clinical efficacy and provides 
the opportunity for major drug-drug interactions.  A number of studies have suggested that 
antidepressant drugs may increase suicide risk when first taken. This is often because 
improvement does not occur in the first few weeks, which may worsen depression and 
suicidality. As a result, close monitoring of at-risk patients must occur during this period. 
Antidepressant drugs are generally administered for 4-6 months, as this timeframe has shown 
to improve symptoms of depression and reduce relapse, however some sufferers of 
depression remain continuously medicated. 
 
19.1.5 Tricyclic Antidepressants 
The tricyclic antidepressants (TCAs) are so named for their characteristic three-ringed 
molecular core. These drugs do not produce euphoria or dependence, and in depressed 
individuals they elevate mood, improve physical activity, appetite and sleep, and reduce 
rumination. The short term mechanism of action of all TCAs is blockade of presynaptic 
noradrenaline and serotonin high affinity reuptake transporters, which effectively increases 
availability of noradrenaline and serotonin in the synapse to act on pre- and post-synaptic 
noradrenergic and serotoninergic receptors. After many weeks of administration, tricyclic 
antidepressants downregulate -adrenoceptors and 5-HT2 receptors, reducing the number and 
activity of these receptors. The time-course of this decrease in -adrenoceptors is in keeping 
with the delayed therapeutic effect. Postsynaptic 5-HT1 receptors in the hippocampus are also 
increased with long-term tricyclic antidepressant use. Further, presynaptic 2-adrenoceptors 
and 5-HT1 autoreceptors, which control noradrenaline and serotonin release, are 
downregulated, facilitating release of these neurotransmitters. 
 
TCAs also block muscarinic acetylcholine, histamine and serotonin (5-HT2, 5-HT3) receptors 
at therapeutic doses, leading to a number of side/adverse effects. These side effects include 
blurred vision, dry mouth, constipation, urinary retention, drowsiness, restlessness, insomnia, 
nausea, anorexia, diarrhoea, and disturbances of libido and potency. Most importantly, TCAs 
may cause adverse cardiovascular effects including hypotension, tachycardia and 
arrhythmias. These may become fatal in overdose through cardiotoxicity, and make the use of 
TCAs dangerous since the narrow therapeutic index allows for a relatively easy overdose. 
 
19.1.6 Monoamine Oxidase Inhibitors 
The monoamine oxidase inhibitors (MAOIs) fall into two categories, the irreversible non-
selective MAOIs (phenelzine) which bind covalently to both MAO-A and MAO-B, and the 
reversible inhibitor of MAO-A (moclobemide) which binds selectively to MAO-A. In 
depressed individuals their efficacy is similar to TCAs, although MAOIs are possibly more 
effective for atypical depression. These drugs inhibit the activity of monoamine oxidase 
enzymes (which function to maintain low cytoplasmic monoamine concentrations), 
preventing breakdown of the monoamines. This increase in the cytoplasmic pool of 
monoamines, without affecting vesicular stores, increases spontaneous leakage of 
monoamines into the synapse and extracellular space. Consequently, noradrenaline and 
serotonin (and dopamine) availability is enhanced to act on pre- and post-synaptic receptors. 
After many weeks of administration, MAOIs downregulate -adrenoceptors and 5-HT2 
receptors, similar to TCAs. They also consistently downregulate α1-adrenoceptors and 
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postsynaptic 5-HT1 receptors. Like TCA’s, MAOIs downregulate presynaptic 2-
adrenoceptors and 5-HT1 autoreceptors, which control noradrenaline and serotonin release, 
thus monoamine release is facilitated. 
 
MAOIs cause fewer side/adverse effects than TCAs. They still have a propensity to cause 
nausea, insomnia, hypotension, dizziness, and disturbances of libido and potency, however 
they cause fewer anticholinergic side effects (dry mouth, blurred vision, urinary retention 
etc.). Nonetheless the usefulness of irreversible MAOIs has been limited by their interaction 
with sympathomimetic agents such as tyramine in foods. This can create a hypertensive 
crisis, the so-called “cheese-reaction”, which may be fatal and requires strict adherence to 
dietary guidelines. The RIMA, moclobemide, is much safer than the irreversible MAOIs due 
to its selectivity for MAO-A. 
 
19.1.7 Selective Serotonin Reuptake Inhibitors 
Selective serotonin reuptake inhibitors (SSRIs) demonstrate similar efficacy to TCAs in 
treating moderate depression, but possibly less efficacy in treating severe depression. These 
drugs have been shown to be very effective in reducing anxiety and agitation associated with 
depression. At therapeutic doses SSRIs demonstrate 50-fold selectivity for serotonin 
transporters over noradrenaline transporters. Owing to this highly selective blockade of the 
serotonin transporters, SSRIs increase levels of serotonin in the synapse. With longer-term 
administration, SSRIs downregulate postsynaptic 5-HT2 receptors and, like TCAs, increase 
sensitivity of postsynaptic 5-HT1 receptors in the hippocampus. Similarly to TCAs and 
MAOIs, SSRIs decrease the sensitivity of presynaptic 5-HT1 autoreceptors, thus facilitating 
serotonin release. In this way, SSRIs enhance serotoninergic transmission by re-establishing 
normal firing rate, increasing serotonin output, and increasing postsynaptic (5-HT1) receptor 
sensitivity in the hippocampus. 
 
Unlike TCAs, SSRIs have little affinity for cholinergic and histaminergic receptors, and it is 
this purity of effect that has led to their popularity, owing to reduction in side effects. 
Nonetheless these drugs produce numerous 5-HT receptor-mediated side effects including 
nausea and vomiting, diarrhoea, agitation, insomnia, tremor, and disturbances of potency and 
libido. Further, a combination of SSRIs with other drugs that enhance serotoninergic 
transmission may lead to ‘serotonin syndrome’ resulting from serotonin toxicity. SSRIs are 
less dangerous in overdose than TCAs and MAOIs due to the lack of cardiotoxicity and their 
large therapeutic index. 
 
19.1.8 Noradrenaline and Serotonin Reuptake Inhibitor 
Venlafaxine is an example of a serotonin-noradrenaline reuptake inhibitor (SNRI). This drug 
acts similarly to TCAs and SSRIs by blocking noradrenaline and/or serotonin reuptake, 
however venlafaxine is highly selective for the transporters, thus obviating numerous side 
effects related to administration of TCAs or SSRIs.  
 
19.1.10 Long Term Adaptive Changes with Antidepressants 
The net effect of chronic treatment with antidepressant drugs is enhancement of 
monoaminergic function. Irrespective of the underlying transmitter imbalance (which remains 
to be well characterized), it seems antidepressant drugs optimize monoamine levels by 
facilitating release and restore receptor sensitivities to normal or permit preferred receptor 
actions. Increasing monoamine levels may be the first step, creating a complex sequelae of 
cellular and molecular changes. The time course of these long term adaptive changes is 
paralleled by mood changes. 
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19.2 Psychosis, Schizophrenia and Antipsychotic Drugs  
 
19.2.1 Psychosis and Schizophrenia 
Psychosis is a phenomenon that is associated with a number of disorders, including bipolar 
affective disorder (manic depression), drug withdrawal, and most evidently, schizophrenia. 
The drugs used to treat schizophrenia are also used to treat other disease entities manifesting 
in psychosis, which is why they are referred to as antipsychotics rather than 
antischizophrenics.  
 
Schizophrenia itself is in fact a syndrome, characterised by a number of symptoms which 
different sufferers demonstrate to different extents.  The symptoms have been grouped into 
three major dimensions; positive symptoms reflecting an excess or distortion of normal 
thinking, negative symptoms reflecting a loss or reduction in normal behaviours, and 
cognitive symptoms reflecting a deficit in some cognitive behaviours such as attention and 
working memory. Positive symptoms are akin to the usual “psychosis”, and may manifest as 
delusions, hallucinations, and disorganised thought and speech. Negative symptoms may 
show as blunted emotional responses, diminution in goal directed behaviours, and lack of 
interest in or inability to experience pleasure. Schizophrenia is characterized as a thought 
disorder, although depression may occur. The symptoms of schizophrenia can be extremely 
distressing, and cause major disruption to social and occupational functioning. The average 
age of onset is adolescence or early adulthood, and course is often chronic, rarely remitting, 
and usually improved through pharmacological intervention.  
 
The cause of schizophrenia remains unknown, but current evidence suggests it involves a 
gene-environment interaction. The collective effect of numerous common genetic variants 
interacts with environmental factors, which are moderated by the genes, causing alterations to 
brain development and, in time, information processing. Environmental factors that have 
been identified include pre-, peri-, and post-natal effects (stress, malnutrition, infection, 
obstetric complication), early-life stress (trauma, separation), frequent drug use (cannabis, 
amphetamines), and stressful life events (migration, illness, adversity etc.). 
 
19.2.2 Neurochemistry of Psychosis and the Dopamine Theory 
The history of dopamine’s involvement in psychosis and schizophrenia is long, and only the 
most recent theories will be considered here, since the early dopamine theories of 
schizophrenia did not withstand testing. The discovery that all early antipsychotics were 
antagonists of dopamine D2 receptors pointed to a role for dopamine in psychosis. It was 
further shown that clinical efficacy of antipsychotics is consistently achieved when D2 
receptor occupancy reaches at least 60% (40-80%), and is correlated linearly with their D2 
receptor affinity. 
 
Davis and colleagues (1991) theorised that reduced dopamine release in prefrontal cortex 
causes negative symptoms of schizophrenia and leads to increased dopamine release in 
subcortical regions (specifically the ventral striatum containing the nucleus accumbens) 
which causes positive symptoms. While this theory accounted for available data and 
integrated knowledge of brain regions and dopamine receptor distributions, clinical evidence 
is still limited, most of the evidence comes from animal studies. Howes and Kapur (2009) 
modified the theory to suggest that increased presynaptic dopamine function in the ventral 
striatum is the ‘final common pathway’ for psychosis. This theory is supported by clinical 
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evidence of elevated presynaptic dopamine, dopamine release, and dopamine receptor density 
in the ventral striatum during psychosis, and animal models showing genetic and 
environmental factors contribute to this. It is thought that elevated dopamine transmission in 
the ventral striatum influences aberrant motivational salience to otherwise innocuous stimuli 
(people, objects and actions), and psychosis arises from an effort to construct plausible 
explanations. 
 
While the role of dopamine is necessary in schizophrenia, it is not sufficient. Dopamine 
dysregulation no doubt accounts for psychosis, but it is thought multiple transmitter systems, 
including GABA and glutamate, underlie the negative and cognitive symptoms.  Researchers 
have suggested dopamine forms the converging pathway in schizophrenia, not the primary 
abnormality, and that deficiencies in one or more other neurotransmitter systems which 
modulate domapine leads to the dopaminergic overactivity. 
 
19.2.3 Antipsychotic Drug Indications and Drug Classes  
Antipsychotics are indicated in the treatment of psychosis and symptoms of schizophrenia, 
and prevention of relapse. 
 
Antipsychotic drugs are divided into two major classes. The first is the ‘typical’ or ‘first 
generation’ antipsychotics. Chlorpromazine was the prototype, a phenothiazine drug 
originally developed as an antihistamine agent. Subsequent to chlorpromazine, numerous 
typical antipsychotics were developed, forming the only types available until the late 1980’s. 
The second class is the ‘atypical’ or ‘second generation’ antipsychotics. The first of these 
developed was clozapine, found to be ‘atypical’ in that at therapeutic doses it was far less 
likely to cause adverse motor and hormone side effects seen with the ‘typical’ antipsychotics. 
Based on clozapine’s chemical structure and receptor binding properties, numerous atypical 
antipsychotics have been developed which now offer first line therapy in the treatment of 
schizophrenia. 
 
19.2.4 Antipsychotic Mechanisms of Action 
Antipsychotic drugs are potent dopamine D2 receptor antagonists. D2 autoreceptors control 
release of dopamine from presynaptic neurons. By blocking elevated ventral striatal 
dopamine release, antipsychotics ameliorate dopamine dysregulation. Animal studies have 
shown that antipsychotics initially increase (due to D2 receptor autoreceptor blockade) and 
then decrease midbrain dopaminergic neuron activity in the substantia nigra and ventral 
tegmental area (containing dopaminergic cell bodies), and dopamine release in regions where 
dopamine cells project to, such as the ventral striatum and prefrontal cortex. This decreased 
dopaminergic activity occurs as D2 receptors upregulate due to chronic blockade, and the 
time course of this increased receptor expression parallels the delayed therapeutic effect of 
the drugs.  
 
The therapeutic effects of antipsychotics, as already mentioned, are thought to occur via the 
mesocortical/mesolimbic dopamine pathway (ventral tegmental area to prefrontal cortex and 
ventral striatum). The side effects commonly seen with antipsychotics are thought to occur 
through antagonism of the nigrostriatal pathway (substantia nigra to caudate/putamen), where 
movement disorders result, and the tuberoinfundibular pathway (hypothalamus to pituitary), 
which lead to endocrine abnormalities 
 
19.2.6 Typical Antipsychotics (First Generation) 
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Typical antipsychotics comprise a number of different types of chemicals, including 
chlorpromazine, and haloperidol).  Both of these drugs ameliorate the positive (psychotic) 
symptoms of schizophrenia but have little effect on negative and cognitive symptoms. These 
drugs, in addition to being potent D2 receptor antagonists demonstrating up to 80% 
occupancy at therapeutic doses, show moderate potency at α-adrenergic, 5-HT2, muscarinic 
acetylcholine, and histamine receptors at therapeutic doses (except haloperidol which is 
highly selective for D2 receptors).  
 
As they block many receptors, the typical antipsychotics, have numerous anticholinergic (dry 
mouth, blurred vision, constipation), antihistaminergic (sedation, drowsiness), adrenergic 
(cardiac side effects, hypotension) and serotoninergic (weight gain) side effects. The most 
severe side effects with these drugs, however, occur through their target dopamine receptors. 
By blocking dopamine transmission in the nigrostriatal pathway, antipsychotic drugs cause 
movement disorders such as tardive dyskinesia (loss of voluntary control of movements 
which is debilitating and may not remit following drug cessation), parkinsonism (tremor, 
shuffling gait, cogwheel rigidity etc.), disordered muscle tone and motor restlessness. 
Blocking dopamine transmission in the tuberinfundibular pathway causes elevated prolactin 
secretion from the pituitary gland, leading to enlarged breasts, weight gain, erectile 
dysfunction and menstrual irregularities. The extent and severity of side effects incurred with 
typical antipsychotic drugs limits their effectiveness as patients are less likely to comply with 
treatment. 
 
19.2.6 Atypical Antipsychotics (Second Generation) 
Atypical antipsychotics are very different chemicals to typical antipsychotics, with different 
receptor binding profiles. The prototype of this group was clozapine, which ameliorates the 
positive symptoms of schizophrenia, and some are quite effective on the negative and 
cognitive symptoms as well. Clozapine has proven most effective, however it is not first line 
therapy owing to its liability to cause agranulocytosis, myocarditis and cardiomyopathy in 
vulnerable individuals. It is reserved for individuals who fail to respond to other drugs, with 
close monitoring.  
 
Most atypical antipsychotics are dopamine D2 receptor antagonists. These drugs occupy 40-
60% of D2 receptors at therapeutic doses. Many of the atypical antipsychotics have high 
affinity for 5-HT2 receptors.  It is considered that the ratio of D2:5-HT2 receptor occupancy 
provides additional therapeutic features of atypical antipsychotics, and reduces their liability 
to cause motor and endocrine side effects, thus making them more tolerable, which improves 
compliance. Clozapine and olanzapine, currently the most effective antipsychotics, also 
show high affinity for dopamine D4 receptors. 
 
Whilst atypical antipsychotics produce fewer side effects than the typical antipsychotics, 
their use has lead to the emergence of another insidious side effect, metabolic syndrome. 
These drugs can cause weight gain, hyperglycaemia and elevated triglycerides, which 
increase risk of obesity, cardiovascular disease and diabetes mellitus. Thus, although these 
drugs appear to be an improvement on the typical antipsychotics, they do not escape 
limitations. 
 
 
19.3 Anxiety and Anxiolytics 
 
19.3.1 Fear, Anxiety and Anxiety Disorders 
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Fear and anxiety are adaptive responses to aversive stimuli (eg: danger, pain, noxious 
conditions) that facilitate survival. Fear represents an immediate, often innate, response to 
threatening stimuli, but can also be learnt (conditioned) so that specific stimuli are predicted 
to be associated with danger, pain or harm. Anxiety is a state of anticipation of danger, 
elicited by less specific cues, and is learnt. It is characterized by vigilance, physiological 
autonomic arousal and subjective distress. Normal fear and anxiety behaviours include 
avoidance, escape or defense.  
 
Anxiety disorders arise when: normal fearful or anxious behaviours become exaggerated or 
prolonged, or occur in the absence of any real threat; anticipation of a feared event or object 
becomes distressing; or increased salience is given to usually innocuous stimuli so that they 
come to be perceived as threatening. Precipitating factors may be external (e.g. situation, 
object) or internal (such as catastrophic cognitions or rationalizations, recall of stressful 
experiences, or physiological autonomic arousal). DSM-IV-TR categorises anxiety disorders 
into a number of subtypes, including social phobia, specific phobias, panic disorder, 
obsessive-compulsive disorder, post-traumatic stress disorder, and generalized anxiety 
disorder. Each of these has unique features, however the common characteristics include 
somatic (motor tension, trembling, palpitations, restlessness, sleep disturbances), emotional 
(distress, fear and anxiety) and cognitive (hypervigilance, derealization, negative self-
evaluation) features. For clinical diagnosis according to DSM-IV-TR, the anxiety must 
interfere significantly with social and occupational functioning, or this interference causes 
significant distress. 
 
19.3.2 Neurochemistry of Anxiety 
Fear and anxiety activate many brain circuits, including those involved in sensory input 
(thalamus and sensory cortex), contextual memory (hippocampus), conditioned emotional 
responses and fear responses (central nucleus of the amygdala), activation of hypothalamic-
pituitary-adrenal (HPA) axis (hypothalamus) and cortisol release, salience and conditioned 
avoidance (striatum), arousal and vigilance (locus coeruleus and raphe nuclei) and cognition 
and executive functions (neocortex, especially prefrontal cortex). Research has shown that 
the central nucleus of the amygdala, mediates certain responses to immediate aversive stimuli 
while other limbic structures such as the bed nucleus of the stria terminalis and 
septohippocampal regions are also implicated in the more contextual, chronic and general 
stimuli involved in the genesis of anxiety. Anxiety disorder sufferers appear to demonstrate 
hyperresponsive amygdala circuitry (involved in fear responses) and decreased prefrontal 
cortex activity that usually functions to suppress fear and anxiety. 
 
The neurotransmitters and hormones implicated in fear and anxiety include γ-aminobutyric 
acid (GABA), serotonin, noradrenaline, adrenaline and corticotropin releasing factor (CRF). 
The involvement of these transmitter substances will be further outlined in subsequent 
sections. 
 
19.3.3 Anxiolytic Drug Indications and Drug Classes 
Anxiolytic drugs act to reduce anxiety. Research has shown that different subtypes of anxiety 
disorders are best managed with different therapies, however the predominant therapies are 
benzodiazepines and antidepressants (such as the SSRIs). It is important to appreciate that 
benzodiazepines are used for a variety of reasons other than anxiolysis, including muscle 
relaxation, sedation and sleep, convulsions, and alcohol withdrawal. Similarly, some 
antidepressant drugs are very effective anxiolytics.  
 
179 
 
Non-pharmacological interventions such as cognitive-behavioural therapy and fear extinction 
may also be highly effective in the treatment of anxiety disorders. Indeed, a combination of 
both psychological and pharmacological treatments is most efficacious.  
 
19.3.4 Benzodiazepines 
Benzodiazepines are allosteric modulators of the GABAA receptors. GABAA receptors are 
ligand-gated ion channels, gated by the amino acid transmitter, GABA. When activated, they 
conduct chloride ions, the net effect being a reduction in membrane excitability and inhibition 
of cell firing.  
 
These receptors are found in many brain regions such as the amygdala (including central 
nucleus), hippocampus, bed nucleus of the stria terminalis, striatum (dorsal and ventral), 
hypothalamus and prefrontal cortex. When GABA is bound, benzodiazepines increase the 
frequency of ion channel opening, thus increasing chloride conductance and the potency of 
GABA.  
 
Examples of benzodiazepines include diazepam, midazolam and temazepam.  These drugs 
are similar in their mechanism of action, however differ in their pharmacokinetics, such that 
some are much shorter-acting (e.g. midazolam) and some are much longer-acting (e.g. 
diazepam,). Shorter acting drugs may be useful for inducing or maintaining sleep, while 
longer acting are preferred for treatment of anxiety disorders.  
 
Benzodiazepines have the advantage of being rapid in onset (within hours) and are therefore 
very useful in treating acute anxiety states, such as panic disorder and phobias, and they are 
also useful in generalised anxiety disorder. Unfortunately, while being very effective 
anxiolytics, benzodiazepines have some unwanted side effects, including sedation, memory 
loss (amnesia) and dependence liability (they are addictive). Their tendency to cause 
drowsiness and confusion in elderly patients also negates their use in this demographic.  
 
Benzodiazepines interact with other depressants such as alcohol, making their use in 
combination dangerous as this enhances sedation, memory loss, and respiratory depression. 
Since they are potentially addictive, benzodiazepines are recommended for acute use, usually 
two weeks at a time, although in some cases chronic use is justified. The withdrawal 
syndrome from benzodiazepines can be quite severe, therefore gradual weaning is required. 
 
19.3.5 Antidepressants 
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, and more recently the 
serotonin-noradrenaline reuptake inhibitors (SNRIs, e.g. venlafaxine), are useful in the 
treatment of some anxiety disorders such as panic disorder, generalised anxiety disorder, 
obsessive-compulsive disorder and post-traumatic stress disorder. In fact, these drugs are 
suggested as first line therapy for many anxiety disorders, especially where chronic treatment 
is required.  
 
Monoamine oxidase inhibitors have been used for phobias, and some tricyclics 
antidepressants are indicated for panic disorder and post-traumatic stress disorder. The 
mechanisms of action and side effects of these drugs are outlined in an earlier section (20.1).  
 
The treatment resistance in roughly one third of individuals given antidepressants occurs not 
only in depression, but also with the use of antidepressants to treat anxiety. The variation in 
response to antidepressants is now thought to be due to pharmacogenetics.  
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19.3.6 Buspirone 
Buspirone is a 5-HT1A receptor partial agonist found to be somewhat useful in treatment of 
panic disorder and generalised anxiety disorder. 5-HT1A receptor activation usually inhibits 
release of neurotransmitters like serotonin from the raphe nuclei and noradrenaline from the 
locus coeruleus. Buspirone therefore partially blocks noradrenaline release, hence centrally-
mediated physiological arousal.  By partially blocking somatic 5-HT1A autoreceptors on 
raphe nuclei, buspirone also facilitates release of serotonin. The therapeutic effects, however, 
take days to weeks to occur, therefore must involve more complex mechanisms for anxiolytic 
action. Side effects of buspirone include dizziness, nausea, headache and restlessness, but it 
avoids the psychomotor impairment and dependence liability incurred with the use of 
benzodiazepines. 
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This section deals with the neurologic drugs.  The neurologic drugs are used to treat epilepsy 
and neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease. The 
opioids for pain management are also discussed in this section. 
20. Epilepsy and an introduction to drugs used to treat 
 20.1.1 Introduction to epilepsy 
Epilepsy is a disruption of the normal electrical activity of the brain resulting in seizures.  
Epilepsy affects 1-2% of Australians.  Thus, about 400,000 Australians have epilepsy. 
There are 40 different types of seizures, but they can be grouped together into about 6 main 
groups.  Seizures are associated with changes in sensation, awareness, and behaviour.  Only 
some times are seizures associated with convulsions, muscle spasms or loss of consciousness. 
15% of people with epilepsy have a learning disability. 
About 50% of cases of epilepsy have no known cause.  For the other 50%, the causes of 
epilepsy include head injury, stroke or brain hemorrhage, lack of oxygen to brain for 
prolonged period (birth trauma, cardiac arrest), brain infections, brain tumours, chronic 
alcohol abuse. Epilepsy is not necessarily lifelong, many children or adults outgrow epilepsy 
or have long term remission from epilepsy. 
The pharmacological treatment of epilepsy is quite successful.  Up to 70% of people with 
epilepsy gain full seizure control with treatment. 
Epilepsy can be divided into partial and generalised seizures.  The partial seizures all 
originate from the cerebral cortex.  The cerebral cortex controls a variety of things include 
attention and consciousness.  The partial seizures can be divided into two types; simple, and 
complex (Table 20.1).  Both simple and complex partial seizures can lead to secondary 
generalized tonic-clonic seizures. 
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Table 20.1 Partial seizures (Copyright QUT, Sheila Doggrell) 
Partial seizures begin focally in the cerebral cortex, and with simple partial seizures, the 
manifestations can be diverse depending on the region of the cortex activated.  For instance, 
if the focal point is in the motor cortex representing the left thumb, the epilepsy maybe clonic 
(jerking) of the left thumb.  There is no loss of consciousness with simple partial seizures. 
In contrast, complex partial seizures are associated with a loss of consciousness, and this 
loss of consciousness lasts for 30 seconds to 2 minutes.  Complex partial seizures are also 
associated with purposeful behaviour such as lip smacking or hand wringing. 
Both simple and complex partial seizures can lead to secondary generalised tonic-clonic 
seizures.  These are associated with a loss of consciousness.  In the tonic phase the body 
becomes stiff due to the sustained contraction of muscles, and this is followed by the clonic 
phase when there is jerking of the muscles throughout the body.  These secondary generalised 
tonic-clonic seizures last about 1-2 minutes. 
Generalised seizures involve both hemispheres of the brain from the start (Table 20.2).  In 
absent seizures (petit mal), there is an abrupt onset of impaired consciousness, and this is 
associated with staring and cessation of ongoing activities (rather like a day dream).  Absent 
seizures last 1-2 minutes.  
Myoclonic seizures are brief shock-like contractions of muscle.  Often myoclonic seizures 
are restricted to one extremity (e.g. one leg) but may be more generalised.   
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Table 20.2 Generalised seizures (Copyright QUT, Sheila Doggrell) 
Finally, there are generalised tonic-clonic seizures (grand mal), which have the same 
characteristics as those that can develop from partial seizures, but are not preceded by partial 
seizures. 
The worst type of epilepsy is status epilepticus.  Most partial and generalised seizures 
terminate spontaneously.  When this does not happen, the ongoing tonic-clonic seizures are 
known as status epilepticus.  The definition of what constitutes status epilepticus is 30 
minutes of continuous seizure activity or a series of seizures without return to full 
consciousness between seizures 
Status epilepticus is a very serious condition.  Overall the mortality is about 20% in status 
epileptics, although death is often related to underlying brain injury.  In neonates (newborns) 
status epilepticus may be related to perinatal (period just before and after birth), hypoxia 
insults or metabolic insults.  In the elderly, status epilepticus is usually secondary to ischemic 
insults 
 20.2 Treatment of partial seizures 
The drugs used to treat partial seizures include carbamazepine, phenytoin and valproate.  
These drugs all interact with Na+ channels in the nerves in the central nervous system.  
Normally, the Na+ channels alternate between the active state, where the channel is open and 
the Na+ flows through the channel to produce nerve activity, and the inactive state (Figure 
20.1).  Carbamazepine, phenytoin and valproate all bind to the inactivated gate of the Na+ 
channels to prolong the inactivation, which prolongs the quiescent state of the nerve. 
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Figure 20.1 Na+ channel (Copyright QUT, Sheila Doggrell) 
Carbamazepine is an important drug for treatment of partial seizures and tonic-clonic 
seizures associated with partial or generalised seizures.  It reduces nerve activity by binding 
to the inactivation gate of the Na+ channel and prolonging the time it is inactive.  
Carbamazepine is absorbed slowly and erratically after oral administration. 
Carbamazepine is metabolised to carbamazepine 10,11-epoxide, which is an active 
metabolite.  Carbamazepine also produces autoinduction of its own metabolism by the liver 
enzyme CYP3A4.  Thus, with constant doses of carbamazepine, the plasma concentrations 
will decrease.  Therapeutic drug monitoring of plasma levels of carbamazepine is done on 
a regular basis to ensure that it remains within the therapeutic range. 
Also, by inducing CYP3A4, carbamazepine induces the metabolism off all the drugs 
metabolised by this enzyme, and this can lead to drug interactions.  This includes induction 
of the metabolism of oral contraceptives, and the levels can fall below those needed for 
contraception. 
The most common untoward effects of carbamazepine are drowsiness, vertigo, ataxia 
(unsteady and clumsy motion of the limbs), diplopia (double vision), and blurred vision. 
Phenytoin is also effective in treatment of partial and tonic-clonic seizures.  It also reduces 
nerve activity by binding to the Na+ channel, and prolonging the time it is inactive.   
Phenytoin is widely used in absence seizures but not particularly effective against these 
seizures.   
Phenytoin is suitable for oral administration.   Phenytoin is principally metabolised by 
CYP2C9/10.  The metabolism of phenytoin is saturable, which is quite rare, and leads to 
zero order kinetics.  Having zero order kinetics leads to phenytoin having a variable half-life.  
The half-life can range from 6 to 24 hours, as it increases with dose.  Therapeutic drug 
monitoring is often required with phenytoin use. 
Phenytoin induces CYPs including CYP3A4, which means it interacts with all the drugs that 
are metabolised by CYP3A4.  This includes the oral contraceptives. 
Gingival hyperplasia (enlargement of the gums) occurs in about 20% of patients during 
chronic use of phenytoin. 
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Valproate, also known as valproic acid, is effective in the treatment of both partial and 
generalised seizures, and is discussed in the next section. 
20.1.3 Treatment of generalised seizures 
In addition to being effective in both partial and generalised seizures, valproate is the 
primary agent used in myoclonic seizures. Like carbamazepine and phenytoin, valproate 
reduces nerve activity by binding to the Na+ channel and prolonging the time it is inactive.  
Valproate also has an addition action; it interacts with the T-type Ca2+ channels.  Ca2+ entry 
via the T-type Ca2+ channel underlies some of the currents observed in generalised seizures. 
Valproate inhibits the flow of Ca2+ through T-type Ca2+ channels. 
Valproate is absorbed rapidly and completely after oral administration.  It has a half-life of 15 
hours, and undergoes metabolism by the liver. 
Most common side effects with valproate are transient gastrointestinal symptoms, including 
anorexia, nausea, and vomiting in about 16% of patients. 
Most barbiturates are active in seizures, but many of the barbiturates cause hypnosis, when 
the subject is in a trance and subject to manipulation.  The only useful barbiturate in epilepsy 
is phenobarbital.  This is because phenobarbital is active in seizures at lower concentrations 
than cause hypnosis.  Phenobarbital is mainly used in myoclonic seizures. 
Phenobarbital is very lipid soluble, and undergoes complete absorption after oral 
administration.  Phenobarbital induces a range of liver metabolising enzymes incluing uridine 
diphosphate-glucuronesyltransferase (UGT) and CYP2C and CYP3A.  Thus, the use of 
phenobarbital will lower the levels of many drugs. 
Sedation is main adverse effect of phenobarbital, and this limits its use.  Phenobarbital 
sometimes causes irritability and hyperactivity in children, and thus is not the primary agent 
for treating epilepsy in children.  Phenobarbital causes agitation and confusion in the elderly, 
and thus it also not the primary agent in the elderly. 
Ethosuximide has as its mechanism of action the ability to inhibit Ca2+ currents through T 
channels, which is one of the mechanisms of valproate.  However, unlike valproate, 
ethosuximide has no effect on Na+ channels.  This inhibition of Ca2+ currents through the T-
type calcium channels includes inhibition of T channels in thalamus, which seem to have a 
major role in absence seizures. 
Ethosuximide is primary agent for the treatment of absence seizures.  Ethosuximide is not 
effective in tonic-clonic seizures.  
The absorption of ethosuximide is complete.  The most common side effects with 
ethosuximide are gastrointestinal (nausea, vomiting, and anorexia) and CNS (drowsiness, 
lethargy, euphoria, dizziness, headache and hiccough/hiccup). 
 20.1.4 Treatment of status epilepticus  
The first line treatment of status epilepticus is the benzodiazepines.  The benzodiazepines are 
used i.v. or rectally.  The benzodiazepines are active after oral administration, but oral 
administration is usually not possible and too slow in status epilepticus.  The benzodiazepines 
most commonly used in the treatment of status epilepticus are lorazepam and diazepam. 
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Lorazepam has short onset of action, and a long t1/2 (14 h).  Thus, lorazepam rapidly 
suppresses neuronal activity, and the suppression of neuronal activity with lorazepam lasts 
for long period.  The alternative is diazepam, which is slower to act and the suppression does 
not last so long.  Thus, when diazepam is used in status epilepticus, the status epilepticus may 
break through, and this requires another dose of diazepam to be given. 
The second line treatment for status epilepticus is phenytoin. 
 
20.2. Neurodegenerative disorders; principles of treatment 
The three neurodegenerative disorders considered in this section are Parkinson’s disease, 
Alzheimer’s disease and amytrophic lateral sclerosis (motor neurone disease). 
20.2.1 Introduction to neurodegenerative disorders 
Neurodegeneration is the progressive and irreversible loss of neurones from specific regions 
of the brain. In Parkinson’s disease, the loss of neurones is predominantly the loss of 
dopaminergic neurones from the basal ganglia.  As the basal ganglia have a major role in 
movement, the loss of the dopaminergic neurones gives abnormalities in movement. 
In Alzheimer’s disease, the loss of neurones is from the hippocampal and cortical areas of 
the brain.  As these areas of the brain have a major role in memory and cognitive function, 
the loss of neurones leads to impairment in memory and cognitive function. 
In Amyotrophic Lateral Sclerosis, which is commonly known as motor neuron disease, 
there is a loss of spinal, bulbar and cortical motor neurones.  As motor neurones have a major 
role in movement, loss of these neurones leads to impaired movement.  
 20.2.2 Parkinson’s disease 
  20.2.2.1 Introduction to Parkinson’s disease 
Normal ageing is associated with a loss of dopaminergic neurones.  However, there is a 
greater loss of dopaminergic neurones in Parkinson’s disease, which was first described by 
Parkinson.  Thus, a 70-80% loss of dopaminergic neurones is associated with Parkinson’s 
disease. Pathologically there is loss of dopaminergic neurones in substantia nigra (which is 
part of the basal ganglia).  Also, pathological studies show the appearance of Lewy bodies, 
which are bits of protein dumped in the cell. 
The cause of Parkinson’s disease is usually sporadic.  Sporadic just means irregularly or 
random, and is a term used when it is not know why the disease has occurred.   Parkinson’s 
disease can be genetic.  The antipsychotic agents (which are potent D2 receptor antagonists) 
can cause symptoms similar to Parkinson’s disease called parkinsonism.  
The clinical syndrome that distinguishes Parkinson’s disease consists of 4 parts.  Firstly, there 
is bradykinesia (which is a slowness/poverty of movement).  Secondly, there is muscular 
rigidity, which makes starting a movement difficult.  There may also be resting tremors but 
these usually abate during voluntary movement.  Thus, if a resting tremor occurs during 
sitting, get up and moving around usually gets rid of the tremor.    Lastly, there is 
impairment of balance, with disturbances of gait (movement of limbs) and the subjects with 
Parkinson’s disease lean forward.  Impairment of balance leads to an increased risk of falling. 
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The main treatment of Parkinson’s disease is to enhance the dopaminergic system.  This is 
an obvious approach as there is underactivity of the dopaminergic system in Parkinson’s 
disease. 
Normally, the control of movement in the substantia nigra is a balance between the 
cholinergic system and the dopaminergic system.  When the dopaminergic system 
degenerates, the cholinergic system is left unopposed, and predominates.  Thus, an 
overactivity of the cholinergic system is observed.  Consequently, the other approach to 
treating Parkinson’s disease is inhibiting the cholinergic muscarinic neurotransmission. 
  20.2.2.2 Dopaminergic system 
Before we can discuss drugs that enhance the dopaminergic system for use in the treatment of 
Parkinson’s disease, we need to understand the dopaminergic system.  The first step in the 
dopaminergic system is the synthesis of dopamine.  In a dopaminergic neurone, dopamine is 
synthesized from L-dopa in the presence of the enzyme L-aromatic acid decarboxylase 
(Figure 43.1).  
 
Figure 20.1 The dopaminergic system (Copyright QUT, Sheila Doggrell) 
The dopamine (DA) is then stored in a storage vesicle until the nerve is activated.  Once, an 
action potential reaches the nerve ending, there is an increased level of Ca2+, and this 
associated with vesicles moving to the cell membrane and dopamine being released.  The 
released dopamine then acts at its receptors on the postjunctional membrane to initiate some 
cell signaling and a final action.   
We can enhance the dopaminergic system at a number of sites in this part of the 
dopaminergic system. For example we can promote the synthesis of dopamine, promote the 
release of dopamine, or stimulate the dopamine receptors. 
 Dopamine is inactivated either by neuronal reuptake (which is similar process as that 
observed with noradrenaline and 5-hydroxytryptamine) or by metabolism.  The metabolism 
involves 3 enzymes; monoamine oxidase (MAO), aldehyde reductase (AD) and catechol-O-
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methyl transferase (COMT).  The enzymes act on the dopamine in sequence either firstly 
monoamine oxidase, followed by aldehyde reductase and COMT or COMT followed by 
monoamine oxidase and aldehyde reductase (Fig 43.2).   
 
Figure 20.2 Metabolism of dopamine (Copyright QUT, Sheila Doggrell) 
Although, the intermediate metabolites are different depending on the order of the enzymes 
(metabolites A and B), the final metabolite is the same (metabolite C). 
Importantly, if we inhibit these enzymes, it will lead to a build up of dopamine, which is 
another way to enhance the dopaminergic system.  Thus, drugs that inhibit either monoamine 
oxidase or catechol-O-methyl transferase will increase the levels of dopamine. 
20.2.2.3 Treatment to enhance the dopaminergic system 
Probably, the most obvious way to enhance the dopaminergic system is to give dopamine.  
However, dopamine is not active after oral administration as it is metabolised by monamine 
oxidase and catechol-O-methyl transferase, which are found in the gut.  To avoid intestinal 
metabolism, dopamine can be administered intravenously.  But, after intravenous 
administration, dopamine does not cross the blood brain barrier to have central effects.  Thus, 
we cannot use dopamine in Parkinson’s disease. 
A very important way to enhance the dopaminergic system is to increase the synthesis of 
dopamine.  L-DOPA is the precursor of dopamine.  It is absorbed from the gut on the 
transport system for the aromatic amino acids.  L-DOPA also gains entry into CNS, with 
transport across the blood brain barrier also being mediated by the transporter for the 
aromatic amino acids.  Once in dopaminergic neurones, L-DOPA is converted to dopamine in 
the presence of the enzyme L-aromatic acid decarboxylase. 
There are dopaminergic nerves in the central nervous system and in the peripheral nervous 
system, which means that after the administration of L-dopa, the levels of dopamine are 
boosted in both the central and peripheral nervous system (Figure 43.3).  
In the central nervous system, this achieves are required goal, increased levels of dopamine, 
enhancing the dopaminergic system to overcome the Parkinson’s disease.  However, in the 
peripheral nervous system, the increased levels of dopamine lead to side effects including 
nausea. 
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Figure 20.3 Effect of L-DOPA (Copyright QUT, Sheila Doggrell) 
To overcome this problem, L-DOPA is used with an inhibitor of L-aromatic amino 
decarboxylase that does not cross the blood brain barrier e.g. carbidopa.  Thus, carbidopa 
inhibits the conversion of L-DOPA to dopamine but only in the peripheral nervous system.  
This removes the detrimental effects associated with a build-up of dopamine in the peripheral 
nervous system.  It also means that there are higher levels of L-DOPA in the circulation that 
can be transported to the central nervous system.  In the central nervous system, the L-DOPA 
can still be converted to dopamine to enhance the dopaminergic system to overcome 
Parkinson’s disease.  Thus, with this combination of L-DOPA and carbidopa, we get the 
benefits of L-DOPA in the central nervous system without the peripheral side effects. 
L-DOPA and carbidopa are formulated together into one tablet, which makes it easier for 
the subject to remember to take.  To be effective on an ongoing basis, three or more 
combination tablets are needed a day.  Initially L-DOPA has a dramatic effect in improving 
or removing the signs and symptoms of Parkinson’s disease.  It is like a miracle, the subject 
has apparent full recovery.  Unfortunately, this does not last. 
Parkinson’s disease is a progressive disease, which means there is a progressive loss of 
dopaminergic neurones.  The dopaminergic neurons are needed to convert the L-DOPA to 
dopamine.  Thus, with a decreasing number of dopaminergic neurones present, there is 
decreasing ability of dopaminergic neurones to convert L-DOPA to dopamine.  Thus, the 
miracle does not last.  This progressive loss of dopaminergic neurones contributes to the loss 
of effectiveness of L-DOPA with long term use. 
With long term use of combination of L-DOPA and carbidopa, there is the “wearing off” 
phenomenon.  In the “wearing off” stage, L-DOPA is only effective for 1 to 2 hours, and then 
rigidity and akinesia (slowness/loss of movement) returns.  This is partly due to the 
progressive nature of Parkinson’s disease, but there may be other factors involved.  
Increasing the dose frequency with the L-DOPA can reduced the rigidity and akinesia, but 
often leads to dyskinesia (excessive and involuntary movements).  In addition to nausea, L-
DOPA may induce hallucinations and confusion in the elderly. 
A second approach to enhancing dopaminergic neurotransmission in Parkinson’s disease, is 
to promote the release of endogenous dopamine.  Amantadine increases the release of 
dopamine from the dopaminergic nerves in the striatum 
Amantadine also has antimuscarinic activity and blocks glutamate NMDA receptors and 
these effects may contribute to its benefit in Parkinson’s disease. The benefit of 
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antimuscarinic activity in Parkinson’s disease is discussed in the next section.  Blockade of 
glutamate NMDA receptors has been shown to be useful in Alzheimer’s disease. 
Amantadine is not very effective alone.  It is only used alone in the early stages of 
Parkinson’s disease where there are still sufficient stores of endogenous dopamine to allow 
amantadine to release dopamine. 
In late-stage Parkinson’s disease, the disease cannot be controlled by L-DOPA/carbidopa, 
and amantadine can be useful in combination with L-DOPA.  It is especially effective where 
there is dyskinesia with the L-DOPA/carbidopa combination. 
A third approach to enhance dopaminergic transmission is to use drugs that are agonists at 
dopamine D receptor receptors.  Dopamine D1- and D2- receptors are abundant in the 
striatum, and the ones to target in Parkinson’s disease.  Stimulation of these receptors will 
mimic the effect of the missing endogenous dopamine.  There are a number of dopamine 
receptor agonists available including older non-selective agonists: e.g. bromocriptine, and 
some agents that select for one receptor.  Cabergoline is a selective agonist for dopamine D2 
receptors. 
Bromocriptine stimulates vascular D1 receptors to induce vasodilation causing hypotension, 
which is an adverse effect in Parkinson’s disease.  This suggests that agents that are selective 
for dopamine D2-receptor may be better than bromocriptine.  Bromocriptine also causes 
nausea and fatigue. 
Cabergoline is selective for the dopamine D2 receptors, and is generally well tolerated.  It 
has a long elimination half-life, which means that cabergoline can be used once a day. 
Cabergoline can be used alone in early Parkinson’s disease.  Unfortunately, none of the 
presently available dopamine receptor agonists are effective for long when used alone in 
Parkinson’s disease.  Cabergoline can be used in late-stage Parkinson’s disease in 
combination with L-DOPA and carbidopa to overcome the fluctuations with L-DOPA. 
A final approach to enhancing dopaminergic transmission is to reduce the inactivation of 
the endogenous dopamine.  Dopamine is inactivated by either monoamine oxidase or 
catechol-O-methyl-transferase.  
Selegilene is a selective inhibitor of monamine oxidase-B, which is the form of monoamine 
oxidase that breaks down dopamine.  Preventing the metabolism of dopamine, by inhibiting 
monoamine oxidase-B, leads to increased levels of dopamine. 
Unfortunately, the benefit observed with selegilene is modest effect and, consequently, it is 
used primarily in early or mild Parkinson’s disease.  The metabolites of selegilene include 
amphetamine and methamphetamine, which may cause anxiety and insomnia.  
Catechol-O-methyl-transferase (COMT) is involved in the metabolism of dopamine. In the 
periphery, catechol-O-methyl-transferase also metabolises L-DOPA, and this metabolism 
leads to inactivation of the L-DOPA. 
Entacapone is an inhibitor of catechol-O-methyl-transferase.  In the periphery, the ability of 
entacapone to inhibit the inactivation of L-DOPA leads to more L-DOPA being available to 
be transported into the central nervous system.  In the central nervous system, entacapone 
lead to increased levels of dopamine by preventing its metabolism by entacapone.   
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The duration of action of entacapone is short; about 2 hours.  Entacapone is not used alone; it 
is usually administered at same time as the L-DOPA/carbidopa combination.  When L-DOPA 
is given alone, up to 99% of it is metabolised in periphery.  The effect of entacapone is 
mainly in the periphery, where inhibiting the metabolism of L-DOPA by catechol-O-
methyltransferase increases the amount of L-DOPA that reaches the central nervous system 
to be converted into dopamine.  Combination tablets of L-DOPA, carbidopa and entacapone 
are available for when the treatment of Parkinson’s disease with the combination of L-DOPA 
and carbidopa is no longer fully effective. 
20.2.2.4 Treatment to inhibit the cholinergic system 
When the dopaminergic system becomes underactive in Parkinson’s disease, it leaves the 
cholinergic system unopposed, and this produces an apparently overactivity cholinergic 
system.  Thus, another approach to the treatment of Parkinson’s disease is to inhibit the 
cholinergic system. 
Four, possibly 5, of the muscarinic subtypes are present in the striatum.  However, inhibition 
of muscarinic receptors only has a modest benefit in Parkinson’s disease.  Thus, the 
antimuscarinic agents are not used alone in Parkinson’s disease, but rather can be used as an 
adjunct to L-DOPA based therapy.  Thus, when the L-DOPA/carbidopa effect is waring off, 
antimuscarinic agent may be added. 
To be effective in the treatment of Parkinson’s disease, it is necessary to have an 
antimuscarinic agent that crosses the blood brain barrier.  Benzotropine crosses the blood 
brain barrier and is used in the treatment of Parkinson’s disease.  Some of the adverse 
effects observed with benzotropine are due to central anti-muscarinic activity e.g. sedation 
and mental confusion.  Benzotropine will also be found in the periphery after oral 
administration.  Consequently, adverse effects are observed to benzotropine which are due to 
peripheral anti-muscarinic activity e.g. constipation, urinary retention, and blurred vision 
through cycloplegia. 
 
20.2.3 Dementia/Alzheimer’s disease 
Alzheimer’s disease (AD) is not the only dementia, although it is the most common.  
Vascular dementia follows stroke, where following the blockage of cerebral blood vessels, 
the lack of oxygen and nutrients initiates the death of neurones.  Vascular dementia can take 
different forms, depending on where the blood vessel is that was blocked.  Dementia with 
Lewy bodies (abnormal spherical structures inside nerve cells) often occurs in subjects with 
long term Parkinson’s disease.  Mixed dementia is when Alzheimer’s disease and vascular 
dementia occur in the same person. 
20.2.3.1 Introduction to Alzheimer’s disease 
The prevalence of Alzheimer’s disease is 10% in those over 65 years of age.  Alzheimer’s 
disease equally affects men and women.  In Alzheimer’s disease there is atrophy of cerebral 
cortex; that is a loss of cortical and subcortical neurones.  Also, in Alzheimer’s disease there 
is the accumulation of senile plaques containing the protein β-amyloid (which is a 
neurotoxin) and of neurofibrillary tangles. 
In Alzheimer’s disease, there is a striking and disproportional loss of the neurotransmitter 
acetylcholine (Ach), but this is not the only loss in Alzheimer’s disease.  There is also a loss 
of tryptaminergic (5-HT), glutaminergic (glutamate) and neuropeptide neurotransmission. 
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Alzheimer’s disease is well known for giving an impairment of cognitive abilities.  This 
impairment is gradual in onset but relentless (keeps getting worse).  There is impairment of 
short-term memory – progresses from decreased ability to calculate, decreased visuospatial 
skills, decreased ability to use common objects/tools,  to decreased arousal/alertness.   Death 
occurs, 6-12 years after onset, usually due to complications of the immobility associated with 
the latter stages of the disease. 
20.2.3.2 Treatment of Alzheimer’s disease 
There are presently no good treatments for Alzheimer’s disease (AD).  The most commonly 
used treatment is to enhance the cholinergic system.  Another approach to the treatment of 
Alzheimer’s is to inhibit glutamate receptors. 
The cholinergic system is enhanced in Alzheimer’s disease by inhibiting 
acetylcholinesterase, the enzyme that breaks down acetylcholine.  Inhibition of 
acetylcholinesterase leads to increased concentrations of acetylcholine in the synapses in the 
brain.  However, improvements with anticholinesterases in Alzheimer’s disease are marginal.  
Overall the anticholinesterases cause a decrease in rate of decline in subjects with 
Alzheimer’s disease (Figure 43.4). 
 
Figure 20.4 Effect of anticholinesterase in AD (Copyright QUT, Sheila Doggrell) 
Most of the benefit of anticholinesterase in Alzheimer’s disease is seen in mild-to-moderate 
disease (i.e. the early stages of Alzheimer’s disease). 
To be useful in the treatment of Alzheimer’s disease, an anticholinesterase agent must cross 
the blood brain barrier and have a prominent effect in the central nervous system.  
Doneprezil is an anticholinesterase that acts predominantly in the central nervous system, but 
will also have effects in the peripheral nervous system.  The side effects of doneprezil are 
due to its widespread ability to increase the levels of acetylcholine in synapses, and they 
include nausea, diarrhea, vomiting and insomnia. 
The other approach to treating Alzheimer’s disease is to use glutamate NMDA receptor 
antagonists.  When glutaminergic neurones breakdown, glutamate is released, and the levels 
of glutamate are very high leading to excessive stimulation of glutamate receptors.  It has 
been shown that the excessive stimulation of the glutamate NMDA receptors may have a role 
in the pathology of Alzheimer’s disease.   
The drugs initially developed as NMDA receptor antagonists had too many adverse effects to 
be used in the clinic.  However, an old drug that had been used for others purpose, which is 
an antagonist at glutamate NMDA receptors is used.  The old drug is memantine.  
Memantine is a non-competitive and relatively weak antagonist at NMDA receptors.  It has 
194 
 
been shown to slow the decline in moderate-to-severe Alzheimer’s disease.  Thus, memantine 
is effective in a later stage of Alzheimer’s disease than doneprezil. 
 
20.2.4 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis is also known as motor neurone disease. 
20.2.4.1 Introduction 
Amyotrophic lateral sclerosis occurs in 5 out of 100,000 people, and occurs more common in 
men than women. About 10% of cases are familial (genetically linked), and 90% of cases are 
sporadic (unknown cause).  Motor neurone disease usually presents between the ages 50-70 
years. 
Amyotrophic lateral sclerosis or motor neurone disease is a disorder of the motor neurones of 
the ventral horn of the spinal cord and the cortical neurones that provide the afferent input to 
that area.  There is a selective loss of the spinal and brainstem motor neurones.   
The symptoms of motor neuron disease are muscle wasting, muscle fasciculation, spasticity 
or stiffness in arms and legs, and overactive tendon reflexes.  Motor neurone disease is 
progressive and fatal.  Death usually occurs after 2-3 years with respiratory compromise and 
pneumonia the most common reasons for death.  
20.2.4.2Treatment  
Riluzole prolongs survival in motor neurone disease by about 60 days, and is considered to 
be disease-modifying.  The mechanism of action of riluzole is unclear.  Riluzole probably 
reduces the neurotoxicity of glutamate by inhibiting the release of glutamate, and blocking 
some of the glutamate receptors.  Riluzole is generally well tolerated.  One precaution when 
using riluzole is to motor liver enzymes (e.g. aminotransferases) as, very occasionally, there 
is toxicity to the liver with riluzole. 
Baclofen, a GABAB receptor antagonist is used for the symptomatic relief of the spasticity 
associated with motor neurone disease. 
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20.3. Pain and opioid analgesics 
20.3.1 Introduction to pain and analgesia 
There are two main types of pain; nociceptive and neuropathic.  Nociceptive pain is due to 
the activation of pain fibres.  The pain fibres may be somatic with the pain coming from the 
skin and muscle or visceral with the pain coming from organs such as the liver. 
Neuropathic pain is due to nerve injury and the nerve injury can be due to disease or 
surgical section occurring in the pain pathway.  Peripheral neuropathic pain is associated 
with disease such as post-herpetic neuralgia (after shingles, herpes zoster can damage 
nerves), or diabetic neuropathy, where the high levels of sugars lead to damage to the nerves.  
Phantom limb pain, where a limb has been removed but the subject is still aware of pain from 
the limb is another example of peripheral neuropathic pain. Central neuropathic pain is 
associated with spinal cord injury, where the nerve is injured by trauma, and stroke, where 
the nerve is damaged as a result of the ischaemia (lack of oxygen/nutrients). 
Pain can be either acute or chronic.  Acute pain is usually rapid onset, short duration, and the 
cause is often known (e.g. disease, trauma).  Pain can also be chronic, which is defined as 
lasting for more than 3 months.  Chronic pain can be cancer or non-cancer pain. 
Opioids are not the only drugs used to relied pain (analgesia).  The analgesic used depends on 
the intensity of the pain (Figure 20.5). 
 
Figure 20.5 Treatment of pain (Copyright QUT, Sheila Doggrell) 
When the intensity of pain is low, the treatment is the non-opioid analgesics, predominantly 
the COX inhibitors such as aspirin, paracetamol, and naproxen.  When the pain is greater 
and cannot be managed with the non-opioids, the weak opioids are used e.g. codeine.  
Codeine is partly metabolised to morphine, and acts as a weak opioid.  The weak opioids are 
often used with the COX inhibitors.  If the pain intensity is such that it cannot be managed 
with the weak opioids, strong opioids such as morphine are used in the treatment.  Most pain 
can be managed be morphine, but if very intense pain cannot be managed with oral, or 
subcutaneous/ intramuscular/intravenous morphine, the morphine or other agents may be 
applied intraspinally.  In addition to morphine, the local anaesthetics are used intraspinally in 
intense pain.   
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20.3.2 Introduction to opioids 
Opium is the juice of the opium poppy.  Opiates (also known as opioids) are the drugs 
derived from opium, and these are morphine and codeine.   
The effects of taking opioids, and even that they were receptor-mediated, was known before 
the endogenous opioid system was discovered.  Thus, we knew that the opioids were 
effective at promoting pain relief, and that the effect was mediated by a receptor in the body 
for opioids, before we knew what the receptors were doing in the body.  
There are opioid receptors in the body to mediate the effects of the endogenous opioid 
peptides.  The endogenous opioids include enkephalins, endorphins, and dynorphins.  There 
are at least three types of opioid receptor for these endogenous opioids, and they are known 
as μ (mu), δ (delta), and κ (kappa) receptors. 
The analgesic effect of opioids is mediate by the μ receptor.  The μ receptors are found in the 
spine (spinal) and in the brain (supraspinal, above the brain).  
The opioids discussed in this chapter include morphine and fentanyl.  Both morphine and 
fentanyl are full agonists at μ receptors.  Codeine is a weak opioid.  Codeine itself is not an 
opioid, but 10% of it is metabolised to morphine, which is an opioid.  Buprenorphine is a 
partial agonist at μ receptor, which means it gives a lesser maximal response that morphine 
does at μ receptors.  Tramadol is a weak agonist at μ receptor.  Tramadol also inhibits the 
SERT (transport of 5-HT) and the NET (transport of noradrenaline) to increase the levels of 
5-HT and noradrenaline in the brain. 
20.3.3 Tolerance and physical dependence 
Tolerance and physical dependence develops to the opioids.  Tolerance is a decrease in 
effectiveness with repeated use of the same dose of a drug.  Tolerance occurs to most of the 
effects of the opioids.  Thus, it is necessary to increase dose to maintain the same effect.  The 
possible mechanisms for the development of tolerance include receptor internalization with 
chronic exposure to the opioids, so that they are no longer activated by the opioid.  An 
alternative mechanism for the tolerance is an altered responsiveness of the cell signaling with 
chronic exposure to the opioids to give a diminished response. 
Physical dependence is a set of changes in the body with chronic exposure leading to a 
withdrawal syndrome when the drug is stopped due to changed homeostasis.  Physical 
dependence can develop to opioids, for example, when morphine is in chronic use for the 
pain of cancer.  Physical dependence is not drug addiction or abuse.  Drug addiction is due to 
psychological dependence and pleasurable effects causing reinforcement of drug use.  
Subjects with pain do not usually have these and are not drug addicts.  Opioids can be 
discontinued in physically dependent patients (subjects who have had chronic pain) without 
subjecting them to withdrawal. Associated with decreasing the dose of opioid by 10 to 20% 
every other day, and eventually stopping the opioid, there is no withdrawal syndrome. 
20.3.4 Effects of opioids 
The reason why opioids are used extensive clinically is that they are potent analgesics. The 
opioids inhibit the ascending nociceptive information from the spinal cord, so that no pain is 
felt.  The opioids also activate descending pain control circuits to reduce pain. 
They reason why opioids are abused extensively is that they cause mood alteration.  
Opioids, especially heroin, cause a feeling of euphoria and tranquillity. 
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The diagnosis of opioid abuse is helped by the fact that they cause miosis.  Miosis with the 
opioids is due to constriction of the pupil by an excitatory action on the parasympathetic 
nerve innervating the pupil that leads to pinpoint pupils.  This is termed pathognomonic, 
which means it is a unique pathological characteristic of opioid use.  Some tolerance to the 
pinpoint pupils does develop, but this is not as great as other tolerances to opioids, and opioid 
abusers continue to have constricted pupils. 
Opioids in high doses can cause nausea and vomiting.  This nausea and vomiting is caused 
by direct stimulation of the chemoreceptor trigger zone, which is the centre in the brain that 
controls nausea and vomiting. 
Opioids in high doses have effects on respiration.  The opioids depress respiration by a 
direct effect on the brainstem respiratory centres.  Respiratory depression is the main cause of 
death with the opioids.  For instance, subjects that abuse the opioids become tolerant, and use 
high doses.  When the supply of heroin dries up, this tolerance reverses.  If the addict then 
takes the high dose of heroin that they were using previously, there will be excessive 
respiratory depression and, possibly, death. 
Opioids depress cough.  Opioids have a direct effect on the cough centre in the medulla, 
which leads to a depression of cough. 
Opioids also have effects where they cause peripheral vasodilation and inhibition of the 
baroreceptor reflex.  These effects lead to a decrease in blood pressure. 
Opioids have effects on the gastrointestinal tract.  They inhibit secretions, and they also 
decrease transit time, which leads to constipation.  This is a major problem with both the 
clinical use and abuse of opioids.  Tolerance does not develop to this effect of the opioids. 
Opioids also have effects on the urinary bladder.  They inhibit the urinary voiding reflex, 
which leads to urinary retention. 
 20.3.5 Agonists at opioid µ receptors 
This section considers the individual drugs that act as agonists at the opioid µ receptors.  One 
of the main agents used clinically is morphine. 
20.3.5.1 Morphine 
Morphine is readily absorbed from the gastrointestinal tract, the rectal mucosa, the skin, and 
muscle.  Morphine is available in oral, suppository preparations (rectal), subcutaneous, and 
intramuscular preparations.  It is used intravenously for fast action.  Morphine can be 
introduced into the epidural or intrathecal space, from which it penetrates into spinal cord.  
As the spinal cord is the site of action of morphine, achieving high concentrations in the 
spinal cords achieves high levels of pain relief. 
Morphine undergoes considerable first pass metabolism, such that bioavailability is only 
about 25% after oral administration.  Thus, high doses of morphine have to be give orally, to 
achieve reasonably plasma levels.  A broad range of steady-state plasma concentrations of 
morphine (16 to 364 ng/ml) is associated with analgesia.  
As morphine is metabolised by the liver, in hepatic dysfunction, it may be necessary to 
decrease the dose of morphine, as bioavailability may be increased. Morphine is metabolised 
to morphine-6-glucuronide and morphine-3-glucuronide.  Morphine-6-glucuronide is an 
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active metabolite.  Morphine-6-glucuronide is actually more potent than morphine as an 
agonist at µ-receptors, and therefore, in causing pain relief. The half-life of morphine is 2 
hours, whereas morphine-6-glucuronide has a longer half life, thus, the pain relieving effect 
of morphine is prolonged, and the prolongation is due to the morphine-6-glucuronide. 
Morphine-6-glucuronide is excreted by the kidney.  In kidney disease, it may be necessary to 
decrease the dose of morphine, as there may be accumulation of the morphine-6-glucuronide.  
Accumulation of morphine-6-glucorinide may lead to excessive respiratory depression. 
Because of the respiratory depression, morphine should be used with caution in people with 
compromised respiratory function.  For instance, morphine should be used with caution in 
subjects with emphysema. 
Most of the unwanted effects of morphine are part of, or extensions of, stimulating the µ-
receptors, and include excessive respiratory depression, nausea and vomiting, and 
constipation.  Morphine also causes hypotension, due to its ability to cause peripheral 
vasodilation and inhibiting the baroreceptor reflex.  Also, morphine can cause urinary 
retention.  
In high doses, the euphoria with morphine goes, and is replaced by dizziness, mental 
clouding, and dysphoria.  Dysphoria is a feeling of anxiety, depression, and unease.   
Morphine can also cause pruritis (itchy skin).  
20.3.5.2 Codeine 
Codeine itself has low affinity for opioid receptors.  However, 10% of codeine is 
metabolised by the liver enzyme CYP2D6 to morphine, and morphine is responsible for the 
analgesic effect with morphine. 
Polymorphisms in CYP2D6 lead to an inability to make morphine from codeine, and these 
polymorphisms affect 10% of Caucasians.  This 10% of Caucasians have an inadequate 
analgesia response to codeine. 
Codeine is considered to be a weak opioid, and is used on the second step in the treatment of 
pain (Figure 20.6).  It is used in mild-to-moderate pain.  Codeine is sometimes used in 
combination with the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) e.g. paracetamol. 
Another use of codeine is as an anti-tussive (in cough).  The mechanism underlying this 
beneficial effect of codeine in cough is unknown but is unlikely to involve μ-receptors, as it 
is not a property observed with the other μ-receptor agonists.  
20.3.5.3 Fentanyl 
Fentanyl is the opioid commonly preferred by anaesthesiologists as an adjunct to general 
anaesthesia.  It is preferred because it is easy to manage.  It has a short time to peak 
analgesic effect (about 5 minutes) and rapid termination of effect after intravenous bolus 
doses are stopped.   
Decreases in blood pressure can be a problem with the opioids.  Fentanyl is preferred by 
anaesthesiologists as it has relative cardiovascular stability i.e. does not have major effects 
on blood pressure. 
Fentanyl is administered epidurally and intrathecally for acute postoperative and chronic pain 
management. 
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Fentanyl is highly lipid soluble and rapidly cross blood brain barrier.  Fentanyl, like all highly 
lipid soluble drugs, is initially distributed to the highly perfused tissues.  Then, it is 
redistributed from highly perfused tissues to those with lower perfusion (muscle and fat). 
Fentanyl undergoes hepatic metabolism and kidney excretion.  There are no active (toxic) 
metabolites of fentanyl, and consequently, it can be used in renal impairment, whereas other 
opioids (e.g. morphine) are difficult to use in renal impairment. 
20.3.3.5 Buprenorphine 
Morphine stimulates opioid -receptors to induce analgesia.  Another effect mediated by 
opioid -receptors is respiratory depression.  Respiratory depression is a common side effect 
associated with full agonists at opioid -receptors (e.g. morphine) 
Buprenorphine is a partial agonist at opioid -receptors.  Buprenorphine causes analgesia 
but is unlikely to cause excessive respiratory depression.  
Buprenorphine is relatively well absorbed from most routes.  It can be used sublingually for 
rapid relief of pain in post-operative patients.  Buprenorphine is a slowly dissociating 
agonist, which means it sticks to the receptors.  When the buprenorphine is associated with 
the receptors, it is not in the plasma.  Thus, the plasma levels of buprenorphine can be very 
low but buprenorphine is still having an effect, as it is bound to receptors. 
Buprenorphine is used as an analgesic.  Buprenorphine is also used in opioid addiction, where 
it can be used to stabilise the addict prior to a gradual reduction of dose. 
20.3.3.6 Tramadol 
Tramadol is a weak agonist at μ-receptors.  Tramadol also inhibits the serotonin transporter 
(SERT) and noradrenaline transporter (NET) to increase the levels of 5-HT and 
noradrenaline, respectively, in the brain.  It has been postulated that this 5-HT and 
noradrenaline may contribute to analgesic effect of tramadol. 
The demethylated metabolite of tramadol is more potent than tramadol at stimulating μ-
receptors.  Thus, the metabolite will contribute to the analgesic effect of tramadol. 
Tramadol is used orally (where it has a 68% bioavailability) or intramuscularly (100% 
bioavailability).  It is used in the treatment of mild-to-moderate pain, which is step 2 of 
Figure 20.1.  Tramadol is not as effective as morphine for the treatment of severe pain (step 
3).  
20.4 Toxicity to opioids 
A number of causes can underlie the toxicity to opioid.  The causes include accidental 
clinical overdosage, accidental overdosage in addicts, and suicide attempts. 
Opioid poisoning is easily recognise by the triad (combination) of coma, pinpoint pupils, 
and depressed respiration.  Treatment of poisoning is always treating the subject first, and 
then treating the poison.  Thus, the initial treatment is artificial ventilation to overcome the 
depressed respiration. 
Then the poison opioid is treated with naloxone, a non-selective opioid antagonist.  In 
subjects who are physically dependent, naloxone can precipitate the opioid withdrawal 
syndrome.  To prevent, this there is the slow administration of low dose of naloxone, with 
constant monitoring of respiration. 
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 21.1 Epidemiology of cigarette smoking 
Cigarette smoking greatly increases the risk of cardiovascular disease.  There is an 
increased risk of heart attacks, strokes, coronary artery disease, peripheral arterial disease, 
impotence, hypertension, and heart failure.  Typically, men who smoke have a 3.5 times and 
women 4.8 times higher risk than never smokers of having a coronary event.  People who 
smoke cigarettes have a three-fold increase in risk of stroke. 
 
Cigarette smoking greatly increases the risk of cancer.  Cancers that cigarette smoking 
increases the risk include cancer of the lung, mouth, larynx, esophagus, bladder, pancreas, 
colon and cervix.  Lung cancer was almost unknown before the introduction of cigarettes.  
 
In addition to cancer, cigarette smoking causes other respiratory disorders such as COPD 
(chronic obstructive pulmonary disease), which is a combination of emphysema and 
bronchitis.  Eighty percent of cases of COPD are due to smoking cigarettes.  Cigarette 
smoking is also a cause of end-stage renal failure.  Smoking during pregnancy leads to an 
increased risk of miscarriage, and premature labor, and the infant’s risk of cot death. 
 
One of the reasons that people are encourage to give up, is that some of the effects of 
cigarette smoking are reversible.  Thus, it is never too late to quit, as 4-6 years after 
quitting, the risk of strokes, heart attacks etc are the same as for non-smokers.  Even 
those smokers who wait until they have a heart attack to quit live longer.  However, some 
effects are not reversible e.g. the lung damage associated with COPD. 
 
Smoking cigarettes is most common cause of preventable death and disease.  The World 
Health Organization estimates that 100 million people will die from tobacco-related diseases 
over the next 30 years, and this is more than from AIDS, tuberculosis, car accidents, 
homicide and suicide combined.   
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In Australia, about half of the Aborigines smoke cigarettes and a third of all Aboriginal 
deaths are due to smoking related disease.  Smoking rates are lower for non-Aborigines in 
Australia, with about one in five smoking cigarettes.  Analysis of who is most likely to smoke 
has shown it is those with no qualifications, unemployed, or earning less than $30,000/year.  
Thus, smoking cigarettes is no longer considered glamorous.  It is not only the tobacco 
(nicotine) in cigarettes that is poisonous, as the tar and carbon monoxide produced by burning 
cigarettes is also toxic.  There is some controversy over the fact that sweeteners are added to 
cigarettes, presumably to make them more palatable, and attract younger people to smoking.   
 
 21.2 Nicotine, addiction and pharmacokinetics 
As discussed previously acetylcholine is widespread neurotransmitter in the autonomic 
nervous system and central nervous systems.  The subtypes of receptors for acetylcholine 
were initially distinguished by using nicotine and muscarinic, which stimulated different 
acetylcholine receptors with those being stimulated by nicotine becoming nicotinic receptors.  
In the periphery, the predominant effect of nicotine is to mimic the sympathetic nervous 
system.  Nicotine does this by stimulating nicotinic acetylcholine receptors on ganglionic 
cells, and hence the release of noradrenaline, and also by stimulating the adrenal medulla to 
secrete adrenaline.  The noradrenaline and adrenaline then cause an increase in heart rate, 
vasoconstriction, and a resulting increase in blood pressure.  
 
In the central nervous system, nicotine stimulates NN-receptors to increase the release of 
dopamine, which is pleasurable.  Nicotine also stimulates memory and alertness.  Nicotine 
also enhances cognitive skills requiring speed, reaction time, vigilance and work 
performance.  In high doses, nicotine causes tremors.  Initially when people try smoking, they 
feel sick, but unfortunately tolerance develops to this effect.  Nicotine causes reinforcement, 
which means the users find it pleasurable, making them wish to take again. 
 
The nicotine in cigarette smoking leads to nicotine addiction.  Probably, the best known 
characteristics of addiction are physical dependence and withdrawal, but they are not the 
main factor underlying addiction, which is psychological dependence.   
 
Physical dependence is a state that develops as a result of adaptation produced by a resetting 
of homeostatic mechanisms in response to repeated drug use.  With nicotine this will be the 
repeated stimulation of the sympathetic and central nicotinic receptors.  Withdrawal is the 
appearance of withdrawal syndrome when the repeated use of a drug is stopped.  The 
withdrawal syndrome with nicotine consists of irritability, impatience, hostility, anxiety, 
depression, difficulty in concentration, restlessness, decreased heart rate, increased appetite, 
and weight gain.  We can treat the physical dependence and withdraw but it is much harder to 
treat the psychological dependence.   
 
Psychological dependence is the main reason why people take drugs.  People smoke 
cigarettes because they find it pleasurable.  Being pleasurable makes the user wish to take the 
drug/nicotine again, and this is known as reinforcement.  The greater the reinforcement, the 
greater the abuse is.   
 
Nicotine is very addictive, the risk of addiction is measured as the number addicted to the 
number of ever use, and tobacco is the highest risk with one in three people who try it 
becoming addicted.  The risk of addiction is higher with nicotine than with heroin, where one 
in four people who try it become addicted.    
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The term substance abuse or addiction is used to cover physical dependence and withdrawal, 
psychological dependence and reinforcement.  Off these, it is the psychological dependence 
which is the most difficult to overcome, as we have drugs to lessen the withdrawal associated 
with the physical dependence. 
 
The pharmacokinetics of nicotine when it is smoked, and when it is used as nicotine 
replacement therapy, are different.  When it is smoked, nicotine is readily absorbed from 
respiratory tract and buccal membranes, and readily crosses the blood brain barrier.  Thus, 
after inhaling nicotine, there can be a central effect in as little as 7 seconds.  The half-life of 
inhaled nicotine is 2 hours.  Nicotine is metabolized mainly in the liver, and nicotine and its 
metabolites are eliminated from kidney.  Nicotine is excreted in the milk of lactating women 
smokers, making their newborns smokers too. 
 
 21.2 Nicotine replacement therapy 
When nicotine replacement therapy is used the pharmacokinetics are different than from 
inhaled nicotine (Figure 21.1).  With smoking a cigarette, the concentrations of nicotine 
become high, and this gives the high associated with smoking cigarettes.  The most common 
form of nicotine replacement therapy is transdermal patches.  Nicotine is readily absorbed 
from the patches, but there is no immediate or great high. 
 
Figure 21.1 Pharmacokinetics of nicotine (Copyright Sheila Doggrell, QUT) 
 
When using replacement therapy to wean a person off of a drug and lessen the effects of 
withdrawal, the principle is always the same, and that is to stabilize on a fixed dose that is 
close to their abuse level, and then gradually reduce the dose.  With nicotine replacement 
therapy, smokers are usually stabilized on 30 cm2/15mg/day for 3 months, and then the dose 
is successively reduced.  Initially, the reduction is to 20cm2/10mg for 2-3 wk, and then the 
transdermal nicotine replacement is reduced to 10cm2/5mg for next 2-3 weeks.  Reducing the 
dose gradually reduces the severity of withdrawal from nicotine.  Unfortunately, contrary to 
instructions - 3 out of 10 continue to smoke when using patches, presumably because they 
miss the high they get from inhaling nicotine. 
 
The pharmaceutical companies promote nicotine replacement therapy as either increasing 
the quitters by 100% or doubling the number of quitters.  What does this mean? Short term 
the quit rates are higher than long term, and it is long term quitting that we need.  Clinical 
trials have shown that at one year, 5% of smokers given placebo patches have quit, and 10-
15% of smokers given nicotine patches have quit.  This means that with the use of nicotine 
replacement therapy, an extra 1 or 2 in 20 gives up smoking, whereas 17 in 20 continue to 
smoke.  Thus, nicotine replacement therapy is not very effective. 
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The latest version of nicotine replacement therapy is pre-quit nicotine patches.  This allows 
subjects to use nicotine replacement patches prior to quitting (i.e. while they are still smoking 
cigarettes).  One of the ideas behind this is that it may reduce smoking reinforcement.  When 
the subject is ready they move on to the standard nicotine replacement regimen.  This 
approach is quite new, and there is no data for 12 months, but it has been shown that with 
pre-quit, the quit rates at 6 months are doubled! Thus, the quit rates are 11% with placebo, 
and 22% with the pre-quit approach.  
 
 21.3 Varenicline 
A new drug that may be useful is varenicline (Champix).  Varenicline is a partial agonist at 
a subtype of nicotinic receptors, nicotinic α4β2 receptors.  As a partial agonist, varenicline 
exerts a lower maximum response that the endogenous ligand acetylcholine or nicotine 
(Figure 21.2).  By mimicking the effect of nicotine, varenicline is able to promote the release 
of dopamine, and prevent the cravings observed with withdrawal from smoking cigarettes.  
Partial agonists with high affinity are capable of removing agonists with less affinity from a 
receptor.  Varenicline has a higher for the nicotinic α4β2 receptors than nicotine, so will 
displace nicotine from the receptor.  This is believed to block the effect of nicotine (from 
cigarettes) to cause re-inforcement. 
 
Figure 21.2 Partial agonist varenicline (Copyright Sheila Doggrell, QUT) 
 
Varenicline is more effective than nicotine replacement therapy, giving quit rates of about 
20% at one year.   
 
Unfortunately, when varenicline was made available to large numbers of people, it was 
shown to worsen neuropsychiatric illness in some, and it is now contraindicated in subjects 
with neuropsychiatric illness.  Varenicline also comes with a warning to monitor subjects 
taking varenicline to make sure that a neuropsychiatric illness does not develop. 
 
 21.4 Bupropion 
Another agent that has been available for some time for smoking cessation is bupropion 
(Zybab).   Bupropion was developed as an anti-depressant, but was not very effective in 
depression.  Bupropion releases dopamine in the brain, and also inhibits NN receptors in 
brain, and these properties suggested that it may be useful in smoking cessation.   
 
After oral administration, the smoking cessation at one year was 11% in the placebo group 
and 22% in the bupropion group.  Bupropion may reduce the weight gain normally observed 
with smoking cessation.  Bupropion has been controversial and is now contraindicated in 
patients with epilepsy, or in those with a predisposition to seizures e.g. alcohol abusers. 
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In conclusion, we are still looking for an effective and save drug to promote smoking 
cessation. 
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22.1 The Control of Excitation and Inhibition 
The glutamate and GABA systems control the intricate balance between excitation and 
inhibition in the central nervous system. Alterations to this homeostasis can have detrimental 
effects. Too much excitation leads to anxiety, insomnia, restlessness, exaggerated responses, 
convulsions and death. Too much inhibition, on the other hand, gives way to sedation, 
depression, ataxia, anaesthesia, coma and death. Glutamate and GABA are amino acid 
transmitters, their chemical structures differing by one carboxylic acid group.  GABA is 
synthesized from glutamate via decarboxylation.  
 
Glutamate and GABA act at a variety of receptor subtypes, however only the receptors 
relevant to the action of alcohol will be discussed here. These include the GABAA and 
glutamate N-methyl-D-aspartate (NMDA) receptors. 
 
When GABA or its structural analogues bind to the GABAA receptors, the ligand gated 
chloride ion channel changes conformation, allowing increased conductance of chloride ions. 
The equilibrium potential for chloride is close to resting membrane potential, therefore 
increased chloride conductance stabilises the membrane, thereby reducing membrane 
excitability. 
 
The glutamate NMDA receptors are similarly significant for their unique properties, they are 
voltage-dependent ligand-gated ion channels, require binding of the co-agonist glycine for 
activation, are highly permeable to calcium ions, and play an important role in synaptic 
plasticity.  
 
22.2 Alcohol and its Behavioural Effects 
The key ingredient of “alcohol” in alcoholic drinks is ethanol. Ethanol is one of the few legal 
psychoactive drugs. 
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Behavioural effects of ethanol include myorelaxation, anxiolysis, sedation, impaired 
cognitive function, and an anticonvulsant effect. At higher doses it can cause motor 
incoordination, ataxia, amnesia, hypnosis and anaesthesia, and eventually respiratory 
depression and coma. 
 
22.3 Mechanism of Alcohol Action 
Ethanol influences many sites in the central nervous system, including 5-HT and glycine 
receptors, and G protein-coupled inwardly rectifying K+ (GIRK) channels. However it 
appears its major sites of action at low to moderate doses are GABAA receptors, and NMDA 
receptors at higher doses. At GABAA receptors it enhanceS GABA activation, by increasing 
the mean ion channel open time and facilitating GABA binding. At NMDA receptors it 
appears to act as a non-competitive inhibitor. Thus ethanol can reduce excitation and 
increase inhibition in the brain, leading to over-inhibition. 
 
Although GABAA receptors are ubiquitously (widely) distributed throughout the CNS, the 
location of GABAA receptors modulated by ethanol is significant. Receptors in the 
cerebellum likely contribute to the impaired motor coordination and ataxia induced by 
ethanol. Receptors in specific thalamic nuclei may mediate some sedative, hypnotic and 
anaesthetic effects, while those in the hippocampus, amygdala and neocortical regions 
contribute to the cognitive impairment, anxiolysis and amnesia. 
 
22.4 General Considerations with the use of Alcohol. 
As with many drugs acting on GABA receptors, sex differences occur with ethanol. Men are 
less sensitive to the intoxicating effects of ethanol than women, and driving regulations and 
drinking guidelines reflect this notable sex difference. For example, men are advised to drink 
no more than two standard drinks in the first hour to avoid going over the legal blood alcohol 
concentration (BAC) limit of 0.05%, while women are advised that more than one standard 
drink per hour will tip them over the limit. Studies have suggested that the sex differences 
may partly be due to the difference in ethanol’s ability to induce neurosteroid synthesis in the 
CNS. 
 
Another important consideration with the use of alcohol is drug-drug interactions. Given 
the numerous sedative, anxiolytic and hypnotic substances acting on GABAA receptors, 
combinations of these drugs with ethanol are dangerous, and have been exploited to induce 
amnesia and sedation in some social settings.  
 
Finally, complications arising from the metabolism of ethanol must be considered in some 
populations. Ethanol is oxidised in the first instance via alcohol dehydrogenase (and at high 
doses, CYP2E1) to acetaldehyde, a highly toxic and unstable compound. Regular heavy 
consumption of ethanol during pregnancy has been shown to lead to birth defects, and one 
mechanism thought to be involved is via the toxic action of acetaldehyde on the developing 
embryo and foetus.  
 
Acetaldehyde is further synthesized via mitochondrial acetaldehyde dehydrogenase to acetic 
acid. Individuals lacking the mitochondrial form of acetaldehyde dehydrogenase, relatively 
common in some Asian populations, may experience increased intoxication. Moreover, acetic 
acid is metabolized to acetyl CoA then to fatty acids in the liver. Prolonged overconsumption 
of alcohol may increase fatty acid synthesis in the liver, leading to steatosis. 
 
22.5 Long-term Adaptive Changes with the use of Alcohol 
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Prolonged use of ethanol alters the balance of neuronal excitation and inhibition, and appears 
to cause adaptive changes in nervous system function. Chronic intermittent or heavy 
prolonged usage can lead to adaptive changes in the brain, including changes in GABAA 
receptor expression and subunit reshuffling. Such changes in expression and subunit 
reshuffling substantially alter the pharmacological properties of GABAA receptors, with 
important functional consequences. 
 
Long-term use of ethanol may lead to tolerance, such that higher doses are required to 
produce the same effect, and dependence, manifesting as cravings for the substance, and a 
physical withdrawal syndrome. The dose required and period of usage to elicit dependence, 
however, may vary between individuals. The rewarding effects of ethanol may arise from its 
action at GABAA receptors in the ventral tegmental area and nucleus accumbens of the 
dopamine mesolimbic “reward/motivational salience” pathway. Mood state also impacts 
upon dependence, and alcohol use disorders are more common in sufferers of anxiety and 
depression. There is also evidence of genetic susceptibility to alcohol dependence, and 
several candidate genes have been identified including genes encoding GABA receptors.  
 
The alcohol withdrawal syndrome manifests as insomnia and sleep disturbances, anxiety, 
hyperexcitability, delirium tremens, hyperalgesia, and lowered seizure threshold (increased 
risk of seizures), and can be treated with benzodiazepines. 
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23.1 Introduction: Principles of biologics and their use as medicines.  
Between 2008 and 2010, 8 of the most costly 20 medications were biologics.  Biologics are 
medications that are produced by means of biological processes involving recombinant DNA 
(rDNA) technology.  rDNA is a form of artificial DNA that is created by combining two or 
more sequences that would not normally occur together through the process of DNA 
replication.  This is a very active area in medicine production. 
The decoding of the human genome revealed that there are 30,000 different genes encoding 
possibly 50,000 different proteins as a result of alternative gene splicing and posttranslational 
modification and that disease may result when one of these proteins is defective or present in 
abnormally high or low concentration. This ability to identify many of the causes of disease 
has presented a number of targets for possible therapies. Further, recombinant DNA 
technology has allowed a new generation of protein-based medicines, termed biologics, to be 
developed to take advantage of these new targets. Protein-based therapies have a number of 
advantages over conventional small-molecule drugs. Biologics often serve a highly specific 
and complex set of functions that cannot be mimicked by simple chemical compounds and 
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there is less potential for protein-based drugs to interfere with normal biological processes 
and cause side effects. Further, since the body naturally produces many of the proteins that 
are used as therapies, biologics are often well tolerated and are less likely to elicit immune 
responses.  
Protein-based therapies come in three classes. Firstly, proteins, purified native or recombinant 
themselves are administered to remedy lesions resulting in disease; secondly, antibodies 
directed against important biochemical pathways have been developed and; thirdly new 
vaccines produced from molecules important in the disease process. 
23.2 Protein biologics used as drugs  
The use of biologics as therapies can be categorised in three ways: A protein that replaces one 
that is deficient or abnormal, a protein that augments an existing biological process or a 
protein that provides a novel function or activity.  
23.2.1 Proteins that function through enzymatic or regulatory activity.  
It is apparent that many pathophysiological states occur when a component, usually a protein 
or a metabolite occurring from the action of that protein, of a normal biological process is 
compromised in some way. Disease may occur when one of these proteins is defective or 
present in abnormally high or low concentrations. Thus supplementation with firstly proteins 
purified from animal sources and, now, with recombinant human protein homologues allows 
for new therapeutic targets in the treatment of these diseases.  
Treatment of type I diabetes mellitus with exogenous insulin is perhaps the best and most 
illustrative example of how a protein has come to be used therapeutically. Diabetes mellitus 
results from an inability to sequester glucose from the blood. Diabetes mellitus occurs when 
circulating insulin levels decline or when the target cells become resistant to the hormone. As 
well as carbohydrates, insulin has a profound effect on the metabolism and utilisation of 
lipids and fats. Insulin was first isolated from porcine and bovine pancreas in 1922 and was 
used therapeutically almost immediately as a lifesaving daily injection. However two 
problems associated with their use became quickly apparent; firstly an immune reaction to 
the animal proteins and secondly, purifying it from animal sources is expensive and time 
consuming. For example, in 1923, Harold Ward Dudley published a purification scheme 
where he was able to purify 74g of insulin from 104kg of pancreas tissue using a procedure 
that took about 3 days.  
Once the human gene for insulin was isolated, it became a prime target for recombinant 
DNA technology. This has resulted in the production of large amounts of human insulin that 
is inexpensive, of low immunogenicity and free from other animal pancreatic substances. 
Indeed recombinant human insulin was approved in the United States in 1982 and was the 
first commercially available recombinant protein drug. More recently, “genetic tinkering” has 
allowed the production of new insulin types with altered properties such as quicker onset and 
longer duration of action. The use of recombinant insulin in the treatment of type I diabetes is 
discussed in Chapter 15. 
However, great success has also been achieved using purified protein preparations from 
animal and microbial sources. For example in cystic fibrosis, defects in the chloride channel 
can result in abnormally thick secretions that can block pancreatic enzymes from travelling 
down the pancreatic duct to the duodenum preventing food being properly digested resulting 
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in patient malnutrition. Patients can be treated with a combination of porcine pancreatic 
enzymes (Pancrease) purified from pigs to aid digestion.  
Similarly, lactose intolerance is the condition in which lactase, an enzyme needed for proper 
metabolism of lactose (a constituent of milk and other dairy products), is not produced in 
adulthood. The management of lactose intolerance includes preparing foods (Digestelact) in 
which the lactose content is decreased by treating with lactase from the food yeast 
Saccharomyces Sp. 
23.2.1.1 Biologics as replacement of a deficient or abnormal protein.  
Insulin has been previously indicated as the prototypical biologic medicine. Treatment by 
addition of exogenous insulin is the preferred treatment for type I diabetes and is used 
extensively in type II diabetes. However, other conditions characterised by deficiencies are 
treated in a similar manner.  
Deficiencies in various coagulation factors typify a number of inherited bleeding disorders.  
Clotting factor VIII deficiency manifests itself in haemophilia A whilst lack of factor IX 
results in haemophilia B. Treatment for both of these conditions is by supplementation of the 
missing proteins using either purified blood products or, more commonly, human 
recombinant proteins. The development and use of recombinant clotting factors in 
conjunction with better screening methods has drastically reduced the incidence of infection 
of haemophiliacs with HIV.  
Growth failure caused by growth hormone (somatotropin) deficiency or as symptoms from 
pathological states such as Prader-Willi disease or Turners syndrome can be treated by 
exogenous administration of recombinant human growth hormone produced either in E. 
coli (Genotropin) or from genetically engineered mammalian cells (Saizen).  
Gaucher’s disease is a lysosomal storage disease caused by a deficiency in the enzyme β-
glucocerebrosidase which hydrolyses glucocerebroside to glucose and ceramide. Deficiency 
in this enzyme results in an accumulation of the substrate in a variety of tissues including 
spleen, liver, kidneys, lungs, brain and bone marrow. Types I and III, the adult forms of the 
disease can be treated by replacement treatment with recombinant β-glucocerebrosidase 
(Imiglucerase), which, when given intravenously every two weeks, can dramatically 
decrease liver and spleen size, reduce skeletal abnormalities, and reverse other 
manifestations.  
23.2.1.2 Proteins that augment an existing biological process.  
Infertility is an example of a biological process that can treated by augmentation with key 
regulatory molecules. Recombinant human chorionic gonadotrophin hormone (Ovidrel) is 
produced from genetically modified Chinese hamster ovary cells and used in women 
undergoing superovulation prior to assisted reproductive techniques such as in vitro 
fertilisation (IVF). Ovidrel is administered to trigger final follicular maturation and 
luteinisation after stimulation of follicular growth. In addition, Ovidrel is administered to 
trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation 
of follicular growth.  
Human recombinant CSF (Leukine) stimulates proliferation and differentiation of 
neutrophils, eosinophils & monocytes in patients with leukopaenia and HIV.  
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Furthermore, it should also be noted that a family of human recombinant interferons have 
been produced for use in a number of conditions such as hepatitis C (Infergen), hepatitis B 
(Intron A) and multiple sclerosis (Betaferon) where they have an undefined but probable 
immunomodulatory effect.  
Lastly the active fragment (1-34) of recombinant human parathyroid hormone 
(Teriparatide) is used to treat osteoporosis by activating osteoblasts and stimulating the 
formation of new bone. 
23.2.1.3 Proteins that provide a novel function or activity.  
 
Erythropoietin (EPO) is probably best known for its use as a performance-enhancing drug 
used by cyclists to increase their red blood cells.  With increased red blood cells, which carry 
oxygen, the cyclist has increased stamina in endurance events. 
 
Physiologically, EPO is an endogenous glycoprotein produced by the kidney, and has a major 
role in promoting red blood cell survival and producing the precursors of red blood cells.  
Erythropoietin is an endogenous glycoprotein that stimulates red blood cell production. 
Recombinant DNA technology has allowed for the production of human erythropoietin 
homologues that vary in their carbohydrate groups but that are indistinguishable from human 
erythropoietin in biological activity and immunological reactivity. These include epoetin alfa 
(Procrit) and darbepoetin alfa (Aranesp) that are purified from Chinese hamster ovary cells 
into which the gene coding for human erythropoietin has been inserted. These drugs are 
indicated for the treatment of anaemia associated with chronic renal failure (CRF) and for 
other condition where there is a reduced number of red blood cells e.g. as a result of the 
treatment of cancer. 
 
Similarly, tenecteplase (Metalyse) is a tissue plasminogen activator (tPA) produced by 
recombinant DNA technology that binds to the fibrin component of the thrombus (blood clot) 
and converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of 
the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to 
inactivation by its endogenous inhibitor compared to native tPA. Metalyse is indicated for 
the thrombolytic treatment of the acute phase of myocardial infarction. 
 
23.2.1.3 Proteins that provide a novel function or activity.  
Introduction of a foreign substance (an antigen) into a vertebrate such as a mouse or a human 
has a profound effect on the body’s defence mechanism, the immune system. One response to 
such an exposure is that some of the immune system's B-cells will turn into plasma cells and 
start to produce antibodies (immunoglobulins) that bind to that antigen. Indeed the word 
antigen is derived from the term antibody generator. Although each activated B-cell is only 
capable of producing one kind of antibody, antigen exposure results in the activation of 
different B-cells that each produce structurally different antibodies that bind to different parts 
(epitopes) of the antigen. This natural mixture of antibodies is known as polyclonal 
antibodies. These circulating antibodies protect their host by binding to and neutralising 
foreign proteins (e.g. toxins) resulting in negation of their deleterious effects. 
23.2.2. Proteins that function through specific targeting activity.  
Although the use of antibodies as therapies for a variety of pathologies has been postulated 
for over one hundred years, a number problems associated with their use were observed. In 
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particular, variability caused by their polyclonal nature and adverse immunological side 
effects had blunted their effectiveness as therapeutic agents. However, the development of 
monoclonal antibodies, in which a myeloma cell line that has lost its ability to secrete 
antibodies is fused with healthy antibody secreting B-cells, coupled with the ability to modify 
their immunogenicity by protein engineering or “humanising” them has revolutionised their 
use. The resultant immortalised fused cells (hybridomas) are able to continuously secrete 
industrial quantities of highly specific, single epitope antibodies for use in a number of 
diseases particularly cancer and autoimmune diseases. In 1986, Muromonab-CD3, used to 
combat tissue rejection in renal transplantation was the first monoclonal antibody approved 
by the FDA. To date, some 150 monoclonal antibodies are used to treat disease.  
23.2.2.1. Monoclonal antibody nomenclature.  
The suffix ending on the name of a monoclonal antibody gives an indication into the nature 
of the molecule. Original monoclonal antibodies were derived from mouse tissues and have 
an -omab suffix (for example Ibrutumomab tiuexetan) whereas chimeric monoclonal 
antibodies, which have an -ximab suffix (infliximab) are derived from mouse antibodies with 
human sequences inserted to reduce immunogenicity. Humanised monoclonal antibodies, in 
which human antibodies have mouse domains grafted onto them, have a –zumab suffix 
(trastuzumab) whilst unmodified human monoclonal antibodies have an –umab ending 
(adalimumab). 
23.2.2.2. Naked monoclonal antibodies.  
Naked monoclonal antibodies are those that have no cytotoxic chemicals or radionuclides 
attached to them. They work by either specifically marking the target cell for the immune 
system to destroy it or attach to cell surface receptors blocking binding of various molecules 
known to enhance cell growth or proliferation.  This group encompasses the vast majority of 
therapeutic antibodies. Naked monoclonal antibodies have been shown to be particularly 
effective in the treatment of cancer, autoimmune disease and cardiac disease. An extensive 
analysis of current use of these antibodies is outwith the remit of this chapter, however, some 
of the more common treatments are as follows.  
Infliximab (Remicade) is a chimeric human-murine monoclonal antibody that binds to 
human tumour necrosis factor alpha (TNFα). TNFα is a pro-inflammatory and 
immunoregulatory cytokine that, when overexpressed, mediates chronic inflammation in 
diseases such as Crohn’s disease and rheumatoid arthritis. Infliximab neutralises the 
biological activity of TNFα by binding with high affinity to the soluble and transmembrane 
forms of TNFα and inhibits binding of TNFα with its receptors.  
Alemtuzumab (MABCampath) is a genetically engineered humanised monoclonal antibody 
specific for a lymphocyte cell surface glycoprotein, (CD52) antigen. Alemtuzumab causes 
the lysis of lymphocytes by binding to CD52 antigen, which is expressed on the surface of all 
B and T lymphocytes (benign and cancerous). As such, alemtuzumab is indicated for the 
treatment of patients with relapsed B-cell chronic lymphocytic leukaemia (CLL). 
Abciximab (ReoPro) is an antibody that binds to the intact platelet GPIIb/IIIa receptor, 
which is the major platelet surface receptor involved in platelet aggregation. Abciximab 
inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor 
and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. Abciximab is 
indicated for percutaneous coronary intervention, the prevention of ischaemic cardiac 
complications in patients undergoing percutaneous coronary intervention (PCI) (balloon 
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angioplasty, atherectomy and stent placement). In patients with unstable angina refractory to 
conventional treatment, where PCI is planned, it may be used 18 to 24 hours prior to the 
planned intervention.  
Trastuzumab (Herceptin) is a recombinant humanised monoclonal antibody that selectively 
targets the extracellular domain of the human epidermal growth factor receptor 2 protein 
(HER2), a protein which is overexpressed in 25%-30% of primary breast cancers. These 
tumours are particularly aggressive and deliver a shortened disease-free survival compared to 
patients whose tumours do not overexpress HER2. Herceptin is indicated for the treatment of 
patients with HER2 positive localised breast cancer in association with chemotherapy. 
Rituximab (MabThera), is a chimeric monoclonal antibody directed against the CD20 
protein, that destroys both normal and malignant B cells that have CD20 on their surfaces. It 
is indicated for non-Hodgkin lymphoma and chronic lymphocytic leukaemia. 
Basiliximab (Simulect) is a chimeric mouse-human monoclonal antibody directed against 
the interleukin-2 (IL-2) receptor found in  T cells and  is used to prevent rejection in organ 
transplantation, especially in kidney transplants.  It acts as an antagonist at the interleukin-2 
binding site of the high affinity IL-2 receptor on the surface of the activated T lymphocytes. 
23.2.2.3. Conjugated monoclonal antibodies.  
Conjugated monoclonal antibodies are those antibodies that are joined to drugs, toxins or 
radionuclides. The antibodies are used as delivery vehicles taking those cytotoxins directly to 
the target cells. Although fewer in number at present than their naked counterparts, it is 
expected that the number of conjugated antibodies will increase in the coming years. 
Conjugates include ozogamycin which is a calicheamicin antibiotic, mafenatox which is an 
enterotoxin isolated from staphylococcus aureus and mertansine, which is a macrolide found 
in the staff vine plant. All of these conjugates have been demonstrated to be excellent 
cytotoxins, particularly useful in the killing of cancer cells.  
Of the two immunotoxin thus far to receive FDA approval for treating cancer, gentuzumab 
ozogamycin (Mylotarg) which contains calicheamicin was used to treat acute myelogenous 
leukaemia (AML).  It was withdrawn from market in 2010 when clinical trials demonstrated 
that the drug increased patient death and added no benefit over conventional cancer therapies.  
The second immunotoxin, brentuximab vedotin, indicated for treat treatment of anaplastic 
large cell lymphoma (ALCL) and Hodgkin lymphoma was approved by the FDA in 2011. 
Other immunotoxins are in various stages of clinical trials including trastuzumab emtansine 
which shows promise for the treatment of HER2 positive breast cancers and it is expected 
that other immunotoxins will be approved in the coming years. 
Radioimmunotherapy uses monoclonal antibodies tagged with a radionuclide to deliver 
cytotoxic radiation to the target cell. In 2003, the FDA approved ibritumomab tiuexetan 
(Zevalin) which is tagged with Yttrium-90 (90Y) for use as a treatment for non-Hodgkin 
lymphoma. The following year, it approved Iodine (131I) tositumomab (Bexxar) as 
treatment for the same disease. 
23.2.3. Recombinant protein vaccines.  
Whereas addition of exogenous antibody can be seen to provide passive immunity against a 
pathological condition, a vaccine is an antigenic preparation that produces an active 
immunity to a disease such as to prevent or ameliorate the effects of infection by any natural 
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or wild strain of the causative organism. Vaccines have been used in one form or another for 
over 200 years when Edward Jenner, using inoculation with cowpox virus demonstrated 
protection against the deadlier smallpox virus.  
Vaccines may be obtained from living, weakened strains of the pathogens (bacteria or virus) 
which intentionally give rise to trivial infections or they may be obtained from killed or 
inactivated (attenuated) pathogens or purified products derived from them.  
Increasingly, however, a new generation of vaccines derived from appropriate immunogenic 
(but non-pathogenic) protein components of a micro-organism produced through recombinant 
DNA technology, has shown that vaccines can be created that provide immunity in an 
individual without exposure of that individual to the risks of infection. Such recombinant 
protein vaccines are proving invaluable in the treatment of infection, autoimmune diseases 
and cancer. For example, a new hepatitis B vaccine was created by from the production of a 
recombinant HBsAg protein, a non-infectious protein of the Hepatitis B virus. Similarly, two 
vaccines, the quadrivalent Gardasil and the bivalent Cervarix have been developed to 
combat human papillomavirus (HPV) infection, the causative agent that is responsible for 
70% of precancerous lesions that can develop into cervical cancer. These vaccines were 
developed from recombinant viral coat proteins and are designed as preventative (rather than 
therapeutic) vaccines, recommended for women who are 9 to 25 years old and have not 
contracted HPV.  
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24. An introduction to anticancer drugs 
24.1 Introduction 
Cancer is defined as a group of diseases which are characterised by uncontrolled cell 
proliferation and subsequent growth of abnormal tissue leading to profound changes in 
physiological function. Cancers can arise from both genetic and lifestyle factors that lead to 
abnormal regulation in the growth of particular stem cell populations or by the 
dedifferentiation of mature cell types. This aberrant control of cell division can lead to either 
a benign tumour, which does not spread to other parts of the body and as such is rarely life 
threatening or to a malignant tumour which can invade other organs, move to other bodily 
locations (metastasise) and become life threatening.  
 
In the most recent overview of cancer statistics in Australia, it was noted that in 2005, over 
100,000 new cases of cancer were diagnosed with over 39,000 deaths recorded in the same 
period. The major form of cancer affecting females is breast cancer which accounts for some 
27% of all diagnoses in 2005. In males, the predominant cancer type is prostate cancer which 
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accounts for 29% of all diagnoses in 2005. In both sexes, the next biggest killers are 
colorectal cancer, lung cancer and melanoma. In all, these five types of cancer account for 
60% of all cancer deaths in men and women. However, there have been great strides in the 
development of a raft of treatments which has led to improvement of survival times in 
sufferers although this has lead to increased disease prevalence. At the end of 2004, over 
650,000 living persons had been diagnosed with cancer at some time in the previous 23 years 
(when national data collection began). This accounts for 1 in every 31 Australians. Indeed, 
one in three men and one in four women will develop some form of cancer by age 75, a risk 
that increases to one in two for men and one in three for women by age 85.  
 
There are a number of options available for treatment of cancer with the preferred choice of 
therapy dependent upon location and type of tumour and the disease stage to which the 
cancer has progressed.  Preferred treatment options include surgery to remove discrete, 
localised tumours such as those found in prostate and breast cancers; radiation therapy using 
ionizing radiation to kill cancer cells and shrink tumours (useful in the treatment of most 
solid tumours as well as leukaemia and lymphoma); and chemotherapy, the treatment of 
cancer cells with drugs to destroy them. 
 
24.2 The rationale behind anticancer drug therapy 
24.2.1 The special characteristics of cancer cells 
It is the special characteristics of cancer cells that has been, and is still, the key to the 
development of pharmacological agents used to treat the disease. These characteristics 
include uncontrolled proliferation, dedifferentiation of cancer cells resulting in loss of 
function, invasiveness and the development of metastases.  
 
In many cancer cells, the mechanisms of cell proliferation are not subject to the same 
regulatory processes found in non-cancerous cells. This leads to uncontrolled cell 
proliferation that usually results in an increase in cell multiplication although a reduction can 
also occur. Interruption of proliferative control leading to cancer generally occurs as a 
consequence of genetic changes or mutations. In particular (i) inactivation of genes, known as 
tumour suppression genes, that have the ability to suppress malignant changes and includes 
p53, pRB1, PTEN and CD95 and; (ii) activation of genes, known as protooncogenes, which 
normally control cell division, into tumour producing oncogenes and includes Src, Abl and 
Ros. Uncontrolled proliferation arising from these gene mutations leads to changes in growth 
factor signalling, in cell cycle function and in apoptosis (programmed cell death). To date, 
over 200 tumour suppression genes and protooncogenes have been discovered and shown to 
be involved in the evolution of cancers such as retinoblastoma, breast carcinoma, colon 
carcinoma, squamous cell carcinoma and chronic myelogenous leukaemia. 
 
Cellular dedifferentiation occurs when there is a loss in the ability of progeny cells to carry 
out normal programmed cellular function, as a result of problems caused by faulty parent 
cells.  Cancers caused by dedifferentiating cells are quick growing and have a poorer 
prognosis than well differentiated cancers.  
 
Under normal conditions, cells tend not to be found outside their designated tissue of origin. 
Therefore liver cells are restricted to the liver, cortical neurones restricted to the brain and so 
on. Any cells escaping from their tissue location tend to undergo programmed cell death 
(apoptosis). However, cancer cell lose the ability to undergo apoptosis and can invade other 
cells within the tissue. For example, in rectal cancer, cancerous mucosal epithelial cells can 
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invade other cell layers of the rectum due their ability to secrete metalloproteinase enzymes 
that destroy the extracellular matrix. These translocated cells, coupled with a loss of apoptotic 
factors can lead to the formation of aggressive tumours. 
 
Lastly, secondary tumours called metastases are formed by cancer cells that have been 
released from the initial primary site and transported to other sites via blood or the lymphatic 
system. Metastases are the principal cause of morbidity (the incidence of a disease) and 
mortality (death from the disease). 
 
24.2.2 The principles of anticancer chemotherapy 
The aim of drug treatment in patients with cancer is to eradicate the presence of malignant 
cells or, if this is not possible, provide effective palliation to lessen the severity of the 
symptoms. This may be achieved by causing a lethal cytotoxic event in the cancer cell that 
will arrest tumour progression. Targets for cytotoxic attack include inhibition of purine and 
pyrimidine synthesis, inhibition of DNA and RNA synthesis and chemical attack on the 
integrity of the structure of cellular DNA. Since these treatments inhibit the mechanisms of 
cell proliferation in general, they are toxic to both tumour cells and normal, non-cancerous 
proliferating cells. Thus selectivity of cytotoxic drugs has traditionally relied on the fact that 
in tumour tissue there is a higher proportion of cells undergoing division and proliferation 
that are susceptible to the effects of the drugs when compared to normal tissue.   Proliferating 
cells in the bone marrow, gastrointestinal tract and hair follicles are particularly sensitive to 
many of these cytotoxic agents resulting in many of the adverse effects associated with these 
drugs (leukopaenia/low/loss of white blood cells, thrombocytopaenia/low/loss of platelets, 
nausea, vomiting, alopecia/hair loss).  
 
However there are a number of problems associated with the use of drugs in chemotherapy. 
These include cytotoxicity, drug resistance and induction of new tumours. As mentioned 
above, by their very nature many anticancer drugs will target and kill normal cells as well as 
tumour cells, thus contributing to the common toxic manifestations of chemotherapy such as 
vomiting, alopecia and diarrhoea. Although these are generally transient side-effects and 
symptoms can be alleviated by the use of concomitant drug therapies such as anti-emetics, 
some more serious, irreversible adverse effects such as myelosuppression (i.e suppression of 
bone marrow leading to reduced synthesis of blood cells) and cardiac, bladder and pulmonary 
toxicities can occur.  
 
Another common problem associated with the use of anticancer drugs is resistance of the 
tumour cells to the drug. Some cancers such as melanoma are inherently resistant to treatment 
whilst others tumour types may acquire resistance. Design of drug regimens that utilise short 
term, intensive intermittent therapy with combinations of drugs are effective in minimising 
drug resistance in most cases. Finally, since most anticancer drugs are mutagens, there is a 
danger of new cancers (neoplasms) arising following treatment. For example, occurrence of 
acute non-lymphoblastic leukaemia some ten years after treatment to cure an original tumour 
has been observed. This is a particular problem with use of the alkylating agent class of 
anticancer drugs.   
 
24.3 Drugs used in cancer 
Anticancer drugs are classified according to their sites of action at specific points in the 
biosynthetic pathways of important biomolecules. Some drugs are effective during specific 
parts of the cell cycle and are used in the treatment of high growth fraction malignancies such 
as blood cancers. The antimetabolites typify this group of drugs. Other anticancer drugs are 
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cell cycle non specific and are effective in the treatment of low growth fraction malignancies 
such as solid tumours. The alkylating agents are prime examples of this drug class.        
 
24.3.1 Alkylating agents 
Alkylating agents exert their cytotoxic effects through the transfer of their alkyl groups to a 
variety of cellular targets, the most notable being the nitrogenous bases of DNA, particularly 
the N7 position of guanine. These covalent additions result in either miscoding of the DNA or 
strand breakage. Although alkylating agents do not distinguish between proliferating and 
resting cells, they are most toxic for rapidly dividing cells. These agents are most effective 
when used in combination with other anticancer agents to treat a variety of lymphatic and 
solid tumours, however, alkylating agents have been shown to be mutagenic and carcinogenic 
and treatment with these drugs can lead to a second cancer such as leukaemia. In general, the 
alkylating agents form into two groups, the nitrogen mustard agents and the nitrosureas 
although others do exist. 
 
The nitrogen mustard group of anticancer agents, typified by cyclophosphamide and the 
structurally related ifosfamide, are similar to mustard gas, a chemical warfare agent deployed 
in the First World War. Both drugs share most of the same toxicities and can be considered as 
prodrugs since they are normally taken orally and become active (and therefore cytotoxic) 
only after generation of their alkylating species, which are produced by hydroxylation in the 
liver by cytochrome P450. The hydroxylated intermediates undergo breakdown to form the 
active ingredients, acrolein and phosphoramide mustard, which interact with DNA to destroy 
the malignant cells. Cyclophosphamide is particularly useful in the treatment of Hodgkin’s 
lymphoma, various leukaemias, adenocarcinoma of the ovary and retinoblastoma whilst 
ifosfamide is used to treat germ cell tumours, ovarian, cervical and breast cancers. The most 
common adverse effects of both drugs (after nausea, vomiting, diarrhoea and alopecia) are 
bone marrow depression and haemhorragic cystitis which can lead to fibrosis of the bladder. 
Secondary malignancies may appear years after initial treatment with these drugs. 
 
The second group of alkylating agents, the nitrosureas, includes the closely related 
carmustine and lomustine. Both of these agents have the ability to penetrate into the central 
nervous system and, as such, are particularly useful in the treatment of brain cancers. They 
work in a similar way to the nitrogen mustards and exert their cytotoxic effects through 
alkylation of DNA bases that results in DNA strand cross-linking that inhibits DNA 
replication and eventually RNA and protein synthesis. Apart from the usual adverse effects 
(alopecia, nausea, vomiting, stomatitis), these agents have been demonstrated to cause 
myelosuppression, leukopaenia, thrombocytopaenia as well as liver, kidney and lung damage. 
 
24.3.2 Cytotoxic antibiotics  
Several antibiotics are widely used as anticancer drugs. They include a group of anticancer 
drugs known as the anthracycline antibiotics, typified by daunorubicin and its close 
structural compound doxorubicin, both isolated from Streptomyces. They owe their cytotoxic 
action principally to their ability to interact with DNA (intercalation) leading to a disruption 
of DNA function. The drugs insert non-specifically between adjacent base pairs in the DNA 
and bind to the phosphate-sugar backbone promoting local uncoiling and blocking DNA and 
RNA synthesis. In addition, these compounds are also able to inhibit the topoisomerase 
enzymes causing irreparable breaks in supercoiled DNA, further inhibiting DNA and RNA 
synthesis. Furthermore, oxygen free radical production by these agents also plays a major 
role in their cytotoxicity, although chronic administration can lead to cardiotoxicity because 
the heart lacks the catalase enzyme required to inactivate the oxygen free radicals.  
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Daunorubicin is used in the treatment of acute myeloblastic and acute lymphoblastic 
leukaemias, whilst doxorubicin, which is one of the most important and widely used 
anticancer drugs, is indicated for a number of cancers including breast and lung carcinomas 
and acute lymphoblastic leukaemia. Both drugs cause irreversible, dose dependent 
cardiotoxicity which is regarded as the major adverse effect associated with them although 
transient bone marrow suppression, stomatitis, vomiting and alopecia can also occur. 
 
Another antibiotic used as a cancer therapeutic is dactinomycin which is isolated from soil 
bacteria of the genus Streptomyces. Similarly to daunorubicin and doxorubicin, dactinomycin 
intercalates into the minor groove of DNA forming a stable complex which interferes with 
RNA polymerase and inhibiting transcription. It is used in the treatment of Wilms’ tumour 
and gestational choriocarcinoma (cancer of the placenta). The major adverse effective is bone 
marrow suppression, thus the drug is immunosuppressive. In addition, common adverse 
effects such as nausea, vomiting, diarrhoea, stomatitis and alopecia have been noted. 
 
A final anticancer antibiotic is another Streptomyces-derived compound, bleomycin. This 
drug, unlike the other antibiotics described above, is cell-cycle specific and mediates its 
effects by causing superoxide-mediated single and double stranded breaks in DNA which 
results in a reduction in DNA synthesis and subsequent inhibition of cell division and growth. 
Bleomycin is used primarily in the treatment of testicular cancers, as part of a cocktail of 
other anticancer drugs including cisplatin and vinblastine.  It is also effective, although not 
curative, for squamous cell carcinomas. 
 
24.3.3 Antimetabolites 
Antimetabolites are compounds that are structurally similar to normal cellular components. 
They exert their cytotoxic effects by blocking or subverting the pathways of DNA synthesis. 
They fall into two main classes; the folate antagonists or antifolates which interfere with 
nucleotide synthesis and the purine and pyrimidine analogues which are incorporated into 
DNA and affect the cell cycle. 
 
The most widely used antifolate is methotrexate which is used in the treatment of acute 
lymphocytic leukaemia, choriocarcinoma, Burkitt’s lymphoma, breast cancer as well as head 
and neck carcinomas. Methotrexate is an analogue of folic acid, a dietary compound which is 
a building block precursor for nucleotide (adenine, guanine, thymidine) and amino acid 
(methionine, serine) synthesis. Folic acid undergoes reduction to the tetrahydrofolate form 
via an enzymatic reaction catalysed by dihydrofolate reductase (DHFR) and it is this 
metabolite that undergoes subsequent reactions to form the essential nucleotides and amino 
acids. Methotrexate is an inhibitor of DHFR. This inhibition deprives the cell of 
tetrahydrofolate and subsequent metabolite production leading to depressed DNA, RNA and 
protein synthesis and ultimately cell death. Adverse reactions include renal, liver and 
pulmonary damage as well as the common adverse effects like nauseas, vomiting, diarrhoea 
and myelosuppression.  
 
The other main class of antimetabolites are the purine and pyrimidine analogues which are 
inserted into DNA and subvert the cell cycle killing susceptible cells. Amongst the purine 
analogues are 6-mercaptopurine which is used in the maintenance of remission of acute 
lymphoblastic leukaemia. 6-mercaptopurine is converted to 6-thioinosinic acid (TIMP) which 
blocks the synthesis of cellular purines. Furthermore, TIMP itself can be incorporated into 
RNA making it non-functional. Bone marrow depression is the common adverse effect 
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associated with 6-mercaptopurine although jaundice as a result of hepatotoxicity occurs in 
about one-third of patients. Anorexia, vomiting and diarrhoea have also been reported. A 
second purine analogue developed as an anticancer agent is 6-thioguanine which is used in 
the treatment of acute non-lymphocytic leukaemia (usually in conjunction with other 
cytotoxic drugs). This drug is converted to nucleotide di- and triphosphate forms which 
inhibit the synthesis of cellular DNA. Bone marrow suppression is the major adverse effect 
associated with this drug.  
 
5-fluoruricil (5-Fu) is a pyrimidine analogue indicated for use against slowly growing solid 
tumours (such as colorectal, breast, ovarian) and in the treatment of superficial basal cell 
carcinomas. 5-Fu is converted to 5-FdUMP which competes with the precursor of dTMP, 
dUMP for thymidylate synthase enzyme. This competition results in a decrease in dTMP 
which affects tumour cell DNA synthesis. As well as the common adverse effects associated 
with anticancer drugs, 5-Fu can cause severe ulceration of the oral and gastrointestinal 
mucosa. Other pyrimidine analogues used as anticancer drugs are capecitabine (metastatic 
breast cancer, colorectal cancer), cytarabine (acute nonlymphocytic leaukamia) and 
gemcitabine (pancreatic cancer, non-small cell lung cancer). 
 
24.3.4 Microtubule inhibitors 
The mitotic spindle is part of a larger intracellular network of microtubules that is formed 
during prophase in the cell cycle. This role of this larger network, termed the cytoskeleton, is 
to move cytoplasmic structures around the cell. The mitotic spindles, which comprise 
chromatin plus a system of tubulin microtubules, attach to the centromeres of the 
chromosomes and facilitate the equal partitioning of newly replicated DNA from the parent 
cell into the two daughter cells during anaphase in eukaryotic cell division. A number of 
plant-derived compounds, the microtubule inhibitors, are able to disrupt the assembly and 
disassembly mechanism of tubulin polymerisation thereby causing cytotoxicity.  
 
The microtubule inhibitors comprise two groups, the vinca alkaloids and the taxanes 
(taxols), which can be distinguished by their different modes of action on the microtubule.  
The vinca alkaloids comprise vincristine and vinblastine, which are structurally related 
compounds derived from the periwinkle plant, Vinca rosa, and vinorelbine which is a newer, 
less toxic semi-synthetic analogue. All three vinca alkaloids have the same mode of action 
and are deemed to work in a cell-cycle specific manner. They bind to the microtubule protein 
tubulin and block its ability to polymerise and form microtubules. Instead aggregates of 
tubulin dimmers and alkaloid drugs are formed. The resulting dysfunctional spindle 
apparatus, frozen in metaphase, prevents chromosomal segregation and cell proliferation.  
Although the vinca alkaloids share a related structure, their therapeutic indications are 
different. Vincristine is used in acute lymphoblastic leukaemia, Hodgkin’s and non-
Hodgkin’s lymphoma and some solid tumours whereas vinblastine, though also used to treat 
lymphoma, is used to treat metastatic testicular carcinoma. Vinorelbine is beneficial in the 
treatment of advanced non-small cell lung cancer. Generalised adverse effects such as nausea, 
vomiting, diarrhoea and alopecia are observed with these drugs whilst more serious adverse 
reactions such as peripheral neuropathy (including parasthesias and ataxia), phlebitis 
(inflammation of veins of the legs and arms) and severe myelosuppression have been noted. 
All of the vinca alkaloids are generally administered with other anticancer drugs. 
The second group of microtubule inhibitors are the taxanes (also known as the taxols). These 
comprise paclitaxol (better known as taxol) which is isolated from the Pacific yew tree and 
docetaxol, a semisynthetic structural analogue of paclitaxol.  
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Although, the taxanes are classified as microtubule inhibitors and are cell-cycle specific, they 
have a mechanism of action which is distinct from the vinca alkaloids.  The taxanes bind to a 
different site on tubulin from the vinca alkaloids, promoting rather than inhibiting 
microtubule formation. This results in unusually stable non-functional microtubules that fail 
to depolymerise, subsequently stopping chromosome desegregation and causing cell death.  
The taxanes have been shown to be effective in the treatment of advanced ovarian cancer, 
metastatic breast cancer and non-small cell lung cancer particularly when used in conjunction 
with other anticancer drugs. A decrease in the neutrophil blood count (neutropaenia) as a 
result of taxane administration is the most serious adverse reaction to these drugs and 
treatment should be discontinued if it occurs. Other adverse effects associated with these 
drugs include bradycardia (slowing of heart rate), fluid retention, alopecia and, in rare cases, 
vomiting and diarrhoea. Because of serious hypersensitivity including hypotension, a patient 
who is to be treated with paclitaxel should be pre-treated with dexamethasone and 
antihistamines.  
24.3.5 Monoclonal antibodies 
Most anticancer drugs exert their therapeutic effects by targeting processes that are integral to 
cell proliferation, a key marker of malignancy. However, since these processes are also 
occurring in normal cells, non-cancer cells are also a target for these drugs. As discussed 
earlier, this lack of selectivity often results in the adverse effects associated with anticancer 
drugs.  The use of monoclonal antibody (mAB) technologies has resulted in an active area 
of drug development for anticancer therapy and other non-cancerous diseases. The ability of 
these molecules to specifically identify targets that arise during cancer development provides 
powerful and selective anticancer treatments that often have fewer adverse effects than 
conventional treatments. 
 
The basic premise of all antibody treatments is to produce a drug that reacts with an antigen 
that is specifically expressed on cancer cells. Interaction of the mAB with the antigen, which 
is usually a component of cell growth and proliferation, leads either to interruption of the 
normal cellular processes that occur, killing the target cell or activation of the host’s immune 
system resulting in the same conclusion. 
 
mABs are produced from B-lymphocytes isolated from immunised mice or hamsters which 
have been infused with an immortalised B-lymphocyte tumour cell line. The resultant hybrid 
cells (or hybridomas) are individually cultured to produce a clonal cell that produces 
antibodies against a single antigen type. Recent advances in recombinant DNA technology 
has allowed for the creation of “humanised” antibodies that can overcome previously 
observed immunological problems associated with administration of animal-derived 
antibodies. Currently, there are several mABs that are indicated for the treatment of cancer. 
These exist in the “naked” form where the immunological properties of the antibody alone 
are enough to disrupt cell function, and the “conjugated” form where the mAB is associated 
with a cytotoxic element such as a toxin or radioactivity.  
 
The first mAB approved as an anticancer therapy was rituximab. This antibody is directed 
against the CD20 surface antigen found in normal and malignant lymphocytes but absent in 
other bone marrow derived cells. CD20 plays an important role in the activation process for 
cell-cycle initiation and cell differentiation. Binding to CD20 by rituximab results in an 
autoimmune response culminating in complement-mediated and antibody-dependent 
cytotoxicity of the B cells. The antibody is commonly used in combination with other drug 
therapies. Severe adverse effects have been noted with administration of rituximab. These 
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include hypotension, bronchospasm, angioedema (swelling below the skin surface), tumour 
lysis syndrome resulting in acute renal failure, and blood cell problems including 
leukopaenia, thrombocytopaenia and neutropaenia. 
 
Trastuzumab (marketed as Herceptin) targets human epidermal growth factor receptor 2 
(HER2) and is used in the treatment of early breast cancer and metastatic breast cancer. 
Activation of HER2 by mitogen agonists promotes cell proliferation. The HER2 gene is 
amplified in some 25-30% of early breast cancers leading to an overexpression of the 
receptor and subsequent increased sensitivity of the malignant tissue to the mitogen, an effect 
blocked by administration of trastuzumab. The most serious adverse effect associated with 
trastuzumab administration is congestive heart failure. Other adverse effects such as infusion-
related fever and chills, headache, dizziness, vomiting, nausea and back pain are well 
tolerated.  
 
Bevacizumab is the first in a new class of anticancer drugs known as anti-angiogenesis 
agents and is indicated for use in the treatment of metastatic colorectal cancer. This antibody 
binds to vascular endothelial growth factor A (VEGFA) neutralising its ability to stimulate 
the formation of new blood vessels thus depriving tumours of oxygen and nutrients essential 
for growth and proliferation. Among the rare serious side effects of bevacizumab are bowel 
perforation and stroke. A second mAB also used to treat metastatic colorectal cancer, 
cetuximab, exerts its anticancer effect by targeting the epidermal growth factor receptors on 
the surface of cancer cells and retarding their growth. Cetuximab has been reported to cause 
breathing difficulties during the first treatment and interstitial lung disease has been reported. 
Other “naked” mABs used in the treatment of cancers are alemtuzumab (chronic 
lymphocytic leukaemia) and panitumumab (metastatic colorectal cancer). It is expected that 
many more will be developed over the next few years. 
A second group of mAB therapies being developed are the “conjugated” mABs which 
comprise couopling the antibody to a cytotoxic element ,usually a toxin or a radioactive 
isotope. The most successful of these is ibritumomab tiuxetan which is an antibody directed 
against the CD20 antigen coupled with a molecule called tiuxetan which contains a 
radionucleotide (either yttrium-90 or indium 111). The antibody binds to the CD20 antigen found 
on the surface of normal and malignant B cells (but not B cell precursors), allowing radiation from the 
attached isotope (mostly beta emission) to kill it and some nearby cells. It is primarily used in the 
treatment of non-Hodgkin lymphoma. A second mAB directed against the CD20 antigen tagged with 
Iodine-131, tositumomab is also available as a therapy for non-Hodgkin lymphoma. However, 
gemtuzumab, an antibody directed against the CD33 surface antigen found in 80% of all patients 
with acute myelocytic leukaemia, and conjugated with the plant toxin, ozogamicin has recently been 
withdrawn from clinical use due to toxicity problems.    
24.3.6 Steroid hormones and their antagonists 
The growth of a number of tumours have been demonstrated, in part, to be positively or 
negatively regulated by the presence of various steroid hormones. This has afforded the 
opportunity to develop treatments specifically targeted to these cancers. For example, many 
breast cancers depend on proliferative signals produced by oestrogens to support their 
growth. Indeed, oestrogen receptors are over-expressed in some 70% of all breast cancers 
making these tissues especially sensitive to the action of the steroids (oestrogen receptor 
positive breast cancer). Treatment involves either the use of agents to inhibit the pathways of 
endogenous oestrogen synthesis (aromatase inhibitors) or SERMs (selective oestrogen 
receptor modulators) that subvert the actions of the steroid. The aromatases are a group of 
enzymes involved in the synthesis of steroids from precursor cholesterol. Principal amongst 
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these reactions is the first stage conversion of cholesterol to pregnenolone which inturn gets 
converted to mineralocorticoids, glucocorticoids, androgens as well as oestrogens. The 
aromatase inhibitors (anastrazole, exemestane, letrozole) block this first step reducing the 
oestrogen biosynthesis and removing proliferative signals to the hormone-sensitive cancer 
tissues. Normal chemotherapeutic adverse effects are seen with these compounds though rare 
instances of thrombosis have been noted with administration of letrozole. SERMs are drugs 
that act specifically on oestrogen receptors where they can behave as agonists or antagonists 
depending on the tissue targeted. Tamoxifen is a SERM indicated for use in oestrogen 
receptor positive breast cancers where it acts as antagonists to the breast tissue oestrogen 
receptors blocking activation of oestrogen-responsive genes stopping RNA synthesis. The 
result is a depletion of oestrogen receptors and suppression of the steroid’s proliferative 
effects. Adverse effects include hot flushes, nausea, vomiting, skin, rash and vaginal bleeding 
and discharge. However, tamoxifen acts as oestrogen receptor agonists is other tissues 
including bone, thereby avoiding the increased risk of osteoporosis that accompanies the 
removal of endogenous oestrogen. 
 
Progression of prostate cancer is under sophisticated hormonal control. Gonadotropin 
releasing hormone (GnRH) is secreted by the hypothalamus and interacts with specific 
receptors on the anterior pituitary gland which in turn facilitates the release of the 
gonadotropic hormones, follicle stimulating hormone (FSH) and luteinising hormone (LH) 
which are responsible for the secretion of testosterone and oestrogen. Exposure of the 
prostate to testosterone is implicit for the growth and survival of certain prostate cancers and 
so blocking the production or action of this hormone presents an important opportunity for 
therapy. Leuprolide and goserelin are analogues of GnRH and act as agonists at the GnRH 
receptor on the anterior pituitary gland. Chronic activation of these receptors by these drugs 
results in downregulation of the receptors and consequent inhibition of gonadotropin release 
resulting in a decrease in tumour growth and survival. These drugs also have some benefit in 
the treatment of advanced breast cancer. Adverse effects include impotence and hot flushes.  
 
Synthetic, non-steroidal, antiandrogens (flutamide, bicalutamide) are also used in the 
treatment of prostate cancer. These drugs bind to androgen receptors (particularly 
testosterone receptors) on the prostate, competing with the endogenous steroid, impairing 
tumour growth.  Adverse effects include gynecomastia (abnormal development of mal breast 
tissue) and gastrointestinal problems.  Liver failure has been noted in rare cases with 
flutamide. 
 
Prednisone is a potent, synthetic glucocorticoid that inhibits cell division by interfering with 
DNA synthesis. It is widely used in the treatment of acute lymphocytic leukaemia and 
Hodgkin and non-Hodgkin lymphoma. Adverse reactions are those primarily associated with 
glucocorticoid treatmentweight gain, ulcers, pancreatitis, cataract and glaucoma formation, 
osteoporosis and mood change (euphoria, psychosis).    
 
24.3.7 Other treatments 
A number of other agents that fall outside the regular classifications are used as anticancer 
treatments. Included in this group are the platinum coordination complexes such as cisplatin 
and carboplatin (both used in the treatment of metastatic testicular cancer, ovarian cancer 
and bladder carcinoma) and oxaliplatin (used in treatment of advanced colorectal cancer). 
All of these agents work in a similar way although cisplatin has severe toxicity issues. They 
crosslink with DNA through a guanine nucleobase and the resulting cytotoxic lesion inhibits 
both DNA replication and RNA synthesis. Adverse effects include severe, persistent 
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vomiting (so anti-emetic agents should be used in conjunction), nephrotoxicity and 
ototoxicity. 
 
Irinotecan (treatment of colorectal carcinoma) and topotecan (treatment of metastatic 
ovarian cancer, small-cell lung cancer) exert their actions by inhibition of topoisomerase I, an 
enzyme essential for the replication of DNA in human cells. In contrast, etopside (treatment 
of acute lymphoblastic leukaemia, lung cancer, testicular cancer) targets a second 
topisomerse enzyme, topoisomerase II and results in arrest of the cells in the late S to G2 
phase of the cell cycle. These compounds cause the common adverse effects associated with 
anticancer drugs, however, etopside may cause leukaemia to develop. 
 
Imatinib belongs to a new class of anticancer agents. These perturb intracellular signalling 
pathways. Imatinib, which is used to treat chronic myeloid lymphoma and gastrointestinal 
stromal tumours, works by blocking the unregulated expression of tyrosine kinases associated 
with tumour growth thus inhibiting cell proliferation. Unusual adverse effects associated with 
this drug include thrombocytopaenia, neutropaenia, oedema and gastrointestinal bleeding. 
Very rare instances of stroke and congestive heart failure have been reported with the use of 
this drug. 
 
Recombinant DNA technology has proved particularly useful in producing usable quantities 
of low abundant biomolecules for use as treatments. In particular, production of interferons 
has proved particularly useful. These are proteins released by lymphocytes in response to 
pathogens or tumour cells. Two subtypes, interferon 2a and 2b have been shown to be 
particularly effective in the treatment of leukaemia, melanoma and AIDS-related Kaposi’s 
sarcoma.    
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25. Drugs affecting blood 
25.1 Introduction 
The circulatory system has a number of important physiological functions. These include 
transport of metabolites, hormonal and temperature regulation and protection against disease. 
All of the molecules needed for normal cellular metabolism are transported in the blood. Red 
blood cells carry oxygen to tissues and remove carbon dioxide waste gases. In addition, the 
blood carries nutrients from digestion and absorption of foodstuffs to target cells and removes 
excess water and unwanted waste products of cellular metabolism to the kidney for excretion. 
Blood also transports hormones and other cellular control molecules from site of synthesis to 
their site of action and is involved in body temperature regulation. Furthermore the 
circulatory system aids in protection against foreign invasion by toxin or bacteria through 
protective white blood cells (leukocytes), whilst clotting mechanisms protect against blood 
loss when the blood vessels of the circulatory system are damaged. 
Blood comprises two portions, a cellular component termed the “formed elements” and a 
“fluid component” termed plasma. The plasma is a pale yellow fluid that consists of water, 
dissolved solutes, soluble metabolites, hormones, antibodies and other proteins including the 
albumins and globulins which are used to transport molecules around the body and 
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fibrinogen, which is an important clotting factor. Within the “formed elements” are the 
cellular components of blood including the erythrocytes (used to transport oxygen via 
haemoglobin), platelets (involved in blood clotting) and the leukocytes (which comprise 
neutrophils, eosinophils, basophils, monocytes and lymphocytes and whose roles include 
phagocytosis and the release of antibodies as an immune response). 
25.2 Important dysfunctions of the blood system 
There are a number of pathophysiological conditions associated with dysfunctions of the 
circulatory system (see Figure at end of this eChapter). The major problems are thrombosis 
(the formation of an unwanted clot within the blood vessels or heart), uncontrolled bleeding 
(as a result of a disease or injury) and anaemia (caused by disease or nutritional deficiencies). 
Other problems that can arise include cancers associated with components of the circulatory 
system (for  example, leukaemia, lymphoma), diseases resulting in reduced or increased 
functioning of the immune system (rheumatoid arthritis, systemic lupus) and 
hyperlipidaemias. These are covered elsewhere. 
 
25.3 Drugs used in to correct dysfunctions of the blood 
25.3.1 Anti-thrombosis treatments 
Thrombosis occurs when there is formation of an unwanted blood clot (thrombus) or 
movement of an existing clot to a location where it can block important blood vessels. When 
there is damage to a blood vessel, a number of co-ordinated processes occur, resulting in the 
formation of a fibrin-platelet thrombus plug that facilitates cessation of bleeding 
(haemostasis) at the site of injury. This process includes movement of platelets to the site of 
injury and their adhesion to, and covering of, the exposed collagen of the subendothelial 
tissues via binding to von Willebrand factor and glycoprotein Ib (GpIb). The platelets then 
become active and release a variety of chemoattractants including ADP, thromboxane A2, 
serotonin and platelet activating factor (PAF) which in turn mobilise other platelets to the site 
of injury where they begin to adhere and aggregate into the growing clot via GpIIb/IIIa 
platelet receptors. Fibrinogen, a soluble plasma protein, simultaneously binds to GpIIb/IIIa 
receptors on two separate platelets resulting in platelet crosslinking and further platelet 
aggregation. Activation of the clotting cascade ultimately results in thrombin production from 
its precursor prothrombin. Thrombin, in turn, converts fibrinogen in the growing thrombus to 
fibrin, consolidating and stabilising the platelet plug.  
 
There are three drug treatments used to prevent formation of clots or to dissolve established 
thrombi. These are the anti-platelet drugs, the anticoagulents and the thrombolytics. 
 
25.3.1.1 Platelet aggregation inhibitors 
The anti-platelet drugs (or platelet aggregation inhibitors) work by decreasing the 
synthesis, release or action of the chemical molecules that promote platelet aggregation 
preventing clot formation. Aspirin inhibits cyclooxygenase-1 (COX-1), the enzyme 
responsible for the production of thromboxane A2 from arachidonic acid, thus blocking the 
synthesis of the aggregating agent. The main adverse effects of aspirin administration are 
gastrointestinal ulcers, stomach bleeding and tinnitus.  
 
Another drug which targets thromboxane A2 synthesis is dipyridamole which is a cyclic 
nucleotide phosphodiesterase inhibitor. Dipyridamole increases intracellular cyclic AMP 
levels which results in decreased thromboxane A2 synthesis. This agent is usually given in 
combination with aspirin or warfarin.  
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Clopidogrel is approved for the prevention of atherosclerotic events following recent 
myocardial infarction, stroke or established peripheral vascular disease. Clopidogrel 
selectively inhibits the binding of ADP to its platelet receptor, an event that leads to 
inhibition of platelet aggregation by blocking activation of the GpIIb/IIIa pathway.  
 
Working in a similar way, abciximab is a monoclonal antibody that is indicated for 
percutaneous coronary intervention (angioplasty). It binds to the platelet GpIIb/IIIa receptor, 
preventing binding of von Willebrand factor, fibrinogen, and other adhesion molecules 
inhibiting receptor-mediated platelet activation and subsequent thrombus formation. The 
major adverse effect is potential for bleeding.  
Eptifibatide and tirofiban have similar indications, adverse reactions and mechanisms of 
action to abciximab except that they are not antibodies but chemical antagonists of the 
GpIIb/IIIa receptor.  
25.3.1.2 Anticoagulants 
The second group of antithrombosis drugs are the anticoagulants. In the process of forming 
a thrombus, fibrinogen is converted to fibrin by thrombin, the end point of the clotting 
cascade. The cascade is a series of reactions that sequentially transform various plasma 
fractions to their active enzymic form. They ultimately produce activated clotting factor Xa 
which converts prothrombin to thrombin. Anticoagulants exert their action by reducing the 
action of specific clotting factors, as in the case of the heparins, or by interfering with clotting 
factor synthesis, as demonstrated by the vitamin K antagonists.  
 
Heparin and its lower molecular weight forms (enoxaparin, dalteparin) exert their effects 
by binding to and activating antithrombin III. Activation of this enzyme results in thrombin 
inactivation and subsequent blocking of clot formation. These drugs are indicated for deep 
vein thrombosis, pulmonary embolism and acute coronary syndrome. Adverse effects of the 
heparins include haemhorrage and thrombocytopaenia.  
 
The coumarin anticoagulants (warfarin) exert their actions by inhibiting the synthesis of 
vitamin K dependent coagulation factors (VII, IX, X, II) perturbing the clotting cascade. 
They are used to prevent the progression or recurrence of deep vein thrombosis and 
pulmonary embolism. The main adverse reaction to warfarin treatment is haemorrhage. 
Warfarin has numerous drug interactions that may potentiate or attenuate its actions. As such 
warfarin administration should be monitored closely. 
 
25.3.1.3 Thrombolytics 
The last group of antithrombosis drugs are the thrombolytics (fibrinolytics). These drugs are 
used to dissolve clots that have already formed. They are usually administered intravenously 
to clear a blocked blood vessel (for example in coronary thrombosis) and work by promoting 
the conversion of plasminogen to plasmin, a serine protease enzyme that hydrolyses fibrin, 
dissolving the clot, allowing reperfusion to occur.  
 
The first drug in this class to be used was streptokinase, a protein isolated from beta-
haemolytic Streptococci. Streptokinase activates plasminogen and promotes its conversion to 
plasmin. However, streptokinase causes a systemic fibrinolytic effect that can lead to 
bleeding problems and this agent has been replaced by tissue-type plasminogen activators 
(tPAs) such as alteplase, tenecteplase and reteplase.  These agents have been produced by 
recombinant DNA technology and work locally on the thrombotic fibrin to produce 
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fibrinolysis. Bleeding complications including gastrointestinal haemorrhage and stroke have 
been shown to occur with their use. 
  
25.3.2 Treatments for anaemia 
Anaemia is a condition where there is decreased plasma haemoglobin levels resulting from 
either a decreased number of circulating red blood cells or a deficiency of functioning 
haemoglobin within the erythrocytes themselves. This impacts on the capacity of the red 
blood cells to transport oxygen and nutrients to target tissues. There are a number of different 
types of anaemias, each characterised by the condition of their red blood cells. In microcytic 
anaemias (iron deficiency, sideroblastic anaemia) the erythrocytes are smaller than normal ;: 
in normocytic anaemia (bone marrow failure, endocrine anaemia), cells are normal sized; in 
macrocytic anaemia (pernicious anaemia, folic acid deficiency, megaloblastic anaemia), cells 
are larger than normal; whilst in haemolytic anaemia (haemaglobinopathies, infections), the 
cells have autolysed. All of these anaemic states cause similar symptoms such as pallor, 
shortness of breath and fatigue.   
 
Normal erythropoeisis requires a number of factors such as iron, vitamin B12 and folic acid, 
and a deficiency in any of these can cause anaemia. The main therapeutic approach to treating 
anaemia relies on replacing such deficiencies.  
 
Iron deficiency is a common cause of anaemia and can result from chronic blood loss (e.g. 
menorrhagia (heavy blood loss during menstrual periods)), from gut abnormalities resulting 
in reduced iron absorption and in heavily menstruating or pregnant women. Iron deficiency 
syndromes can be treated with oral or parental iron salt (ferrous sulphate, ferrous 
gluconate, ferrous glycine sulphate) supplementation. Gastrointestinal disturbances, 
particularly constipation are the most common side effects of these treatments.  
 
Vitamin B12 deficiency, either as a result of poor absorption of the vitamin itself or more 
commonly, failure to produce the intrinsic factor needed for vitamin B12 function, results in 
megaloblastic and pernicious anaemias. Treatment is by administration of various 
colbalamins (methylcobalamin, cyanocobalamin, hydroxocobalamin) which are 
chemically related forms of vitamin B12.  
 
Folic acid is required for DNA and amino acid synthesis. Deficiency can be caused by 
increased folate demand during pregnancy and lactation, poor absorption caused by disease 
of the small intestine, alcoholism or concomitant treatment with folate inhibitor drugs such as 
methotrexate.  Folica acid deficiencyleads to megaloblastic anaemia. Treatment is by oral 
folic acid administration.  
Erythropoietin is a glycoprotein hormone, produced in the kidney, that regulates red blood 
cell proliferation and differentiation in the bone marrow.  Recombinant human erythropoietin 
and darbepoetin, a variant with a longer half-life, are used to treat anaemias resulting from 
chronic kidney disease and from some chemotherapy treatments, particularly the platinum-
containing anticancer drugs.  
Sickle cell anaemia is a hereditary disorder in which a point mutation in one haemoglobin 
chains results in a valine being substituted for a glutamic acid. This haemoglobin, HbS, 
becomes sickle shaped when oxygenated resulting in impaired erythrocyte function. 
Treatment is with hydroxyurea which activates production of foetal haemoglobin, a process 
that occurs over many months, diluting the abnormal HbS.     
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25.3.3 Treatments for bleeding disorders 
Uncontrolled bleeding occurs as a consequence of either a hereditary disease (haemophilia A, 
haemophilia B, von Willebrand’s disease) or an acquired condition (vitamin K deficiency, 
thrombocytopaenia, fibrinolysis after surgery).  
Hereditary bleeding disorders 
Haemophilic disease occurs as a result of a genetic lesion affecting one or more factors in the 
clotting cascade. Previous treatments involved administration of concentrated preparations of 
these factors isolated from donated human blood, a practice used less today with the ability of 
recombinant DNA technology to produce large amount of these components. Thus 
haemophilia A is treated with administration of clotting factor VIII and haemophilia B with 
clotting factor IX.   
 
Acquired bleeding disorders 
Treatment of acquired, uncontrolled bleeding is more problematical. In general, these 
episodes are caused by an individual being in a fibrinolytic state and treatment negates the 
cause of bleeding or potentiates the clotting mechanism.  
 
Vitamin K1 administration promotes the formation of various clotting factors (II, VI, IX, X) 
and can reverse an abnormal coagulation status (for example treatment after surgery) or 
bleeding due to vitamin K1 deficiency.  
 
Protamine sulphate is a heparin antagonist and is used to counteract the effect of this drug 
before and after surgery.  
 
Tranexamic acid is a competitive inhibitor of the plasminogen activation process resulting in 
decreased production of plasmin and subsequent plasmin-mediated fibrinolysis. It is used to 
treat menorrhagia and patients with clotting disorders undergoing surgery.  However, a 
potential side effect of treatment with tranexamic acid is intravascular thrombosis.  
 
Similarly, aprotinin a serine protease used to reduce perioperative blood loss, also stops 
bleeding by blocking the action of plasmin.  
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26.1	Migraine	
Migraine	 affects	 10‐15%	of	 the	 population,	 being	more	 common	 in	 females,	 and	with	
peak	 prevalence	 between	 35	 and	 45	 years	 of	 age.	 Migraine	 symptoms	 comprise	 a	
unilateral	(sometimes	contralateral),	localized,	throbbing	headache	that	may	persist	for	
72	 hours,	 often	 accompanied	 by	 nausea	 and	 vomiting,	 photophobia	 (light	 sensitivity)	
and	 phonophobia	 (sound	 sensitivity).	 Roughly	 20%	 of	 sufferers	 experience	 an	 “aura”	
preceding	the	headache.	The	aura	may	involve	visual	disturbances	such	as	scintillating	
zig‐zag	lines,	scotoma	(blind	spot),	or	blurred	vision,	accompanied	by	transient	aphasia,	
chills,	vertigo,	or	unilateral	parasthesia	(numbness	or	weakness).	
	
The	actual	cause	of	migraine	is	unknown,	and	it	can	be	triggered	by	almost	anything,	but	
most	 commonly	 psychosocial,	 environmental,	 neurochemical	 and	 neuroendocrine	
changes.	 Known	 triggers	 in	 susceptible	 individuals	 include	 cheese,	 chocolate,	 alcohol,	
chemicals,	sunlight,	hormones,	and	the	contraceptive	pill.	
	
26.2	Pathogenesis	of	Migraine	
While	the	biochemical	initiators	of	migraine	or	underlying	abnormality	that	predisposes	
some	 individuals	are	not	well	known,	migraine	 is	now	recognized	 to	have	neural	 and	
vascular	 involvement,	 highlighting	 the	 important	 interaction	 between	 nerves	 and	 the	
cerebral	vessels.	The	headache	originates	 from	pain‐sensitive	extracerebral	structures	
such	as	 the	meninges	and	 large	arteries,	which	are	 innervated	by	nociceptive	sensory	
nerves	 of	 the	 trigeminal	 system,	 paving	 the	 way	 for	 the	 neurogenic	 inflammation.	
Another	 important	 phenomenon	 that	 occurs	 in	 migraine	 is	 cortical	 spreading	
depression,	thought	to	explain	the	aura	or	increased	susceptibility	to	migraine.	
	
26.3	Cortical	Spreading	Depression	
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Cortical	 spreading	 depression	 can	 be	 viewed	 as	 a	wave	 of	 transient	 neural	 inhibition	
(spontaneous	and	evoked	activity)	that	progresses	slowly	over	the	cortex	at	2‐6	mm	per	
minute.	This	wave	of	depression	is	preceded	by	a	transient	wave	of	 intense	excitation	
associated	with	very	high	extracellular	K+	and	reduced	blood	flow.	Although	the	trigger	
of	excitability	is	not	known,	accumulation	of	extracellular	K+	due	to	enhanced	excitation	
depolarises	 adjacent	 neurons,	 causing	 the	 phenomenon	 to	 spread.	 Changes	 in	 blood	
flow	or	 spreading	excitation	and	depression	may	 initiate	 the	headache.	Moreover,	 the	
localised	 spreading	 depression	 may	 activate	 the	 trigeminal	 nucleus	 caudalis	 (of	 the	
central	pain	pathway),	sensitising	the	central	pain	pathway.	
	
26.4	Neurogenic	Inflammation	Theory	
The	trigeminocerebrovascular	system	comprises	the	ophthalmic	trigeminal	ganglia,	the	
cells	of	which	innervate	major	vessels	regulating	cerebral	blood	flow,	smaller	meningeal	
(especially	 dura	mater)	 vessels,	 the	meninges,	 and	 centrally	 projecting	 sensory	 fibres	
synapsing	 on	 to	 the	 trigeminal	 nucleus	 caudalis	 in	 the	 caudal	 brainstem	 and	 cervical	
spinal	cord.	The	pain	sensitive	structures	include	the	blood	vessels	and	meninges,	thus	
trigeminal	 fibres	afford	a	 conduit	 for	nociceptive	 information	originating	 in	 the	blood	
vessels	and	meninges	to	the	central	nervous	system.		
	
Stimulation	of	the	trigeminal	fibres,	which	are	nociceptive	C	fibres,	causes	pain	directly,	
as	 well	 as	 release	 of	 neuropeptides	 such	 as	 calcitonin	 gene‐related	 peptide	 (CGRP),	
substance	 P	 and	 neurokinin,	 and	 also	 nitric	 oxide,	 leading	 to	 vasodilation.	 Following	
sufficient	activation	resulting	perhaps	from	cortical	excitation,	blood	vessel	constriction	
or	 lowered	 sensitisation	 threshold	 to	 certain	 stimuli,	 inflammatory	 events	 occur	
including	 plasma	 extravasation	 (leakage	 from	 vessels),	 platelet	 activation,	 5‐HT	
secretion,	 mast	 cell	 degranulation	 and	 secretion	 of	 bradykinin,	 histamine	 and	
prostaglandins.	 This	 provides	 a	 localised	 “inflammatory	 soup”	 that	 continues	 to	
sensitise	and	activate	the	C	fibres,	contributing	to	neurogenic	inflammation	of	the	dura	
mater	and	blood	vessels.	
	
CGRP	release	 is	thought	to	regulate	normal	blood	flow,	since	vasoconstriction	triggers	
antidromic	 (feed	 forward)	 release	 of	 CGRP	 from	 trigeminal	 nerves,	 leading	 to	
vasodilation.	 Interestingly,	 CGRP	 is	 released	 in	 correspondence	 with	 the	 pain	 of	
migraine	 and	 its	 concentration	 has	 been	 shown	 to	 correlate	with	 headache	 intensity.	
CGRP	 is	 also	 a	 marker	 of	 trigeminal	 activity.	 Thus,	 migraine	 may	 involve	 a	 lowered	
threshold	 of	 trigeminal	 activation,	 and	 hypersensitivity	 to	 local	 neuropeptide	 release,	
including	 CGRP,	 which	 not	 only	 causes	 vasodilation	 in	 pain‐sensitive	 structures,	 but	
causes	 chemical	 irritation	 and	may	 lower	 the	 pain	 threshold	 to	 previously	 innocuous	
stimuli.		
	
Figure	 26.1	 schematically	 depicts	 the	 trigeminocerebrovascular	 pathways	 and	
highlights	 the	 important	 neuropeptides	 and	 neurotransmitters	 involved	 in	 these	
pathways.	
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Figure	26.1:	Schematic	depiction	of	the	trigeminocerebrovascular	pathway	highlighting	the	role	of	
neurogenic	inflammation	in	the	pathogenesis	of	migraine	and	the	neurpetides	involved.	Location	
of	 5‐HT	 receptors	 is	 also	 shown,	 highlighting	 their	 crucial	 role	 in	migraine	 and	 its	 treatment.	
(Copyright	The	University	of	Sydney,	Tina	Hinton)	
	
26.5	Role	for	5‐HT	in	Migraine	
5‐HT	is	thought	to	be	intrinsically	linked	to	migraine.	Evidence	shows	a	sharp	increase	
in	urinary	5‐HIAA	(the	catabolic	product	of	5‐HT)	and	a	fall	in	blood	5‐HT	concentration	
during	 a	 migraine	 attack.	 Moreover,	 migraine	 sufferers	 display	 perturbed	 5‐HT	
metabolism	and	transmission.	5‐HT1B	and	5‐HT2	receptors	are	 found	on	extracerebral	
blood	vessels.	Stimulation	of	5‐HT2	receptors	indirectly	causes	vasodilation	via	release	
of	 nitric	 oxide,	 while	 activation	 of	 5‐HT1B	 receptors	 leads	 to	 vasoconstriction.	 As	
highlighted	in	Figure	1,	5HT1B,	1D	and	1F	receptors,	located	on	trigeminal	nerve	fibres	and	
the	 trigeminal	 nucleus	 caudalis,	 become	 important	 regulators	 of	 the	
trigeminocerebrovascular	system,	since	their	activation	would	have	an	inhibitory	effect	
on	neurotransmission.	
	
26.5	Acute	Treatment	of	Migraine	
It	 is	 important	 to	 distinguish	 between	 drugs	 that	 are	 used	 to	 treat	 acute	 migraine	
attacks,	 and	 drugs	 used	 in	 migraine	 prophylaxis,	 required	 for	 cases	 of	 at	 least	 two	
migraine	attacks	per	month.	
	
Acute	attacks	are	treated	with	non‐steroidal	anti‐inflammatory	drugs	(NSAIDs)	such	as	
aspirin	 and	 paracetamol,	 ergotamines,	 and	 more	 commonly,	 triptans.	 NSAIDs	 are	
usually	effective	for	mild	attacks	and	when	taken	shortly	after	the	onset	of	pain.			
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For	 over	 70	 years	 ergotamines	 such	 as	 ergotamine	 tartrate	 and	 dihydroergotamine	
were	the	classical	treatment	for	migraine.	These	drugs	can	relieve	the	pain	of	migraine	
even	when	taken	more	than	four	hours	after	onset.	Ergotamines	are	partial	agonists	at	
5‐HT1D	 receptors,	 thus	 blocking	 trigeminal	 nerve	 transmission,	 however	 they	 act	 at	
many	 additional	monoamine	 receptors,	 including	5‐HT1B,	 5‐HT2,	 dopamine	D1	 and	D2,	
noradrenergic	 α1	 and	 α2	 receptors.	 Subsequently,	 their	 usefulness	 is	 limited	 by	 their	
propensity	 to	 cause	 vasoconstriction,	 including	 of	 the	 coronary	 vessels,	 and	 foetal	
damage.	They	also	cause	nausea	and	vomiting	due	to	activation	of	area	postrema.	
	
Triptans	 have	 become	 first	 line	 treatment	 for	 acute	 severe	 migraine,	 replacing	
ergotamines.	 A	 number	 of	 triptans	 are	 available,	 including	 sumaptriptan	 (the	
prototype),	 zolmitriptan,	 almotriptan	 and	 naratriptan.	 The	 differences	 between	 these	
drugs	lie	in	their	plasma	half	life	and	time	to	peak	plasma	levels.	Moreover,	sumatriptan	
does	not	cross	the	blood	brain	barrier,	while	the	other	drugs	do.	Up	to	80%	of	patients	
respond	 to	 triptans	 within	 two	 hours	 of	 administration,	 and	 up	 to	 40%	 experience	
headache	recurrence	within	24	hours	of	initial	relief.	
	
All	 triptans	 are	 5‐HT1B/1D	 agonists,	 and	 their	 effects	 on	 migraine	 are	 numerous.	
Activation	of	these	receptors	on	trigeminal	ganglia	and	trigeminal	nucleus	caudalis	cells	
inhibits	 transmission	of	nociceptive	 information	 from	the	blood	vessels	and	meninges	
to	the	brainstem	and	central	pain	pathways.	Additionally,	stimulation	of	presynaptic	5‐
HT1B/1D	autoreceptors	on	trigeminal	cell	bodies	inhibits	release	of	neuropeptides	from	
trigeminal	 ganglia	 cells,	 thus	 reducing	 neurogenic	 inflammation.	 Moreover,	 on	
extracerebral	 blood	 vessels,	 activation	 of	 5HT1B/1D	 receptors	 causes	 vasoconstriction,	
thus	facilitating	restoration	of	normal	vascular	tone.	Finally,	triptans	relieve	the	nausea	
associated	 with	 migraine.	 One	 drawback,	 however,	 is	 their	 ability	 to	 cause	
vasoconstriction	 of	 coronary	 arteries	 via	 5‐HT1B	 receptors,	 thus	 they	 are	
contraindicated	in	cardiovascular	disease.	
	
26.6	Prophylactic	Treatment	of	Migraine	
Drugs	used	 in	prophylactic	 treatment	of	migraine	 include	β‐adrenoceptor	antagonists,	
5‐HT2	receptor	antagonists,	anticonvulsants	and	calcium	channel	antagonists.	The	type	
of	 prophylactic	 drug	 is	 chosen	 on	 the	 basis	 of	 factors	 such	 as	 contraindications,	 co‐
morbid	conditions	and	tolerability.	Even	when	used,	only	50%	of	sufferers	can	expect	a	
reduction	in	migraine	frequency.	
	
‐adrenoceptor	 antagonists	 such	 as	 propranolol	 and	 metoprolol	 have	 been	 used	
successfully	in	the	prophylactic	treatment	of	migraine.	The	mechanism	of	prophylaxis	is	
unknown,	but	it	may	be	due	to	vasoconstrictor	effects.	These	drugs	are	contraindicated	
in	 respiratory	 diseases	 such	 as	 asthma,	 and	 side	 effects	 include	 fatigue	 and	
bronchoconstriction.	
	
5‐HT2	 antagonists	 such	 as	 pizotifen,	 cyproheptadine	 and	 methysergide	 act	 by	
preventing	5‐HT2	receptor‐induced	vasodilation,	 secondary	 to	nitric	oxide	production,	
and	consequent	inflammation.	Adverse	effects	include	weight	gain	and	methysergide	is	
now	rarely	used	owing	to	the	risk	of	retroperitoneal	fibrosis	and	renal	failure	with	long‐
term	use.	
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Anticonvulsants	 such	 as	 sodium	valproate,	 gabapentin	 and	 topiramate	 are	 thought	 to	
prevent	 migraine	 by	 increasing	 inhibitory	 GABAergic	 and	 Ca2+	 channel	 activity,	 thus	
reducing	cortical	excitability	and	possibly	the	threshold	for	triggering	migraine	attacks.	
These	drugs	may	reduce	cortical	spreading	excitation,	hence	depression,	and	trigeminal	
neurotransmission,	 however	 they	 are	 teratogens	 thus	 their	 use	 is	 excluded	 during	
pregnancy	and	lactation.	
	
Finally,	 calcium	 channel	 antagonists	 like	 nifedipine	 and	 verapamil	 have	 shown	 some	
efficacy,	and	act	to	decrease	cellular	excitability	by	reducing	Ca2+	entry	into	cells.	
	
The	need	remains	for	improved	drugs,	with	greater	selectivity	and	fewer	side	effects,	for	
treatment	of	migraine.	Drugs	that	act	selectively	on	5‐HT1D/1F	receptors	would	remove	
5‐HT1B‐induced	 constriction	 of	 coronary	 and	 cerebral	 arteries.	 The	 role	 of	 CGRP	 in	
regulation	 of	 vascular	 tone	 and	 in	 the	 pathogenesis	 of	migraine	 is	 being	 increasingly	
recognised,	and	CGRP	antagonists	such	as	olcegepant.		
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27.1 Introduction.   
It is a condition of use of many drugs that extra care and attention should be used when 
administered to pregnant women. It is well established that some drugs can have temporary 
or permanent effects on the developing foetus. Drugs that have such an effect are known as 
teratogens, the most notorious being thalidomide which was prescribed to pregnant women 
as a treatment for morning sickness and resulted in a variety of serious birth defects for many 
thousands of babies. However, this chapter is concerned with drugs that are used to treat 
medical complaints arising from problems occurring in pregnancy and labour and not with 
adverse effects on mother or foetus as a result of drug administration. 
27.2 Common complaints in pregnancy and labour and their treatments 
27.2.1 Pre-eclampsia and eclampsia.  
Pre-eclampsia is defined as a hypertensive state of unknown cause occurring in pregnancy. 
Pre-eclampsia is diagnosed when consistent systolic pressures over 140mm Hg and/or 
diastolic pressures over 90 mm Hg are observed. These changes are accompanied by elevated 
protein levels in the urine (hyperproteinuria). Pre-eclampsia can progress to eclampsia, a 
condition characterised by tonic clonic convulsive seizures. Treatment involves reduction of 
blood pressure with antihypertensives and control of seizures with anticonvulsives. If these 
treatments are unsuccessful, abortion or delivery of the foetus is the only effective alternative.  
Most antihypertensives exert their effects by dilating blood vessels, easing constricted blood 
flow and reducing intravessel pressure. These drugs are used to treat a number of disease 
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states including angina, congestive heart failure and acute myocardial infarction in which 
lowering of blood pressure is crucial in alleviating symptoms. Antihypertensives used in the 
treatment of pre-eclampsia include nifedipine, hydralazine, labetalol and methyldopa.  
Nifedipine is a selective blocker of L-type voltage-sensitive calcium channels in arterial 
smooth muscle. Inhibition of these channels results in reduced calcium entry into these cells 
causing vasodilation. Adverse effects of nifedipine include headache, flushing, nausea, 
vomiting and peripheral oedema.  
A second antihypertensive used in the treatment of pre-eclampsia is hydralazine. Although 
its exact mechanism of action is unclear, hydralazine degrades to nitric oxide which is a 
direct acting vasodilator. Hydralazine has similar adverse effects to nifedipine.  
Labetalol is a mixed  adrenoceptor antagonist () which produces peripheral 
vasodilation by blocking the effects of sympathetic nervous system thereby reducing blood 
pressure. Labetalol has a number of adverse effects including postural hypotension and 
bronchoconstriction and as such should not be used in patients with asthma, bradycardia and 
second or third degree atrioventricular block.  
Methyldopa is converted to its active metabolite -methylnoradrenaline in sympathetic 
neurons and stored in the secretory vesicles of these cells. When released, α-
methylnoradrenaline acts as an agonist of presynaptic central nervous system α2-adrenergic 
receptors. Activation of these receptors in the brainstem appears to inhibit sympathetic 
nervous system output and lower blood pressure. However, it is contraindicated in patients 
with active liver disease and phaeochromocytoma (tumour of the adrenal gland) and use of 
methyldopa may exacerbate depression in sufferers. Adverse effects are those associated 
with sympathetic disruption and include sedation, orthostatic hypotension, dry mouth and 
rash. 
Progression of pre-eclampsia to eclampsia is characterised by the appearance of tonic clonic 
seizures. Magnesium sulphate is the drug of choice to prevent these convulsions.  The 
resultant elevated blood magnesium levels (hypermagnesaemia) depresses neuronal activity, 
reducing excitation and calming the uncontrolled nerve firing that can result in seizures. The 
magnesium competes with excitatory calcium decreasing neurotransmitter release at the 
synapse. This treatment is contraindicated with patients with existing elevated blood 
magnesium levels and those with kidney problems. Concomitant use of magnesium sulphate 
and nifedipine can result in hypotension and use of these drugs in combination should be 
monitored. Adverse effects include myasthenia gravis, muscle weakness, respiratory 
depression, bradycardia and thirst. 
When pharmacological treatment for pre-eclampsia and eclampsia fails, there is real concern 
for the safety of the mother. Abortion or delivery by caesarean section or labour induction is 
the treatment of choice. Myometrial stimulants (also known as oxytocics) are used for 
induction and augmentation of labour, prevention and treatment of post-partum haemorrhage, 
control of bleeding due to incomplete abortion, active management of the third stage of 
labour. The oxytocics most commonly used are oxytocin, prostaglandin E and ergometrine.  
Oxytocin is a 9 amino acid produced in the posterior pituitary gland. Exogenous oxytocin, 
administered by means of continuous infusion by pump, stimulates the frequency and force of 
uterine contractions, initiating labour and parturition. Prolonged use can result in water 
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intoxication, uterine rupture and hypotension in the mother and bradycardia, brain damage, 
seizures and death in the infant.  
Prostaglandin E2 (dinoprostone) and prostaglandin E1 (misoprostol) are first line drugs 
of choice as labour inductor. These form part of the eicosanoids, a family of lipid derived 
hormones which have a multiplicity of different cellular functions including smooth muscle 
contraction.  
Finally, ergometrine, an alkaloid structurally similar to LSD can also be used to facilitate 
delivery of the placenta and to prevent bleeding after childbirth by reducing blood flow 
through constriction of smooth muscle in the blood vessel walls causing vessel narrowing. It 
is usually combined with oxytocin as syntometrine. 
27.2.2 Suppression of early labour.  
A number of drugs are used as uterine relaxants. These drugs, known as tocolytics, are 
particularly useful in the suppression of early or premature labour affording time for further 
foetal development and prolonging foetal survival. Several drug classes have been shown to 
possess tocolytic properties. These include 2 adrenergic receptor agonists, oxytocin 
antagonists and calcium channel blockers.   
Included in the 2 adrenoceptor agonist class are terbutaline, ritodrine, salbutamol, 
fenoterol and adrenaline. These drugs work by directly activating adrenergic receptors that 
mediate smooth muscle relaxation terminating uterine contractions. However, these drugs can 
have a number of adverse effects on both the mother and the foetus due to their ability to act 
on the respiratory and cardiovascular systems. Common maternal adverse effects include 
cardiac arrhythmias, altered thyroid function and tachycardia whilst tachycardia, 
hypoglycaemia, hypotension and myocardial ischaemia have been noted in the foetus and 
neonate.  
Atosiban is a peptide analogue of oxytocin which antagonises the uterine contracting 
properties of the hormone at its receptor resulting in cessation of preterm labour. It is 
preferred over the 2 adrenergic agonists due to its lower incidence of adverse effects 
although reactions to the drug such as nausea, vomiting and hyperglycaemia have been noted.  
Calcium channel blockers such as nifedipine, which has previously been discussed for its use 
as an antihypertensive in pre-eclampsia is also has tocolytic properties.   
27.2.3 Neonatal respiratory distress syndrome.  
One consequence of premature birth is impairment of lung development in the neonate. This 
manifests itself as neonatal respiratory distress syndrome and is characterised by a deficiency 
in lung surfactant which causes the integrity of the lung structure to collapse resulting in 
severe breathing difficulties. Intraventricular haemorrhage and death may follow. 
Corticosteroids such as dexamethasone and bexamethasone are used in conjunction with 
tocolytics as therapies to treat this syndrome. The tocolytics prevent premature birth giving 
the lungs extra time to develop whilst the steroids act via cell surface receptors to directly 
activate survival genes. Adverse reactions to these steroids include fluid and electrolyte 
imbalances, muscle weakness, GI disturbances and hypertension. 
27.2.4 Postpartum haemorrhage.  
238 
 
Postpartum haemorrhage is the leading cause of maternal mortality causing approximately 
140000 deaths each year.  Oxytocics, particularly oxytocin, are the preferred treatment. 
Problems associated with the use of oxytocin are outlined above.  
27.2.5 Prolactin excess.  
Prolactin is a peptide hormone secreted by lactotrophic cells in the anterior pituitary. 
Increases in prolactin secretion, during pregnancy, results in maturation of milk secreting 
duct in the mammary gland. Although not restricted to pregnant women, excess production of 
prolactin (hyperprolactinaemia) will result in overactive, secreting mammary tissue. 
Prolactin secretion is under the control of D2 dopamine receptors in the lactotrophic cells.  
Dopamine, secreted from the hypothalamus, acts on these receptors to inhibit the prolactin 
production. Hyperprolactinaemia results when circulating levels of dopamine drop and the 
inhibitory processes compromised resulting in large levels of circulating prolactin in the 
blood. Treatment is with bromocriptine, a dopamine receptor agonist, which decreases 
excessive prolactin secretion. Adverse effects include nausea and vomiting, dizziness and 
constipation. 
27.2.6 Nausea.  
Nausea and vomiting during pregnancy (also known as morning sickness) is common during 
the early stages of pregnancy. These are multiple causes ranging from changes in circulating 
steroid hormones such as oestrogen and progesterone to hypoglycaemia resulting from 
placental transfer of glucose from the mother to the foetus. In most cases no treatment is 
required as the condition will normally disappear after the first trimester of pregnancy. 
However, severe morning sickness known as hyperemesis gravidarum (HG) affecting around 
one in 1,000 pregnant women can occur. The symptoms of hyperemesis gravidarum include 
repeated vomiting, weight loss and dehydration. Treatment usually involves hospitalisation, 
and the administering of intravenous liquids and nutrition. The possible complications 
associated with untreated hyperemesis gravidarum include electrolyte imbalances, extreme 
depression and anxiety and malnourishment of the foetus.   
In extreme cases of morning sickness, antiemetics may be prescribed. These drugs work by 
blocking neurotransmitter inputs to the chemoreceptor trigger zone (CTZ), the principal 
vomiting control centre, of the medulla. First choice is ondansetron, a blocker of 5HT-3 
receptors found in the CTZ, given orally or by injection. This drug, which is also used as an 
antiemetic during cancer chemotherapy, has a number of unwanted effects such as headache 
and GI upset. Other drugs used include promethazine (histamine H1 receptor blocker) and 
metoclopramide and chlorpromazine (dopamine D2 receptor blockers).  
 
